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Aim 
To understand the pharmacologic mechanisms of action, efficacy and toxicity of any 
anti-cancer drug it is important to know how the compound is transformed in the body: 
either into active metabolites or inactive and toxic (degradation) products. This 
information may lead to the success or failure of a drug in arresting cancer cell growth, 
and facilitates the design of more effective drugs. To quantify the drug and to follow its 
absorption, distribution, metabolism, and elimination (ADME) in body fluids, ultra 
sensitive and specific analytical methods are of pivotal importance. In recent years, 
High Performance Liquid Chromatography coupled to tandem triple quadrupole Mass 
Spectrometry (HPLC-MS/MS) technique has shown a steep, fascinating development 
into the most powerful and important tool in the quantitative determination of 
(investigational) anti-cancer agents and identification of metabolites.  
For this thesis, the major aim was to develop and to validate sensitive analytical HPLC-
MS/MS methods for the analysis of anticancer agents, metabolites and degradation 
products in biological matrices. These methods were applied to support 
pharmacokinetic studies of established and experimental anticancer agents. For our 
studies we selected the investigational cytotoxic agents: apaziquone (EO9), 5-
methylindirubine and the licensed drugs: paclitaxel, gemcitabine and capecitabine. 
 
Outline 
Chapter 1.1 presents an overview of the most common locally administered cytotoxic 
drugs with particular focus on available, sensitive bioanalytical assays developed to 
determine the low levels of the drugs that could have passed into the bloodstream and 
which may lead to the systemic toxicity. Chapters 2.1 and 2.2 describe an extensive 
study on the development of ultra sensitive HPLC-MS/MS assays for the bioanalysis of 
the promising anti-cancer agent EO9 in the treatment of the superficial bladder cancer. 
We also investigated stability implications of this compound in the various 
pharmaceutical formulations, human plasma, and urine (Chapter 2.3 and 2.4). A new 
degradation product of EO9 was discovered and identified as EO9-Cl, and the HPLC-
MS/MS assay for the determination of EO9 and both degradation products, EO5a and 
EO9-Cl, in urine was validated (Chapter 2.5). The assays have been used to support 
several (pre)clinical studies with EOquin® (pharmaceutical formulation of EO9 for 
administration into the bladder).  
Aim and Outline 
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Chapter 3.1 deals with the development of a hyphenated HPLC-MS/MS assay for the 
taxane anti-cancer agent paclitaxel and its metabolites in human plasma. The method 
we developed allowed us to quantitatively determine the major hepatic metabolite 6α-
hydroxy paclitaxel and a minor metabolite 3’-p-hydroxy paclitaxel. Chapter 4.1 reports 
the analytical HPLC-MS/MS assay for the experimental anti-cancer agent 5-
methylindirubine. The method is used for a pharmacokinetic study in mice with the drug 
being administered orally. 
Chapter 5.1 illustrates the ultra-sensitive assay with the registered, widely used, 
anticancer drug gemcitabine and its metabolite 2', 2'- difluorodeoxyuridine (dFdU) in 
human plasma with the lower limit of quantitation of 0.5 ng/mL. Chapter 6.1 describes a 
novel HPLC-MS/MS method for the simultaneous quantitation of capecitabine and its 
metabolites 5΄-deoxy-5-fluorocytidine (5΄-DFCR), 5΄-deoxy-5-fluorouridine (5΄-DFUR), 5-
fluorouracil (5-FU) and 5-fluorodihydrouracil (FUH2) in human plasma. In Chapter 7, the 
results of the thesis are evaluated and future research is discussed. 
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Abstract 
Local administration routes have been investigated to reduce the systemic toxicity and 
to increase the local efficacy of cytotoxic drugs. Some examples of local administration 
strategies are cutaneous, intraperitoneal, intrathecal and intravesical chemotherapy. 
When administered locally, high local drug concentrations can be achieved resulting in 
increased local antitumor activity and low systemic toxicity, at the condition that only 
small amounts of drug are being absorbed into the bloodstream. 
Our main purpose is to provide an inventory and to comment on the availability of 
ultrasensitive bioanalytical assays that could detect traces of drugs that may have 
passed into the bloodstream after local application. We conclude that in the last years, 
multiple ultrasensitive assays have been designed enabling quantitative determination 
of very low levels of cytotoxic agents. Most methods are based on hyphenated liquid 
chromatography with tandem triple quadrupole mass spectrometric detection. 
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1.  Introduction 
In this overview, we focus on ultrasensitive assays developed to determine the leakage 
of locally administered anti-cancer agents into the systemic circulation (Figure 1). 
Intravenous and oral chemotherapy are the most important cancer treatments, 
however, they can be associated with considerable side-effects. In the past years, local 
administration routes have been investigated to reduce the systemic toxicity and to 
increase local antitumor activity. Some examples are cutaneous, intraperitoneal, 
intrathecal and intravesical chemotherapy. Important advantages of these 
administration routes are that high local drug concentrations are reached, that drugs 
can be used that are unsuitable for systemic administration, and that this approach 
results in low systemic toxicity, if only small amounts of drug are absorbed into the 
systemic circulation. 
Obviously, it is pivotal to investigate whether the locally administered cytotoxic drug will 
pass into the bloodstream in sufficient high concentrations that could lead to systemic 
toxicity. For this purpose ultrasensitive analytical assays are needed because of the 
anticipated low systemic drug concentrations that are reached after most local 
administrations. 
 
       local
administration Systemic circulation?
Stability implications
Stability/metabolism
Implications
Ultra sensitive bioanalytical assays 
 
Figure 1. Model for systemic exposure of locally administered agents. 
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This article gives an overview of ultrasensitive bioanalytical assays of locally 
administered cytotoxic drugs. For other pharmacologic research questions 
ultrasensitive assays are also needed e.g. metronomic therapies (1,2), microdosing (3), 
long-term effects (4), monitoring of hospital personnel potentially exposed to cytotoxic 
agents (5), and for which this review may be useful. 
 
2. Bioanalytical methods 
To quantify drug and to follow its absorption, distribution, metabolism, and elimination 
(ADME) in body fluids, sensitive and specific analytical methods are required. 
Originally, high performance liquid chromatography (HPLC) or gas chromatography 
(GC) in combination with ultraviolet (UV), fluorescence, or electrochemical detection 
have been employed to quantify drugs in biomatrices. However, most anti-cancer 
agents and their metabolites are non-volatile, thermolabile and small polar molecules 
and therefore, not susceptible to GC (6). UV detection suffers from low specificity and 
sensitivity, especially when small polar molecules are the target. Fluorescence and 
electrochemical detection are more sensitive and specific than UV detection, but they 
have a disadvantage as they are only useful for analytes with fluorescent or electro-
active groups. Selective and ultrasensitive detection in bioanalytical analysis was 
achieved, when HPLC was successfully coupled to mass spectrometry (MS). This 
hyphenation allowed the selective and ultrasensitive detection of a broad range of anti-
cancer compounds and their metabolites (6). With the introduction of atmospheric 
pressure ionization (API), atmospheric pressure chemical ionization (APCI) and 
electrospray ionization (ESI) in the 1980’s these techniques were applied more and 
more for quantitative drug analysis. Nowadays, the use of the improved LC-MS 
interfaces such as ionspray (ISP, pneumatically assisted ESI), turbo-ionspray or heated 
electrospray (TISP or HESI; pneumatically assisted ESI with an additional hot drying 
gas perpendicular to the spray) and heated nebulizer (HN)-APCI (pneumatically 
assisted APCI) immensely facilitated the evaporation of the HPLC solvents, leading to 
better ionization and detection of the analytes of interest. Triple-quadrupole mass 
spectrometers (TSQ) became the ‘working horse’ for quantitative analysis in the 
selected reaction mode (SRM). With the introduction of the orthogonal-acceleration 
reflection time-of-flight (oa-TOF) instruments, which combine the ability to perform 
accurate mass determination with excellent full-scan ability and the ion-trap storage-
Review: Ultrasensitive bioanalytical assays for locally administered cytotoxic drugs  
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reflection TOF instruments, it became possible to detect and quantify not only the 
parent drugs, but also to identify their metabolites and degradation products accurately 
and at low concentrations. Another exciting development was the hyphenation of HPLC 
and nuclear magnetic resonance (HPLC-NMR) technology, facilitating molecular 
structures identification of e.g. unknown metabolites (7). 
In conclusion, these techniques made it possible to develop highly specific and 
sensitive methods. We are especially interested in the use of these MS based 
technologies to quantify very low levels of anti-cancer agents and their metabolites e.g. 
in situations after local administration where leakage into the systemic circulation is of 
interest, conceivably causing toxicity. 
 
3. Cutaneously administered anti-cancer agents 
Cytotoxic agents, applied to the skin, are used for their local effects to treat primary or 
metastatic skin cancers (Table 1). This administration route is advantageous in 
selected cases due to the high local drug concentrations and low systemic toxicity. 
However, one must be aware of the regional differences in drug penetration: the face, 
scalp and scrotum are reasonably more permeable than the leg or a forearm. In those 
cases, drug penetration may lead to unwanted systemic effects. To study this, 
ultrasensitive assays are required. 
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3.1  Anti-metabolites 
3.1.1 5-Fluorouracil 
5-Fluorouracil (5-FU) is a chemotherapeutic agent that can be used both topically and 
intravenously. 5-FU inhibits thymidylate synthetase, which leads to inhibition of DNA 
synthesis and cell death (31). 5-FU is enzymatically cleared from plasma to produce 
dihydro-5-fluorouracil (FUH2), which is the rate-limiting step catalyzed by 
dihydropyrimidine dehydrogenase (DPD). Two following steps result in the formation of 
fluoroureidopropionic acid and α-fluoro-β-alanine (FBAL), respectively with release of 
CO2 and NH3 (Figure 2) (32). 
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Figure 2. Metabolic pathway of 5-FU: DPD, Dihydropyrimidine dehydrogenase; DHP, 
Dihydropyrimidinase; BUP, β-ureidopropionase; FUH2, dihydro-5-fluorouracil; FUPA, 
fluoroureidopropionic acid; FBAL, α-fluoro-β-alanine. 
 
Bioanalysis of 5-FU and its metabolites is complex due to its hydrophilic nature and the 
fact that it is a small molecule, making it cumbersome to separate it from endogenous 
substances and to detect it selectively using HPLC-UV or even HPLC-MS. There are 
two ultrasensitive methods with a lower limit of quantitation (LLOQ) of 1 ng/mL. Wang 
et al. presented an HPLC-MS/MS assay where 5-FU is extracted from plasma using 
liquid-liquid extraction with ethyl acetate and derivatized with 4-bromo-methyl-7-
methoxycoumarin (BMC) to yield a di-derivatized product with a higher molecular 
weight and lipophilicity, which allowed the chromatographic separation and reduced the 
background noise observed in the mass spectrometer with the low weight molecules 
(Figure 3) (33). Derivatized 5-FU eluted from the reversed phase column using an 
eluent which contained 65% organic modifier. 500 µL samples aliquots were processed 
and the LLOQ was 1ng/mL using negative APCI mode. Matsushima et al. described 
another method utilizing gas chromatography-negative ion chemical ionization MS (GC-
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NICI-MS) method for the analysis of 5-FU (along with tegafur, 5-chloro-2,4-
dihydroxypyridine and potassium oxonate) in human plasma (8). 
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Figure 3. Derivatization of 5-fluorouracil (5-FU) with 4-bromo-methyl-7-
methoxycoumarin (BMC). 
 
This method also yields a LLOQ of 1 ng/mL, but requires 250 µL human plasma 
aliquots, which is 2 times less than required by the method described by Wang et al. 
However, this method is more cumbersome and requires an extensive sample 
pretreatment. In this method, tegafur was extracted from plasma using liquid-liquid 
extraction by means of dichloromethane, followed by the extraction of 5-FU with ethyl 
acetate from the residual layer after extraction of tegafur and conversion into its PFB 
derivative by addition of pentafluorobenzylbromide and thriethylamine (8). 
Consequently, if 500 µL of samples aliquots are available, the HPLC-MS/MS method 
described by Wang is preferred with a LLOQ of 1 ng/mL, due to its simplicity. 
The 5% 5-FU formulation was approved as a treatment of actinic keratoses (AK) in the 
early 1970s. 5-FU has been used to treat localized skin cancers and urological cancers, 
with good response (around 80-90%). When applied topically, 5-FU is less toxic than 
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systemic chemotherapy. Usually 5-FU is applied to premalignant or malignant skin 
lesions as 5% Efudix® cream/ointment (31,34-37). The local side effects include pain, 
irritation, inflammation and soreness. The applied dosage varies greatly from the size of 
lesional area treated and the thickness of the applied cream. Usually, the dosages of 
cutaneously applied 5-FU vary between 2 mg and 250 mg (35). However, there are 
cases when 5% 5-FU ointment is applied to the total body surface for the treatment of 
the extensive non-melanoma skin cancer. A case represents a 73-year-old man, who 
received topical 5-FU 5% cream twice weekly to the total body using 20 g per 
application (38). The treatment period was 6 weeks and the blood samples were taken 
before, 30, 60, 90, 120, 240 minutes after and 24 h after application in order to 
measure the intravenous (i.v.) 5-FU levels. Using a HPLC-UV method with LLOQ of 10 
ng/mL (39), no detectable levels of 5-FU were observed (38). Although, no systemic 
toxicity was observed, apparently this method is not sensitive enough to determine the 
traces of 5-FU in plasma. Yet, with the methods described by Matsushima and Wang 
with the LLOQ of 1 ng/mL it might be possible to determine 5-FU levels in the systemic 
circulation after topical administration. 
 
3.2 DNA alkylating agents 
DNA alkylating agents were the first compounds identified to kill cancer cells. They 
contain reactive alkyl moieties that can covalently bind to vital cellular components. 
They form a variety of interstrand cross-linked adducts, that alter DNA structure or 
function. The nitrogen mustards are the largest class of alkylating agents. The most 
common site of alkylation is the N-7 position of guanine in the DNA.  
 
3.2.1 Temozolomide 
Temozolomide is an imidazotetrazine derivative of the alkylating agent dacarbazine 
(DTIC), which spontaneously degrades in physiological fluid to generate the cytotoxic 
methylating agent, MTIC (5(3-methyl-1-triazeno)imidazole-4-carboxamide), which 
subsequently fragments to the DNA-methylating agent, methyldiazonium (40-42). It is 
believed, that MTIC alkylates the O6 and N7 positions of guanine in the DNA. In this 
process, MTIC itself is converted to 5(4)-aminoimidazole-4(5)-carbozamide (AIC) 
(Figure 4) (13-15). 
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Figure 4. Metabolism of Temozolomide (MTIC, (5(3-methyl-1-triazeno)imidazole-4-
carboxamide; AIC, 5(4)-aminoimidazole-4(5)-carbozamide) 
 
Temozolomide, in addition to nausea and vomiting, causes dose-limiting myelotoxicity 
following oral administration, and haematological toxicity often led to disrupt treatment. 
Therefore, the cutaneous route of administration was tested recently (40). Shen et al. 
presented an HPLC-UV assay to determine temozolomide in human plasma with the 
LLOQ of 200 ng/mL. 100 mg C18-endcapped cartridges to extract temozolomide from 
the plasma and 100 µL sample aliquots were used (13). Hong Kim et al. presented an 
assay with a LLOQ of 100 ng/mL. Temozolomide is extracted using ethyl acetate 
followed by separation on a reversed phase C-18 column and quantified by UV 
absorbance at 316 nm using 500 µL aliquot human plasma (14). Although the last 
assay seems to be more sensitive, 5 times more sample aliquot is required compared 
to an assay described by Shen (13). Since temozolomide exerts its antitumor activity 
via its degradation product MTIC, it is important to also determine MTIC plasma 
concentrations following cutaneous administration of temozolomide to evaluate its 
systemic exposure (14,16). MTIC is a highly unstable compound and, consequently, 
the chosen sample pretreatment is usually a simple protein precipitation on ice with ice-
cold reagents followed by immediate analysis. Chowdhury et al. developed an HPLC-
MS/MS method for the determination of MTIC in dog and rat plasma with a LLOQ of 10 
ng/mL utilizing only 70 µL of dog/rat plasma (15). Sample purification was achieved by 
means of a simple protein precipitation with 70 µL of methanol and MS was operated in 
the positive ion mode. Another method, described by Kim et al., utilizes 200 µL human 
plasma and protein precipitation with 100 µL methanol (14). This method was 
developed using HPLC-UV with a LLOQ for MTIC in human plasma of 10 ng/mL. 
Although this HPLC-UV method has the same LLOQ for temozolomide as the HPLC-
MS/MS method (10 ng/mL), the assay presented by Kim et al. (LC-MS/MS) is relatively 
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more sensitive utilizing only 70 µL of plasma instead of 200 µL. To determine whether 
cutaneously administered temozolomide will reach the systemic circulation, the LLOQ 
of 10 ng/mL should be low enough. With topical application at a dose of 20 
mg/mouse/day, the newly synthesized temozolomide hexyl ester, effectively inhibited 
tumor growth in tumor bearing mice model, inoculated with MV3 human melanoma 
cells (40). Although, no study was executed to verify the systemic exposure to 
temozolomide and MTIC after cutaneous administration, the methods of  Kim et al. (14) 
and Chowdhury et al. (15) with a LLOQ of 10 ng/mL are probably sensitive enough to 
determine any temozolomide/MTIC reaching the systemic circulation after cutaneous 
administration. 
 
3.2.2 Nitrogen mustard 
Nitrogen mustard (mechlorethamine hydrochloride, mustine) is an alkylating anti-cancer 
agent discovered in 1940’s and is used in the treatment of Hodgkin’s disease, non-
Hodgkin’s lymphoma, leukemia, and multiple myeloma (43,44). This compound can 
alkylate a DNA base or crosslink between two bases (guanine and adenine) of a DNA 
helix (45). In urine, nitrogen mustard hydrolyses to N-methyldiethylamine (MDEA). 
Others than the i.v. routes have been tested, and mechlorethamine has been 
particularly successful in a topical treatment of mycosis fungoids (MF) and Langerhans 
cell histiocytosis (LCH) (43,44,46-48). Topical nitrogen mustard has been shown to be 
effective for patients with early stages of MF. There is, however, only one article 
describing the determination of nitrogen mustard in human plasma (18). Here, 
mechlorethamine is treated first with diethyldithiocarbamic acid (DDTC) to form the 
disubstituted derivative, which is then analyzed by HPLC-UV with a LLOQ of 100 ng/mL 
(Figure 5) (18). Mass and NMR spectrometry confirmed that one molecule of DDTC 
reacts with each arm of the nitrogen mustard, displacing a chlorine atom to form a 
stable disubstituted adduct. The HPLC-UV method is, however, probably not sensitive 
enough to measure any absorbed nitrogen mustard. 
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Figure 5. Proposed reaction mechanism of the derivatization of mechlorethamine with 
diethyldithiocarbamic acid (DDTC). 
 
After all, no evidence of systemic toxicity was observed as measured by normal blood 
count and chemistries. In conclusion, further research has to be executed.  
 
3.3  Vitamines 
3.3.1 Isotretinoin 
Isotretinoin, a derivative of retinoic acid (13-cis-retinoic acid), which is a natural 
derivative of Vitamine A, plays an important role in tissue growth, differentiation and 
development (49). However, when administered orally, isotretinoin has some severe 
side effects, and both isomers of retinoic acid (isotretinoin and tretinoin) and their 
respective 4-oxo metabolites are teratogenic. Therefore, gel pharmaceutical 
formulations containing 0.05% (w/w) isotretinoin for the cutaneous administration, have 
been developed (49,50). 
Lehman et al. described a highly sensitive assay with a LLOQ for isotretinoin as low as 
0.05 ng/mL human plasma (22). 0.5-mL aliquots plasma samples were protein 
precipitated with 2-propanol followed by solid phase extraction. The retinoic acids were 
derivatized to the pentafluorobenzyl (PFB) ester by the addition of 10 µL of neat PFB 
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bromide and 10 µL of 10 mg/mL potassium carbonate in acetonitrile-water (50:50, v/v) 
solution to the solid phase extraction acetonitrile eluate. The chromatographic 
separation was performed by means of HPLC and the highly sensitive detection was 
obtained using mass spectrometry particle beam interface (HPLC/PB/MS) (22). 
Willoughby and Browner (51) demonstrated promising performance characteristics of a 
system consisting of an aerosol generator, a desolvation chamber, and a particle beam 
separator. This design was named MAGIC, but with the commercial development of 
several variations of MAGIC, became known as a particle beam interface (52). 
HPLC/PB/MS has proven to be a valuable tool for the detection of the thermolabile and 
nonvolatile analytes.  
The use of PFB ester derivative and negative chemical ionization using methane as the 
ionization reagent yielded only one significant negative ion fragment, contributing to the 
high sensitivity of this method , the carboxylate anion of the parent acid (M-PFB)-. This 
method could not only quantify endogenous retinoic acid plasma levels (between 0.8 
and 3.5 ng/mL), but also provided the latitude to discriminate very small changes in 
those levels (22). The administered amount of isotretinoin in a gel formulation (0.05% 
or 0.5 mg/g) is described to be 0.2 g (50).  
Consequently, if topically administered isotreinoin will exhibit leakage into the systemic 
circulation, the traces of isotretinoin can quantified by this ultrasensitive method 
developed by Lehman et al. with a LLOQ of 0.05 ng/mL, allowing determination of even 
the minimal changes in the endogenous levels of isotretinoin (22). 
 
3.4  Anti-hormones 
Anti-hormones modify the expression of specific genes and block the action of a 
hormone on receptor sites.  
 
3.4.1 Toremifene 
Toremifene is a new triphenylethylene with activity in patients with breast and 
endometrial cancer (53). When applied i.v., toremifene is extensively metabolized and 
over twenty metabolites have been identified, however, the two major metabolites of 
toremifene, N-desmethyl-toremifene (TOR-I) and (deaminohydroxy)toremifene (TOR III) 
are present in human plasma in significant quantities and are believed to be active 
(Figure 6) (54). Besides the i.v. administration, toremifene was also tested topically to 
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obtain high concentrations in superficial tumors while minimizing the systemic exposure 
(53). 
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Figure 6. Structural formulas of toremifene and its two major metabolites TOR-I and 
TOR-III. 
 
Webster et al. described a simple quantitative HPLC determination of toremifene and 
its major metabolites in human plasma by means of protein precipitation with 
acetonitrile and UV detection with a LLOQ of 100 ng/mL utilizing 100 µL plasma 
aliquots (54).  
Thus far, the most sensitive assay for the determination of toremifene and its major 
metabolites in human plasma is presented by Holleran et al. (25). Plasma samples 
were spiked with nafoxidine, an internal standard, and extracted with 2% n-butanol in 
hexane. The aliquots of the extracted plasma components were injected onto a C-18 
reversed phase column and eluted isocratically with a mobile phase consisting of water 
and triethylamine in methanol. The detection was performed by means of fluorescence 
detection with a LLOQ of 25 ng/mL for all compounds and the lower limit of detection 
(LOD) of 8, 15 and 5 ng/mL for toremifene, N-desmethyl-toremifene and 4-hydroxy-
toremifene, respectively (25). 
The distribution and the cytotoxic effects of topically applied toremifene (0.5-1 mg/day 
for 5 days) in the ultraviolet B (UVB)-induced melanoma model was examined (53). The 
topical administration of toremifene yielded high local concentration with minimal 
systemic distribution. In addition, toremifene exhibited a cytotoxic effect at achievable 
concentrations in a variety of melanomatous cell lines. In plasma, toremifene could only 
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be detected in one animal out of six, at 16 ng/mL. The authors used the method 
described by Holleran et al. and the detected 16 ng/mL is lower that the LLOQ, but 
higher than LOD. Hence, this method is not sensitive enough to quantify the traces of 
systemically absorbed tamoxifen in this study. To achieve a greater sensitivity a HPLC-
MS/MS technology instead of HPLC-UV and the fluorescence method used here, can 
possibly provide better results. 
 
3.4.2 4-Hydroxytamoxifen 
4-Hydroxytamoxifen (4-OHT) is the most active metabolite of tamoxifene, which binds 
to the estrogen receptor with higher affinity than tamoxifen (Figure 7) (55). 
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Figure 7. Chemical structures of tamoxifen and its active metabolite 4-
hydroxytamoxifen (4-OHT). 
 
It was found that the cutaneous application of 4-OHT gel (0.5, 1 or 2 mg/day) to the 
skin of the breast produced high and consistent tumor concentrations of 4-OHT and 
much lower plasma levels. Thus far, there is only one, but a highly sensitive method to 
determine 4-OHT concentration in human plasma with a LLOQ of 0.02 ng/mL (27). The 
drug and deuterated internal standard (4-OHT-d4) were measured by GC/negative 
chemical ionization MS with methane as the reactant gas. 4-OHT and internal standard 
were isolated from the complex biological matrices using a solid-phase extraction 
procedure with Extrelut 1 columns. 4-OHT was converted to the fluorinated derivative 
with pentafluorobenzyl chloride. This assay required 0.5 ml of plasma or 0.5 g of 
mammary tissue. The mass spectra showed abundant and stable molecular ions of 4-
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OHT and 4-OHT-d4, which were generated by electron capture process. This assay 
showed low relative standard deviation (27) 
Recently, a randomized study was performed to analyze whether 4-OHT gel, 
administered cutaneously on the breast skin, can inhibit the proliferation of malignant 
breast cells to the same extent as orally administered tamoxifen (55). Several doses 
were tested to determine the best ratio efficacy/safety. After the administration of 0.5 
mg/day, 1.0 mg/day and 2.0 mg/day 4-OHT gel, the concentrations of 18-144, 20-84 
and 31-306 pg/mL of 4-OHT in plasma were measured using the method described 
above. Consequently, the LLOQ of this ultrasensitive method is sufficient for this 
application. 
 
3.4.3 Miltefosine 
Miltefosine (hexadecylphospholine, He-PC) is an alkylphospholine with a long-chain 
fatty acids-like backbone belonging to a new therapeutic class of cytotoxic agents that 
are related to phospholipids (Figure 8) (56). 
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Figure 8. Structural formula of miltefosine. 
 
The cytotoxic effect of miltefosine has been demonstrated in a wide range of tumors. 
When administered systemically, miltefosine induces major gastrointestinal toxicity. 
However, when combined with glycerol ethers it is absorbed through the cutaneous 
tissue and can be delivered topically (56-58). Thus far, miltefosine proved to be 
therapeutically active when administered topically in 6% miltefosine solution against 
cutaneous metastases from breast cancer (56-59). The lowest administered dose was 
1 drop (0.025 mL) of 6% (60 mg/mL) miltefosine solution, yielding a total dose of 1.5 
mg. Thus far published HPLC coupled to evaporative light scattering detector (ELSD) 
analytical method utilizing solid phase extraction as means of sample pretreatment, 
allowed quantification of miltefosine in human plasma with a LLOQ of 340 ng/ml (28). 
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However, recently at our lab, Dorlo et al. succeeded to develop a more sensitive 
method utilizing a reversed phase HPLC-MS/MS technology with a LLOQ for 
miltefosine of 4 ng/mL. Solid phase extraction utilizing Phenyl Bond Elut - SPE 
cartridges was used as means of samples pretreatment and 250 µL sample aliquots 
were processed. (30). Use of a 0.9 M aqueous acetic acid buffer solution set at pH 4.5 
for dilution of the samples and conditioning of the solid phase extraction cartridges, 
resulted in a slightly better recovery compared to the above described method (28) and, 
more importantly, highly reproducible results. Because the structure of miltefosine lacks 
any chromophores, it makes UV or fluorescence detection very difficult, and MS 
detection is an obvious choice offering a sufficiently high sensitivity to measure 
miltefosine in human plasma (30). 
 
4. Ocularly administered anti-cancer agents 
Anti-cancer agents used to treat eye disorders can be mixed with inactive substances 
to make a liquid, gel or ointment, so that they can be applied to the eye (Table 2). 
Ocular agents are almost always only used for their local effects after they are 
absorbed through the cornea and conjunctiva. However, some of these drugs may then 
enter the bloodstream and might have unwanted effects on other parts of the body.  
 
4.1  Anti-metabolites 
4.1.1 5-Fluorouracil 
The spectrum of squamous neoplasia of the conjuctiva and cornea ranges from mild to 
severe epithelial dysplasia, full thickness epithelial involvement (carcinoma in situ) to 
invasive squamous cell carcinoma. The surgical excision of the neoplastic lesions has 
been the standard treatment, however due to the high recurrence rate (15-50%) after 
the surgery, other methods of treatment have been investigated and used alone or as 
an adjunct to surgery (60). Topical 1% 5-FU has been shown to be effective in treating 
conjunctival and corneal intraepithelial neoplasia (CIN); it has been well tolerated and 
effective method of treatment (60). The 1% 5-FU therapeutic formulation was prepared 
using a preservative-free methylcellulose solution as a vehicle. 
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The sensitive analytical assays to determine 5-FU in human plasma are described in 
section 3.3.1, however due to the lack of information on the possible plasma levels 
obtained after the ocular administration of 5-FU, we can not draw any conclusion on the 
usefulness of these methods for the described clinical application. 
 
4.2  DNA alkylating agents 
4.2.1 Mitomycin C 
Mitomycin C (MMC) is a chemotherapeutic antibiotic isolated from Streptomyces 
caespitosus. It is an alkylating agent, which causes breakage of single-strand DNA. 
MMC functions in all phases of the cell cycle, especially in rapid dividing cells. The 
most significant toxicity of MMC in humans is myelosuppression, confirmed to be 
delayed and dose-related effect. As a consequence of chemical degradation or quinone 
reduction three primary metabolites of MMC can be produced: 2,7-diaminomitosene 
(2,7-DM) 1,2-cis- and 1,2-trans-hydroxy-2,7-diaminomitosene (cis-hydro and trans-
hydro) (Figure 9). The formation of the metabolites is pH-dependant. Moreover, the 
factors such as oxygen tension and level of free radicals can influence the formation of 
the metabolites (61). 
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Figure 9. Structural formula of Mitomycin C (MMC) and conversion products. 
Review: Ultrasensitive bioanalytical assays for locally administered cytotoxic drugs  
 
                                                                                                                                               37 
Over the years there have been numerous HPLC with UV or PDA detection methods 
developed for the quantification of mitomycins in various biological matrices (61-71). 
Paroni et al. described an ultra sensitive method for the determination of MMC in 
human plasma with the LLOQ of 0.5 ng/mL (69). Relatively high amount of 1000 µL 
sample aliquots were processed using solid-phase extraction under vacuum and the 
injection volume of 100-200 µL into the HPLC column is utilized. Chromatographic 
analysis was performed on a reversed-phase C18 column and MMC was detected by 
means of the UV detection set at 365 nm (69). Dalton et al. described a more simple 
HPLC-UV method for MMC in plasma with the LLOQ of 0.5 ng/mL (65). 1000 µL 
sample aliquots were mixed with 10 µL of internal standard porfiromycin (1.07 mg in 
0.5M phosphate buffer pH 7) and 90 µL 2.0 M phosphate buffer pH 7. MMC and its 
internal standard were extracted from human plasma with 10 mL ethyl acetate and 50 
µL was injected into the HPLC. Dalton et al. describe the difficulties associated with the 
sample pretreatment of MMC. The tight binding of the MMC to the glass tube under 
vacuum conditions was observed during the extraction. This problem was solved by 
first evaporating ethylacetate with dissolved MMC in 10-ml disposable glass tube to 
dryness under a stream of nitrogen at ambient temperature, followed by rinsing the 
used glass tube with two separate 100 µL aliquots of methanol, transferring the 
methanol fraction to an eppendorf tube and evaporating again in the vortex vacuum 
evaporator (65).  
Topical MMC has been successfully used in the treatment of recurrent conjunctival-
corneal intraepithelial neoplasia (CCIN) since 1994 with reported success rates of 85-
100% (72,73). Various concentrations and durations of the treatment have been tested: 
from 0.002% to 0.04% MMC in sterile distilled water. No study has been executed 
where systemical concentrations of topically administered MMC were determined. The 
ultrasensitive assay described by Dalton et al. may be sufficiently sensitive to measure 
any MMC in the systemic circulation. 
 
5. Other topically administered anti-cancer agents 
5.1 Ear  
5.1.1 Anti-metabolites 
5.1.1.1 5-Fluorouracil 
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Retraction and abnormal proliferation of the eardrum epithelium are believed to consist 
of pathogenic processes of cholesteatoma (36). 5% 5-FU topical cream has been 
effective (88% of the 50 patients) with no serious side effects (36). 2-3 mm3 (0.002-
0.003 mL) of 5% 5-FU (50 mg/mL) cream is applied on the outer surface of 
cholesteatoma transmeatally under the microscope 2 to 5 times with interval of 2 weeks 
(Table 3) (36). No study was executed where the systemic exposure was measured. 
 
5.2 Pharynx 
5.2.1 Anti-metabolites 
5.2.1.1 5-Fluorouracil 
There is only one case reported when 5% 5-FU cream is used to treat squamous cell 
carcinoma recurrence on a reconstructive free flap in the pharynx (31). The protocol 
consisted of five applications of ribbon gauze coated with 20 g of 5% Efudix® (50 mg/g; 
5-FU ointment) at three-weekly intervals. The patient experienced no side effects of the 
treatment and 28 months post-treatment was still clinically and histologically disease-
free. The administered dose was 1,000 mg. Although, no study was executed to 
establish the systemic exposure to 5-FU after this topical administration, with the 
methods described by Matsushima and Wang with a LLOQ of 1 ng/mL it might be 
possible to determine traces of 5-FU in the systemic circulation. 
 
5.3 Mouth 
5.3.1 Antitumor antibiotics 
5.3.1.1 Bleomycin 
Bleomycin is an antitumor antibiotic drug isolated from Streptomyces verticillus 
consisting of bleomycin A2 and B2 (Figure 10). Its cytotoxic activities are believed to be 
the result from the effect of the drug on physical DNA integrity: DNA binding and DNA 
cleaving are thought to be the two essential steps in the cytotoxic process. The 
aminopeptidase B-like enzyme Bleomycin hydrolase, acts on the carboxamide group of 
the aminoalanine moiety of bleomycin converting it into its inactive metabolite deamido-
bleomycin. This inactivation of bleomycin has been shown to be an important step in 
limiting its antitumor activity (74). Thus far, there is only one HPLC method for the 
quantitative determination and extraction of bleomycin (A2 and B2) from biological 
matrix (human plasma) with a LLOQ of 70 ng/mL (74). 
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In this assay, bleomycin in 300 µL plasma aliquots was purified from plasma 
components by a double protein precipitation step with trichloroacetic acid (TCA) 
containing 1mM CuSO4 to improve the HPLC peak performance. The two supernatants 
were mixed and 100 µL was twice injected into the reversed phase HPLC coupled with 
fluorescence detection, which was more sensitive than previously described HPLC-UV 
techniques (74). 
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Figure 10. Structures of Bleomycin A2 and B2. 
 
Topical application of 1% bleomycin in dimethylsulfoxide (DMSO) has been evaluated 
in clinical trials, resulting in regression and resolution of leukoplakia (75). The treatment 
solutions were applied to the involved area (tongue, lip, etc) by soaking pledgets of 
cotton in the solution with continuous application to the area for 5 min, once daily for 14 
days. No plasma samples were measured to determine whether the topically applied 
bleomycin may have passed into the systemic circulation. However, the bioanalytical 
assay with a LLOQ of 70 ng/mL, described above, might be sensitive enough to 
determine systemic bleomycin after the topical application of high dosages. More 
research is warranted. 
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6.  Intraperitoneally administered anti-cancer agents 
Intraperitoneal (i.p.; administration into the abdomen) chemotherapy is used as means 
of improving the selectivity of chemotherapy of intra-abdominal tumors, including 
ovarian, gastro-intestinal, pancreatic and colorectal cancers (Table 4) (76-79). Dedrick 
et al. suggested that i.p. administered agents would allow much greater peritoneal drug 
exposure and lesser systemic exposure (80). Most of the investigations have indeed 
shown that i.p. drug administration results in large favorable concentration differences 
between the peritoneal perfusate and blood for a variety of agents (81). The 
pharmacological advantage of i.p. therapy is an exposure of the i.p. disease to 
extremely high concentrations of anti-cancer drug while minimizing the systemic 
toxicity. For example, in the case of ovarian cancer, i.p. therapy appears to be a 
reasonable therapeutic approach, and it has been investigated for years (82).  
 
6.1 Anti-metabolites  
6.1.1 Methotrexate 
Methotrexate (MTX) acts as an antimetabolite and is commonly used for the treatment 
of various malignant diseases, such as acute leukemia, osteosarcoma, non-Hodgkin 
lymphoma and breast carcinoma. MTX is converted to 7-hydroxymethotrexate (7OH-
MTX), which is around 200 times less cytotoxic that MTX (Figure 11).  
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Figure 11. Structures of methotrexate and its metabolite 7-hydroxymethotrexate. 
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MTX is a polar, non-volatile and thermally unstable compound, therefore, the analysis 
of this compound is quite a challenge. 7OH-MTX is less polar compared to MTX due to 
an intra-molecular bonding between the hydroxyl and one of the carboxylic acid groups. 
With the introduction of the electrospray ionization MS, the analysis of MTX became 
possible and several methods have been developed and published (83-86). A quite 
elegant method is presented by Steinborner and Henion, involving the semirobotic 
liquid-liquid extraction in deep-well 96-well plates and detection of MTX and 7OH-MTX 
by means of positive ion turbo-ionspray selected reaction monitoring mass 
spectrometry (SRM LC/MS) (83). The sample pretreatment time was reasonably short: 
384 samples could be processed in only 90 min (four 96-well plates). The 200 µL 
sample aliquots were first protein precipitated with 500 µL acetonitrile followed by 
liquid-liquid extraction with chloroform. All steps were performed in 96-well plates and 
were automated (87). A dual column system, consisting of a trapping column 
configuration and an analytical column, was used to concentrate the analytes and to 
separate it from matrix components. 80 µL aliquots of the aqueous layer were used to 
be injected onto the trapping column. A small, 1 mm internal diameter analytical column 
was employed to achieve improved electrospray HPLC-MS sensitivity, with as result a 
LLOQ of 0.1 ng/mL for MTX and 0.3 ng/mL for 7OH-MTX (87). 
I.p. administration of MTX has been investigated in mice and rats in combination with 
i.v. administration of antidrug antibodies (or fragments; collectively abbreviated as 
ADAb). The i.p administered dose in animals varied between 1.9 and 10 mg/kg animal, 
which was well tolerated (76,81). Interestingly, the pharmacokinetics of MTX given i.v. 
or i.p. was similar and no plasma protein binding was observed and the lowest 
detectable concentrations of approximately 3 µg/mL were yielded (81). Consequently, 
the currently available method for the determination of MTX in human plasma with the 
LLOQ of 0.1 ng/mL is very adequate for this application. 
 
6.1.2 5-Fluorouracil 
Uptake of 5-FU in tumor was higher when 5-FU was given i.p. compared to i.v. in a rat 
model. Moreover, it was found that a considerable uptake of 5-FU in the lymphatic 
vessels and lymph nodes was observed in the abdominal cavity in pigs.  
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Based on these findings, and to investigate the safety, toxicity and efficacy of i.p. 5-FU, 
phase I/II study with i.p. 5-FU in non-resectable pancreatic cancer was executed (88-
92). Between 1994 en 2003, 68 patients with non-resectable pancreatic cancer TNM 
stages III and IV, were enrolled to receive i.p. 5-FU instillation of 750-1500 mg/m2. 
Although the systemic concentration of 5-FU after i.p. administration is low due to an 
eighty percent elimination in the first passage through the liver, it could still lead to dose 
limiting toxicity (88). The authors concluded that the treatment was well tolerated; tumor 
response was 4.4% and median survival time 8 months. The lowest plasma levels of 5-
FU detected were approximately 60 ng/mL using an assay with a LLOQ of 6.6 ng/mL 
(88). Therefore, this and the ultrasensitive assay described in section 3.3.1, can provide 
accurate data on the systemic leakage of i.p. administered 5-FU. 
 
6.2 DNA alkylating agents 
6.2.1 Mitomycin C 
Verwaal et al. performed a phase III study with patients who had carcinomatosis from 
colorectal cancer (93). Patients who received cytoreduction plus hyperthermic 
intraoperative i.p. MMC chemotherapy had a median survival of 22.3 months compared 
to 12.6 for patients treated by palliative surgery plus systemic chemotherapy (P=0.032) 
(93,94). Therefore, Sugarbaker et al. executed a study with i.p. MMC to provide data 
regarding the effect of volume of chemotherapy solution on the pharmacokinetics of i.p. 
chemotherapy. The dose of MMC administered to 48 patients was 12.5 mg/m2 in male 
and 10 mg/m2 in female (94). 
Blood samples were obtained every 15 minutes for 90 minutes and the last sample was 
obtained at 120 minutes. Sugarbaker et al. concluded that between 55.7 (±9.8) % and 
82 (±4.4) % of MMC was cleared from the peritoneal cavity after 90 minutes, depending 
on the volume of the chemotherapy. The lowest determined concentrations in plasma 
were approximately 70 ng/mL, obtained using an analytical method with a LLOQ of 5 
ng/mL (63). Consequently, using the ultrasensitive method for the determination of 
MMC in human plasma described in section 4.3.1, accurate pharmacokinetic curves 
can be obtained and the leakage of MMC into the systemic circulation can be 
quantified. 
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6.2.2 Melphalan 
Melphalan is an antineoplastic alkylating agent used in the treatment of multiple 
myeloma, ovarian carcinoma, and breast cancer (95). It exerts a cytotoxic effect 
through the formation of inter- or intrastrand DNA cross-links or DNA-protein cross-links 
via the two chlorethyl groups of the molecule (Figure 12). Unlike other mustards, 
melphalan does not require metabolic activation in order to become cytotoxic; it 
dechlorinates spontaneously and forms a highly reactive intermediate aziridinium ion, 
which immediately reacts with DNA forming melphalan adducts (Figure 12) (96).  
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Figure 12. Molecular structures of Melphalan, its reactive intermediate and its 
hydrolysis products monohydroxymelphalan (MOH) and dihydroxymelphalan (DOH). 
 
Melphalan undergoes rapid spontaneous hydrolysis in aqueous solution at room 
temperature and yields two hydrolysis products, monohydroxy-melphalan (MOH) and 
dihydroxy-melphalan (DOH); neither of these degradation products have cytotoxic 
activity (97,98). Various analytical assays have been published to determine melphalan 
in human plasma (95,97,99-102). However, most of the methods involve labor intensive 
sample pretreatment, long chromatographic run times and considerable volumes of the 
sample and reagents. The most sensitive assay for melphalan analysis in human 
plasma is presented by Davies et al. utilizing a HPLC-MS/MS method with the LLOQ of 
2 ng/mL (103). In this assay, automated solid phase extraction is carried out with C18 
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sorbent packed in a 96 well format microlitre plate using a robotic sample processor. 
The extracts are analyzed by reversed phase liquid chromatography using 
pneumatically and thermally assisted electrospray ionization with selected ion reaction 
monitoring. Melphalan and its stable isotopically labeled internal standard were 
chromatographed in less than 2 minutes since no chromatographic separation between 
the analyte and the internal standard was needed due to the mass selective nature of 
the mass spectrometry. Using the sample volumes of 200 µL the LLOQ was 2 ng/mL 
(103). 
Several studies have been performed with i.p. administered melphalan alone or with 
other cytotoxic drugs, such as cisplatin. The administered dose of melphalan varied 
from 16 mg/kg to 30 mg/kg (104,105). Recently, Sugarbaker et al. described the study 
with i.p. melphalan to assess the pharmacokinetics and to evaluate the potential clinical 
advantages of heated intraoperative i.p. melphalan as adjuvant therapy for patients with 
residual disease after cytoreductive surgery for peritoneal surface malignancies (106). 
The dose of 70 mg/m2 was given to the patients and the lowest determined 
concentration of melphalan in plasma was 100 ng/mL (the LLOQ of the used method 
was not mentioned). Consequently, the method developed by Davies et al. with a 
LLOQ of 2 ng/mL is far sufficient to measure the systemic exposure to melphalan after 
i.p. administration. 
 
6.2.3  Thiotepa 
Thiotepa is a DNA alkylating agent. It is extensively metabolized by the liver to tepa, 
which is also cytotoxic. Van Maanen et al. identified in urine a new metabolite of 
thiotepa with alkylating capacity, thiotepa-mercapturate (107). De Jonge et al. has 
developed and validated a HPLC-MS/MS method for the quantitation of thiotepa and 
tepa with a LLOQ of 5 ng/mL (108). Sample pretreatment consisted of protein 
precipitation with a mixture of methanol and acetonitrile using only 100 µL human 
plasma. Chromatographic separation was achieved on Zorbax Extend C18 column and 
the detection was performed by means of triple quadrupole mass spectrometer, which 
was operating in the positive ion mode and multiple reaction monitoring (MRM) was 
used for drug quantification. (108,109). Interestingly, while most other assays employ 
an acidic eluent, such as acetic acid and formic acid, the successful use of an alkaline 
eluent containing ammonium hydroxide combined with LC-MS/MS in the positive 
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ionization mode is demonstrated here.  Positive ionization in the electrospray ion 
source in the presence of ammonium hydroxide most likely results from ion-molecule 
reactions (IMR) between the analyte molecule (M) and ammonium ions or collision–
induced dissociation (CID) of ammonium adducts of the analyte under influence of the 
electrospray voltage, as proposed by Zhou at al (110): 
IMR: NH+4 (g) + M   →  NH3 (g) + MH+ (g) 
or  
CID: (NH3-H+-M) (g) → NH3(g) + MH+ (g) 
For either reaction to be thermodynamically favoured requires that thiotepa and tepa is 
a stronger gas-phase base than NH3. This approach has demonstrated to be very 
useful for the quantitative analysis of basic anti-cancer agents, such as ABT-518, 
Kahalalide F and paclitaxel and its metabolites (111-114). 
 
Thiotepa at doses of 0.8 mg/kg has been administered i.p. to prevent recurrence of 
ascites in ovarian cancer (115-118). Treatment was well tolerated and no acute 
inflammatory reactions were seen. After experimental administration of 32P-radiolabeled 
thiotepa, the drug was slowly reabsorbed from peritoneal fluid. It was observed, that the 
radioactivity measured in the peritoneal fluid was 10-100-fold higher after i.p. 
administration compared to i.v., concluding that thiotepa might prove to be a useful 
component of i.p. chemotherapy (115). In studies, thiotepa was given at doses varying 
from 30 mg/m2 to 80 mg/m2 as i.p. instillation (115,119). In the Phase I study performed 
by Lewis et al., 15 patients received a total of 50 courses with thiotepa ranging from 30 
mg/m2 to 80 mg/m2 (120). The dose limiting toxicity was myelosuppression, which 
occurred at 80 mg/m2. Peritoneal fluid concentrations declined rapidly in a first-order 
fashion (120). Approximately 93% of the drug was absorbed during a 4 h dwell time. 
The detected plasma concentrations were approximately 25 ng/mL, and consequently 
detectable by the sensitive method for the determination of thiotepa in human plasma 
with a LLOQ of 5 ng/mL as described by de Jonge et al. (108). 
 
6.3 Platinum anti-cancer drugs 
6.3.1 Cisplatin 
Cisplatin is a platinum based drug that is widely used in the clinical treatment of 
testicular, ovarian, lung, head and neck cancers (Figure 13) [(121-124). Indirectly, 
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cisplatin reacts with DNA to form cross-links leading to inhibition of DNA replication, cell 
division and induce apoptosis (124). After intraveneous infusion, cisplatin and its 
reactive metabolites become rapidly portioned into plasma protein-bound platinum (Pt), 
free plasma Pt, tissue Pt, Pt in peripheral blood mononuclear cells and erythrocyte-
sequestered Pt (125). Currently available methods to determine cisplatin employ 
inductively coupled plasma mass spectrometry (ICP-MS) and have LLOQ of 2 ng/mL in 
human plasma ultrafiltrate (121,126). However, once cisplatin will enter into the 
systemic circulation, it will form a variety of hydrolyzed intermediates. 
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Figure 13. Structural formula of cisplatin, carboplatin and oxaliplatin. 
 
These intermediates will be partitioned into plasma protein-bound metal, free plasma 
metal, tissue metal, white blood cell metal, and erythrocyte-sequestered metal. 
Therefore, it is technically very difficult to measure cisplatin intact, and usually the total 
platinum content is measured to investigate the pharmacokinetics of the platinum 
compound. An ultrasensitive ICP-MS method for the quantification of platinum in 
plasma ultrafiltrate with the LLOQ of 7.5 pg/mL has recently been presented by 
Brouwers et al. (127). Since the first application of ICP-MS for oncology research in 
1990, ICP-MS has become an accepted and very important technique for the analysis 
of Pt anti-cancer agents. Atomic absorption spectrometry (AAS) is also an useful 
technique to determine Pt and other metals, but ICP-MS proved to be a far more 
sensitive instrument, however, it is also more costly. ICP-MS has several advantages 
over other methods, including a wide linear range, LLOQ, potential for isotope 
determinations and multi-element capability (128). It is also a less labor-intensive 
method, because the signal intensities are dependent only on the chemical structure of 
the analyte incorporating the metal and hence the method does not need standards of 
analyte/metabolite/adduct (128). For the determination of platinum originating from 
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cisplatin, Brouwers et al. used dilution of samples 100-fold with 1% nitric acid as a 
means of sample pretreatment. The detection was performed by ICP-MS. This method 
was validated according to the FDA guidelines, as far as applicable for ICP-MS (127). 
Cisplatin is used in the treatment of the ovarian cancer, however because of its toxicity, 
including nephro-, oto-, and neurotoxicity, other platinum anti-cancer agents, such as 
carboplatin are employed (123,129). In addition, there are three large randomized 
phase III studies comparing i.p. vs. i.v. cisplatin-based chemotherapy (130-132). 
Although all trials have shown survival benefit of i.p. chemotherapy, this approach has 
not yet been accepted as a standard treatment for selected ovarian cancer patients. I.p. 
cisplatin is given at a dose of 100 mg/m2.  
Recently, Royer et al. investigated the serum and i.p. pharmacokinetics of cisplatin 
within intraoperative i.p. chemotherapy (133). Serum and i.p. measurements of total 
and unltrafilterable platinum were quantified to determine pharmacokinetic parameters 
in 11 consecutive patients who received a 2 h intraoperative i.p. chemotherapy with 50 
mg/m2 cisplatin. I.p. platinum concentration decreased rapidly; the mean lowest 
systemic concentration of Pt was approximately 50 ng/mL after 25 h, concluding that 
the method developed by Brouwers et al. with a LLOQ of 7.5 pg/mL would be very 
sufficient to measure the traces of the systemical present Pt after i.p. cisplatin.  
 
6.3.2 Carboplatin 
Carboplatin (Figure 13) is less toxic than cisplatin and therefore, it was reasonable to 
test its role in the i.p. treatment of ovarian cancer. However, despite the fact that i.v. 
administration of carboplatin has now become a standard platinum agent in the 
treatment of the epithelial cancer, i.p. administration of carboplatin has been ignored for 
years (130). There is one available HPLC-MS/MS method to determine intact 
carboplatin in rat plasma ultrafiltrate with a LLOQ of 70 ng/mL, presented by Gou et al. 
(134). Carboplatin was extracted from only 50 µL rat plasma ultrafiltrate using solid 
phase extraction cartridges, with 10 µL aliquots were injected onto the reversed phase 
HPLC system and analyzed by positive electrospray MS (134). The full scan spectrum 
was dominated by three major isotopes of platinum at m/z of 370.3, 371.3 and 372.3 
with similar relative intensities. In the blanks, trace peaks at m/z of 371.3 and 372.3 
were observed with a signal intensity of about two-to three-fold higher than baseline. 
Therefore, the m/z of 370.3 was chosen for detecting carboplatin in biological matrices 
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(134). Another method by Brouwers et al., as described in the previous section, allowed 
determination of the Pt resulting from carboplatin, cisplatin and oxaliplatin in human 
plasma ultrafiltrate at a LLOQ of 7.5 pg/mL (127). Although this method is more 
sensitive for Pt, some researchers prefer not to atomize the compound but to detect the 
intact drug as this may yield more adequate pharmacokinetic profiles (134). 
Recently, several studies have been executed investigating i.p. carboplatin. It was 
found that the administered dose of carboplatin had to be almost 6 times higher than 
that of cisplatin to achieve comparable tissue concentration for the same effect. 
Therefore, 400 mg/m2 of carboplatin has been used with sufficient effect (130,135).  
Miyagi et al. investigated whether i.p. carboplatin infusion may be indeed a 
pharmacologically more reasonable route than i.v. administration as a systemic therapy 
(82). The lowest systemic Pt concentration after i.p. administration of carboplatin was 
approximately 80 ng/mL after 25 h. Thus the assay designed by Brouwers et al. will be 
very applicable to measure the systemic concentrations of Pt after i.p. administration of 
carboplatin. 
 
6.3.3 Oxaliplatin 
Oxaliplatin is anti-cancer agent (Figure 13), which is currently used on a large scale to 
treat colorectal cancers. An ICP-MS method for the determination of total Pt levels has 
been described in human plasma ultrafiltrate with an LLOQ of 7.5 pg/mL (127). 
Peritoneal carcinomatosis (PC) is one of the most common causes of incurability of 
intra-abdominal cancers. Surgery or chemotherapy alone is not able to cure this 
disease. However, when surgery was combined with hyperthermic i.p. chemotherapy 
(HIPEC), promising results were achieved (136). Oxaliplatin does not cause renal or 
hepatic toxicity and is used as chemotherapeutic agent for HIPEC therapy. In the 
prospective phase II study described by Elias et al., a total of 106 patients were 
included and after complete resection of the PC, HIPEC was executed with oxaliplatin 
(360 mg/m2) combined with irinotecan (360 mg/m2) in 2 L/m2 of 5% dextrose, over 30 
minutes at a real i.p. temperature of 430C (136). Unfortunately, no human plasma 
measurements were performed to investigate the systemic leakage of oxaliplatin. 
However, recently, another study by Gesson-Paute et al. described the 
pharmacokinetics of oxaliplatin in pigs after i.p. administration at a dose of 460 mg/m2 
(137). Platinum levels were measured using AAS analysis with a LLOQ of 20.9 ng/mL 
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in plasma ultrafiltrate. The lowest concentration measured in this study is approximately 
300 ng/mL. Thus, the published ICP-MS methods will be of value to determine Pt in 
human plasma ultrafiltrate after i.p. oxaliplatin administration (127).  
 
6.4 Antimitotic agents 
Antimitotic drugs inhibit cell division by binding to tubulin. This class of compounds 
predominantly consists of vinca alkaloids, such as vinorelbine, vinblastine, vincristine, 
and the taxanes, paclitaxel and docetaxel. 
 
6.4.1 Paclitaxel 
Cytotoxic activity of paclitaxel is derived from its ability to increase the assembly and 
stability of microtubules in dividing cells, thereby blocking the cell cycle. Paclitaxel has 
significant clinical activity against a broad range of tumor types including breast, lung, 
head and neck, bladder, and platinum-refractory ovarian carcinoma (138,139). 
Paclitaxel is metabolized in the human liver by cytochromes P450 (CYP) 2C8 and 3A4 
(140-142). Previous studies have shown that the major hepatic metabolite is 6α-
hydroxy paclitaxel (6OHP) with an OH-group at C6 at the taxane ring (143) and a minor 
metabolite is 3’-p-hydroxy paclitaxel (3’OHP) with an OH-group at the C3’ of the phenyl 
in the side chain at C13 (144). Both metabolites exhibit the excessive microtubule 
stabilizing properties of the parent compound (141). Furtermore, these metabolites can 
be oxidized to 6α-, 3’-p-dihydroxy paclitaxel (3’,6OHP) (145) (Figure 14). 
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Compound R1 R2 
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Figure 14. Chemical structures of paclitaxel, 3´-p-hydroxy paclitaxel and 6-α-hydroxy 
paclitaxel and 6-α-, 3´-p-dihydroxy paclitaxel. 
 
Many assays for the quantitative determination of paclitaxel have been described using 
HPLC-UV and HPLC-MS/MS (111,114,146-156). Most of the HPLC-UV methods utilize 
a significant amount of sample, e.g. 1000 µL and the lowest LLOQ is approximately 5 
ng/mL. The use of the HPLC-MS for the determination of paclitaxel resulted in a more 
than 50% reduction of the chromatographic run time and a 25-fold increase in 
sensitivity. Thus far, the most sensitive HPLC-MS/MS assay utilizes 400 µL of sample 
aliquots, a simple liquid-liquid extraction with tert-butylmethylether and detection of 
polar 6OHP and 3OHP metabolites with a LLOQ of 0.1 ng/mL (149). This assay by 
Alexander et al. describes the use of 13C6-paclitaxel as an internal standard, which 
yielded excellent results on accuracy and precision. There are several other assays 
developed with a LLOQ of 0.25 ng/mL and 0.5 ng/mL for paclitaxel and its metabolites 
utilizing less plasma sample aliquots, e.g. 200 µL (111,114).  
Several clinical trials demonstrated the activity of i.p. paclitaxel against advanced 
ovarian cancer (157,157,158,158-165). The results from 6 randomized trials showed 
that i.p. therapy yielded approximately 21% decrease in the risk of death and 12-month 
longer overall survival time. The first clinical trials were conducted with the Cremophor 
EL: ethanol (Taxol®, referred as Cremophor) formulation. In humans, Cremophor is 
slowly cleared from the peritoneal cavity. Because the entrapment of paclitaxel in 
Cremophor micelles reduces the free drug fraction available to tumors, it is still 
uncertain whether a longer residence of the Cremophor formulation translates to 
greater antitumor activity (159). Recently, Tsai et al. investigated the effects of carrier 
on the disposition and efficacy of i.p. paclitaxel. Three paclitaxel formulations with 
different particle size and release rates have been tested: Cremophor formulation, 
Cremophor-free paclitaxel-loaded gelatin nanoparticles and Cremophor-free paclitaxel-
loaded polymeric microparticles (159). Several preclinical and phase I studies have 
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been performed with i.p. administered paclitaxel. One of the latest studies with i.p. 
sustained-release paclitaxel microspheres in recurrent ovarian cancer has been 
executed by Armstrong et al. (158). The dose varied from 60 mg/m2 to 1200 mg/m2. 
Even the highest dose was well tolerated, and low but persistent detection of plasma 
levels indicated that paclitaxel continued to be released for at least 8 weeks after 
paclitaxel microparticles treatment. Armstrong et al. could not detect any systemic 
levels of paclitaxel after the lowest dose of 60 mg/m2 treatment, using an ultra sensitive 
analytical method with a LLOQ of 0.1 ng/mL. Consequently, more sensitive methods 
are needed to determine the traces of the leaked paclitaxel after the i.p. dose of 60 
mg/m2. 
 
6.4.2 Docetaxel 
Docetaxel (Taxotere®) is a semisynthetic and a more potent analogue of paclitaxel. 
Although, paclitaxel is currently the most commonly used taxane, docetaxel seems to 
be as effective in systemic chemotherapy for primary or recurrent advanced epithelial 
ovarian cancer (166-169). Several HPLC-MS/MS methods have been developed for the 
quantitation of docetaxel in human plasma (147,150,170). Wang et al. reported a 
simple and sensitive HPLC-MS/MS method for the determination of docetaxel in human 
plasma by means of a simple liquid-liquid extraction with ter-butylmethyl ether utilizing 
only 50 µL sample aliquots and yielding a LLOQ of 5 ng/mL (170). The run time of this 
assay was 3 minutes and positive mode of ionization was used. Although, the method 
described by Parise et al. yields a lower LLOQ of only 0.2 ng/mL, it requires 1000 µL 
sample aliquots and a time consuming solid phase extraction (150). 
Recently, Yokogawa et al. studied the disposition kinetics of docetaxel after i.p. 
administration in rats (162). Rats received 40 mg/kg of docetaxel and the lowest 
detectable concentration in plasma was approximately 80 ng/mL, measured by the 
method described by Loos et al., with a LLQQ of 50 ng/mL which proved to be 
adequate for this application. Another pharmacokinetic study of docetaxel in 
intraoperative hyperthermic i.p. therapy for ovarian cancer was executed by de Bree et 
al. (166). The purpose of this study was to evaluate the pharmacokinetics and toxicity 
of docetaxel in continuous hyperthermic perfusion peritoneal chemotherapy after 
cytoreductive surgery for peritoneal involvement of gynecological malignancies, mainly 
ovarian cancer. 18 patients received 75 mg/m2 docetaxel at 41-430C. The use of 
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docetaxel resulted in high i.p. versus systemic ratio, however the lowest Cmax in 
plasma was detected at 75 ng/mL, measured by the method developed by Rosing et 
al.(147) with a LLOQ of 10 ng/mL. Consequently, the LLOQ’s of this and the method 
developed by Parise et al. (150) are sufficient to determine the systemic leakage of i.p. 
paclitaxel. 
 
6.5 Topo-isomerase inhibitors 
The nuclear enzymes topo-isomerase I and II transiently break a single strand or 
double strand of DNA, respectively, during DNA replication, and thereby reducing 
torsional strain. Inhibitors of these enzymes damage DNA, leading to cell death. This 
family of anti-cancer drugs has grown rapidly in recent years. 
 
6.5.1 Topotecan 
Topotecan is a semisynthetic and water soluble analogue of camptothecin, which 
showed a potent inhibition of the topoisomerase I enzyme, interfering with the 
replication and transcription process in tumor cells. This compound has anti-cancer 
activity against a variety of solid tumors. Topotecan is known to undergo a pH-
dependant, reversible hydrolytic dissociation of its lactone moiety into the hydroxyl 
carboxylate form (171,172). Demethylation to form N-desmethyltopotecan has been 
identified as a metabolic pathway for topotecan in humans (Figure 15) (173). This 
metabolite was found in plasma and urine of patients treated with topotecan. In vitro 
and in vivo pharmacological studies suggest that antitumor activity of the lactone form 
is higher than that of the carboxylate form. In the last years, several HPLC methods 
using fluorescence detection were developed (171-177). Topotecan is a basic, highly 
polar compound in its protonated form. Most of the methods measure the lactone and 
carboxylate forms separately, but a few methods exist where both forms are measured 
simultaneously in one assay, chromatographically separated. Beijnen et al. described 
the first assay of topotecan with a LLOQ of 1 ng/ml utilizing only 100 µL human plasma 
(172). 
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Figure 15. Chemical structures of topotecan and N-desmethyltopotecan and their 
degradation products, undergoing pH-dependant hydrolysis. 
 
Later, Rosing et al. presented an ultra sensitive assay for the lactone and carboxylate 
forms with a LLOQ of 0.05 ng/mL using 100 µL human plasma aliquots, but these forms 
were not analyzed simultaneously (173,176). Recently, Vali et al. documented a simple 
and rapid HPLC-fluorescence method for the simultaneous separation of lactone and 
carboxylate forms of topotecan in human plasma with a LLOQ of 0.05 ng/mL for both 
forms of topotecan (174). However, compared to 100 µL human plasma aliquots used 
by Rosing et al., this method requires 400 µL human plasma. Vali et al. used reversed-
phase HPLC with C18 column and a mobile phase consisting of ammonium acetate 
buffer, acetonitrile, triethylamine (TEA) and tetrabutyl ammonium hydrogen sulphate 
(TBAHS), which enabled the simultaneous separation of carboxylate and lactone 
species of topotecan with less than 10 minutes. The use of TBAHS had a large impact 
on the peak sharpness and decrease in the retention of the lactone form of topotecan, 
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moreover, TBAHS had no effect on the retention of the carboxylate form, leading to 
good resolution of the peaks and short run time. TEA was incorporated in the assay to 
minimize the peak tailing and to improve precision of the method an internal standard, 
tetracycline HCl, was used. 
The pharmacokinetics of topotecan suggests that a substantional pharmacokinetic 
advantage might be obtained following i.p. injection. The peritoneal/plasma 
concentration ratio at steady-state is proportional to the peritoneal and plasma 
clearances of the drug (178-180). Three phase I pharmacokinetic studies have been 
performed. Plaxe et al. administered the dose of 3 mg/m2- 4 mg/m2 to seventeen 
patients in a total of 43 cycles at 21-day interval. The acute dose-limiting toxicity was 
neutropenia. Plasma pharmacokinetic behavior was best described by first-order 
kinetics with a half-life of 3.9 hours. The lowest detectable concentrations in plasma 
were approximately 4 ng/mL using the method described by Rosing et al. with a LLOQ 
of 0.05 ng/mL (178). Hofstra et al. performed a phase I study to evaluate the feasibility 
and pharmacology of i.p. topotecan (180). Fifteen patients with recurrent ovarian 
cancer were treated with escalating i.p. topotecan doses (5-30 mg/m2) for 
pharmacokinetic analysis. The lowest detectable concentration of topotecan in plasma 
was approximately 3 ng/mL, measured by an assay with a LLOQ of 0.05 ng/mL (176). 
Recently executed phase I study by Bos et al. aimed to determine the maximum 
tolerated dose (MTD) of i.p. topotecan (179). Woman with primary ovarian cancer 
received 6 cycles with escalating topotecan doses of 10-25 mg/m2. In this setting the 
MTD of i.p. topotecan was 20 mg/m2. The lowest detectable concentrations were 
measured after 20 hours and were 3-4 ng/mL. Consequently, the LLOQ’s of several 
methods are sufficient to determine the systemic leakage of i.p. administered 
topotecan. 
 
7. Intrathecally administered anti-cancer agents 
For the inthrathecal (i.t.) route, a needle is inserted between two vertebrae in the lower 
spine and into the space around the spinal cord. This way the drug is injected into the 
spinal canal. Usually, a small amount of local anesthetic is used to numb the injection 
site. This route is used when a drug is needed to produce rapid and local effects on the 
brain, spinal cord or the layers of tissue covering them (meninges) (Table 6). 
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7.1 Anti-metabolites 
7.1.1 Methotrexate 
Although the usual route of administration of MTX is oral or i.v., this antimetabolite is 
also administered i.t. for the prophylactic treatment of the central nervous system 
sanctuary sites in leukemia, lymphoma and in the treatment of meningeal carcinomas. 
For i.t. treatment, the usual dose of MTX is 12-15 mg (181-184). There have been 
several studies executed with i.t. MTX. The kinetics of MTX disappearance from the 
CSF after i.t. injection was studied extensively by Bode and others (185-190). Thyss et 
al. investigated the systemic effect of i.t. MTX during initial phase of treatment of 
childhood acute lymphoblastic leukemia. The results demonstrated a therapeutic 
systemic effect of low doses of MTX (186,189). Moreover, as described by Thyss et al. 
and Ettinger et al. plasma levels of approximately 50 to 300 ng/mL occur 3 to 12 hours 
after i.t. injection, and then decrease in a bi-exponential manner with a terminal half-life 
of 5 to 10 hours (186). Consequently, the method for the determination of MTX in 
human plasma, described by Steinborner et al. with a LLOQ of 0.1 ng/mL, is sufficient 
to measure these concentrations. 
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7.1.2 Cytarabine 
Cytarabine (ara-C) is an antineoplastic antimetabolite used in the treatment of 
leukemia. Ara-C is metabolized intracellularly into the active triphosphate form to 
damage DNA by various mechanisms, such as inhibition of DNA repair through an 
effect on β-DNA polymerase and incorporation into DNA. Liposomal cytarabine is a 
slow-release formulation of cytarabine produced by encapsulating the aqueous drug 
solution in spherical multivesicular particles known as DepoFoam. The compound is 
slowly released from the DepoFoam into the cerebrospinal fluid, resulting in 40 times 
longer drug exposure compared to standard cytarabine. The LLOQ of the available 
analytical HPLC-UV method for the determination of cytarabine in human plasma, 
published by Fahmy et al., is 450 ng/mL (12). Hence, Hsieh et al. described three 
elegant methods for the determination of highly polar cytarabine in mouse plasma by 
means of (i) porous graphitic carbon column (Hypercarb) coupled to tandem MS; (ii) 
ion-pairing liquid chromatography interfaced with atmospheric chemical ionization 
source and a tandem MS; (iii) supercritical fluid chromatography/tandem MS method 
with a LLOQ of 50 ng/mL for all three methods (191-193). All three methods were 
complimentary to each other and investigated interesting properties of the Hypercarb, 
ion-paring and supercritical liquid chromatography. Porous graphitic carbon column is 
composed of flat sheets of hexagonally arranged carbon atoms, which is stable 
throughout the entire pH range and chemically inert to aggressive solvents. Moreover, 
due to its peculiar properties, Hypercarb enables the analysis and the chromatographic 
separation of analytes with extensive polarities (191). Ion-paring reagents added into 
the mobile phase are used to improve chromatographic retention on the liphophilic 
stationary phase through the formation of neutral ion pairs. In this assay, the volatile 
perfluorinated carboxylic acid ion-pairing reagents, HFBA and NFPA, were added to 
mobile phase A (water) and B (acetonitrile), respectively, with the goal to establish a 
robust HPLC-MS/MS assay for monitoring highly polar cytarabine in mouse plasma 
samples following a simple protein precipitation with methanol (192). In their recently 
published article, the potential of packed-column supercritical fluid chromatography 
(pSFC)-MS/MS method as a complimentary coverage to the HPLC-MS/MS methods for 
the quantification of cytarabine in mouse plasma samples was investigated (193). CO2, 
which is the most commonly used mobile phase in SFC, possesses low viscosity and 
high diffusivity. The coupling of CO2/methanol normal phase pSFC to the APCI 
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interface showed good potential for maximum separation efficiency and the detection of 
the analyte (193). All three methods, described above, appeared to be complimentary 
and accurately and specifically measure cytarabine with a LLOQ of 50 ng/mL.  
I.t. cytarabine is used in the prophylaxis and treatment of acute lymphocytic leukemia 
and neoplastic meningitis (184,194-199). The standard administered doses range from 
15-70 mg. 
Bomgaars et al. presented a phase I trial of i.t. liposomal cytarabine (196). 18 patients 
received i.t. cytarabine at the doses of 25 to 50 mg. Blood samples were analyzed and 
plasma concentrations of cytarabine were rarely detectable, with only two plasma 
concentrations of 220 and 620 ng/mL. Possibly, the above described methods with a 
LLOQ of 50 ng/mL, could have measured lower levels of cytarabine in plasma after i.t. 
administration. 
 
7.2 DNA alkylating agent 
7.2.1 Thiotepa 
Thiotepa has been investigated for the treatment of leptomeningeal metastases (LM). 
LM are cancer cells that circulate along cerebrospinal fluid (CSF) pathways and seed 
the meningitis. This results in leptomeningeal neoplasia. Thiotepa is administered i.t. in 
a dose of 5-11.5 mg/m2(200,201). However, some studies suggest that i.t. thiotepa 
does not appear to be advantageous over systemic administration in patients with brain 
and meningeal leukaemia (200). Unfortunately, no study has been performed yet where 
systemic exposure to thiotepa was measured after i.t. therapy. 
 
7.2.2 Busulfan 
Busulfan (1,4-butanediol dimethanesulfonate) is a bifunctional alkylating agent which is 
commonly administered in preparative chemotherapy regimens for bone marrow 
transplantation for patients with heamatological malignancies and non-malignant 
disorders (202). This alkylating agent has also been used in the treatment of chronic 
myelogenous leukemia. Recently, a water soluble microcrystalline formulation of 
Busulfan (Spartaject Busulfan) became available for experimental use (203)  
Several methods using GC-electrochemical detection, GC-MS, HPLC-UV and HPLC-
fluorescence have been described (202,204-208). Because busulfan is a very polar 
compound with poor UV absorbancy, most of these methods require pre-column or 
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online derivatization with either 8-mercaptoquinoline (207), or 2,3,5,6-
tetrafluorothiophenol to obtain di-TFTP-butane (205), or with sodium 
diethyldithiocarbamate (206), to form a non-polar compound with a specific UV 
absorbancy and to facilitate the detection. With the introduction of HPLC coupled with 
tandem MS, the development of a highly sensitive method for the determination of 
busulfan in human plasma could be accomplished. The methods described by Quernin 
et al. and dos Reis et al. report major advantages compared to previous methods 
(202,204). They eliminated the derivatization and extraction of busulfan, which 
shortened the run time by at least 2.5 h. Moreover, the LLOQ of 5 ng/mL was achieved 
by means of HPLC-MS. Both groups describe the extraction of busulfan from 200 µL-
plasma aliquots using liquid-liquid extraction with ethyl acetate. Quernin et al. used 
HPLC coupled with positive mode MS and a chromatographic run time of 10 minutes. 
Hence, dos Reis et al. employ a more selective tandem MS and a rapid 
chromatographic run time of only 3.5 minutes (202). 
Recently, a phase I trial of i.t. Spartaject Busulfan in children with neoplastic meningitis 
was executed and presented by Gururangan et al. (203). Patients received doses 
varying from 5-17 mg. I.t. busulfan was well tolerated in children with neoplastic 
meningtitis from brain tumors, and the recommended dose for future phase II is 13 mg. 
The concentration of busulfan in plasma was measured using the analytical method by 
Lindley et al. with a LLOQ of 50 ng/mL and the observed plasma concentrations were 
between 150-380 ng/mL. Consequently, this method and obviously the bioanalytical 
assay presented by dos Reis et al., have a sufficient LLOQ to quantitate the traces of 
drug in plasma of i.t. administered busulfan. 
 
7.2.3  Mafosfamide 
Cyclophosphamide (2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 
2-oxide; CP) is a cytotoxic alkylating agent widely used in the treatment of various 
malignancies. Cyclophosphamide is a prodrug and requires oxidation by cytochrome 
P450 enzyme system (CYP) to produce its pharmacologically active metabolite 4-
hydroxycyclophosphamide (4OHCP). This active metabolite is unstable and undergoes 
spontaneous degradation to biologically active species such as phosphoramide 
mustard. Mafosfamide (4-sulfoethylthio-cyclophosphamide L-lysine) is a preactivated 
chemically stable thioethane sulfonic acid derivative of cyclophosphamide, which does 
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not require hepatic activation and undergoes spontaneous conversion to the active 
species in aqueous media (Figure 16, as depicted by Blaney et al.) (209,210). Due to 
the rapid degradation of mafosfamide into the active 4OHCP, the determination of 
4OHCP is of crucial importance. However, measuring 4OHCP levels in plasma is 
cumbersome, because of its instability. This compound requires trapping by 
derivatization to stop the enzymatic metabolism and chemical degradation. In the 
literature, derivatization with methyl-hydroxylamine, semicarbazide, p-
nitrophenylhydrazine, potassium cyanide and 4-aminophanol/hydroxyl-
aminehydrochloride have been described (108,210-214). The most simple and rapid 
assay with a LLOQ of 50 ng/mL for 4OHCP was described by de Jonge et al.(108). 
Recently, Ekhart et at. presented an  improved assay by means of using a stable 
isotope as internal standard and consequently reducing the runtime from 9 to 6 minutes 
(215). Immediately after sample collection, the compound was derivatized with 
semicarbazide, followed by simple protein precipitation using methanol-acetonitrile (1:1, 
v/v) containing isotopically labeled CP and hexamethylphosphoramide as internal 
standards, utilizing 100 µL plasma aliquots. With the use of reversed phase 
chromatography with a flow of 0.4 ml/min, the total run time of only 6 minutes could be 
obtained. The employment of an alkaline mobile phase containing ammonium 
hydroxide combined with the HPLC-MS/MS in the positive ion mode yielded a LLOQ for 
4OHCP of 50 ng/mL.  
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Figure 16. Structure of mafosfamide and its metabolites/degradation products (as 
proposed by Blaney at al. (198)). 
 
In vitro and in vivo studies showed a significant activity against a number of 
transplantable tumors and solid tumors, respectively. Moreover, it was demonstrated 
that the cytotoxic activity of mafosfamide was comparable to or even exceeding that of 
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activated cyclophosphamide (4-hydroperoxy-cyclophosphamide, a preactivated 
cyclophosphamide derivative that has been used to purge tumor cells from stem-cell 
collections before reinfusion). A preclinical and phase I study was executed by Blaney 
et al. (216,217) The patients received i.t. doses ranging from 1 to 6.5 mg. I.t. 
mafosfamide was generally well tolerated. The dose limiting toxicity was irritability and 
pain at the higher dose levels. The plasma concentrations were measured by a method 
described by Alacron et al. (218)with a LLOQ of 55 ng/mL and no 4OHCP was 
detected. Consequently, this method was not sensitive enough. Currently, the most 
sensitive assay has been developed by Ekhart et al. with LLOQ for 4OHCP of 50 ng/mL 
(215). Possibly, this method could have detected 4OHCP after i.t. mafosfamide. 
 
7.3 Topo-isomerase inhibitors 
7.3.1 Topotecan 
Studies to investigate the CSF pharmacokinetics of topotecan following systemic 
administration in a non-human primate model demonstrated that the CSF penetration of 
the active lactone form of topotecan was approximately 30% (219,220). Due to the 
excellent CSF penetration and the lack of neurotoxicity after systemic administration, 
studies were performed to evaluate the feasibility of i.t. topotecan in a non-human 
primate model. Following direct intraventricular topotecan administration, a 450-fold 
greater CSF exposure could be achieved with 1/100th of systemic dose; namely, 0.1 mg 
i.t. administered topotecan was well tolerated (219,221,222).  
Several studies with i.t. administered topotecan were executed and, compared with 
systemic topotecan, i.t. administration provided a significant pharmacokinetic 
advantage in terms of CSF drug exposure and did not produce any significant 
neurotoxicity (219,220,222). The maximum tolerated dose is 0.4 mg.  
Unfortunately, in the recently described phase I clinical trials i.t. topotecan was 
measured in CSF fluids and not in plasma, and no conclusion can be made regarding 
the usefulness of the described bioanalytical assays to measure topotecan in plasma 
after i.t. administration. 
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8. Intravesically administered anti-cancer agents 
Bladder chemotherapy instillation, or intravesical chemotherapy, is used in the 
treatment of superficial bladder cancer by filling the bladder with medication (Table 6). 
During a bladder instillation, the bladder is filled with a therapeutic solution that flows in 
through a narrow tube inserted through the urethra and into the bladder. The instillation 
is held for varying periods of time, from 1 to 2 hours or more, before being drained or 
voided. Superficial bladder cancers are usually an early form of cancer, which may 
recur after initial surgical removal. However, by using treatment which sets medication 
directly in contact with the bladder wall, it may be possible to prevent recurrence or 
lengthen the time until recurrence. In the case of advanced stage of bladder cancer, 
surgical removal or endoscopic thansurethral resection of tumor (TUR-B) is executed, 
however, due to the high rate of recurrence of the cancer, intravesical chemotherapy is 
also used as an adjuvant therapy (223-241).  
Usually, the intravesically administered drugs are given at a high dosage for a high 
local efficacy; however it is extremely important that, while penetrating the cellular 
levels of the bladder wall to reach the cancer cells, the drug won’t pass into the 
systemic circulation, which can lead to systemic toxicity of the agent. Drug diffusion 
across the bladder wall is dependant on the molecular weight and lipid solubility of the 
applied agent. 
 
8.1 DNA alkylating agent 
8.1.1 Mitomycin C 
MMC is a bioreductive agent and it is activated by intracellular reductive enzymes to 
form cytotoxic species, which then alkylate the DNA. When administered intravesically, 
the systemic toxicity is limited, however local toxicity is common. Chemical cystitis 
occurs in approximately 16% of patients. The dose varies between 2-60 mg MMC. It is 
diluted with water and applied intravesically in the concentration of 0.5-2 mg/mL with 1-
2 hours of retention in the bladder (223-230). MMC has a molecular weight of 334 Da, 
and it is relatively hydrophobic. 
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Therefore its diffusion and absorption rate will be relatively slow, resulting in a slower 
decline in concentration over the depth of the bladder wall and making this agent a 
suitable drug for deeper bladder wall tumors (223). 
Several pharmacokinetic studies have been executed to determine the penetration of 
MMC in human bladder (242,243). Treatment consisted of transurethral tumor resection 
followed by six weekly intravesical treatments with MMC (20 mg/40 mL water) for a 
total of 28 treatments. The plasma concentrations averaged 2.1 and 181 ng/mL and, 
consequently, the ultrasenstive analytical method for the determination of MMC with the 
LLOQ of 0.5 ng/mL (as described in section 4.3.1), is adequate to determine the traces 
of MMC in human plasma when administered intravesically. Detected concentrations 
were significantly lower than the mitomycin plasma concentrations of 400 ng/mL 
leading to myelosuppression (244). 
 
8.1.2 EO9 (Apaziquone) 
EO9 (EOquin® or apaziquone) is an indoloquinone derivative of MMC. EO9 also 
belongs to the class of anti-cancer agents, known as bioreductive drugs, which are 
inactive prodrugs that require metabolic activation to generate cytotoxic species. 
Although, EO9 is indeed structurally related to MMC, it has a different mechanism of 
action and activity profile. The main metabolite of EO9 is an open ring analogue, EO5a, 
which is inactive. Recently, we identified another degradation product of EO9, EO9-CL, 
where Cl is covalently attached to the aziridine ring-opened EO9 molecule  (Figure 17) 
(245-247). The administered dose is usually 4 mg of formulated EO9/40 mL of 
instillation solution. The pharmaceutical formulation consisted of 4 mg of EO9, 25 mg 
mannitol, 10 mg sodium bicarbonate and 40 mL of the diluent. The diluent formulation 
contains 10 mg/mL sodium bicarbonate, 0.2 mg/mL EDTA, and 0.6 mL propylene glycol 
in 2.0 mL sterile water for injection. The pH of the instillation solution is 8.5, which is 
where EO9 is most stable. If pH shifts in any directions from 8.5, EO9 degrades into 
inactive degradation products. Recently, an enhanced resolution HPLC-MS/MS method 
for the determination of EO9 and its inactive metabolite EO5a was developed in our 
department with a LLOQ of 0.5 ng/mL plasma (248). 
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Figure 17. Proposed degradation mechanism of EO9 in slightly acidic urine. 
 
To extract the drug from human plasma, liquid-liquid extraction was employed using 
ethylacetate and reversed phase HPLC coupled to tandem MS was applied. The 
detection was executed by a Finnigan TSQ Quantum Ultra equipped with the 
electrospray ion source operated in positive mode, with enhanced mass-resolution 
capability. It demonstrated improved sensitivity with a factor 10-20 for EO9 and EO5a 
over 3-decades dynamic range, with acceptable accuracy and precision, when 
compared with the previously described assay for EO9 and EO5a, developed by our 
group, using an API 2000 (244,245). 
In the two phase II studies, which recently were executed, EO9 proved to be very active 
and showed a complete response in 67% of the 41 included patients (236,237). A 
phase III study is currently ongoing in the USA.  
To determine the systemic absorption of EO9, a multicenter, non-randomized, open-
label phase II study was performed. Patients with high risk superficial bladder cancer 
were treated once a week for 6 weeks with intravesical instillation of EOquin® (4 mg 
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EO9 in 40 mL instillate).  Moreover, another phase II clinical study to determine the 
toxicity of the drug was performed in 20 patients.  Patients with ≤ 4 tumors received 
EOquin® within 6 hours of Transurethral Resection of Bladder Tumor (TUR-B). Plasma 
samples were measured using the above HPLC-MS/MS method with the LLOQ for 
EO9 and EO5a of 0.5 ng/mL. No detectable levels of either EO9 or EO5a were 
measured in the samples from both studies.  
 
8.1.3 Thiotepa 
Thiotepa is given intravesically in a variety of schedules to treat superficial bladder 
cancer. Usually, it is administered, as most of the intravesically administered agents, 
after TUR-B. Since thiotepa has a molecular weight of only 188 Da and it is lipophilic, 
diffusion rate is rapid and absorption is extensive. Systemic absorption may result in 
myelosuppression. The standard intravesical dose is 30-60 mg, with a concentration of 
1 mg/mL of normal saline or water (225,226,238).  
Masters et al. described thiotepa pharmacokinetics during intravesical chemotherapy 
(238). Thiotepa was given intravesically in a variety of schedules to treat superficial 
bladder cancer (from 30-60 mg). Blood samples were obtained for 8 h following 
instillation, and both thiotepa and tepa were measured. The lowest thiotepa 
concentration measured in the plasma of the patients was 5 ng/mL (and the highest 
approximately 200 ng/mL) and no tepa was detected in plasma, using the analytical 
assay by McDermott et al. with a LLOQ of 5 ng/mL (256). A more sensitive method is 
thus needed to determine the metabolite of thiotepa, tepa, in human plasma after the 
intravesical administration of thiotepa. 
 
8.2 Antibiotics 
8.2.1 Doxorubicin 
Doxorubicin (adriamycin) is an anthracycline antibiotic that acts as an intercalating 
agent and an inhibitor of topoisomerase II (225). Doxorubicin is most toxic in the S-
phase. This drug undergoes an extensive metabolism by the liver and is excreted 
primarily in the bile. Enzyme-mediated reduction and deglycosidation of doxorubicin 
results in the formation of several structurally related hydroxylated and aglycone 
metabolites. Doxorubicinol is produced by cytosolic carbonyl reductase through 
NADPH-dependant aldo-keto reduction of a carbonyl moiety at the C-13 position. (257). 
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Doxorubicinone and doxorubicinolone are produced by deglycosidation at the 
daunosamine sugar at C-7 position. The formed hydroxyl group may be metabolized to 
7-deoxydoxorubicinone and 7-deoxydoxorubicinolone (Figure 18). 
Doxorubicin displays a broad spectrum of antitumor activity against acute leukemias, 
Hodgkin and non-Hodgkin’s lymphomas, breast cancer, lung cancer and bladder 
cancer (257). Patients who fail to respond to alkylating agents (MMC or thiotepa) may 
be best treated with an intercalating agent, such as doxorubicin or epirubicin, or visa 
versa. When administered intravesically, the systemic absorption is limited, due to the 
high molecular weight of 580 Da. Systemic reactions consist of mild nausea and 
vomiting, diarrhea and fever. The major dose limiting factor is cardiotoxicity. Local side 
effects consist of chemical cystitis. Doxorubicin is administered in doses of 30-100 mg 
and diluted with saline solution to a concentration of 0.5-2 mg/mL (225-227). Over the 
years, there have been numerous analytical methods developed to determine 
anthracyclins and their metabolites in biological matrices (247-249,257-272). Camaggi 
et al. developed a highly sensitive assay for the determination of doxorubicin and its 
fluorescent metabolites, doxorubicinol, doxorubicinone and doxorubicinolone, 7-
deoxydoxorubicinone and 7-deoxydoxorubicinolone, in human plasma utilizing HPLC 
with fluorescence detection, which yielded a LLOQ of 0.3 ng/mL (259). Sample aliquots 
of 1000 µL were processed using solid phase extraction, which yielded a higher 
recovery compared to other methods. 
The use of capillary electrophoresis with laser-induced fluorescence detection in the 
separation and determination of doxorubicin and its metabolites in cells have been 
demonstrated (270,272). Recently, using this technique, Anderson et al. described the 
quantitation of doxorubicin and its metabolites in cell extracts with a LLOQ ranging from 
0.1 to 1.1 fmol per cell in single cell analysis (272,273). Using borate and sodium 
dodecyl sulfate (pH 9.3) as a separation buffer (for the metabolites), the 488 nm argon-
ion laser line for fluorescence excitation, and a 635 ± 27.5 nm bandpass filter for 
detection, the limit of detection for doxorubicin in cells was 61 ± 13 zmol (272). 
Moreover, fluorescence detection and laser-induced fluorescence detection proved to 
yield a lower LLOQ in plasma for doxorubicin compared with the previously described 
electrochemical detection (247-249,257-272). 
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Figure 18. Structure of doxorubicin and its metabolites. 
 
Wientjes et al. performed a study with intravesical doxorubicin to investigate the 
penetration of doxorubicin in human bladders (274). The commonly used dosing 
solution of 40 mg (doxorubicin)/20 ml instillation was instilled prior to the start of surgery 
and maintained for 60-115 minutes until just prior to bladder excision. The lowest 
detected plasma levels were approximately 0.4 ng/mL after 3 hours of administration 
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(LLOQ of the method is not mentioned). Consequently, the available analytical methods 
with a LLOQ of 0.3 ng/mL for doxorubicin is sufficient to measure low levels of 
doxorubicin which might have leaked into the systemic circulation.  
 
8.2.2 Epirubicin 
Epirubicin, a derivative of doxorubicin, was developed to reduce toxicity while 
maintaining an anti-tumor effect similar to that of doxorubicin (234,235). When given 
intravesically, the main side effects are irritative bladder symptoms. The reported 
systemic absorption of this drug is minimal (226). The standard dose varies between 20 
and 80 mg diluted in saline at a concentration of 0.5-1.6 mg/mL (225,233). Several 
bioanalytical methods have been developed to determine epirubicin and its metabolites 
in human plasma (247,249,275-277). The most sensitive assay was developed by 
Camaggi et al., as described in 10.2.1 (247). The LLOQ’s of epirubicin and its 
metabolites, epirubicinol, 4’-O-β-d-glucuronyl-4’-epirubicin and 4’-O-β-d-glucuronyl 13-
dihydro-epirubicin were 0.3, 0.2, 0.2 and 0.2 ng/mL, respectively (247). 
Tsushima et al. investigated the absorption of epirubicin instilled intravesically 
immediately after transurethral resection of superficial bladder cancer (278). Epirubicin 
was administered in the doses varying from 20 and 50 mg and the systemic plasma 
concentrations of this compound were measured. After the administration of 50 mg, 
plasma concentrations of 5 ng/mL could be measured, however, no detectable levels 
were observed after the dose of 20 mg (the LLOQ of the method is not mentioned). 
Consequently, with the ultrasensitive analytical method for the quantitation of epirubicin 
with the LLOQ of 0.3 ng/mL, developed by Camaggi et al., trace levels in plasma of the 
intravesically administered epirubicin should be reasonably found. 
 
8.3 Nucleosides 
8.3.1 Gemcitabine 
Gemcitabine (2’-2’-difluorodeoxycytidine) is a pyrimidine analog that exhibits antitumor 
activity against a variety of solid tumors. In blood, gemcitabine is rapidly deaminated by 
cytidine deaminase, resulting in the inactive metabolite dFdU (2’-2’-
difluorodeoxyuridine) (Figure 19).  
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Several HPLC-UV, HPLC-PDA and HPLC-MS/MS methods for the quantitation of 
gemcitabine and dFdU in human plasma have been described (279-286). Thus for, the 
most sensitive HPLC-MS/MS method for the determination of gemcitabine and its 
inactive metabolite dFdU was developed in our department with the LLOQ for 
gemcitabine of 0.5 ng/mL and for dFdU of 5 ng/mL (250). Gemcitabine and dFdU were 
extracted from 200-μL aliquot human plasma using solid phase extraction. Dried 
extracts were reconstituted in 1 mM ammonium acetate – acetonitrile (97:3, v/v) and 10 
μL-volumes were injected onto the HPLC system. Separation was achieved on a 150 x 
2.1 mm C18 bonded phase endcapped with polar groups (Synergi Hydro-RP column) 
using the eluent composed of 1 mM ammonium acetate pH 6.8 - acetonitrile (94:6, v/v). 
Detection was performed by positive ion electrospray followed by tandem MS , which 
yielded the lowest LLOQ published thus far of 0.5 ng/mL for gemcitabine (250). 
Recent studies have shown gemcitabine to produce robust response rates in patients 
with superficial bladder cancer. Therefore, intravesical application of gemcitabine was 
tested, which was well tolerated with minimal systemic toxicity and promising efficacy in 
treatment of superficial bladder cancer (243).  
Witjes et al. and Laufer et al. described two separate phase I and pharmacokinetic 
studies (243,287,288). Gemcitabine was administered in the dose of 500 to 2,000 mg. 
Both studies concluded that intravesical gemcitabine, at doses up to 2 g/week is well 
tolerated, and associated with minimal systemic absorption. Moreover intravesical 
gemcitabine has promising efficacy in treatment of superficial bladder cancers. The 
lowest gemcitabine concentrations of 200 ng/mL were observed in plasma of four 
patients and the lowest concentrations of 10 ng/mL were observed for dFdU. The 
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LLOQ of the above described ultrasensitive method for the determination of 
gemcitabine and dFdU in human plasma is thus far sufficient for this application. 
 
9. Conclusions and perspectives 
The route of administration significantly influences the concentration of the drug in the 
systemic circulation, toxicity and the efficacy of the drug. Most anti-cancer agents are 
administered i.v. because this route is the most direct one and leads to immediate and 
complete bioavailability. At the same time, this is usually the most toxic route of 
administration because high concentrations of the cytotoxic agents may be delivered to 
normal tissues and cells. Moreover, the i.v. administration usually needs to be 
performed in a hospitalized environment, which can be inconvenient for patients. Oral 
administration is patient friendly, but may suffer from patient non-compliance and 
insufficient bioavailability, as observed often with antitumour agents. 
In this review we have discussed the advantages and feasibilities of the local 
administration routes, such as cutaneous, i.p, i.t. and intravesical chemotherapies. 
Important advantages of these routes are high local drug concentrations at the site of 
action often resulting in higher local antitumor activity than after systemic administration 
of the drug. However, because sometimes very high doses of the anti-cancer drugs are 
applied, it is of pivotal importance that none or only small amounts are absorbed into 
the bloodstream. To determine the low concentrations of locally administered drugs and 
their degradation products or metabolites that enter the systemic circulation, 
ultrasensitive bioanalytical methods have been developed in the last 10-20 years. Not 
all assays, however, are sensitive enough to determine systemic traces of the locally 
administered agents. Especially with topically applied agents, systemic exposure has 
not been investigated thus far. Interestingly, relatively old HPLC-UV techniques still 
cover a significant part of the assays developed for anti-cancer agents as discussed in 
this review. However, MS detection provides in all cases, without doubt, a better 
sensitivity and selectivity than UV detection. In recent years, the HPLC-MS technique 
has shown a steep, fascinating development and has become the most important tool 
in the quantitative determination of known and experimental anti-cancer agents as well 
as identification of metabolites. Hence the more sensitive HPLC-MS/MS assays should 
be developed to quantitate systemic exposure of locally administered agents, which is 
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pivotal to predict and to understand their toxicity in the early stage of the development 
and later clinical use. 
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Abstract 
A sensitive and specific LC-MS/MS assay for the quantitative determination of EO9 and 
its metabolite EO5a is presented. A 200-μL-human plasma aliquot was spiked with a 
mixture of deuterated internal standards EO9-d3 and EO5a-d4 and extracted with 1.25 
mL ethyl acetate. Dried extracts were reconstituted in 0.1 M ammonium acetate – 
methanol (7:3, v/v) and 25 μL-volumes were injected onto the HPLC system. 
Separation was achieved on a 150 x 2.1 mm C18 column using an alkaline eluent (1 
mM ammonium hydroxide – methanol (gradient system)). Detection was performed by 
positive ion electrospray followed by tandem mass spectrometry. The assay quantifies 
a range from 5 ng/mL to 2,500 ng/mL for EO9 and from 10 ng/mL to 2,500 ng/mL for 
EO5a using 200 μL of human plasma samples. Validation results demonstrate that EO9 
and EO5a concentrations can be accurately and precisely quantified in human plasma. 
This assay will be used to support pre-clinical and clinical pharmacologic studies with 
EO9. 
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1. Introduction 
In the early 1990s, the indoloquinone compound EO9 (3-hydroxy-5-aziridinyl-1-methyl-
2[indole-4,7-dione]-prop-β-en-α-ol) was the center of considerable interest as a 
potential bioreductive agent: it was selected for clinical evaluation on the basis of a 
novel mechanism of action and promising preclinical activity (1,2).  
Bioreductive alkylating agents such as EO9 are designed to require reduction for their 
activation to form cytotoxic species (3). EO9 is thus a pro-drug and exerts activity 
through redox cycling and formation of alkylating intermediates under bioreductive 
conditions (4). The mechanism of action of EO9 has been assumed to involve enzyme 
(NQO1) catalyzed one- or two-electron reduction, followed by the generation of either 
drug-derived DNA alkylating moieties or DNA-damaging reactive oxygen species (5). 
EO9 is extensively metabolized. One of the principal metabolites is EO5a, which has an 
open aziridine ring and much lower cytotoxicity that EO9 (6). 
Despite three partial responses in phase I evaluation, no anti-tumor activity was 
reported in subsequent phase II studies in breast, gastric, non-small cell lung cancer 
(NSCLC), pancreatic and colorectal cancers (7-9). 
EO9 has a very short half-life in plasma (t ½ values ranging from 0.8 to 19 min in 
humans) and a relatively poor ability to penetrate through multicell layers in vitro (7,10). 
These properties are assumed to be the main reason for EO9’s lack of clinical activity 
(10).  
Interestingly, this disadvantage may be advantageous for chemotherapeutic treatment 
of cancers that arise in a delimited compartment, such as superficial bladder cancer 
(11). In this case, drug delivery can be accomplished via the intravesical route and drug 
exposure of tumor tissue can be maintained with therapeutically relevant drug 
concentrations within the bladder cavity (11).  
When the drug is intravesically administered, it is of the utmost importance to be able to 
determine if any EO9 and/or EO5a passes into the central blood circulation from the 
bladder in order to predict the toxicity of the drug. So far only one analytical assay has 
been published describing the determination of EO9 in human plasma using high-
performance liquid chromatography coupled to the ultraviolet detection (12). 
Unfortunately, this initial method with solid-phase extraction as sample pre-treatment, 
required a large amount of samples, and a run time of 20 min, which is 
disadvantageous for the high throughput analysis required for the upcoming phase III 
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studies. Also, no internal standard was used to correct for the loss of the drug during 
sample preparation steps prior to analysis and for the HPLC injection variability during 
the analysis of EO9 and EO5a. In order to improve this assay, we developed a 
sensitive, specific, accurate, and rapid assay for the quantification of the EO9 and 
EO5a in human plasma using a high-performance liquid chromatography coupled to 
mass spectrometry (HPLC-MS/MS). Deuterated internal standards for EO9 and EO5a 
were used for quantification. The method has been fully validated according to the FDA 
guidelines on bioanalytical validation (13), and will be applied in the clinical 
pharmacokinetic studies with EO9. 
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Figure 1.Chemical structures of EO9 (A), EO9-d3 (B), EO5a (C) and EO5a-d4 (D). 
 
2. Experimental 
2.1 Materials 
EO9 (C15H16N2O4; Figure 1), EO9-d3 internal standard (C15H13D3N2O4; Figure 1) and 
EO5a-d4 internal standard (C15H14D4N2O5; Figure 1) were supplied by Spectrum 
Pharmaceuticals, Inc (Irvine, USA). The metabolite EO5a (C15H18N2O5; Figure 1) was 
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synthesized from the EO9. Methanol (LC gradient grade) was obtained from Bissolve 
Ltd. (Amsterdam, The Netherlands). All other solvents or chemicals were analytical 
grade or better. Distilled water was used throughout the analyses. Drug-free human 
heparinized plasma was obtained from the Central Laboratory for Blood Transfusion 
(Sanquin Amsterdam, The Netherlands). 
 
2.2 Preparation of stock and working solutions 
Two sets of stock solutions of EO9 were prepared from two independent weighings and 
dissolution in ethanol at a target concentration of 1 mg/mL. The solutions had to be 
placed in the ultrasonic bath for 2 hours to dissolve all the EO9 in ethanol. The same 
procedure was repeated each time the solutions were taken out of the freezer. These 
solutions were further diluted with control human plasma to obtain working solutions. 
One set of working solutions was used to prepare calibration standards, the other to 
prepare quality control samples. The plasma working solutions of EO9 were further 
diluted in control human plasma to yield the concentrations of 100,000, 25,000, 20,000, 
10,000, 5,000, 1,000, 500, 100 and 50 ng/mL.  
EO5a was prepared by adding 500 μL 1 mM HClO4 (pH=2.0) to 500 μL 10 mg/mL EO9 
in DMSO. After incubating for 1 min at ambient temperatures, 4 mL of 0.1 M ammonium 
acetate buffer pH 8.5 – methanol (7:3, v/v) was added to yield approximately 1 mg/mL 
EO5a. Two sets of stock solutions of EO5a were prepared in this manner. These 
solutions were also further diluted with control human plasma to obtain working 
solutions. One set of working solutions was used to prepare calibration standards, the 
other to prepare quality control samples. The plasma working solutions of EO5a were 
further diluted to yield the concentrations of 100,000, 25,000, 20,000, 10,000, 5,000, 
1,000, 500, 250 and 100 ng/mL.  
Separate stock solutions of EO9-d3 and EO5a-d4 were prepared in ethanol at a 
concentration of 1 mg/mL. An internal standards working solution was prepared by 
transferring 500 μL of EO9-d3 stock solution and 500 μL of EO5a-d4 stock solution to a 
50.0 mL volumetric flask and adding 0.1 M ammonium acetate buffer pH 8.5 - methanol 
(7:3, v/v) to give a final concentration of 10,000 ng/mL for EO9-d3 and EO5a-d4. All 
solutions were stored at -20oC. 
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2.3 Preparation of calibration standards and quality control samples in human plasma 
Before use, control human plasma (heparinized) was centrifuged for approximately 5 
min at 3,900 g. 
Calibration standards containing both EO9 and EO5a were prepared freshly in a range 
from 5 ng/mL to 2,500 ng/mL for EO9 and from 10 ng/mL to 2,500 ng/mL for EO5a by 
adding 50 μL of EO9 and EO5a working solutions (described in section 2.2) to 450 μL 
of control human plasma. The calibration standards were vortex-mixed for 
approximately 30 sec before processing. Standards were processed in singlicate and 
analyzed in duplicate. 
Validation samples for EO9 and EO5a were prepared in human plasma at 
concentrations of 5, 15, 500, and 1,500 ng/mL for EO9 and 10, 30, 500, and 1,500 
ng/mL for EO5a, by diluting the working solutions for quality control samples in control 
human plasma in volumetric flasks. Replicate 200 µL aliquots were transferred to 2.0 
mL tubes for storage at nominally –20°C. The quality control samples were vortex-
mixed for approximately 30 seconds before processing. 
 
2.4 Sample preparation 
Sample pretreatment was performed at ambient temperatures. EO9, EO5a and internal 
standards were extracted from plasma using liquid-liquid extraction (LLE). To 200 μL 
sample aliquots, 20 μL of internal standard working solution in 0.1 M ammonium 
acetate pH 8.5 - methanol (7:3, v/v) and subsequently 1.25 mL of ethyl acetate were 
added. The samples were vortexed for 10 sec, followed by automatic shaking for 10 
min at 1,250 rpm (Labinco, Breda, The Netherlands). Samples were then centrifuged 
for 10 min at 23,100 g, the aqueous layer was frozen in an ethanol-dry ice mixture and 
the organic layer was decanted into a clean 2.0 mL-eppendorf tube. The organic 
solvent was evaporated under a gentle stream of nitrogen gas at 40oC. The residue 
was reconstituted with 150 µL of reconstitution solvent (0.1 M ammonium acetate – 
methanol (7:3, v/v)) by vortex-mixing for 30 seconds. After shaking for 15 min and 
centrifuging for 10 min at 23,100 g, the clean supernatant was transferred to a glass 
autosampler vial with insert. 
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2.5 HPLC 
The HPLC system comprises an HP1100 binary pump, degasser and HP1100 
autosampler (Agilent Technologies, Palo Alto, CA). Gradient chromatography was 
performed using a Gemini C18 column (150 x 2.1 mm ID, particle size 5 μm). The 
mobile phase consisted of 1 mM ammonium hydroxide in water (A) and 100% methanol 
(B) and was pumped at a flow-rate of 0.2 mL/min. In the first 0.3 min, an eluent 
consisting of 60% A and 40% B, followed by 90% B for 2.7 min. To stabilize the 
column, 40% B was used for 2 min. Sample injections of 25 μL were carried out and the 
autosampler temperature was gauged at 10oC.  
 
2.6 Mass spectrometry 
The LC eluate was fed directly into an API 2000 triple quadrupole MS equipped with an 
electrospray (ESI) ion source (Sciex, Thornhill, ON, Canada). Positive ions were 
created at atmospheric pressure and the mass analyzer was operated in the multiple 
reaction monitoring (MRM) mode using unit resolution for the quadrupoles. The 
resulting MRM chromatograms were used for quantification utilizing Analyst™ software 
version 1.2 (Sciex). Mass transitions of m/z 271 → 241 and 274 → 244 were optimized 
for EO9 and EO9-d3, respectively, with dwell times of 150 ms. Mass transitions of m/z 
307 → 231 and 311 → 231 were optimized for EO5a and EO5a-d4, respectively, with 
dwell times of 150 ms. Nebulizer gas (compressed air), turbo gas (compressed air), 
curtain gas (N2), and collision activated dissociation gas (N2) were operated at 40, 65, 
20, and 4 psi, respectively. Furtermore, declustering potential (DP) for EO9 and its 
internal standard was 66 V and for EO5a and its internal standard was 31 V. Focussing 
potential (FP) for EO9 and EO9-d3 was 310 V and for EO5a and EO5a-d4 was 350. 
The optimised collision energy (CE) was 17 V for EO9 and EO9-d3 and 45 V for EO5a 
and EO5a-d4. Finally, the ionspray voltage was kept at 5500 V, with a source 
temperature of 250oC. 
 
2.7 Validation procedures 
Validation of the method was performed according to the FDA guidelines (13). 
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2.7.1 Linearity 
For the validation, calibration standards (8 non-zero standards of the analytes) were 
prepared in control human heparinized plasma and analyzed in duplicate in three 
analytical runs.  
The linear regression of the ratio of the areas of the analyte and internal standard 
peaks versus the concentration were weighed by 1/x2 (the reciprocal of the squared 
concentration). Concentrations were back-calculated from the constructed calibration 
curve and deviations from the nominal concentrations should be within ± 20% for the 
lower limit of quantitation (LLOQ) and within ± 15% for other concentrations with 
coefficient of variation (C.V.) values less than 20% and 15% respectively (13,14). 
 
2.7.2 Accuracy and precision 
Five replicates of each human plasma sample were analyzed in three analytical runs 
together with a calibration curve independently prepared from the quality control 
samples containing 5, 10, 500, and 1,500 ng/mL of EO9 and 10, 30, 500, and 1,500 
ng/mL of EO5a, as described in Section 2.3.  
Accuracies were determined as the percentage difference of the measured 
concentration from the nominal concentration and the C.V. was used to report the 
precision.   
The intra and inter-assay accuracies (% bias) should be within ±20% at the LLOQ level 
and within ±15% at the other concentrations (13,14). The intra and inter-assay 
precisions should be less than 20% at the LLOQ level and less than 15% at the other 
concentrations (13,14).  
The ability to dilute samples originally above the upper limit of quantitation (ULOQ) of 
the calibration curve was demonstrated by analyzing validation samples containing 10 
times the ULOQ for EO9 and EO5a. Five replicates of each sample were analyzed in 
one analytical run after dilution in control human heparinized plasma. 
 
2.7.3 Limit of detection 
The limit of detection (LOD) for EO9 and EO5a, with the responses of the analytes at 2 
times the response of the blank was established in three analytical runs.  
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2.7.4 Specificity and selectivity 
To investigate whether endogenous matrix constituents interfered with the assay, six 
individual batches of control drug-free plasma samples containing neither analyte nor 
internal standard (double blank), samples containing only internal standard (blank), and 
samples spiked at the LLOQ were prepared. Samples were prepared and analyzed 
according to the described procedures. Peak areas of compounds co-eluting with the 
analyte or internal standard should not exceed 20% of the analyte peak area at the 
LLOQ or 5% of the internal standard area. Deviations from the nominal concentrations 
should be within ± 20% for the LLOQ samples (13,14).  
 
2.7.5 Ion suppression and recovery 
For the determination of ion suppression, control drug-free plasma was processed and 
dry extracts were dissolved in solutions that represented 100% recovery containing the 
analytes and internal standard in 0.1 M ammonium acetate pH 8.5 - methanol (7:3, v/v). 
Ion-suppression was determined by comparing the analytical response of these 
samples to that of the unprocessed samples. Liquid-liquid extraction (LLE) recovery 
was determined by comparing the analytical response of processed quality control 
samples with the analytical response of blank samples reconstituted with solutions as 
described above. These experiments were performed in triplicate at three concentration 
levels. Overall recovery corresponded to the net response after subtraction of the ion-
suppression and signal loss due to the extraction. Ion suppression and recovery 
experiments for the internal standard were performed in a similar way.  
 
2.7.6 Stability 
To test the stability of EO9 and EO5a during processing at the clinical sites, the stability 
of EO9 and EO5a was evaluated in control human whole blood maintained on an 
ice/water bath. The stability of analytes in human plasma after 3 freeze/thaw was 
investigated by comparing quality control samples that had been frozen and thawed 
three times with freshly prepared quality control samples. The stability of EO9 and 
EO5a in human plasma under processing (ambient temperatures) and storage (-20oC) 
conditions was evaluated. Additionally, the stability of the dry extract at 4oC and in the 
reconstituted extract was determined for both EO9 and EO5a. Also, the re-injection 
reproducibility in the auto sampler was determined after 48h. Finally, the stability of 
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EO9 and EO5a was evaluated in the stock solutions and working solutions after 
storage at -20oC. The long-term stability of EO9 and EO5a in human plasma and the 
stability of working solutions at -70 oC are ongoing. 
The above described stability experiments were executed at 2 concentration levels for 
EO9 (15 and 1,500 ng/mL) and EO5a (30 and 1,500 ng/mL) in triplicate. The analytes 
were spiked separately to the biological matrix. The EO9 and EO5a are considered 
stable in the stock and working solutions when 90-110% of the fresh sample’s ratio is 
found and they are considered stable in biological matrixes or extracts when 85-115% 
of the initial concentration is recovered.  
 
3. Results and Discussion 
3.1  Sample pretreatment 
Different methods of sample pretreatment were investigated. Recoveries were 
determined by comparing responses from human plasma samples processed 
according to the procedures mentioned below to responses of EO9 and EO5a standard 
solutions in reconstitution solvent (0.1 M ammonium acetate buffer pH 8.5 – methanol 
(7:3, v/v)), which represented 100% recovery. Protein precipitation of plasma samples 
containing EO9 and EO5a using methanol was tested because it is a straightforward, 
simple, and fast extraction method. However, this resulted in non-reproducible 
recoveries, extremely broad peaks and insufficiently clean samples. Protein 
precipitation was discarded for these reasons. Subsequently, liquid-liquid extraction 
(LLE) was investigated as an alternative means of sample pretreatment using diethyl 
ether, ethyl acetate, dichloromethane, dichloromethane-methanol (1:1, v/v), ethyl 
acetate-methanol (1:1, v/v) and dichloromethane - diethyl ether - isobutyl alcohol 
(60:40:5, v/v/v) as reported by Schellens et al (12) (data not shown). Ethyl acetate 
yielded the most reproducible and high recoveries for both EO9 and EO5a, along with 
sufficiently clean samples. Therefore the sample pretreatment using LLE with ethyl 
acetate was chosen for further study. 
To concentrate the analytes, the organic layer was evaporated under a stream of 
nitrogen gas at 40 oC. We observed that when the EO9 samples were evaporated 
together with other moieties present containing even the smallest amount of an acidic 
fraction along with the organic fraction, no EO9 was found in the EO9 samples. A 
possible explanation could be that the acid-sensitive EO9, affected by the evaporation 
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of acid, degrades. Therefore, it is pivotal that the organic layer in the samples 
containing EO9 is evaporated separately from any other samples, particularly those 
containing acids. 
The EO9 molecule owes its significant anti-tumor activity to the very reactive aziridine 
moiety. To stabilize this reactive group during sample pretreatment and analysis, EO9 
was kept at pH 8.5, at which it is most stable (15). A strong buffer was required, 
compatible with the MS and not reacting with the aziridine moiety in the EO9 molecule. 
We investigated different buffers and 0.1 M ammonium acetate buffer pH 8.5 appeared 
to be suitable. The buffer was mixed with a lower percentage of methanol (30%) 
compared to the staring conditions of the gradient (40%) to concentrate the analytes on 
the top of the analytical column. Subsequently, the reconstitution solvent consisted of 
0.1 M ammonium acetate buffer pH 8.5 – methanol (7:3, v/v).  
 
3.2 Chromatography 
To our knowledge, no other assay has been described so far for the determination of 
EO9 and EO5a in human plasma using HPLC coupled to the tandem MS. We found 
that the most appropriate eluent is an alkaline mixture of an aqueous 1 mM ammonium 
hydroxide solution and methanol. The highest signal to noise ratio was observed using 
1 mM ammonium hydroxide in the eluent. Stokvis et al. have stated earlier that alkaline 
mobile phases containing ammonium hydroxide in combination with positive ionization 
can be very well suited for the bioanalysis of weak basic drugs (16).  
 
A      B 
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C      D 
 
 
Figure 2. Representative HPLC-MS/MS chromatograms of an LLOQ sample for EO9 (5 
ng/mL; A). EO9-d3 (1,000 ng/mL; B), EO5a (10 ng/mL, C) and EO5a-d4 (1,000 ng/mL, 
D) from control human plasma. 
 
Apparently, predominantly protonated molecules are formed under these conditions. 
Positive ionization in the electrospray ion source in the presence of ammonium 
hydroxide most likely results from ion-molecule reactions (IMR) between the analyte 
molecule (M) and ammonium ions or collision–induced dissociation (CID) of ammonium 
adducts of the analyte under influence of the electrospray voltage (16,17). 
Representative chromatograms of EO9, EO5a and the internal standards at their LLOQ 
levels in human plasma are depicted in Figure 2. Peak shapes were excellent with the 
asymmetry factors of 1.0 for EO9 and EO9-d3 and 1.2 for EO5a and EO5a-d4 and the 
capacity factors (k') for all analytes of approximately 3. LC run time was only 6 min. 
 
3.3  Mass Spectrometry 
MS detection was chosen because of its high sensitivity and selectivity, which is 
especially important in the analysis of structurally analogous compounds. The first 
steps in the assay for the quantification of EO9 and EO5a were developed using an 
HPLC-UV method. However, sensitivity and selectivity were insufficient considering the 
fact that EO9 will be applied intravesically and the assay should measure any EO9 
and/or EO5a absorbed from the bladder cavity into the systemic circulation. Therefore 
an HPLC method using MS/MS detection was developed.  
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Figure 3 . Q1 (m/z 200-400) mass spectrum of EO9. The asterisks represent fragment 
ions. 
 
Figure 4 . MS/MS product ion scan of EO9 (precursor ion m/z 271). 
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Figure 5 . Q1 (m/z 200-400) mass spectrum of EO5a.The asterisks represent fragment 
ions. 
 
 
Figure 6. MS/MS product ion scan of EO5a (precursor ion m/z 307). 
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In Figure 3 and 5, Q1 mass spectra of EO9 and EO5a, respectively, are presented. 
Apart from the protonated species at m/z 289 for EO9 and m/z 307 for EO5a, sodium 
adducts are also visible (m/z 311 and m/z 329, respectively). An ion corresponding to 
the elimination of water (m/z 271) from the molecular ion of EO9 is the most prominent, 
indicating that the elimination of water is a favorable reaction for the molecule, which 
occurs immediately in the ion source. 
An ion corresponding to the loss of water from the molecular ion is also observed for 
EO5a (m/z 289). The ions in the spectra labeled with asterisks represent fragment ions 
also formed in the ion source. The protonated molecular ion corresponding to the 
elimination of water (iminium ion) from the molecular ion of EO9 (m/z 271) and the 
protonated molecular ion of EO5a (m/z 307) were induced to fragment in the collision 
cell. The resulting product ion spectra and the proposed fragmentation patterns are 
presented in Figure 4 for EO9 and Figure 6 for EO5a. The main fragment ion in the 
spectrum of EO9 corresponds to the loss of the CH2O from the allylic alcohol (m/z 241). 
Various Q1 and Q3 transitions were investigated, but the highest response to noise 
ratio was acquired from using the protonated molecular ion corresponding to the 
elimination of water from EO9 as a selected mass in first quadrupole, and the fragment 
ion corresponding to the further loss of the CH2O from the allylic alcohol in the third. 
The main fragment ion in the spectrum of EO5a corresponds to the cleavage of the 
amine moiety and the elimination of water (m/z 231). After optimization of the MS 
parameters, the fragment ion at m/z 241 for EO9 and the fragment ion at m/z 231 for 
EO5a were the most abundant and used for quantitative MRM (multiple reaction 
monitoring). 
Notably, the elimination of water from the molecular ion of EO5a observed in Q1 is 
reproducible (as for EO9), but far less abundantly than for EO9. Although speculative, 
this could be because the hydroxyl group from the amine moiety at C5 stabilizes the 
EO5a molecule by forming a hydrogen bond with the hydroxy group at the position 3a, 
whereas the EO9 molecule lacks this stabilizing property because of its closed aziridine 
ring.  
For EO9-d3 and EO5a-d4 similar transitions as for EO9 and EO5a, respectively, were 
selected and optimized. 
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3.4 Validation 
3.4.1 Linearity 
The assay was linear over a concentration range of 5-2,500 ng/mL for EO9 and 10-
2,500 ng/mL for EO5a in human plasma. Using linear regression and 1/x2 weighing, the 
lowest total bias and the most constant bias across the range were obtained. 
Correlation coefficients of the calibration curves were better than 0.9963 for EO9 and 
better than 0.9976 for EO5a. At all concentration levels, deviation of measured 
concentrations from nominal concentration were between -8.2% and 8.1% with C.V. 
values less than 9.7%. 
 
3.4.1 Accuracy and precision 
Assay performance (inter-assay accuracies and precisions) data for EO9 and EO5a is 
summarized in Table I. The intra-assay accuracies (% bias) for EO9 were within ± 6.4% 
for all concentrations and found to be acceptable (data not shown) (13,14). The intra-
assay accuracies (% bias) for EO5a were within ± 7.6% for all concentrations and were 
also acceptable (data not shown).  
 
Table I. Assay performance data for EO9 and EO5a. 
 
 Nominal Measured  Overall Within-run Between-run Number 
Compound concentration concentration Accuracy Precision Precision Of 
  (ng/mL) (ng/mL) (%) (%) (%) replicates 
EO9 5.35 5.28 98.8 13.3 9.73 15 
 16.1 15.7 97.8 7.05 5.90 15 
 535 536 100 5.62 4.64 15 
 1610 1577 98.0 5.43 4.02 15 
EO5a 10.5 10.7 102 10.0 8.04 15 
 31.4 29.7 94.7 12.3 9.55 15 
 523 529 101 4.57 4.08 15 
  1570 1621 103 5.14 4.11 15 
 
The intra-assay precisions for EO9 were less than 13.3% for all concentrations and 
found to be acceptable (13,14). The intra-assay precisions for EO5a were less than 
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12.3% for all concentrations and thus acceptable. As defined by the lower and upper 
validation sample concentrations possessing acceptable accuracy and precision, the 
validated range for EO9 and EO5a based on 200 μL of human plasma is from 5 to 
2,500 ng/mL and from 10 to 2,500 ng/mL, respectively. 
 
3.4.2 Limit of detection 
The limit of detection is the concentration of EO9 and EO5a in which the response of 
the analyte is 2 times higher than the response of the blank, and is established in three 
analytical runs. The mean LOD concentration is estimated at 0.6 ng/mL for EO9, and 3 
ng/mL for EO5a.  
 
3.4.3 Specificity and selectivity 
MRM chromatograms of six batches of control drug-free plasma contained no co-
eluting peaks >20% of the EO9 and EO5a area at the LLOQ level, and no co-eluting 
peaks >5% of the area of internal standards. Deviations from the nominal 
concentrations at the LLOQ level were between -18.1 and 1.7 % for EO9 and found to 
be acceptable (13,14). Deviations from the nominal concentrations at the LLOQ level 
for EO5a were between -18.9 and 0.0 % and also acceptable (13,14). 
 
3.4.4 Ion suppression and recovery 
The mean ion-suppressions for EO9 and its internal standard EO9-d3 were 4.7 % and – 
15.1 %, respectively. The ion-suppression of 4.7% for EO9 can be considered 
negligible, while the ion-enhancement for EO9-d3 is unusual. There are several 
explanations for this phenomenon of ion-enhancement (18-21). One, which might apply 
in this case, is that the observed degree of ion suppression is dependent on the 
concentration of the analyte being monitored and which relates to the matrix / analyte 
ratio (18,21). In our case, ion-suppression was determined for EO9-d3 using one 
concentration (1,000 ng/mL), contrary to the three concentrations used for EO9 (16.1, 
535 and 1610 ng/mL), which may explain the ion-enhancement seen for EO9-d3. Liang 
et al also reported that sometimes a co-eluting drug and its IS suppress or enhance 
each other’s responses (21). They also mentioned that in some cases, the 
enhancement of IS signals by their corresponding drugs may be concentration-
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dependant, and the peak areas for the IS can increase with the increasing drug 
concentrations in calibration curves. 
The mean ion-suppressions for EO5a and its internal standard EO5a-d4 were 2.6 % 
and 7.5 %, respectively.  
LLE recoveries for EO9, EO9-d3, EO5a and EO5a-d4 were 78.5, 88.2, 78.8 and 76.5 
%, respectively. The total recoveries of EO9, EO9-d3, EO5a and EO5a-d4 were 74.8, 
101.5, 76.7 and 70.8 %, respectively.  
 
3.4.5 Stability 
The stability data are summarized in Table 2. EO9 and EO5a are stable in whole blood 
for up to 1 h on an ice/water bath. For both compounds, the measured concentration 
against the theoretical concentration spiked in whole blood was calculated (BIAS%) 
and was within ±15%. However, at low concentrations the percentage of EO9 detected 
in the plasma fraction was lower when compared to the high concentrations. This might 
be due to EO9 binding to the blood cells or the metabolism of EO9 by blood cells. 
Loadman et al. found that EO9 was stable in plasma, however, it was rapidly 
metabolized by murine whole blood (t ½ = 15.6 ± 2.0 min). Furthermore, the authors 
suggested that the metabolism of EO9 by blood cells is responsible for its rapid half-life 
in murine whole blood at 37oC (22). One has to question of course whether parallels 
can be drawn between murine and human whole blood in this regard. Further research 
is needed to clarify the effect of the blood cells on the metabolism of EO9. 
EO9 and EO5a are stable in human plasma for at least three freeze (-20 oC) / thaw 
cycles, and are also stable in human plasma stored at nominally ambient temperatures 
for up to 6 hours. Furthermore, EO9 and EO5a are stable up to 7 days in the dry extract 
and up to 14 days in the final extract at ambient temperatures. Re-injection 
reproducibility was established and the analytical run can be re-injected after at least 48 
hours of storage in the autosampler. 
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Table II. Stability data of EO9 and EO5a. 
 
Compound Conditions Matrix Initial conc Found conc Dev C.V. Number  
      (ng/mL) (ng/mL) (%) (%) of replicates 
EO9 ice/water batch, 1h Whole blood 10.7 10.6 -1.03 3.34 3 
   1783 1690 -5.23 2.58 3 
EO9 3 freeze (-20ºC) - thaw Plasma 14.6 15.5 5.69 2.08 3 
 cycles  1563 1610 2.99 8.12 3 
EO9 Ambient, 6h Plasma 16.4 15.9 -2.85 3.83 3 
   1717 1657 -3.50 3.88 3 
EO9 4ºC, 7 days Dry extract 14.4 15.1 5.34 4.40 3 
   1663 1747 5.01 5.19 3 
EO9 4ºC, 14 days Reconstitution solvent 18.2 16.3 -10.3 1.97 3 
   1840 1820 -1.09 2.20 3 
EO9 Autosampler, 10ºC, 48h Reconstitution solvent 15.9 15.1 -5.29 4.40 3 
   526 539 2.41 1.50 3 
   1557 1593 2.30 1.92 3 
EO9  -20ºC, 6 months Ethanol(stock solution) 48400 46807 -3.29 0.23 3 
EO9  -20ºC, 3 months Reconstitution 103 101 -2.15 1.29 3 
  solvent (working  1026 1067 3.99 0.01 3 
  solution) 10261 10318 0.261 0.61 3 
   102614 98103 -4.41 4.24 3 
EO9  -20ºC, 3 months Plasma (working  103 104 0.315 7.59 3 
  solution) 1026 1008 -1.49 4.54 3 
      10261 9735 -4.97 1.30 3 
EO5a ice/water batch, 1h Whole blood 29.3 31.1 6.26 5.46 3 
   2017 1990 -1.32 5.60 3 
EO5a 3 freeze (-20ºC) - thaw Plasma 26.9 27.3 1.24 21.8 3 
 cycles  1510 1543 2.21 1.87 3 
EO5a Ambient, 6h Plasma 27.4 31.2 13.9 7.16 3 
   1467 1427 -2.73 4.67 3 
EO5a 4ºC, 7 days Dry extract 26.3 24.7 -6.20 12.7 3 
   1437 1393 -3.02 4.08 3 
EO5a 4ºC, 14 days Reconstitution solvent 28.1 26.5 -5.81 12.4 3 
   1397 1370 -1.91 2.19 3 
EO5a Autosampler, 10ºC, 48h Reconstitution solvent 31.8 31.6 -0.421 2.10 3 
   541 531 -1.76 4.38 3 
EO5a  -20ºC, 6 months Ethanol (stock solution) 14300 13462 -5.68 1.24 3 
   22267 23019 3.38 2.88 3 
EO5a  -20ºC, 6 months Reconstitution solvent  105 103 -2.1 6.14 3 
  (working solution) 1050 978 -6.88 2.66 3 
   10500 9676 -7.90 1.24 3 
   105000 99467 -5.33 0.992 3 
EO5a  -20ºC, 6 months Plasma  105 95.1 -9.44 4.46 3 
  (working solution) 1050 1109 5.76 5.24 3 
   10500 11367 8.32 5.83 3 
      105000 114825 9.29 3.17 3 
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Finally, EO9 and EO5a are stable in the stock solutions for up to 6 months of storage at 
–20°C; EO9 is stable in the working solutions in control human heparinized plasma and 
in 0.1 M ammonium acetate buffer pH 8.5 – MeOH (7:3, v/v) for up to 3 months at 
nominally -20°C, but appeared to be unstable when stored longer than 3 months at -
20°C. Therefore, the long-term stability of EO9 in the working solutions in control 
human heparinized plasma and in 0.1 M ammonium acetate buffer pH 8.5 – MeOH 
(7:3, v/v) at -70oC is being investigated. EO5a is stable in the working solutions in  
control human heparinized plasma and in 0.1 M ammonium acetate buffer pH 8.5 – 
MeOH (7:3, v/v) for up to 6 months of storage at nominally –20°C.  
 
4. Conclusions 
An accurate, simple, reproducible, and selective LC-MS/MS assay has been developed 
for the quantification of EO9 and its metabolite EO5a in human plasma. Using 200 μL 
human plasma aliquots, the assay quantifies a range of 5 ng/mL to 2,500 ng/mL for 
EO9, and 10 ng/mL to 2,500 ng/mL for EO5a. Validation results demonstrate that the 
EO9 and EO5a concentrations can be accurately and precisely quantified in human 
plasma. This assay will be used to support clinical pharmacologic studies with EO9.  
 
5. References 
1.  Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, et al. EO9: a novel bioreductive 
 alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical 
 models. European Journal of Cancer. 1993; 29A: 897. 
2.  Phillips RM, Jaffar M, Maitland DJ, Loadman PM, Shnyder SD, Steans G, Cooper PA, Race A, Patterson 
 AV, Stratford IJ. Pharmacological and biological evaluation of a series of substituted 1,4-naphtholoquinone 
 bioreductive drugs. Biochemical Pharmacology. 2004; 68: 2107. 
3. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anti-cancer Drug Design. 1998; 
 13:519. 
4 McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B. Phase I pharmacokinetics and 
 limited sampling strategies for the bioreductive alkylating drug EO9. European Journal of Cancer. 1996; 32: 
 1518. 
5. Cummings J, Spanswick VJ, Gardiner J, Ritchie A, Smyth JF. Pharmacological and Biochemical  
 Determinants of the Antitumor Activity of the Indoloquinone EO9. Biochemical Pharmacology. 1998; 55: 
 252. 
6. Workman O, Stratford IJ. The experimental development of bioreductive drugs  and their role in cancer 
 therapy. Cancer and Metastasis Reviews. 1993; 12: 73. 
Quantitative analysis of EO9 and EO5a in human plasma on API 2000  
 
                                                                                                                                             117 
7. Schellens JHM, Planting AST, van Acker BAC, Loos WJ, de Boer-Dennert M, van der Brug MEL, Koier L, 
 Krediet RT, Stoter G, Verweij J. Phase I and Pharmacological study of the Novel Indoloquinone 
 Bioreductive alkylating Cytotoxic Drug EO9. Journal of the National Cancer Institute. 1994; 86: 906. 
8. Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, ten Bokkel Huinink WW, Pavlidis N, Sorio R, 
 Gamucci T, Wolff I, te Velde A, Lan J, Verweij J. EO9 phase II study in advanced breast , gastric, 
 pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. European Journal of 
 Cancer. 1996; 88: 258. 
9. Pavlidis N, Hanauske AR, Gamucci T, Smyth J, Lehnert M, te Velde A, Lan J, Verweij J. A randomized 
 phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of 
 the EORTC Early Clinical Studies Group (ECSG). Annals of Oncology. 1996; 7: 529. 
10. Phillips RM, Loadman PM, Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration 
 into a vascular regions of tumors. British Journal of Cancer. 1998; 77: 2112. 
11. Choudry GA, Hamilton Stewart PA, Double JA, Krul MRL, Naylor B, Flanningan GM, Shah TK, Brown JE, 
 Phillips RM. A novel strategy for NQO1 (NAD(P)H: quinone oxidoreductase, EC 1.6.99.2) mediated 
 therapy of baldder cancer based on the pharmacological properties of EO9. British Journal of  
 Cancer. 2002; 85: 1137. 
12. Schellens JHM, Loos W, Beijnen JH, Stoter G, Verweij J. Sensitive isocratic high-performance liquid 
 chromatographic determination of a novel indoloquinone cytoroxic drug (EO9) in human plasma and urine. 
 Journal of Chromatography. 1993; 615: 309. 
13. U.S. Food and Drug Administration: Centre for Drug Evaluation and Research: Guidance for Industry: 
 Bioanalytical Method Validation. 2001; www.fda.gov/cder/quidance/4252fnl.htm 
14. Rosing H, Man W, Doyle E, Bult A, Beijnen JH. Bioanalytical liquid chromatographic method validation: a 
 review of current practices and procedures. Journal of Liquid Chromatography and Related 
 Technologies. 2000; 23: 329. 
15. Jonkman-de Vries JD, Winkelhorst J, Underberg WJM, Henrar REC, Beijnen JH. A systematic study on 
 the chemical stability of the novel indoloquinone antitumor agent EO9. International Journal of 
 Pharmaceutics.1993; 100: 181.  
16. Stokvis E, Rosing H, Beijnen JH. Liquid chromatography – mass spectrometry for the quantitative 
 bioanalysis of anticancer drugs. Mass Spectrometry Reviews. 2005; 24: 887 
17. Zhou S, Cook RD. Protonation in electrospray mass spectrometry: wrong-way-round or right-way-round? 
 Journal of the American Society for Mass Spectrometry. 2000; 11: 961. 
18. Annesley TM. Ion suppression in Mass Spectrometry. Clinical Chemistry. 2003,  49:1041. 
19. Topics in Solid Phase Extraction. Part 1. Ion Suppression in LC/MS Analysis: A Review. www.waters.com 
20. Mallet CR, Lu Z, Mazzeo JR. A study of ion suppression effects in electrospray ionization from mobile 
 phase additives and solid-phase extracts. Rapid Communications in Mass Spectrometry. 2004; 18: 49. 
21. Liang HR., Foltz RL, Meng M, Bennett P. Ionization enhancement in atmospheric pressure chemical 
 ionization and suppression in electrospray ionization between target drugs and stable-isotope-labeled 
 internal standards in quantitative liquid chromatography/tandem mass spectrometry. Rapid 
 Communications in Mass Spectrometry. 2003; 17: 2815. 
Chapter 2.1 
 
118 
22. Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of 
 indoloquinone bioreductive drugs based on the clinically  inactive agent EO9. British Journal of 
 Pharmacology. 2002; 137: 701. 
 Chapter 2.2  
 
Enhanced resolution triple-quadrupole mass spectrometry 
for ultra-sensitive and quantitative analysis of the 
investigational anticancer agent EO9 (apaziquone) and its 
metabolite EO5a in human and dog plasma to support 
(pre)-clinical studies of EOquin® given intravesically 
 
 
 
 
Accepted for publication in: Rapid Commun Mass Spectrom 
 
 
 
 
 
Liia D. Vainchtein 
Hilde Rosing 
Dorla Mirejovsky 
Van Huynh 
Luigi Lenaz 
Jan H.M. Schellens 
Jos H. Beijnen 
 
 
 
Chapter 2.2 
 
120 
Abstract 
A highly sensitive and selective liquid chromatography/tandem mass spectrometric (LC-
MS/MS) method was developed to quantify the experimental anticancer agent EO9 and 
its metabolite EO5a in biological matrices. A 200-μL-human/dog plasma aliquot was 
spiked with a mixture of deuterated internal standards EO9-d3 and EO5a-d4 and 
extracted with 1.25 mL ethyl acetate. Dried extracts were reconstituted in 0.1 M 
ammonium acetate – methanol (7:3, v/v) and 20 μL-volumes were injected onto the 
HPLC system. Separation was achieved on a 150 x 2.1 mm C18 column using an 
alkaline eluent (1 mM ammonium hydroxide – methanol (gradient system)). The 
detection was performed by a Finnigan TSQ Quantum Ultra equipped with the 
electrospray ion source operated in positive mode and enhanced mass-resolution 
capability. It demonstrated improved sensitivity with a factor 10-20 for EO9 and EO5a 
over a 3-decades dynamic range, with acceptable accuracy and precision, when 
compared with the previously described assay for EO9 and EO5a, developed by our 
group, using an API 2000.  The assay quantifies a range from 0.5 to 500 ng/mL for EO9 
and EO5a using 200 μL of human plasma and dog samples. The described mass 
resolution method was successfully applied for the evaluation of the pharmacokinetic 
profile of EO9 and its metabolite EO5a in human and dog plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enhanced resolution mass spectrometry for EO9 and EO5a on TSQ Quantum Ultra 
 
                                                                                                                         121 
1. Introduction 
The indoloquinone compound apaziquone (3-hydroxy-5-aziridinyl-1-methyl-2[indole-
4,7-dione]-prop-β-en-α-ol; EO9; Figure 1) is a bioreductive anticancer drug that was 
selected for clinical evaluation on the basis of a novel and promising mechanism of 
action and good preclinical anti-tumor activity (1;2).  
EO9 is an inactive pro-drug that undergoes redox cycling leading to the formation of 
alkylating intermediates (3-5). These alkylating intermediate species are capable of 
forming adducts with DNA (single - strand breaks and DNA cross-linking) leading to cell 
kill (6). Particularly, the acid-catalyzed degradation plays an important role in the 
activation of EO9 (7). 
One of the principal known metabolites/degradation products is EO5a (Figure 1), which 
has an open aziridine ring and shows less cytotoxicity than EO9 (8). 
Currently ongoing clinical trials investigating the efficacy of EO9 in superficial bladder 
tumors with local drug delivery (intravesical administration) showed promising complete 
response rates in 67% of the patients (9-11). 
Thus far only one analytical assay, which was developed by our group, has been 
published describing the determination of EO9 in human plasma using high-
performance liquid chromatography coupled to tandem mass spectrometry (12) with 
lower limit of quantitation for EO9 of 5 ng/mL and for EO5a of 10 ng/mL. However, 
when the drug is intravesically administered, it is pivotal to be able to determine if any 
EO9 and/or EO5a will pass from the bladder into the central blood circulation in order to 
predict the systemic toxicity of the drug. For this purpose a highly sensitive method is 
required to support preclinical and clinical studies with EO9. 
We investigated the use of a Finnigan TSQ Quantum Ultra triple quadrupole mass 
spectrometer for these purposes. This platform exhibited increased analyte sensitivities 
when operating at unit mass resolution, and has demonstrated improved performance 
in terms of selectivity and sensitivity, due to its ability to apply enhanced mass 
resolution. Consequently, a sensitive, specific and accurate assay in human and dog 
plasma using a high-performance liquid chromatography coupled to mass spectrometry 
(HPLC-MS/MS) was developed enabling a low limit of quantitation of 0.5 ng/mL for EO9 
and EO5a. Deuterated internal standards for EO9 and EO5a were used for 
quantification.  
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The method has been fully validated according to the FDA guidelines on bioanalytical 
validation (13), and is applied in the (pre)clinical pharmacokinetic studies with EO9. 
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Figure 1.Chemical structures of EO9 (A), EO9-d3 (B), EO5a (C) and EO5a-d4 (D). 
 
2. Experimental 
2.1 Chemicals and reagents 
EO9 (C15H16N2O4; Figure 1A), its metabolite/degradation product EO5a (C15H18N2O5; 
Figure 1C), EO9-d3 internal standard (C15H13D3N2O4; Figure 1B), and EO5a-d4 internal 
standard (C15H14D4N2O5; Figure 1D) were supplied by Spectrum Pharmaceuticals, Inc 
(Irvine, USA). Methanol (LC gradient grade) was obtained from Bissolve Ltd. 
(Amsterdam, The Netherlands). All other solvents or chemicals were analytical grade or 
higher quality. Distilled water was used throughout the analyses. Drug-free human 
lithium heparinized plasma was obtained from Bioreclamations (Hicksville, NY, USA). 
Drug free dog sodium EDTA plasma was obtained from MPI research (Mattawan, MI, 
USA). 
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2.2 Preparation of stock and working solutions 
Two sets of stock solutions of both EO9 and EO5a were prepared from two 
independent weighings. The reference standards were dissolved in ethanol at a target 
concentration of 1 mg/mL. The solutions had to be placed in an ultrasonic bath for 2 
hours to dissolve the analytes in ethanol. The same procedure was repeated each time 
the solutions were taken out of the freezer. Stock solutions were further diluted with 
control human heparinized plasma to obtain working solutions. One set of working 
solutions was used to prepare calibration standards, the other to prepare quality control 
samples. Separate plasma working solutions used to prepare calibration standards of 
EO9 and EO5a were further diluted in control human plasma to yield concentrations of 
100,000, 10,000, 1,000, 750, 500, 100, 50, 25, 10 and 5 ng/mL. The quality control 
working solutions in human and dog plasma contained 100,000, 10,000, 1,000, 100 
and 10 ng/mL for EO9 and EO5a. 
Separate stock solutions of EO9-d3 and EO5a-d4 were prepared in ethanol at a 
concentration of 1 mg/mL. An internal standard working solution was prepared by 
adding 5 μL of EO9-d3 stock solution and 10 μL of EO5a-d4 stock solution to 50.0 mL 
of 0.1 M ammonium acetate buffer pH 8.5 - methanol (7:3, v/v) to yield a final 
concentration of 100 ng/mL for EO9-d3 and 200 ng/mL for EO5a-d4. All solutions were 
stored at -70oC. 
 
2.3 Preparation of calibration standards and quality control samples 
Before use, control human/dog plasma was centrifuged for approximately 5 min at 
3,900 g. 
Calibration standards containing both EO9 and EO5a were prepared freshly at the 
concentrations of 0.5, 1.0, 2.5, 5.0, 10, 50, 75 and 100 ng/mL for EO9 and EO5a by 
adding 50 μL of EO9 and EO5a working solutions (described in section 2.2) to 450 μL 
of control human plasma. The calibration standards were vortex-mixed for 
approximately 30 sec before processing. Standards were processed singularly and 
analyzed in duplicate. 
Quality control samples for EO9 and EO5a were prepared by spiking control human 
and dog plasma at concentrations of 0.5, 1.5, 25, and 75 ng/mL for EO9 and EO5a, by 
diluting the working solutions for quality control samples in either control human 
heparinized or control dog EDTA plasma in volumetric flasks. Replicate 200 µL aliquots 
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were transferred to 2.0 mL tubes for storage at nominally –70°C. The quality control 
samples were vortex-mixed for approximately 30 seconds before processing. 
 
2.4 Sample processing 
Sample pretreatment was performed at ambient temperatures as described previously 
in an assay for EO9 and EO5a in human plasma using API 2000 triple quadrupole 
mass spectrometer (12).  
 
2.5 Chromatography 
Chromatography was carried out using an HP1100 binary pump, degasser and HP1100 
autosampler (Agilent Technologies, Palo Alto, CA) and a Solvent delivery system LC-
20AD Prominence, degasser and Sil – HTc with SCL -10 Avp system controler 
(Shimadzu, Kyoto, Japan). Gradient chromatography was performed using a Gemini 
C18 column (150 x 2.1 mm ID, particle size 5 μm; Phenomenex, Torrance, CA, USA). 
Gradient elution was applied with 1 mM ammonium hydroxide in water (A) and 100% 
methanol (B) at a flow-rate of 0.2 mL/min. In the first 0.3 min, an eluent consisting of 
60% A and 40% B, followed by 90% B for 2.7 min. To stabilize the column, 40% B was 
used for 2 min. Sample injections of 20 μL were carried out and the autosampler 
temperature was gauged at 10oC.  
 
2.6 Mass spectrometry and analytical data processing 
The mass spectrometric analyses were performed using an API 2000 triple quadrupole 
Mass Spectrometer equipped with an electrospray (ESI) ion source (Sciex, Thornhill, 
ON, Canada) and a Finnigan TSQ Quantum Ultra Triple Quadrupole Mass 
Spectrometer equipped with a heated electrospray (HESI) and electrospray (ESI) ion 
sources (Thermo Fisher, Waltham, MA, USA). The mass spectrometers were operating 
in positive mode to obtain both the mass spectra (MS1) and the product ion spectra 
(MS2). Positive ions were created at atmospheric pressure. API 2000 was operating in 
the multiple reaction monitoring (MRM) mode using unit resolution for the quadrupoles. 
The Finnigan TSQ Quantum Ultra was operating in positive ESI selective reaction 
monitoring (MRM) mode at unit resolution, with the Q1/Q3 resolution set at 0.7 Th 
(Da/z) full width at half maximum (FWHM). When operating in enchanced mass 
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resolution mode the mass spectrometer was set at Q1 resolution of 0.4 Th FWHM and 
Q3 resolution of 0.7 Th FWHM.  
The following parameters were chosen for API 2000 triple quadrupole Mass 
Spectrometer equipped with an ESI ion source. 
Mass transitions of m/z 271 → 241 and 274 → 244 were optimized for EO9 and EO9-d3, 
respectively, and mass transitions of m/z 307 → 231 and 311 → 231 were optimized for 
EO5a and EO5a-d4, respectively, with dwell times of 150 ms. Nebulizer gas 
(compressed air), turbo gas (compressed air), curtain gas (N2), and collision activated 
dissociation gas (N2) were operated at 40, 65, 20, and 4 psi, respectively. Furthermore, 
declustering potential (DP) for EO9 and its internal standard was 66 V and for EO5a 
and its internal standard was 31 V. Focusing potential (FP) for EO9 and EO9-d3 was 
310 V and for EO5a and EO5a-d4 was 350. The optimised collision energy (CE) was 
17 V for EO9 and EO9-d3 and 45 V for EO5a and EO5a-d4. Finally, the ionspray 
voltage was kept at 5500 V, with a source temperature of 250oC. 
The ESI-MS/MS operating parameters of Finnigan TSQ Ultra used in this study are 
listed below. 
Mass transitions of m/z 289 → 241 and 292 → 244 were optimized for EO9 and EO9-d3, 
respectively, and mass transitions of m/z 307 → 231 and 311 → 231 were optimized for 
EO5a and EO5a-d4, respectively, with dwell times of 200 ms. Sheath gas (N2), ion 
sweep gas (N2), and aux gas (N2) were operated at 29, 2, and 5 psi, respectively. 
Furthermore, tube lens voltage for EO9 and its internal standard was 89 V and for 
EO5a and its internal standard was 120 V. Source CID collision energy for EO9 and 
EO9-d3 was 18 V, for EO5a 20 V and for EO5a-d4 22 V. The optimized collision energy 
(CE) was 20 V for EO9 and EO9-d3 and 46 V and 43 V for EO5a and EO5a-d4, 
respectively. Finally, the ionspray voltage was kept at 4800 V, with a capillary 
temperature of 200oC. 
Analyst™ software version 1.2 (Sciex) was used to process the data obtained from the 
API 2000 and LCquan™ 2.5 software (Thermo Fisher) for the Finnigan TSQ Ultra 
instrument.  
 
2.7 Validation procedures 
A full validation of the assay according to the FDA guidelines was performed earlier 
using API 2000 Mass Spectrometer (12). To improve the sensitivity of the assay, the 
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method was transferred to a Finnigan TSQ Ultra mass spectrometer. Therefore, a re-
validation of the method was needed and, consequently, has been performed 
according to the FDA quidelines (13;14). For the assay in dog EDTA plasma, a partial 
validation was executed by means of accuracy and precision using Finnigan TSQ Ultra 
Mass Spectrometer. 
 
2.7.1 Linearity 
For the validation, calibration standards (8 non-zero standards of the analytes as 
described in section 2.3) were prepared in control human heparinized plasma and 
analyzed in duplicate in three analytical runs.  
The linear regression of the ratio of the areas of the analyte and internal standard 
peaks versus the concentration were weighed by 1/x2 (the reciprocal of the squared 
concentration). Concentrations were back-calculated from the constructed calibration 
curve and deviations from the nominal concentrations should be within ± 20% for the 
lower limit of quantitation (LLOQ) and within ± 15% for other concentrations with 
coefficient of variation (C.V.) values less than 20% and 15% respectively (13;14). 
 
2.7.2 Accuracy and precision 
Five replicates of each human plasma sample were analyzed in three analytical runs 
together with calibration standards independently prepared from the quality control 
samples containing 0.5, 1.5, 25 and 75 ng/mL of EO9 and EO5a, as described in 
Section 2.3. To investigate the accuracy and precision in dog EDTA plasma, five 
replicates of each dog EDTA plasma samples were analyzed in one analytical run 
together with calibration standards prepared in control human plasma. 
Accuracies were determined as the percentage difference of the measured 
concentration from the nominal concentration and the C.V. was used to report the 
precision.   
The intra and inter-assay accuracies (% bias) should be within ±20% at the LLOQ level 
and within ±15% at the other concentrations (13;14). The intra and inter-assay 
precisions should be less than 20% at the LLOQ level and less than 15% at the other 
concentrations (13;14).  
The ability to dilute samples originally above the upper limit of quantitation (ULOQ) of 
the calibration curve was demonstrated by analyzing validation samples containing 20 
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times the ULOQ for EO9 and EO5a. Five replicates of each sample were analyzed in 
one analytical run after dilution in control human heparinized plasma. 
 
2.7.3 Specificity and selectivity 
To investigate whether endogenous matrix constituents interfered with the assay, six 
individual batches of control drug-free plasma samples containing neither analyte nor 
internal standard (double blank), samples containing only internal standard (blank), and 
samples spiked at the LLOQ were prepared. Samples were prepared and analyzed 
according to the described procedures. Peak areas of compounds co-eluting with the 
analyte or internal standard should not exceed 20% of the analyte peak area at the 
LLOQ or 5% of the internal standard area. Deviations from the nominal concentrations 
should be within ± 20% for the LLOQ samples (13;14). 
 
2.7.4 Matrix effect 
For the determination of the matrix effect (ion suppression), control drug-free plasma 
was processed and dry extracts were dissolved in solutions that represented 100% 
recovery containing the analytes (at concentrations of 2.0, 33.3 and 100 ng/mL for EO9 
and EO5a) and internal standards (at concentrations of 133 ng/mL for EO9-d3 and 266 
ng/mL for EO5a-d4) in 0.1 M ammonium acetate pH 8.5 - methanol (7:3, v/v). The 
concentrations of the matrix effect samples are 1.33 times higher than that of the 
processed quality control samples, due to the concentration step in the extraction 
procedure. Ion-suppression was determined by comparing the analytical response of 
these samples to that of the unprocessed samples (15). 
 
2.7.5 Recovery 
Liquid-liquid extraction (LLE) recovery was determined by comparing the analytical 
response of processed quality control samples (at concentrations of 1.5, 2.5 and 75 
ng/mL for EO9 and EO5a, 100 ng/mL for EO9-d3 and 200 ng/mL for EO5a-d4) with the 
analytical response of blank samples reconstituted with solutions as described in 
section 2.7.5. These experiments were performed in triplicate at three concentration 
levels.  
Overall recovery corresponded to the net response after subtraction of the ion-
suppression and signal loss due to the extraction.  
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2.7.6 Stability 
The stability of EO9 and EO5a is described earlier by our group (12). However, 
because of the improved sensitivity, it was important to determine the stability of the 
EO9 and EO5a at low concentrations. 
The stability of analytes in human plasma after 3 freeze/thaw was investigated by 
comparing quality control samples that had been frozen and thawed three times with 
freshly prepared quality control samples. The stability of EO9 and EO5a in human 
plasma under processing (ambient temperatures) and storage (-70oC) conditions was 
evaluated. Additionally, the stability of the dry extract at 2-8oC and in the reconstituted 
extract was determined for both EO9 and EO5a. Also, the re-injection reproducibility in 
the auto sampler was determined after 24 h. The long-term stability of EO9 and EO5a 
in human plasma and the stability of working solutions at -70 oC are ongoing.The above 
described stability experiments were executed at 2 concentration levels for both EO9 
and EO5a (1.5 and 75 ng/mL) in triplicate. The analytes were spiked separately to the 
biological matrix. The EO9 and EO5a are considered stable in the stock and working 
solutions when 90-110% of the fresh sample’s ratio is found and they are considered 
stable in biological matrixes or extracts when 85-115% of the initial concentration is 
recovered.  
 
2.7.7 (Pre)clinical studies 
The following three studies were executed. 
1. Preclinical Study. In the intravesical dose range finding study in beagle dogs, two 
dogs (male and female) per treatment (0.4 and 3.2 mg/kg/day) were dosed with EO9 by 
intravesical instillation in the bladder. Blood samples were collected at several time 
points and after centrifugation, the plasma was removed and stored at – 70 oC until 
analysis.  
2. Clinical Study SPI-05-003. To determine the systemic absorption of EO9, a 
multicenter, non-randomized, open-label phase II study (protocol SPI–05-003) was 
performed. Patients with high risk superficial bladder cancer were treated once a week 
for 6 weeks with intravesical instillation of EOquin® (4 mg EO9 in 40 mL instillate).  EO9 
was retained in the bladder for 1 hour.  Plasma and urine samples were collected 
(before instillation, at 0, 5, 10, 20, 40, 60 and 75 minutes of instillation) in 10 patients for 
determining the absorption of EO9 and its metabolite EO5a from bladder mucosa.  
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3. Clinical Study 515. To determine the toxicity of the drug, a multicenter, single-arm, 
open-label, phase II study was performed in 20 patients (Protocol 515).  Patients with ≤ 
4 tumors received 4 mg of EO9 in 40 mL instillate within 6 hours of Transurethral 
Resection of Bladder Tumor. 40 mL of EOquin® was instilled via an indwelling Foley 
catheter and retained for one hour.  After one hour the bladder was drained and the 
catheter was removed.  Plasma samples for drug level assay were obtained at six time 
points: before instillation, at 5, 15, 30, 45 and 60 minutes of instillation. These samples 
were measured using the previously described method (12), which covered the range of 
5 to 2,500 ng/mL for EO9 and 10 to 2,500 ng/mL for EO5a) and the newly described 
method, which gained 10-fold more sensitivity for EO9 and 20-fold for EO5a. 
 
3. Results and Discussion 
Sensitivity of the method developed earlier was insufficient considering the fact that 
EO9 will be applied intravesically and the assay should measure the lowest possible 
amounts of EO9 and/or EO5a absorbed from the bladder cavity into the systemic 
circulation. Therefore a more selective and sensitive method was needed to insure 
accurate measurements. To achieve this, a highly sensitive TSQ Quantum triple 
quadrupole mass spectrometer with improved resolution/transmission characteristics 
for quadrupole mass spectrometers, was selected. 
 
3.1 Ion source studies 
Several mass spectrometers and ion sources were investigated: API 2000 (Sciex, 
Toronto, Canada) equipped with turboionspray and Finnigan TSQ Ultra equipped with 
the heated electrospray ionization (HESI) and electrospray ionization (ESI) sources.  
Q1 spectra obtained using API 2000 in combination with turboionspray and Finnigan 
TSQ Ultra equipped with HESI (Figure 2) showed an ion corresponding to the 
elimination of water (m/z 271) from the protonated molecule of EO9 to be the most 
prominent, indicating that the elimination of water is a favorable reaction for the 
molecule, which occurs immediately in the ion source of API 2000 machine as well as 
in Finnigan TSQ Ultra equipped with HESI.  
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Figure 2 . API 2000 and Finnigan TSQ Ultra equipped with HESI:Q1 (m/z 200-400) 
mass spectrum of EO9. 
 
Figure 3. API 2000 and Finnigan TSQ Ultra equipped with HESI and ESI: Q1 (m/z 200-
400) mass spectrum of EO5a. 
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Notably, the elimination of water from the protonated molecule of EO5a (Figure 3) 
observed in Q1 is reproducible (as for EO9), but far less abundant than for EO9, which 
could be caused by the hydroxyl group from the amine moiety at C5 stabilizing the 
EO5a molecule by forming a hydrogen bond with the hydroxyl group at the position 3a. 
EO9 molecule lacks this stabilizing property because of its closed aziridine ring.  
On contrary, when Finnigan TSQ Ultra equipped with ESI sources was used, mainly 
only the protonated molecules of EO9 were observed in Q1 spectrum (Figure 4). This 
may be explained by the fact that the turboionspray source in the API Sciex machines 
and HESI are heated, but the ESI in the Finnigan TSQ Ultra is not. As will be explained 
in section 3.2.2, the temperature is a very critical parameter for the optimization of the 
response of EO9.  
 
Figure 4 . Finnigan TSQ Ultra equipped with ESI: Q1 (m/z 200-400) mass spectrum of 
EO9. 
 
3.2 Ion Tranfer Capillary tube temperature study 
Due to the chemical instability of EO9, the effects of the ion transfer capillary tube 
temperature on the degradation of this molecule were investigated. The results are 
presented in Figure 5, where the relative signal to noise ratio was measured in relation 
to the capillary temperature.  
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Figure 5 . Effect of the capillary temperature on the signal to noise ratio of EO9 and 
EO5a at the concentration of 1 ng/mL using Finnigan TSQ Ultra equipped with ESI. 
 
As seen in this Figure, the degradation of EO9 is strongly dependant on the 
temperature. The optimum temperature for the protonated molecule of EO9 was found 
to be 200 ºC. However, with the increase in the temperature from 200 ºC to 250 ºC, the 
elimination of water from the protonated molecule (iminium ion) becomes a favorable 
reaction and an optimum of 250 ºC was observed for the protonated iminium ion. 
Moreover, we can conclude, that with the increase in temperature (from 200 ºC for the 
protonated molecule or from the 250 ºC for the protonated iminium ion), EO9 
degradation rate increased. Interestingly, EO5a, did not undergo any degradation and 
its signal to noise ratio was not dependant on the temperature at all. Consequently, we 
selected the ion transfer capillary temperature of 200 ºC for the detection of the 
protonated molecular ion of EO9.  
 
3.3 Comparison of sensitivity under enhanced resolution and unit resolution 
The chromatograms shown in Figures 6A and 7A were obtained from the analysis of 
the EO9 and EO5a LLOQ samples, respectively, using API 2000 HPLC-MS/MS system 
in the positive mode and with unit mass resolution (peak width set to 0.7 Th FWHM). 
Under these conditions, the background noise was around 10 cps for EO9 and 5 cps 
for EO5a.  
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Figure 6. Chromatograms at the LLOQ for EO9 on the API 2000 (5 ng/mL; A), Finnigan 
TSQ Ultra using unit resolution (1 ng/mL; B) and enhanced resolution (0.5 ng/mL; C). 
 
The LLOQ of EO9 for this assay was set at 5 ng/mL and the LLOQ of EO5a was set at 
10 ng/mL with the signal to noice ratio (s/n) of 20 for EO9 and 10 for EO5a, as shown in 
Figures 6A and 7A. When the same LLOQ samples were injected onto the Finnigan 
TSQ Quantum Ultra HPLC-MS/MS system in the positive ESI mode with unit resolution 
(peak width set to 0.7 Th FWHM), the peak intensity for EO5a was increased 20-fold 
and for EO9 5-fold. From this data, we concluded that the TSQ Quantum Ultra 
enhanced sensitivity of the assay by increasing the signal of the protonated molecules 
of EO5a and EO9. Under these conditions, the LLOQ for EO9 was set at 1 ng/mL (s/n = 
20) and the LLOQ for EO5a was set at 0.5 ng/mL (s/n = 10) (Figures 6B and 7B), which 
is 5-fold more sensitive for EO9 and 20-fold more sensitive for EO5a compared to our 
previous method on API 2000 (12). 
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Figure 7. Chromatograms at LLOQ for EO5a on the API 2000 (10 ng/mL; A), Finnigan 
TSQ Ultra using unit resolution (0.5 ng/mL; B) and enhanced resolution (0.5 ng/mL; C). 
 
The improved sensitivity may be attributed to several advancements in the TSQ 
Quantum Ultra instrument (16;18). Namely, ionization efficiency has been improved by 
the advanced design of a new orthogonal ion source. Ion transmission has been 
improved by the use of a larger orifice supported by a triple stage turbo pump (16). And 
finally, the hyperbolic quadrupole rods and the accompanying radio frequency (RF) 
circuitry have been redesigned, which allows the user to obtain enhanced mass 
resolution with only a small loss in signal intensity (17;18). Namely, resolution of a 
quadrupole mass filter is proportional to the number of RF cycles an ion experiences 
while traversing the quadrupole rods that, in turn, is related to the RF frequency and the 
length of the quadrupole rods. For the TSQ Quantum Ultra, the m/z range was reduced 
to 1500, so that the RF frequency could be kept as high as possible at the maximum 
RF voltage and, consequently, increasing the resolving power (16). 
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To increase the sensitivity of the assay for EO9, the enhanced mass resolution function 
of the Finnigan TSQ Quantum Ultra mass spectrometer has been tested.  
To determine the most suitable resolution for EO9 and EO5a, the dependence of the 
signal to noise ratio of the peaks as a function of the Q1 resolution of the TSQ 
Quantum Ultra, was investigated. The results are presented in Figure 8, where it is 
clear that the highest signal to noise ratio for EO9 was obtained when enhanced Q1 
resolution of 0.4 Th FWHM was used. Interestingly, that signal to noise ratio of EO5a 
was not influenced by the changes in the resolution, due to already a very low 
background noise (5 cps) in the transition of EO5a (Figure 7C). 
Using Finnigan TSQ Ultra equipped with ESI in the positive mode with enhanced 
resolution, the 10-fold increase in the signal to noise ratio was achieved for EO9 in 
comparison to the API 2000 mass spectrometer and 2-fold increase in signal to noise 
ratio was seen when compared to Finnigan TSQ Ultra in the positive ESI mode with 
unit resolution (Figure 6C). 
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Figure 8. Influence of the Q1 resolution on the signal to noise ratio of EO9 and EO5a at 
the concentration of 1 ng/mL using a Finnigan TSQ Ultra instrument equipped with ESI. 
Consequently, the Finnigan TSQ Ultra equipped with ESI in the positive mode with 
enhanced resolution (Q1 at 0.4 Th FWHM) was chosen for further method 
development. Under these conditions, the LLOQs for EO9 and EO5a were set at 0.5 
ng/mL.  
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Using Finnigan TSQ Ultra mass spectrometer operated in enhanced resolution mode, 
mainly the protonated molecules at m/z 289 and m/z 307 for EO9 and EO5a, were 
visible. In addition, the peaks corresponding to the elimination of water from the 
molecular ions of EO9 and EO5a and their sodium adducts were observed (m/z 271 
and m/z 311 for EO9 and m/z 289 and m/z 347 for EO5a, respectively). The resulting 
product ion spectra (with proposed fragmentation patterns) are presented in Figures 9 
and 10 for EO9 and EO5a, respectively. For EO9, the main fragment ion corresponds 
to the elimination of water and loss of the CH2O from the allylic alcohol (m/z 241). The 
main fragment ion of EO5a corresponds to the cleavage of the amine moiety and the 
elimination of water (m/z 231). Consequently, multiple reaction monitoring (MRM) 
parameters were optimized on the m/z of 289 / 241 and 307 / 231 for EO9 and EO5a, 
respectively.  
For EO9-d3 and EO5a-d4 similar transitions as for EO9 and EO5a, respectively, were 
optimized. 
 
Figure 9. MS/MS product ion scan of EO9 (precursor ion m/z 289). 
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Figure 10. MS/MS product ion scan of EO5a (precursor ion m/z 307). 
 
It has to be noted that an appropriate procedure should be followed for a routine use of 
an enhanced resolution in quantitative bioanalytical method (MRM-based), where Q1 
FWHM is set at 0.4 Th. It is recommended to determine the appropriate precursor ion 
mass prior to the start of the analytical run in order to ascertain the maximum sensitivity 
of the mass spectrometer during the course of the analysis (19;20). Nevertheless, 
based on our finding, three validation runs of 24 hours each and a total amount of 
around 300 samples could be processed without the loss in sensitivity during the 
analysis. Moreover, no mass shift was observed during this period. 
 
3.4 Validation 
3.4.1 Linearity 
The assay was linear over a concentration range of 0.5 to 500 ng/mL for EO9 and 
EO5a in human plasma. Using linear regression and 1/x2 weighing, the lowest total bias 
and the most constant bias across the range were obtained. Correlation coefficients (r2) 
of the calibration curves were better than 0.99 for EO9 and EO5a. At all concentration 
levels, deviation of measured concentrations from nominal concentration were between 
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-11.4% and 4.95% with C.V. values less than 12.4% for EO9 and between -4.97% and 
4.24% with C.V. values less than 13.5% for EO5a. 
The samples containing EO9 and EO5a can be diluted 20 times in human heparinized 
plasma resulting in acceptable accuracy and precision values. 
 
3.4.2 Accuracy and precision 
Assay performance (inter-assay accuracies and precisions) data for EO9 and EO5a in 
human heparinized and dog EDTA plasma is summarized in Table 1. The intra-assay 
accuracies (% bias) in human heparinized plasma were within ± 10.6% for EO9, and 
within ±9.71% for EO5a for all concentrations and found to be acceptable (data not 
shown) (13;14).  
 
3.4.3 Specificity and selectivity 
MRM chromatograms of six batches of control drug-free plasma contained no co-
eluting peaks >20% of the EO9 and EO5a area at the LLOQ level, and no co-eluting 
peaks >5% of the area of internal standards. Deviations from the nominal 
concentrations at the LLOQ level were between -10.7% and 10.9% for EO9 and found 
to be acceptable (13;14). Deviations from the nominal concentrations at the LLOQ level 
for EO5a were between -0.00% and 19.1 % and also acceptable (13;14). 
 
3.4.4 Matrix effect 
The mean ion-suppressions for EO9 and its internal standard EO9-d3 were 19.2% and 
5.08%, respectively. The mean ion-suppressions for EO5a and its internal standard 
EO5a-d4 were 4.27% and  -6.04% (ion-enhancement), respectively.  
 
3.4.5 Recovery 
LLE recoveries for EO9, EO9-d3, EO5a and EO5a-d4 were 70.1% ± 6.85%, 70.2%, 
65.0% ± 1.55% and 68.4 %, respectively. The total recoveries of EO9, EO9-d3, EO5a 
and EO5a-d4 were 56.7% ± 7.33%, 66.6%, 62.2% ± 3.02% and 72.5%, respectively.  
 
 
 
Enhanced resolution mass spectrometry for EO9 and EO5a on TSQ Quantum Ultra 
 
                                                                                                                         139 
Table 1. Assay performance data for EO9 and EO5a in human heparinized and dog 
EDTA plasma. 
  Nominal Measured  Overall Intra-assay Inter-assay Number 
Compound Matrix concentration Concentration Accuracy Precision Precision of 
   (ng/mL) (ng/mL) (%) (%) (%) replicates 
EO9 Human 0.494 0.520 105 16.7 14.4 15 
 Human 1.48 1.45 98.1 11.8 10.8 15 
 Human 24.7 25.5 103 7.24 6.12 15 
 Human 74.1 68.0 91.8 6.36 5.06 15 
EO9 Dog 0.494 0.484 98.0 13.6 - 5 
 Dog 1.48 1.56 105 5.23 - 5 
 Dog 24.7 26.6 108 4.57 - 5 
  Dog 74.1 74.5 101 5.13 - 5 
EO5a Human 0.481 0.452 93.9 17.3 13.1 15 
 Human 1.44 1.46 101 12.2 9.40 15 
 Human 24.1 25.6 106 6.04 4.98 15 
  Human 72.2 76.7 106 2.85 2.48 15 
EO5a Dog 0.481 0.439 91.3 13.5 - 5 
 Dog 1.44 1.40 97.2 15.0 - 5 
 Dog 24.1 21.7 90.0 3.65 - 5 
  Dog 72.2 63.8 88.4 2.86 - 5 
 
3.4.6 Stability 
The stability data are summarized in Table 2. EO9 and EO5a are stable in human 
plasma for at least three freeze (-20 oC) / thaw cycles, and are also stable in human 
plasma stored at nominally ambient temperatures for up to 6 hours.  
Furthermore, EO9 and EO5a are stable up to 3 and 10 days, respectively, in the dry 
extract and up to 7 and 10 days, respectively, in the final extract at ambient 
temperatures. Re-injection reproducibility was established and the analytical run can be 
re-injected after at least 24 hours of storage in the autosampler. 
 
Table 2. Stability data of EO9 and EO5a in human plasma 
Compound Conditions Matrix Initial conc Found conc Dev C.V. Number  
      (ng/mL) (ng/mL) (%) (%) of replicates 
        
EO9 3 freeze (-20ºC) - thaw Plasma 1.63 1.58 -3.07 12.5 3 
 cycles  71.2 72.7 2.15 4.75 3 
EO9 Ambient, 6h Plasma 1.48 1.43 -3.60 6.29 3 
   73.5 73.1 -0.544 4.48 3 
EO9 4ºC, 3 days Dry extract 1.48 1.52 2.47 14.3 3 
   73.5 66.9 -9.07 5.96 3 
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EO9 4ºC, 7 days Reconstitution  1.48 1.59 6.97 12.0 3 
  solvent 73.5 67.4 -8.39 10.5 3 
EO9 Autosampler, 10ºC, 24h Reconstitution 1.41 1.31 -7.61 18.7 3 
  solvent 26.2 27.3 4.27 1.39 3 
   69.0 72.1 4.34 9.72 3 
        
EO5a 3 freeze (-20ºC) - thaw Plasma 1.77 1.70 -3.95 11.8 3 
 cycles  75.0 83.4 11.3 13.2 3 
EO5a Ambient, 6h Plasma 1.40 1.36 -2.86 9.18 3 
   69.1 74.5 7.82 5.57 3 
EO5a 4ºC, 10 days Dry extract 1.33 1.32 -0.251 13.0 3 
   67.9 64.1 -5.50 3.59 3 
EO5a 4ºC, 10 days Reconstitution 1.33 1.49 12.1 4.11 3 
  solvent 67.9 63.5 -6.39 4.83 3 
EO5a Autosampler, 10ºC, 48h Reconstitution 1.58 1.53 -2.83 5.85 3 
  solvent 25.5 27.1 6.03 2.30 3 
   73.3 77.5 5..38 5.74 3 
 
3.5 (Pre) clinical studies 
1. Preclinical Study. In Figure 11, the EO9 concentration in plasma vs. time plots are 
presented for EO9 from the dogs treated intravesically with 0.4 mg/kg/day (8 mg/m2) 
and 3.2 mg/kg/day (64 mg/m2), which is approximately 4 and 32 times more, 
respectively, than the doses which will be administered in humans. 40 minutes after 
administration of the drug a maximum EO9 concentration of 20 ng/mL was reached. It 
is remarkable that the male dogs showed higher levels of EO9 compared to the female 
dogs. This might be due to the lower urine pH in female dogs, whereby EO9 more 
easily degrades into other products. No detectable EO5a levels were measured.  
2 and 3. Clinical Studies. No detectable levels of either EO9 or EO5a were found in the 
samples from the SPI-05-003 and 515 studies. Considering the fact that the samples 
from the 515 study were measured using both methods and no level of either analyte 
was detected, it is plausible to conclude that EO9 and EO5a do not pass from the 
bladder into the central blood circulation. This analytical observation was in line with the 
fact that no systemic toxicity was observed in these patients. However, it is 
advantageous that we did detect some low levels of EO9 in the dog plasma after a high 
dose of EO9 given to dogs, which indicates that EO9 can be indeed absorbed through 
the cellular levels in the bladder supporting its uptake by the tumour cells. 
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Figure 11. Plasma concentration vs. time profile for EO9 from beagle dogs treated 
intravesically with EO9 
 
4. Conclusions 
An accurate, sensitive and selective LC-MS/MS assay has been developed for the 
quantification of EO9 and its metabolite EO5a in human and dog plasma. Using 200 μL 
human plasma aliquots, the assay quantifies a range of 0.5 ng/mL to 500 ng/mL for 
EO9 and EO5a. Validation results demonstrate that the EO9 and EO5a concentrations 
can be accurately and precisely quantified in human and dog plasma. This assay has 
been used to support (pre)clinical pharmacologic studies of EO9.  
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Abstract 
EO9 (apaziquone) is a novel, promising anticancer agent which is currently being 
investigated for the intravesical treatment of bladder cancer. EO9 contains a highly 
reactive aziridine ring in its structure that limits its chemical stability in acidic aqueous 
solutions. The stability of the pharmaceutically formulated EO9 in human urine, 
including the effects of several parameters such as temperature, buffer strength and 
pH have been investigated. Urine extracts were analyzed by high-performance liquid 
chromatography coupled to electrospray tandem mass spectrometry (HPLC-MS/MS) 
using a TurboIonspray interface and positive-ion multiple reaction monitoring. EO9 was 
unstable in urine at 43˚C during the instillation for longer than 1 hour. However, the 
drug was stable in human urine for 3 hours at 37˚C. EO9 is stable in urine stabilized 
with TRIS buffer (pH 9.0; 5mM) for up to 3 freeze/thaw cycles at – 20˚C and – 70˚C 
and 3 months of storage at – 70˚C. The results also illustrated that with the lower pH in 
urine, EO9 became more unstable. Furthermore, a new degradation product of EO9 
was discovered and successfully identified as EO9-Cl.  
The outcomes of these stability experiments will be implemented to insure proper 
sample handling at the clinical sites, transport, storage, and sample handling during 
analysis in the forthcoming (pre)clinical studies of EO9 in superficial bladder cancer, 
supported by bioanalysis and pharmacokinetic monitoring. 
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1. Introduction 
The indoloquinone compound apaziquone (3-hydroxy-5-azir-idinyl-1-methyl-2(indole-
4,7-dione)-prop-β-en-α-ol; EO9) is a bioreductive drug that was selected for clinical 
evaluation on the basis of a novel mechanism of action and good preclinical antitumor 
activity (1,2). Currently ongoing clinical trials investigating EO9 in superficial bladder 
tumors with local drug delivery show promising response rates (3).  
EO9 is an inactive pro-drug that undergoes redox cycling leading to the formation of 
alkylating intermediates (4-6). These alkylating intermediate species are capable of 
forming adducts with DNA (single - strand breaks and DNA cross-linking) leading to 
cell kill (7). Particularly, the acid-catalyzed degradation plays an important role in the 
activation of EO9 (8).  
EO9 has a very short half-life (< 10 min in humans) after intravenous administration. It 
is extensively metabolized. One of the principal known metabolites is EO5a, which has 
an open aziridine ring and shows less cytotoxicity than EO9 (9). Another degradation 
product, which was discovered by us and introduced for the first time in this article, is 
EO9 with covalently attached chlorine (EO9-Cl). It is formed in the acid-catalyzed 
reaction of EO9 in the presence of chloride anions in urine. 
Studies have been conducted dealing with the bioactivation and mechanism of action 
(8, 10-25), pharmacokinetics (25-32), distribution and metabolism of EO9 (25,33-36) 
and the bioanalysis (37-39) of EO9. An extensive study on the chemical stability of 
EO9 in aqueous solution using reversed-phase high-performance liquid 
chromatography with ultraviolet detection and ultraviolet spectrometry has been 
performed by de Vries et al. (6). They studied the degradation of EO9 as a function of 
pH, buffer composition, ionic strength and temperature, and found it followed (pseudo) 
first-order kinetics. Moreover, the degradation rate was strongly affected by phosphate 
buffer components, but not by acetate and carbonate buffers. Both the degradation 
rate and activation mechanism of EO9 were found to be strongly pH-dependent: the 
further the pH shifted in either direction from 8.5, the more unstable EO9 became.  
No study, however, was performed to describe the stability of EO9 in human urine 
under various conditions. Since EO9 will be administered intravesically, knowledge on 
the stability of EO9 in urine is of considerable importance to understand conditions in 
the bladder during instillation and to ensure correct sample handling during transport, 
storage, and bioanalysis.  
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This study was initiated with the objective of obtaining detailed knowledge on the 
stability of EO9 in human urine, including the effect of the several parameters, such as 
pH, buffer, and temperature in this matrix, in order to support clinical studies of EO9 in 
bladder instillations.  
 
2. Experimental 
2.1 Materials 
EO9 (C15H16N2O4; Figure 1), EO9-d3 internal standard (C15H13D3N2O4; Figure 1), and 
EO5a-d4 internal standard (C15H14D4N2O5; Figure 1) were supplied by Spectrum 
Pharmaceuticals, Inc (Irvine, CA, USA).  
A      B 
O
O
N
OH
OHCH3
N
1
2
3
3a
4
5
6
7
 
 
C      D 
 
O
O
N
OH
OHCH3
N
H
OH
1
2
3
3a
4
5
6
7
 
E 
N
H
Cl
O
O
N
OH
OHCH3
 
Figure 1.Chemical structures of EO9 (A), EO9-d3 (B), EO5a (C), EO5a-d4 (D) and 
EO9-Cl (E). 
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The metabolite EO5a (C15H18N2O5; Figure 1) was synthesized from the EO9. Methanol 
(LC gradient grade) was obtained from Bissolve Ltd. (Amsterdam, The Netherlands). 
All other solvents or chemicals were analytical grade or better. Distilled water was used 
throughout the analyses. Drug free human urine was obtained from volunteers from the 
laboratory of the Department of Pharmacy&Pharmacology at the Slotervaart Hospital 
(Amsterdam, The Netherlands).  
 
2.2 Preparation of stock and working solutions 
A stock solution of EO9 was prepared in ethanol at a concentration of 1 mg/mL. The 
solution had to be placed in an ultrasonic bath for 2 hours in order to dissolve the 
compound. The same procedure was repeated each time this solution was thawed. 
This solution was further diluted with ammonium acetate buffer (pH 8.5; 0.1 M) - 
methanol (7:3, v/v) to obtain working solutions.  
EO5a was prepared by adding 500 μL HClO4 (pH 2.0; 10 mM) to 10 mg/mL (500 μL) 
EO9 in DMSO. After incubating for 1 min at ambient temperature, 4 mL of ammonium 
acetate buffer (pH 8.5; 0.1M) – methanol (7:3, v/v) was added to yield 1 mg/mL EO5a 
(the purity was verified by HPLC). 
This solution was further diluted with ammonium acetate buffer (pH 8.5; 0.1M) - 
methanol (7:3, v/v) to obtain working solutions. The working solutions of EO9 and 
EO5a were further diluted in ammonium acetate buffer (pH 8.5; 0.1M) – MeOH (7:3, 
v/v) to yield concentrations ranging from 100 to 15,000 ng/mL. These working solutions 
were used to prepare the calibration standards.  
Separate stock solutions of EO9-d3 and EO5a-d4 were prepared in ethanol at a 
concentration of 1 mg/mL.  
A working solution containing the internal standards was prepared by transferring 500 
μL of EO9-d3 stock solution and 500 μL of EO5a-d4 stock solution to a 50.0 mL 
volumetric flask and adding ammonium acetate buffer (pH 8.5; 0.1M) - methanol (7:3, 
v/v) to give a final concentration of 10,000 ng/mL for EO9-d3 and EO5a-d4. 
All solutions were stored at -20oC. 
 
2.3 Preparation of calibration standards 
Calibration standards containing both EO9 and EO5a were prepared freshly in 
ammonium acetate buffer (pH 8.5; 0.1M) - methanol (7:3, v/v), ranging from 10 to 
Chapter 2.3 
 
148 
1,500 ng/mL, from the working solutions of EO9 and EO5a, and vortex-mixed for 
approximately 30 seconds before analysis. Standards were analyzed in duplicate. 
 
2.4 Reconstitution of formulated product of EO9 (EOquin™) 
One vial of lyophilized product, containing 4 mg of EO9, 25 mg mannitol and 10 mg 
sodium bicarbonate was reconstituted with 2x10 mL of the diluent. The diluent 
formulation contained 10 mg/mL sodium bicarbonate, 0.2 mg/mL EDTA, and 0.6 mL 
propylene glycol in 1.0 mL sterile water for injection (SWFI). This 20 mL solution was 
further diluted with 20 mL of SWFI to yield 40 mL of EO9 drug solution.  
 
2.5 Preparation of non-stabilized urine 
A volume of 5 mL of the EO9 solution was transferred to a 30.0 mL polypropylene tube 
and placed on ice. A volume of 10 mL of urine was added to the tube and vortex-mixed 
for 10 seconds. The batch was immediately divided into 20 portions of 500 µL each. 
Another two batches of 5 mL EO9 solution and 10 mL urine were prepared in the same 
way. Three batches of non-stabilized urine (60 samples) were acquired. Three 
samples from each batch were analysed at time zero and the other samples were used 
for the experiments with non-stabilized urine (section 2.10).  
The average volume collected after 60 min of instillation is approximately 120 ± 47 mL. 
The total volume of instillation fluid is 40 mL (section 2.4). Therefore, in order to mimic 
the clinical situation, a volume of control human urine was added to the EOquin 
formulation in the ratio of 2:1 (v/v) as described above. 
 
2.6 Preparation of urine stabilized with TRIS buffer (pH 9.0; 5mM) 
A volume of 2 mL of EO9 drug solution was transferred to a 30.0 mL polypropylene 
tube and placed on ice. A volume of 4 mL of urine and 6 mL of TRIS buffer (pH 9.0; 
5mM) were added to the tube and vortex-mixed for 10 seconds. The batch was 
immediately divided into 24 portions of 500 µL each. Another two batches of 2 mL EO9 
solution, urine and TRIS buffer (pH 9.0; 5mM) were prepared in the same way. Three 
batches of non-stabilized urine (72 samples) were obtained. Three samples from each 
batch were analyzed at time zero and the other samples were used for the 
experiments with the stabilized urine (section 2.10). 
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2.7 Sample pretreatment 
At each time point (Table 1), 150 µL of a working solution containing the internal 
standards was added to 50 µL of human urine aliquots and diluted 30 times (1,200 µL) 
in ammonium acetate (pH 8.5; 0.1M) – methanol (7:3, v/v) to yield initial EO9 analyte 
concentrations between 1.93 and 3.65 µM. 
 
2.8 HPLC 
The HPLC system comprise an HP1100 (Agilent Technologies, Palo Alto, CA) binary 
pump, degasser and HP1100 auto sampler (Agilent Technologies). Gradient 
chromatography was performed using a Gemini C18 column (150 x 2.1 mm ID, particle 
size 5 μm). The mobile phase consisted of ammonium hydroxide (pH 8.5; 1 mM) in 
water (A) and methanol (B), pumped at a flow-rate of 0.2 mL/min. In the first 0.3 min, 
the eluent consisted of 60% A and 40% B, followed by 90% B for 2.7 min. To stabilize 
the column, 40% B was used for 2 min. Sample injections of 25 μL were carried out 
and the autosampler temperature was gauged at 10oC.  
 
2.9 Mass spectrometry 
The LC eluate was directed into an API 2000 triple quadrupole MS equipped with an 
electrospray (ESI) ion source (Sciex, Thornhill, ON, Canada). Positive ions were 
created at atmospheric pressure and the mass analyzer was operated in the multiple 
reaction monitoring (MRM) mode using unit resolution for the quadrupoles. The 
resulting MRM chromatograms were used for quantification utilizing Analyst™ software 
version 1.2 (Sciex). Mass transitions of m/z 271 → 241, 274 → 244, 307 → 231, 311 → 
231, 325 → 241 were optimized for EO9, EO9-d3, EO5a, EO5a-d4 and EO9-Cl 
(C15H17N2O4Cl; Figure 1), respectively, with dwell times of 150 ms. The response of 
EO9-Cl was quantified using the EO9 calibration standards due to the absence of 
EO9-Cl reference standard. Nebulizer gas (compressed air), turbo gas (compressed 
air), curtain gas (N2), and collision activated dissociation gas (N2) were operated at 40, 
65, 20, and 4 psi, respectively. Finally, the ion spray voltage was kept at 5500 V, with a 
source temperature of 250oC. 
 
 
 
Chapter 2.3 
 
150 
2.10 The evaluated conditions 
Sample stability was evaluated under the conditions listed in Table 1. Three different 
urine batches with a pH in the range from 5 to 7 were tested (3 
measurements/batch/time point).  
EO9 is considered stable in the biological matrix when 85-115% of the initial 
concentration is recovered (40,41). 
 
Table 1.The evaluated conditions 
Matrix Conditions Initial EO9 conc. (µM)  Timepoints 
Non-stabilized urine1 43°C 115.6 0, 1, 2, 3h 
Non-stabilized urine 37°C 115.6 0, 1, 2, 3 h 
Non-stabilized urine Room temp. 115.6 0, 1, 2, 3 h 
Non-stabilized urine On ice 115.6 0, 1, 2, 3, 6, 24 h 
Stabilized urine2 On ice 57.8 0, 1, 2, 3, 6, 24 h 
Stabilized urine -20°C 57.8 0, 1, 2, 3 months 
Stabilized urine -70°C 57.8 0, 1, 2, 3 months 
Stabilized urine Freeze/thaw  -20°C 57.8 0, 1, 2, 3 cycles 
Stabilized urine Freeze/thaw  -70°C 57.8 0, 1, 2, 3 cycles 
1 urine collected from the bladder    
2 urine collected from the bladder and stabilized with TRIS buffer (pH 9.0; 5mM)    
 
3. Results and Discussion 
3.1 Sample pretreatment 
Liquid-liquid extraction (LLE) was investigated for the extraction of EO9 an EO5a from 
urine, but the recoveries of EO9 were low and not reproducible (data not shown). 
Therefore, the urine samples were diluted with ammonium acetate (pH 8.5; 0.1M) – 
methanol (7:3, v/v) to examine whether the recovery of EO9 could be increased more 
reproducibly with a direct injection. This approach was indeed successful and 
interestingly, we also detected another compound in the urine, which was later 
identified as EO9-Cl (section 3.4). 
Therefore, dilution of the urine samples was chosen as the sample pretreatment. The 
samples were diluted 30 times prior to analysis to ascertain that the final concentration 
would fit into the linear calibration range and to prevent contamination of the mass 
spectrometer with salts present in urine. The chromatographic system provided 
excellent peak shapes and the LC run time was only 6 min. 
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Figure 2 . MS/MS product ion scan of EO9 (precursor ion m/z 271). 
 
Figure 3. MS/MS product ion scan of EO5a (precursor ion m/z 307). 
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3.2 Detection of EO9 and EO5a by the HPLC-MS/MS  
Apart from the protonated species at m/z 289 for EO9 and m/z 307 for EO5a, sodium 
adducts were also visible (m/z 311 and m/z 329, respectively) in the Q1 mass spectra 
of EO9 and respectively EO5a (spectra not shown).  
An ion corresponding to the elimination of water (m/z 271) from the molecular ion of 
EO9 was the most prominent, indicating that the elimination of water is a favorable 
reaction for the molecule, which occurs immediately in Q1. An ion corresponding to the 
loss of water from the molecular ion is also observed for EO5a (m/z 289). The 
protonated ion after the elimination of water (iminium ion) from EO9 (m/z 271) and the 
protonated molecular ion of EO5a were induced to fragment in the collision cell. The 
resulting product ion spectra and the proposed fragmentation patterns are presented in 
Figure 2 for EO9 and Figure 3 for EO5a. The main fragment ion in the spectrum of 
EO9 corresponds to the loss of the CH2O from the allylic alcohol (m/z 241). The main 
fragment ion in the spectrum of EO5a corresponds to the cleavage of the amine moiety 
and the elimination of water (m/z 231). After optimization of the MS parameters, the 
fragment ion at m/z 241 for EO9 and the fragment ion at m/z 231 for EO5a were the 
most abundant and used for quantitative multiple reaction monitoring (MRM) of EO9 
and EO5a, respectively.  
For EO9-d3 and EO5a-d4 similar transitions as for EO9 and EO5a, respectively, were 
selected and optimized. 
 
3.3 The identification of EO9-Cl, a new degradation product of EO9 
The EO9 molecule owes its significant anti-tumor activity to the reactive aziridine 
moiety. However, because of its reactivity, it can react with other nucleophiles e.g. 
solvents or salts prior to its biological target. 
After diluting an acidic urine sample (pH ~ 4) containing EO9 with ammonium acetate 
buffer (pH 8.5; 0.1M) - MeOH (7:3, v/v) and recording the total ion current (TIC) scan of 
the injected sample, the presence of EO9, the degradation product EO5a, and an other 
unknown compound was accounted for. A closer look at the newly formed compound, 
the natural isotopic peak abundances (see further below), and the recognition that the 
urine contains high levels of nucleophilic chloride anion, pointed out that the new 
degradation product of EO9 could be the chloride adduct of EO9.  
In Figure 4, a Q1 mass spectrum of EO9-Cl is presented.  
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Apart from the protonated species at m/z 325, sodium adducts are also visible (m/z 
347). Special attention should be given to the characteristic Cl- isotope abundances in 
the MS. Since ions are separated in mass spectrometry according to their m/z values, 
the mass spectrum exhibits a peak for each of these ions. Mass spectrometry offers 
one of the best ways to identify and quantify the presence of different isotopes in a 
sample (42).  
 
 
 
 
0.0E+00
2.0E+07
4.0E+07
6.0E+07
8.0E+07
200 240 280 320 360 400
m/z (amu)
In
te
ns
ity
 (c
ps
)
 
Figure 4. Q1 (m/z 200-400) mass spectrum of EO9-Cl.  
 
The elemental composition of an ion can be determined from the ratio of the intensity 
of the isotope peaks to the intensity of the nominal mass peak. The chlorine atom has 
two naturally occurring stable isotopes that differ by 2 amu. In addition, 35Cl accounts 
for about 75% of natural Cl; while 37Cl accounts for the rest. If the notation P(X) is used 
to denote the probability that a given isotope or set of isotopes will occur, the presence 
of one Cl atom in an ion can be written as the probability of finding each of the 
individual isotopes, for example P (35Cl) = 0.75 and P (37Cl) = 0.25, where the 
numerical probabilities are the approximate natural isotopic abundances of 35Cl and 
37Cl, adjusted so that their sum is 1.0. The ratio of the intensities of the two peaks 
caused by the presence of the Cl atom is given by the equation (X)/(X+2) = 
(M+H)+- H2O 
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(X+)/((X+2)+) = P(35Cl)/ P(37Cl) = 0.75/0.25 = 3/1 = 100/33.3, where (X) is the intensity 
of the peak corresponding to the ion having the lower m/z value (X+), and (X+2) is the 
intensity of the peak 2 amu higher. These intensities are directly proportional to the 
relative abundances of the corresponding ions, which are denoted by the terms (X+) 
and ((X+2)+) (42). This is shown in the Q1 mass scan in the Figure 4. The ratio of the 
intensities of the peak corresponding to m/z 325.1 and the peak corresponding to m/z 
327.1 is 8.1E7 cps / 2.8E7 cps = 100 / 34.6 and consequentially indicates that the 
chlorine ion is indeed present in the molecule of EO9. 
An ion corresponding to the elimination of water from the molecular ion is also 
observed (m/z 307). It is clear from the isotopic pattern of the ions around m/z 307 that 
chlorine is still present in the remainder of the molecule.  
The protonated molecular ion of EO9-Cl was induced to fragment in the collision cell 
and the resulting product ion spectrum is presented in Figure 5. The main fragment ion 
corresponds to the loss of the CH2O from the allylic alcohol and the elimination of the 
Cl atom (m/z 241). As expected, no typical Cl pattern is seen at the m/z of 241. After 
optimization of the MS parameters, the fragment ion at m/z 241 was the most 
abundant and used for quantitative MRM of EO9-Cl. 
 
Figure 5 . MS/MS product ion scan of EO9-Cl (precursor ion m/z 325) 
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3.4 Non-stabilized urine 
The stability of EO9 in non-stabilized urine was assessed at an initial concentration of 
115.6 µM of EO9 by comparing the mean calculated concentrations against the 
concentration measured at time zero. The results are summarized in Table 2. EO9 was 
not stable in non-stabilized acidic urine at pH 5.1 at 43˚C. After 3 hours, only 82.0% of 
the initial EO9 concentration was recovered. The main degradation products were 
EO5a (13.3%) and EO9-Cl (4.35%). Since the total recovery was around 100% 
(99.7%), it can be concluded that under these conditions EO9 degrades exclusively 
into EO5a and EO9-Cl. However during the 1-hour instillation (43˚C, pH 5.1) it can be 
expected that approximately 6.6% of EO9 will be converted into EO5a and 2.1% into 
EO9-Cl (data not shown). 
EO9 was stable under other tested conditions in non-stabilized urine at pH 5.1-7.3. The 
coefficient of variation (C.V.) values for EO9 were less than 10.4%. 
 
Table 2. Stability data of EO9 in non-stabilized urine. 
Condition Time point Final pH EO9 rec (%) EO5a rec (%) EO9-Cl rec (%) Mass Balance (%) 
       
43ºC 3h 5.1 82.0 13.3 4.35 99.7 
43ºC 3h 5.9 86.2 8.60 4.54 99.3 
43ºC 3h 7.3 101 2.43 0.950 104 
       
37ºC 3h 5.1 92.5 9.58 3.56 106 
37ºC 3h 5.9 93.6 6.27 3.41 103 
37ºC 3h 7.3 92.1 1.61 0.637 94.3 
       
room temp. 3h 5.10 98.8 4.41 2.35 106 
room temp. 3h 5.90 95.1 2.60 1.33 99.0 
room temp. 3h 7.30 103 0.780 0.210 104 
       
Ice 24h 5.1 95.6 3.18 1.26 100 
Ice 24h 5.9 97.2 0.732 0.393 98.3 
Ice 24h 7.3 102 0.347 0.158 102 
 
3.5 Stabilized urine 
Stability of EO9 in urine stabilized with TRIS buffer (5mM, pH 9.0) (1:1, v/v) was 
assessed at an initial concentration of 57.8 µM of EO9 by comparing the mean 
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calculated concentrations against the concentration measured at time zero. The results 
are summarized in Table 3. 
EO9 was not stable in a stabilized urine with the final pH 7.3 and 7.4 after 3 months of 
storage at – 20˚C. Only 72.1% of the initial EO9 concentration at pH 7.3 was 
recovered. The main degradation products were EO5a (3.49%) and EO9-Cl (16.2%). 
When the recoveries of EO9, EO5a, and EO9-Cl were added together, the total 
recovery ended up being 91.8%. This may suggest that other unknown degradation 
products were formed along with EO5a and EO9-Cl. Further research is needed to 
clarify the lack of mass balance. 
 
Table 3. Stability data of EO9 in stabilized urine. 
Condition Time point Final pH EO9 rec (%) EO5a rec (%) EO9-Cl rec (%) Mass Bal (%) 
ice 24h 7.3 101 1.61 0.347 103 
ice 24h 7.4 96.1 0.902 0.695 97.7 
ice 24h 8.3 104 0.693 0.0279 105 
 -20ºC 3 months 7.3 72.1 3.49 16.2 91.8 
 -20ºC 3 months 7.4 83.3 2.32 13.8 99.4 
 -20ºC 3 months 8.3 88.3 0.447 0.961 89.7 
       
 -70ºC 3 months 7.3 107 1.05 1.15 109 
 -70ºC 3 months 7.4 96.1 0.920 0.997 98.0 
 -70ºC 3 months 8.3 110 0.444 -0.219 110 
 freeze/thaw at -20ºC 3 cycles 7.30 98.7 0.702 0.669 100 
 freeze/thaw at -20ºC 3 cycles 7.40 99.3 1.09 0.772 101 
 freeze/thaw at -20ºC 3 cycles 8.30 112 0.0927 0.0853 112 
 freeze/thaw at -70ºC 3 cycles 7.30 98.5 1.03 0.515 100 
 freeze/thaw at -70ºC 3 cycles 7.40 106 0.706 0.561 108 
 freeze/thaw at -70ºC 3 cycles 8.30 110 0.0995 0.0585 110 
 
At a higher pH level (urine batch 3; pH 8.3), the percent difference from time zero was 
less than 15%, indicating that EO9 can be considered stable for 3 months during 
storage at – 20˚C. Less than 1% of EO9-Cl was formed in comparison to the more 
acidic urine, however, the total recovery was also around 90%. 
EO9 was stable for the rest of the tested conditions in stabilized urine at pH 7.3-8.3. 
The C.V. values for EO9 were less than 6.74%. 
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The graph in Figure 6 displays the stability plot of EO9 in urine at pH 5.1 for analyzed 
conditions. 
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Figure 6. Stability plot for EO9 in urine batch 1 (pH 5.1). 
 
3.6 Buffer strength 
When the urine at an initial pH of 5.1 was stabilized with an equal volume of TRIS 
buffer (pH 9.0; 5mM), the resulting urine pH was 7.3. With more acidic urine, it can be 
expected that higher buffer strength is needed. 
 
3.7 Proposed degradation scheme of EO9 
In acidic medium EO9 decomposes principally into EO5a (6). The degradation scheme 
for EO9 in acidic medium is proposed in Figure 7. The initial step of the reaction is 
thought to be protonation of the trivalent nitrogen in the aziridine ring, yielding an 
iminium ion. This electrophilic center is then attacked by nucleophiles, such as water 
molecules, resulting in a degradation product with an ethanolamine group at C5 (6). 
In urine that contains high content of chloride anions, an EO9-Cl product is formed 
(especially at the lower pH) (Figure 7). The initial step of the reaction is again the 
protonation of the trivalent nitrogen in the aziridine ring, followed by a nucleophilic 
chloride attack resulting in the formation of EO9-Cl. 
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Figure 7. Proposed degradation scheme of EO9 in (acidic) urine. 
 
In time, there is substantially more EO9-Cl found in urine than EO5a, indicating that Cl- 
is far more reactive than water molecules in this regard. To proof that EO9-Cl is not 
formed from EO5a, we incubated urine with EO5a. The experiments showed that 
EO5a is fairly stable in urine and was not converted into EO9-Cl. 
 
4. Conclusion 
Stability experiments with EO9 in human urine revealed that during instillation (1h, 
43˚C, pH 5.1) it can be expected that approximately 6.6% of the drug would be 
converted into EO5a and 2.1% into EO9-Cl. After the collection of urine (pH 5.1-7.3) 
and stabilization with TRIS buffer (pH 9.0; 5mM), urine samples can be frozen (at – 
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20˚C and – 70˚C) and thawed at ambient temperature for up to 3 times and stored for 
up to 3 months at – 70 ˚C.  
A newly found degradation product of EO9, EO9-Cl, has been identified. The proposed 
degradation mechanism of EO9 in (acidic) urine is supported by the degradation 
mechanism described earlier by de Vries et al. in aqueous buffer solutions (6). Results 
illustrate that EO9 becomes more stable in urine with increased pH, which is also in 
accordance with previous presented results (6).  
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Abstract 
A bladder instillation of EO9 (EOquinTM) is currently used in phase II clinical trials for 
the treatment of superficial bladder cancer. Three alternative formulations were 
developed to improve its pharmaceutical properties and clinical acceptability. Freeze-
dried products composed of EO9, 2-hydroxypropyl-β-cyclodextrin (HPβCD), 
tri(hydroxymethyl) aminomethane (Tris), and sodium bicarbonate (NaHCO3) were 
tested. Selection of one formulation for further development was based on stability 
studies. These studies comprised stability of the freeze dried products, stability after 
reconstitution and dilution and stability during bladder instillation in an experimental 
set-up. The stability study of the freeze dried products showed that the formulation 
composed of EO9/HPβCD/Tris (4/600/1 mg/vial) was most stable. After reconstitution 
and dilution all products were stable for at least 8 hours. The product composed of 
EO9/HPβCD/NaHCO3 (4/600/20 mg/vial) was the least stable product both as freeze-
dried formulation and after reconstitution and dilution. The bladder instillation 
simulation experiment showed that all products were stable when mixed with urine of 
pH 8 and unstable in urine of pH 4 and 6. The degradation products formed in urine 
were EO5a and EO9-Cl.  
Based on these results, the product composed of EO9/HPβCD/Tris (4/600/1 mg/vial) 
was selected for further pharmaceutical development. 
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1. Introduction 
EO9 is a bioreductive alkylating indoloquinone (Fig. 1) and an analogue of the 
antitumour antibiotic mitomycin C. EO9 is an inactive prodrug, which is activated by 
reduction of the quinone moiety to semiquinone or hydroquinone, generating an 
intermediate with an electrophilic aziridine ring system, which serves as a target for 
nucleophilic DNA. This reaction mechanism is common for bioreductive alkylating 
indoloquinones (1-3) . For the treatment of superficial bladder cancer an investigational 
pharmaceutical product of EO9 (EOquin™) is currently used successfully in phase II 
clinical trials. This formulation is a freeze-dried product which has to be reconstituted 
with a separate solution composed of propylene glycol/water for injection (WfI)/sodium 
bicarbonate (NaHCO3)/sodium edetate 60/40/2/0.02% (v/v/w/w). The need of this 
special reconstitution solution results in higher costs, requires more planning in the 
logistic field and is less user friendly than reconstitution with WfI and normal saline. 
Furthermore, the bladder instillation contains 30% (v/v) propylene glycol after 
reconstitution and dilution, which is hyper-osmotic and could cause local irritation of the 
bladder tissue. Therefore, efforts were made to design a new pharmaceutical product 
for intravesical administration of EO9. This resulted in three prototype freeze-dried 
products containing per vial 4 mg EO9, 600 mg 2-hydroxypropyl-β-cyclodextrin 
(HPβCD) and one of the alkalizers NaHCO3 (20 mg) or 
tri(hydroxymethyl)aminomethane (Tris, 1 or 6 mg). HPβCD was selected as 
complexing agent, because it dramatically increases the solubility of EO9 in aqueous 
solutions. To be able to select the best formulation for further development, stability 
data are required. Therefore, the next step in the pharmaceutical development was a 
stability study. For this product three kinds of stability are of importance: the stability of 
the freeze dried product in the primary packaging material to determine storage 
conditions between manufacture and administration, the stability of the product after 
reconstitution and dilution to determine storage and handling conditions between 
preparation of the bladder instillation and administration, and the “in vivo” stability of 
the product during bladder installation.  
This article describes how these stability studies and the selection of the best 
formulation are performed. Furthermore, it also provides practical instructions how to 
handle this new investigational anticancer agent for the treatment of superficial bladder 
cancer. 
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Figure 1.Chemical structures of EO9 (A), EO5a (B) and EO9-Cl (C). 
 
2. Materials and methods 
2.1 Materials 
EO9 drug substance (C15H16N2O4, Mw=288Da) originated from IRIX, Inc. (Irvine, CA, 
USA). EO9-d3 internal standard (C15H13D3N2O4), EO9-Cl (C15H17N2O4Cl, degradation 
product of EO9), EO5a (C15H18N2O5, degradation product of EO9), and EO5a-d4 
internal standard (C15H14D4N2O5) were all kindly supplied by Spectrum 
Pharmaceuticals, Inc. (Irvine, USA). WfI and normal saline were originated from B. 
Braun (Melsungen, Germany). HPβCD (Mw = 1399 Da) was purchased from Roquette 
Freres (Lestrum, France). Methanol (LC gradient grade) was obtained from Biosolve 
Ltd. (Amsterdam, The Netherlands). All other solvents or chemicals used were of 
analytical grade. Distilled water was used throughout the analyses. Drug free human 
urine was obtained from a healthy volunteer from the laboratory of the Pharmacy at the 
Slotervaart Hospital (Amsterdam, The Netherlands). All freeze-dried products were 
prepared in-house (Slotervaart Hospital, Amsterdam, The Netherlands). 
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2.2 Manufacturing and stability of the freeze dried product 
Formulation solutions composed of EO9/HPβCD/NaHCO3 (2/300/10 mg/ml), 
EO9/HPβCD/Tris (2/300/0.5 mg/ml), and EO9/HPβCD/Tris (2/300/3 mg/ml) in 20% 
(v/v) tert-butyl alcohol (TBA) were sonicated for 2 h. Aliquots of 2 ml were filled in 8 ml 
glass vials (hydrolytic class I type Fiolax-clear, Aluglas, Uithoorn, The Netherlands), 
partially closed with grey butyl rubber lyophilization stoppers (Type FM157/1, Helvoet 
Pharma N.V., Alken, Belgium) and subsequently freeze dried (Model Lyovac GT4, 
STERIS, Hürth, Germany). The solutions were frozen to −35 °C in 1 h. The primary 
drying phase started after 2 h and was performed at a shelf temperature of −35 °C and 
a chamber pressure of 0.20 mbar for 45 h. The product temperature during primary 
drying was −30 °C. For secondary drying the temperature was raised to +25 °C in 15 h. 
The chamber pressure of 0.20 mbar was maintained. Vials were closed at a chamber 
pressure of 0.20 mbar after 3 h of secondary drying. Subsequently, the freeze dried 
products were stored at −20 ± 3 °C, 5 ± 3 °C and at the accelerated storage conditions 
25 ± 2 °C/60 ± 5% relative humidity (RH) and 40 ± 2 °C/75 ± 5%RH, all in the dark. 
Samples were taken in time and analyzed using HPLC–UV. 
 
2.3 Stability after reconstitution and dilution 
The stability after reconstitution and dilution was determined in triplicate. Three vials of 
each product were reconstituted with 1.45 ml WfI and shaken manually. Part of the 
reconstituted solutions was filtered using Millex® HV filters (0.45 μm × 4 mm, Millipore, 
Etten Leur, The Netherlands) and diluted 20 times with normal saline to a final 
concentration of 100 μg/ml EO9, corresponding to the target dose of 4 mg EO9 per 
bladder instillation of 40 ml. All solutions were stored in glass containers at room 
temperature and ambient light. Samples were taken after 2, 4, 6, and 8 h and analyzed 
with HPLC–UV. 
 
2.4 In vivo simulation experiment 
The exact compositions of the bladder instillations tested are given in Table 1. To 
mimic the situation in the bladder of the patient, the instillations were mixed with urine. 
Typically, a wide variation in urine production is seen, with a mean of approximately 
60–120 ml/h (4) . 
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Table 1. Composition of five freeze dried products and reconstitution solutions used in 
the stability study. 
Product Reconstitution solution Dilution solvent Final EO9 Final 
  Composition Volume Solvent Volume Concentration Volume 
1 EOquinTM * PG/WfI/NaHCO3/SE** 
60/40/2/0.02% v/v/w/w 
20 ml WfI 20 ml 100 µg/ml 40 ml 
2 EOquinTM * PG/WfI/NaHCO3/SE** 
60/40/1/0.02% v/v/w/w 
20 ml WfI 20 ml 100 µg/ml 40 ml 
3 EO9/HPβCD/Tris 
4/600/6 mg/vial 
WfI 1.45 ml Normal 
saline 
38 ml 100 µg/ml 40 ml 
4 EO9/HPβCD/Tris 
4/600/1 mg/vial 
WfI 1.45 ml Normal 
saline 
38 ml 100 µg/ml 40 ml 
5 EO9/HPβCD/NaHCO3 
4/600/20 mg/vial 
WfI 1.45 ml Normal 
saline 
38 ml 100 µg/ml 40 ml 
* EOquinTM is a freeze dried product composed of EO9/mannitol/NaHCO3 4/25/10 mg per vial 
** PG = propylene glycol, SE = sodium edetate 
 
Because the bladder instillations (with a volume of 40 ml) are administered into empty 
bladders and must be hold there for 1 h, the mean amount of urine present during this 
hour will be approximately 30–60 ml. Therefore, bladder instillation: urine ratios of 
40:30 ml and 40:60 ml were chosen for this experiment. Because a wide pH range is 
common in urine, the stability was tested in urine with pH 4, 6, and 8. The pH of the 
urine was adjusted to pH 4, 6, and 8 using HCl and NaOH. The pH was analyzed using 
a pH meter Model 654 (Metrohm, Herisau, Switzerland) equipped with a 3 M KCl 
electrode (Bonaduz, Switzerland). Immediately after preparation of the bladder 
instillation, urine was added, the pH was determined and the mixtures were stored at 
37 °C in the dark in a water bath. Samples were taken after 0, 15, 30, 45, 60 and 120 
min and stored immediately at −70 °C in the dark to prevent further degradation. 
Furthermore, the stability of all bladder instillations (i.e. after reconstitution and dilution 
of the freeze dried products) was determined at the same conditions and samples were 
taken at the same time points. Samples were analyzed using HPLC–MS/MS. This 
experiment was performed in triplicate. 
 
3. Experimental 
3.1 High performance liquid chromatography with UV detection (HPLC-UV) 
3.1.1 Preparation of calibration standards 
Two calibration standards were prepared by dissolving EO9 drug substance in 
methanol to a concentration of 500 μg/ml followed by a five-fold dilution with mobile 
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phase, resulting in a final EO9 concentration of 100 μg/ml. Subsequently, a system 
suitability test was performed. The requirements of this test were a deviation ≤1% 
between six repetitive injections from one calibration standard and a deviation ≤1.5% 
between the response factors of both calibration standards. 
 
3.1.2 Analysis 
HPLC–UV analysis was performed using an isocratic P1000 pump, AS 3000 
autosampler and an UV 1000 UV/VIS detector, all from Thermo Separation Products 
(Breda, The Netherlands). The mobile phase consisted of 5 mM phosphate buffer pH 
7/methanol 70/30% (w/w). A Zorbax SB-C18 analytical column (750 mm × 4.6 mm i.d., 
particle size 3.5 μm, Agilent Technologies, Palo Alto, California, USA) preceded by a 
guard column (reversed phase 10 mm × 3 mm, Varian, Palo Alto, California, USA) was 
used. Detection was performed at 270 nm. An injection volume of 10 μl, flow rate of 0.7 
ml/min and run time of 10 min were applied. Samples were diluted prior to analysis 
with mobile phase to a concentration of 100 μg/ml. Chromatograms were processed 
using Chromeleon software (Dionex Corporation, Sunnyvale, CA, USA). 
 
3.2 High performance liquid chromatography with tandem mass spectrometry (HPLC-
MS/MS) 
3.2.1 Preparation of calibration standards 
Stock solutions of 1 mg/ml of EO9, EO5a and EO9-Cl in ethanol were prepared. 
Working solutions of EO9, EO5a and EO9-Cl were obtained by dilution of the stock 
solutions with ammonium acetate buffer (pH 8.5; 0.1 M)/methanol (70/30%, v/v). 
Subsequently, the working solutions of EO9, EO5a and EO9-Cl were further diluted in 
ammonium acetate buffer (pH 8.5; 0.1 M)/methanol (70/30%, v/v) to concentrations 
ranging from 100 to 25,000 ng/ml. These diluted working solutions were used to 
prepare the calibration standards. 
Furthermore, stock solutions of 1 mg/ml of the internal standards EO9-d3 and EO5a-d4 
in ethanol were prepared. Subsequently, one working solution of the internal standards 
was prepared by transferring 500 μl of EO9-d3 stock solution and 500 μl of EO5a-d4 
stock solution to a 50.0 ml volumetric flask. Subsequently, a mixture of ammonium 
acetate buffer (pH 8.5; 0.1 M)/methanol (70/30%, v/v) was added to obtain a final  
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concentration of 1000 ng/ml for both EO9-d3 and EO5a-d4. All solutions were stored at 
−20 ± 3 °C. 
Prior to analysis, calibration standards containing EO9, EO5a and EO9-Cl were freshly 
prepared in a range from 10 to 2500 ng/ml by dilution of the working solutions of EO9, 
EO5a and EO9-Cl ten times with ammonium acetate buffer (pH 8.5; 0.1 M)/methanol 
mixture (70/30%, v/v), followed by vortex-mixing for approximately 30 s. The calibration 
standards were analyzed in duplicate. 
 
3.2.2 Analysis 
The HPLC system comprised an HP1100 (Agilent Technologies, Palo Alto, CA) binary 
pump, degasser and HP1100 auto sampler (Agilent Technologies, CA). Gradient 
chromatography was performed using a Gemini C18 column (150 mm × 2.1 mm i.d., 
particle size 5 μm). The mobile phase consisted of ammonium hydroxide (pH 8.5; 
1mM) in water (A) and methanol (B), pumped at a flow-rate of 0.2 ml/min. In the first 
0.3 min, the eluent consisted of 60% A and 40% B, followed by 90% B for 2.7 min. The 
column was stabilized with 40% B for 2 min. The autosampler temperature was 10 °C 
and 25 μl of pre-treated samples were injected into the HPLC system. Sample pre-
treatment was performed by mixing aliquots of 30 μl of the bladder instillation/urine 
samples with 150 μl working solution of the internal standards and 1320 μl ammonium 
acetate (pH 8.5; 0.1 M)/methanol (70/30%, v/v) solution. 
The HPLC eluate was fed directly into an API 2000 triple quadrupole MS equipped with 
an electrospray (ESI) ion source (Sciex, Thornhill, ON, Canada). Positive ions were 
created at atmospheric pressure and the mass analyzer was operated in the multiple 
reaction monitoring (MRM) mode using unit resolution for the quadrupoles. The 
resulting MRM chromatograms were used for quantification utilizing Analyst™ software 
version 1.2 (Sciex). Mass transitions of m/z 271 → 241 and 274 → 244 were optimized 
for EO9 and EO9-d3, respectively, with dwell times of 150 ms. Mass transitions of m/z 
307 → 231 and 311 → 231 were optimized for EO5a and EO5a-d4, respectively, with 
dwell times of 150 ms. Mass transition of m/z 325 → 241 was optimized for EO9-Cl with 
a dwell time of 150 ms. EO9 and EO9-Cl were quantified using EO9-d3 as internal 
standard and EO5a using EO5a-d4 as internal standard. Nebulizer gas (compressed 
air), turbo gas (compressed air), curtain gas (N2), and collision activated dissociation 
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gas (N2) were operated at 40, 65, 20, and 4 psi, respectively. Finally, the ionspray 
voltage was kept at 5500 V, with a source temperature of 250 °C. 
 
4. Results and discussion 
4.1 Stability of freeze dried products 
Due to the chemical instability of EO9  (5) freeze-drying was selected to keep EO9 
pharmaceutical product stable for a longer period of time. The stabilities of the freeze-
dried products EOquin™, EO9/HPβCD/Tris (4/600/6 mg/vial), EO9/HPβCD/Tris 
(4/600/1 mg/vial), and EO9/HPβCD/NaHCO3 (4/600/20 mg/vial) are given in Table 2. A 
product is defined as “stable” if the degradation is less than or equal to 5%. This limit is 
derived from The Council of European Communities in which it is stated that the API 
content of finished products at time of release should not exceed ±5% (6) . According 
to this definition, the freeze-dried product with 6 mg Tris/vial (Product 3) was stable for 
at least 3 months at 5 °C, and less than 1 month both at 25 °C/60%RH and 40 
°C/75%RH. The product containing 1 mg Tris/vial (Product 4) is more stable than 
Product 3, with stabilities of at least 5 months at 5 °C, 3–5 months at 25 °C/60%RH 
and 1 month at 40 °C/75%RH. The freeze-dried product containing HPβCD/NaHCO3 
(Product 5) was less stable than Products 3 and 4. Product 5 was stable for 1 month at 
25 °C/60%RH and less than 1 month at 40 °C/75%RH. At 5 °C, this product was stable 
for at least 2 months at 5 °C (data not shown). However, within those 2 months a slight 
decrease in purity of 1% was seen, indicating a slow, but measurable degradation in 
this period of time. Therefore, the vials stored 2 months at 5 °C were transferred to −20 
°C for long term stability testing. After 1 year of storage at −20 °C no significant 
decrease in purity was seen, indicating that this product is stable for at least 1 year at 
−20 °C, in the dark. In all products, EO5a was one of the main degradation products 
formed (Fig. 1). These results indicate that of the HPβCD-containing products, Product 
4 (EO9/HPβCD/Tris 4/600/1 mg/vial) is most stable. Long term stability testing is still 
ingoing, but because Product 5 was stable for at least 1 year at −20 °C and the 
accelerated stability study showed that Product 4 is much more stable than Product 5, 
it is expected that Product 4 will be stable for a longer period of time than 1 year at −20 
°C. 
 
 
Chapter 2.4 
 
170 
Table 2. Stability of the freeze dried products. 
Product* Storage time Purity (%)**   
 (months) -20ºC 5ºC 25ºC/60%RH 40ºC/75%RH 
1/2 0 99.01 ± 0.19 - - - 
3 0 99.30 ± 0.02 - - - 
4 0 99.48 ± 0.03 - - - 
5 0 98.84 ± 0.07 - - - 
1/2 1 - - - 97.89 ± 0.37 
3 1 99.24 ± 0.01 98.83 ± 0.10 91.93 ± 1.45 70.44 ± 2.00 
4 1 - - 99.09 ± 0.04 95.53 ± 0.19 
5 1 - 98.99 ± 0.03 95.43 ± 0.44 69.96 ± 6.29 
1/2 3 - 99.37 ± 0.05 98.73 ± 0.14 97.20 ± 0.31 
3 3 99.37 ± 0.01 98.34 ± 0.46 83.50 ± 1.06 41.59 ± 3.00 
4 3 99.42 ± 0.00 99.33 ± 0.03 96.65 ± 0.17 86.80 ± 0.96 
5 3 - - 85.28 ± 0.89 27.82 ± 2.54 
4 5 - 99.38 ± 0.09 94.47 ± 0.17 78.83 ± 2.23 
* 1/2 = EOquinTM  (see Table 1) 
3 = EO9/HPβCD/Tris (4/600/6 mg/vial) 
4 = EO9/HPβCD/Tris (4/600/1 mg/vial) 
5 = EO9/HPβCD/NaHCO3 (4/600/20 mg/vial) 
** Area of the peak of EO9 expressed as % of the total area of all peaks detected with HPLC-UV analysis.  
 
As reference, the stability of EOquin™ (Product 1/2) is also given. This product was 
stable for at least 3 months at 5 °C, 25 °C/60%RH and 40 °C/75%RH. This might 
indicate that the HPβCD-containing freeze-dried products are all less stable than the 
currently used freeze-dried product. However, this may not be a problem if the product 
is stable for at least 1 year at −20 °C, considered as an acceptable storage time. 
 
4.2 Stability after reconstitution and dilution 
This study was performed to determine the storage condition and storage time in the 
clinic between preparation of the bladder instillation and administration to the patient. 
Normally, in the clinic bladder instillations are prepared at room temperature and 
ambient light and therefore, these conditions were chosen for the stability study. 
Reconstitution of the freeze-dried products with 1.45 ml WfI resulted in a final volume 
of 2.0 ml. The pH values of the reconstituted products were 8.6, 8.3, and 9.9 for the 
freeze-dried products containing 6 mg Tris (Table 1, Product 3), 1 mg Tris (Table 1, 
Product 4), and 20 mg NaHCO3 (Table 1, Product 5), respectively. All solutions 
remained clear and purple after dilution with normal saline to a final volume of 40 ml. 
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The pH values after dilution were 8.7, 7.2, and 9.5 for the final bladder instillations of 
Products 3–5, respectively. The results of the stability study of the reconstituted and 
diluted products are depicted in Fig. 2.  
We defined a maximum allowed degradation limit of 5%, indicated in the figure. The 
results clearly show that both reconstituted products containing Tris (Products 3 and 4) 
are stable for at least 8 h at room temperature and ambient light. Reconstituted 
Product 5 (the HPβCD/NaHCO3-containing product) however, is only stable for 4 h. On 
the other hand, this product is stable for at least 8 h after further dilution. These 
differences in stability are all due to a pH-effect. The pH of Products 3 and 4 is very 
near the optimal pH (i.e. maximum stability) of EO9 (pH 8.75) (5). For Product 5 
however, the pH after dilution (pH 9.5) is closer to the optimal pH of EO9 than after 
reconstitution (pH 9.9). 
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Figure 2. Stability of freeze dried products composed of EO-9/HPβCD/Tris (4/600/6 mg 
per vial, Product 3) after reconstitution with WfI (¼) and after dilution in normal saline 
(U),EO-9/HPβCD/Tris (4/600/1 mg per vial, Product 4) after reconstitution with WfI () 
and after dilution in normal saline (¡), and EO-9/HPβCD/NaHCO3 (4/600/20 mg/vial, 
Product 5) after reconstitution in WfI (×) and dilution in normal saline (S). 
 
Furthermore, it was shown that 1 mg Tris is not sufficient to maintain the pH at 8.3 after 
dilution. Due to this decrease in pH a decrease in stability was seen in time. The purity 
Stability level 
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of this product after dilution was 99.1, 98.1, 97.1% after 1, 6, and 8 h of storage 
respectively. With 6 mg Tris/vial, no change in pH was seen after dilution and 
therefore, EO9 was most stable in this formulation.  
Because in the clinic the instillation duration is 1 h, a bladder instillation must be stable 
for at least 1 h plus the additional time necessary for preparation at the hospital 
pharmacy and transfer to the bedside. Therefore, a stability of 8 h (a working day) is 
preferred, which gives a feasible time-span from a logistic point of view. Both bladder 
instillations composed of EO9/HPβCD/Tris are stable for at least 8 h after 
reconstitution and dilution and are therefore suited for the clinic. 
 
4.3 In vivo simulation experiment 
With this experiment a good estimation of drug stability in the bladder instillations after 
administration into the bladder of the patient can be obtained. The bladder instillation 
indicated as Product 1 (Table 1) is the product, which is currently used in phase II 
clinical trials. The stability of this product was analyzed as reference for the alternative 
HPβCD-containing formulations. Furthermore, the stability of EOquin™ using a 
reconstitution solution containing 1% (w/v) instead of 2% (w/v) NaHCO3 (Product 2, 
Table 1) was also analyzed to determine the effect of the NaHCO3 concentration on 
the in vivo stability of EOquin™.  
The results show that all formulations are stable (i.e. have an EO9 content ≥95% 
calculated as percentage of the theoretical content at t = 0) after reconstitution and 
dilution for at least 1 h at 37 °C in the dark (Table 3). No significant differences were 
seen between the five formulations. However, the bladder instillation composed of 
EO9/HPβCD/NaHCO3 (Product 5) showed a tendency to be less stable than the other 
instillations. This corresponds to the data found in the stability study after reconstitution 
and dilution. 
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Table 3. Degradation of EO9 in the bladder instillation and after mixing with urine pH 4, 
6, 8 in the ratios bladder instillation: urine of 40:30 and 40:60 after storage for one hour 
at 37°C in the dark. 
Product ** Mixture 
Instillation/urine 
pH urine pH 
mixture 
EO9 
(%)* 
RSD 
(%)* 
EO5a 
(%)* 
EO9-Cl 
(%)* 
Mass balance 
(%)* 
1 100/0 — 9.2 103 5.1 0.2 0.0 103 
2 100/0 — 9.3 102 7.3 0.2 0.0 103 
3 100/0 — 8.8 102 4.8 0.3 0.6 103 
4 100/0 — 8.1 101 4.2 0.5 1.1 102 
5 100/0 — 9.6 97.0 4.8 0.4 0.4 97.7 
1 40/30 4 8.2 95.9 2.7 0.3 0.0 96.2 
2 40/30 4 7.6 94.8 3.8 0.5 0.0 95.3 
3 40/30 4 4.5 1.5 7.4 42.1 49.3 92.9 
4 40/30 4 4.2 1.2 12.1 40.9 54.8 97.0 
5 40/30 4 5.7 18.6 7.3 39.1 34.5 92.2 
1 40/30 6 8.7 97.4 4.1 0.3 0.0 97.6 
2 40/30 6 8.4 98.1 2.9 0.3 0.0 98.4 
3 40/30 6 6.5 78.0 6.5 8.6 24.6 111 
4 40/30 6 6.2 47.0 4.3 14.6 46.7 108 
5 40/30 6 6.9 95.7 2.0 3.8 6.8 106 
1 40/30 8 8.9 96.7 2.2 0.1 0.0 96.8 
2 40/30 8 8.9 97.9 4.0 0.1 0.0 98.0 
3 40/30 8 8.2 105 2.8 0.6 0.7 107 
4 40/30 8 7.9 102 2.9 0.6 5.7 109 
5 40/30 8 8.6 99.8 2.9 0.8 0.7 101 
1 40/60 4 7.6 97.4 3.9 0.5 0.0 97.8 
2 40/60 4 7.2 93.1 1.3 1.5 0.3 95.0 
3 40/60 4 4.3 1.3 5.3 45.3 46.5 93.1 
4 40/60 4 4.1 1.2 12.4 43.1 50.6 94.9 
5 40/60 4 5.0 1.2 5.8 47.6 34.0 82.8 
1 40/60 6 8.1 98.7 2.1 0.1 0.0 98.8 
2 40/60 6 7.9 96.7 1.7 0.6 0.0 97.3 
3 40/60 6 6.1 56.6 1.5 15.7 29.3 102 
4 40/60 6 6.2 61.2 3.2 16.9 28.3 106 
5 40/60 6 6.6 83.1 6.6 6.0 7.2 96.4 
1 40/60 8 8.7 97.4 2.4 0.1 0.0 97.5 
2 40/60 8 8.7 94.8 1.6 0.3 0.0 95.1 
3 40/60 8 8.2 99.2 6.3 0.7 0.7 101 
4 40/60 8 7.9 102 1.8 0.8 2.3 105 
5 40/60 8 8.3 97.9 5.9 0.6 1.7 100 
 
* The amounts of EO9, EO9-Cl and EO5a are given as percentages of the initial molar amounts of EO9. 
**Composition of products as indicated in Table 1. 
 
The stability of the five bladder instillations mixed with urine in the ratio bladder 
instillation:urine of 40:60 stored at 37 °C in the dark are depicted in Fig. 3A–C for urine 
of pH 8, 6 and 4, respectively. All curves start at t = 5 min because 5 min were required 
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to measure the pH before the mixtures were placed in the water bath. Fig. 3A clearly 
shows that there was no difference in stability of the bladder instillations when they 
were mixed with urine pH 8. This was expected because EO9 is quite stable at this pH 
(5) . However, after mixing with urine of pH 6, the bladder instillations containing 
EO9/HPβCD/Tris (Products 3 and 4) were less stable than Product 5. Furthermore, all 
HPβCD-containing instillations (Products 3–5) were less stable than both EOquin™ 
(Products 1 and 2) bladder instillations (Fig. 3B). This was due to pH differences. The 
pH of the EO9/HPβCD/NaHCO3 bladder instillation mixed with urine pH 6 in the ratio 
bladder instillation:urine of 40:60 was 6.6 compared to pH 7.9 and 8.1 for the EOquin™ 
bladder instillations (Table 3). Further decrease of the pH of urine to pH 4 resulted in a 
dramatic decrease in stability of EO9 in all bladder instillations containing HPβCD (Fig. 
3C). However, it is likely that this was not due to the presence of HPβCD, but due to 
low concentrations of alkalizer resulting in low pH levels (4.1–5.0) of the mixtures. The 
EOquin™ bladder instillations are more stable upon dilution with urine due to the 
relatively high NaHCO3 concentrations of the reconstitution solutions. Both EOquin™ 
bladder instillations were stable when mixed with urine pH 4 (Fig. 3C).  
 
A: Stability of EO9 bladder instillations mixed with urine pH 8 in 40:60 ratio. 
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B: Stability of EO9 bladder instillations mixed with urine pH 6 in 40:60 ratio. 
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C: Stability of EO9 bladder instillations mixed with urine pH 4 in 40:60 ratio. 
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Figure 3. Stability of five bladder instillations (EO-9/HPβCD/Tris 4/600/6 mg/vial (), 
EO-9/HPβCD/Tris 4/600/1 mg/vial (), EO-9/HPβCD/NaHCO3 4/600/20 mg/vial (), 
EOquinTM reconstituted with PG/WfI/NaHCO3/sodium edetate 60/40/2/0.02% v/v/w/w 
(U), and EOquinTM reconstituted with PG/WfI/NaHCO3/sodium edetate 60/40/1/0.02% 
v/v/w/w ()) mixed with urine pH 4, 6, 8 in 40:60 ratio. 
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Degradation of EO9 in the bladder instillation of Product 4 mixed with urine pH 6 in the 
ratio 40:60 is depicted in Fig. 4. This figure shows that degradation of EO9 in urine 
results in the formation of EO9-Cl and EO5a (Fig. 1). Furthermore, the mass balance 
shows that no other degradation products were formed. The formation of EO9-Cl and 
EO5a was also seen for the other HPβCD-containing bladder instillations (Table 3). 
Very minor degradation of the EOquin™ bladder instillations was seen. The formation 
of EO5a was seen in both EOquin™ bladder instillations, but the formation of EO9-Cl 
was only found in the bladder instillation prepared with the reconstitution solution 
containing 10 mg/ml NaHCO3 mixed with urine pH 4 in the ratio bladder instillation: 
urine of 40:60 (Table 3). This indicates that EO5a is probably formed more easily than 
EO9-Cl. Furthermore, the formation of EO9-Cl increases with decreasing pH for all 
bladder instillations at both bladder instillation : urine ratios   (Table 3). 
These results show that the pH of the urine of patients must be increased (i.e. 
alkalizing of patients with NaHCO3 tablets) prior to administration of one of the 
HPβCD-containing bladder instillations to hold EO9 stable during the instillation of 1 h. 
Alkalizing of patients was also performed in a randomized clinical trial to study the 
efficacy of intravesical Mitomycin C (7). 
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Figure 4. Degradation of EO-9 bladder instillation prepared from the freeze dried 
product composed of EO-9/HPβCD/Tris 4/600/1 mg/vial mixed with urine pH 6 in the 
volume ratio bladder instillation:urine = 40:60. The amounts of EO-9 (), EO-5a (U), 
EO-9-Cl () and the total mass balance () are depicted. 
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5. Conclusion 
Based on the stability studies of the freeze dried products, after reconstitution and 
dilution and the “in vivo” simulation the pharmaceutical formulation composed of 
EO9/HPβCD/Tris 4/600/1 mg/vial was selected as alternative formulation for EOquin™. 
Long term stability of this freeze dried product is still ongoing. Nevertheless, the 
product seems to be less stable than the product currently used in phase II clinical 
trials. However, based on the current stability data it is expected that this product is 
stable for at least 1 year at −20 °C, in the dark. Furthermore, this product is stable for 8 
h after reconstitution and dilution, indicating that the bladder instillation can be 
prepared well before administration, which is practical for use in the clinic. A probable 
disadvantage may be that alkalizing of patients is required as pre-treatment. However, 
this is a non-invasive procedure, which can be performed with administration of 
NaHCO3 tablets. 
The disadvantage of a slightly lower stability of the freeze-dried product and the need 
to alkalize patients is compensated by the advantage of reconstitution and dilution with 
WfI and normal saline instead of a special reconstitution solution. Furthermore, less 
irritation of bladder tissue may occur because this alternative instillation is iso-osmotic. 
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Abstract 
A sensitive and specific LC-MS/MS assay for the quantitative determination of 
anticancer agent EO9 and its conversion products EO5a and EO9-Cl in human and dog 
urine is presented. A 20-μL-urine aliquot was spiked with a mixture of deuterated 
internal standards EO9-d3 and EO5a-d4 and diluted with 180 µL 0.1 M ammonium 
acetate – methanol (7:3, v/v). 25 μL-volumes were injected onto the HPLC system. 
Separation was achieved on a 150 x 2.1 mm C18 column using an alkaline eluent (1 
mM ammonium hydroxide – methanol (gradient system)). Detection was executed by 
positive ion electrospray followed by tandem mass spectrometry. The assay quantifies 
a range from 0.1 µg/mL to 50 µg/mL for EO9, from 0.2 µg/mL to 50 µg/mL for EO5a and 
0.1 µg/mL to 4 µg/mL for EO9-Cl using 20 μL of stabilized urine samples. Validation 
results demonstrate that EO9, EO5a and EO9-Cl concentrations can be accurately and 
precisely quantified in human and dog urine. This assay is used now to support pre-
clinical and clinical pharmacologic studies with intravesically administered EO9. 
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1. Introduction 
The indoloquinone compound apaziquone (3-hydroxy-5-aziridinyl-1-methyl-2[indole-
4,7-dione]-prop-β-en-α-ol; EO9) is a bioreductive anticancer drug that was selected for 
clinical evaluation on the basis of a novel mechanism of action and good preclinical 
anti-tumor activity (1-3).  
EO9 is an inactive pro-drug that undergoes redox cycling leading to the formation of 
drug-derived DNA alkylating moieties or DNA-damaging reactive oxygen species (4-7). 
These alkylating intermediate species are capable of forming DNA adducts with single - 
strand breaks and DNA cross-linking and leading to cell kill.  
EO9 is extensively metabolized. One of the principal known metabolites/degradation 
products is EO5a, which has an open aziridine ring and shows less cytotoxicity than 
EO9 (8). Another degradation product, which was discovered by us and described 
earlier (9), is EO9 with covalently attached chlorine (EO9-Cl). It is formed in the acid-
catalyzed reaction of EO9 in the presence of chloride anions in urine. 
EO9 has a very short half-life in plasma (t½ values ranging from 0.8 to 19 min in 
humans) and a relatively poor ability to penetrate through multicell layers in vitro (10,11) 
However, this is an advantage for chemotherapeutic treatment of cancers that arise in a 
delimited compartment, such as superficial bladder cancer (12). In this case, drug 
delivery can be accomplished via the intravesical route and drug exposure of tumor 
tissue can be maintained with therapeutically relevant drug concentrations within the 
bladder cavity (12). Consequently, currently ongoing clinical trials investigating EO9 in 
superficial bladder tumors with local drug delivery show promising response rates 
(1,13,14). Drug analysis in voided urine provides insight into the pharmacologic 
behavior of EO9 after intravesical administration. 
So far, however, only one analytical assay has been published describing the 
determination of EO9 and EO5a, but not EO9-Cl, in human urine using high-
performance liquid chromatography coupled to the ultraviolet detection with low 
specificity (15). We have published earlier a high performance liquid chromatography 
coupled to tandem mass spectrometry method (HPLC-MS/MS) method for the analysis 
of EO9 and EO5a in human plasma (16). This assay was, however, not suitable for 
urine analysis. In order to quantify all three compounds of interest, EO9, EO5a and 
EO9-Cl in ongoing and upcoming preclinical and clinical studies, we developed a 
sensitive, specific, accurate, and rapid assay for the quantification of these analytes in 
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human and dog urine using an HPLC-MS/MS. Deuterated internal standards for EO9 
and EO5a were used for quantification. The method has been fully validated according 
to the FDA guidelines on bioanalytical validation (17,18), and will be applied in the 
pharmacokinetic studies with intravesically administered EO9. 
 
2. Experimental 
2.1 Materials 
EO9 (C15H16N2O4), EO9-d3 internal standard (C15H13D3N2O4), EO5a (C15H18N2O5), 
EO5a-d4 internal standard (C15H14D4N2O5) and the degradation product EO9-Cl 
(C15H17N2O4Cl) (Figures 1) were supplied by Spectrum Pharmaceuticals, Inc (Irvine, 
CA, USA). Methanol (LC gradient grade) was from Bissolve Ltd. (Amsterdam, The 
Netherlands). All other solvents or chemicals were analytical grade or better. Distilled 
water was used throughout the analyses. Drug free human urine was obtained from 
volunteers from the laboratory of the Department of Pharmacy & Pharmacology at the 
Slotervaart Hospital (Amsterdam, The Netherlands). Drug free dog urine was obtained 
from MPI research (Mattawan, MI, USA). 
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Figure 1.Chemical structures of EO9 (A), EO9-d3 (B), EO5a (C), EO5a-d4 (D) and 
EO9-Cl (E). 
 
2.2 Preparation of stock and working solutions 
Two sets of stock solutions of EO9, EO5a and EO9-Cl were prepared from two 
independent weighings and dissolution in ethanol at a target concentration of 1 mg/mL. 
The solutions had to be placed in the ultrasonic bath for 2 hours to dissolve all the 
compounds in ethanol. The same procedure was repeated each time the solutions 
were taken out of the freezer. These solutions were further diluted with ethanol to yield 
separate working solutions for EO9, EO5a and EO9-Cl. One set of each working 
solutions was used to prepare calibration standards, the other to prepare quality control 
samples. The obtained concentrations of calibration standards working solutions were 
800, 400, 200, 40, 20, 4 and 2 µg/mL for EO9; 800, 400, 200, 40, 20, 10 and 4 µg/mL 
for EO5a and 400, 100, 80, 60, 40, 30, 20, 10, 4 and 2 µg/mL for EO9-Cl. The quality 
control working solutions concentrations were 800, 200, 6 and 2 µg/mL for EO9; 800, 
200, 12 and 4 µg/mL for EO5a and 60, 40, 20, 6 and 2 µg/mL for EO9-Cl. Separate 
stock solutions of EO9-d3 and EO5a-d4 were prepared in ethanol at a concentration of 
1 mg/mL. An internal standards working solution was prepared by transferring 500 μL 
of EO9-d3 stock solution and 500 μL of EO5a-d4 stock solution to a 50.0 mL volumetric 
flask and adding 0.1 M ammonium acetate buffer pH 8.5 - methanol (7:3, v/v) to give a 
final concentration of 10,000 ng/mL for both internal standards. All solutions were 
stored at -20oC. 
 
2.3 Preparation of control human and dog stabilized urine 
The formulated product of EO9 (EOquin™) is used in clinical studies. This formulation 
consisted of 4 mg of EO9, 25 mg mannitol, 10 mg sodium bicarbonate  and 40 mL of 
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the diluent. The diluent formulation contained 10 mg/mL sodium bicarbonate (20 mg/mL 
for dogs), 0.2 mg/mL EDTA, and 0.6 mL propylene glycol in sterile water for injection 
(SWFI). The average volume collected after 60 min of instillation was 120 ± 47 mL, 
which consisted of EOquin formulation solution – human urine (1:2, v/v)15. In dogs 
however, the total collected urine was approximately 80 mL, which consisted of EOquin 
formulation solution – dog urine (1:1, v/v). After the collection of samples, an equal 
volume of TRIS buffer (5mM; pH 9.0) was added to raise the pH of urine and therefore 
prevent ex vivo degradation (stabilization of urine).  
EO9 is most stable at approximately pH 8.5 (7). To mimic the in vivo situation, we 
prepared the stabilized control human urine solutions, which consisted of 100 mL blank 
formulation (0.525 g sodium bicarbonate, 0.01 g EDTA, 62.5 mg mannitol, 30 mL 
propylene glycol in 70 mL SWFI), 200 mL control human urine and 300 mL TRIS buffer 
(5mM; pH 9.0). The stabilized control dog urine solution consisted of 100 mL blank 
formulation (1.03 g sodium bicarbonate, 0.01 g EDTA, 62.5 mg mannitol, 30 mL 
propylene glycol in 70 mL SWFI), 100 mL control dog urine and 200 mL TRIS buffer 
(5mM; pH 9.0). 
 
2.4 Preparation of calibration standards and quality control samples in stabilized human 
and dog urine 
Calibration standards containing EO9, EO5a and EO9-Cl were prepared freshly in a 
range from 0.1 µg/mL to 50 µg/mL for EO9, from 0.2 µg/mL to 50 µg/mL for EO5a and 
0.1 µg/mL to 4 µg/mL for EO9-Cl by adding 25 μL of EO9, EO5a and EO9-Cl working 
solutions in ethanol (described in section 2.2) to 2 mL-eppendorf tubes. This solutions 
were evaporated and the compounds were redissolved in stabilized human urine and 
stabilized dog urine, respectively, to yield concentrations of 0.1, 0.2, 1.0, 2.0, 10, 20, 40 
and 50 µg/mL for EO9; 0.2, 0.5, 1.0, 2.0, 10, 20, 40 and 50 µg/mL for EO5a, and 0.1, 
0.2, 0.5, 1.0, 1.5, 2.0, 3.0 and 4.0 µg/mL for EO9-Cl in human and dog urine.  
The calibration standards were vortex-mixed for approximately 30 sec before 
processing. Standards were processed in singular and analyzed in duplicate. 
Quality control samples for EO9, EO5a and EO9-Cl were prepared in stabilized human 
respectively dog urine at concentrations of 0.1, 0.3, 10 and 40 µg/mL for EO9; 0.2, 0.6, 
10 and 40 µg/mL for EO5a, and 0.1, 0.2, 2.0 and 3.0 µg/mL for EO9-Cl using the same 
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procedure as described above for the calibration standards. The calibration standards 
and quality control samples were prepared fresh for each validation run. 
 
2.5 Sample preparation 
Sample pretreatment was performed at ambient temperatures. 20 µL of a working 
solution containing the internal standards was added to 20 µL of stabilized human or 
dog urine aliquots and diluted with 180 µL 0.1 M ammonium acetate buffer pH 8.5 – 
methanol (7:3, v/v). The samples were vortexed for 10 sec and the clean solution was 
transferred to a glass autosampler vial with insert. 
 
2.6 HPLC 
The HPLC system comprises an HP1100 binary pump, degasser and HP1100 
autosampler (Agilent Technologies, Palo Alto, CA). Gradient chromatography was 
performed using a Gemini C18 column (150 x 2.1 mm ID, particle size 5 µm). The 
mobile phase consisted of 1 mM ammonium hydroxide in water (A) and 100% methanol 
(B) and was pumped at a flow-rate of 0.2 mL/min. In the first 0.3 min, the eluent 
consisted of 60% A and 40% B, followed by 90% B for 2.7 min. To stabilize the column, 
40% B was used for 2 min. Sample injections of 25 μL were carried out and the 
autosampler temperature was kept at 10oC.  
 
2.7 Mass spectrometry 
The LC eluate was directed into an API 2000 triple quadrupole MS equipped with an 
electrospray (ESI) ion source (Sciex, Thornhill, ON, Canada). Positive ions were 
created at atmospheric pressure and the mass analyzer was operated in the multiple 
reaction monitoring (MRM) mode using unit resolution for the quadrupoles. The 
resulting MRM chromatograms were used for quantification utilizing Analyst™ software 
version 1.2 (Sciex). Mass transitions of m/z 271 → 241, 274 → 244, 307 → 231, 311 → 
231, 325 → 241 were optimized for EO9, EO9-d3, EO5a, EO5a-d4 and EO9-Cl, 
respectively, with dwell times of 150 ms. EO9-d3 was used as an internal standard for 
EO9 and EO9-Cl. EO5a-d4 was used to quantify EO5a. Nebulizer gas (compressed 
air), turbo gas (compressed air), curtain gas (N2), and collision activated dissociation 
gas (N2) were operated at 40, 65, 20, and 4 psi, respectively. Furthermore, declustering 
potential (DP) for EO9 and EO9-d3 was 66 V and for EO5a, EO9-Cl and EO5a-d4 was 
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31 V. Focusing potential (FP) for EO9 and EO9-d3 was 310 V and for EO5a, EO9-Cl 
and EO5a-d4 was 350 V. The optimized collision energy (CE) was 17 V for EO9 and 
EO9-d3, 45 V for EO5a and EO5a-d4 and 40 V for EO9-Cl. Finally, the ion spray 
voltage was kept at 5500 V, with a source temperature of 250oC. 
 
2.8 Validation procedures 
A full validation programme according to the FDA guidelines was performed for the 
assay in human urine (18). For the assay in dog urine partial validation was executed 
by means of accuracy and precision, specificity and selectivity and stability in urine 
under storage conditions according to FDA rules (17,18).  
 
2.8.1 Linearity 
For the validation of the assay in human urine, calibration standards (8 non-zero 
standards of the analytes) were prepared in stabilized control human urine and 
analyzed in duplicate in three analytical runs. For the validation of the assay in dog 
urine, calibration standards (8 non-zero standards of the analytes) were prepared in 
stabilized control dog urine and analyzed in duplicate in one analytical run.  
The linear regression of the ratio of the areas of the analyte and internal standard 
peaks versus the concentration were weighed by 1/x2 (the reciprocal of the squared 
concentration). Concentrations were back-calculated from the constructed calibration 
curve and deviations from the nominal concentrations should be within ± 20% for the 
lower limit of quantitation (LLOQ) and within ± 15% for other concentrations with 
coefficient of variation (C.V.) values less than 20% and 15% respectively (17,18). 
 
2.8.2 Accuracy and precision 
Five replicates of the quality control samples (see section 2.4) were analyzed in each 
analytical run together with the calibration standards. Accuracies were determined as 
the percentage difference of the measured concentration from the nominal 
concentration and the C.V. was used to report the precision.   
The intra and inter-assay accuracies (% bias) should be within ±20% at the LLOQ level 
and within ±15% at the other concentrations (17,18). The intra and inter-assay 
precisions should be less than 20% at the LLOQ level and less than 15% at the other 
concentrations (17,18).  
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The ability to dilute samples originally above the upper limit of quantitation (ULOQ) of 
the calibration curve was demonstrated by and analyzing validation samples containing 
5 times the ULOQ for EO9, EO5a and EO9-Cl. Five replicates of each sample were 
analyzed in one analytical run after 20 time dilution in stabilized control human and 
control dog urine. 
 
2.8.3 Limit of detection 
The limit of detection (LOD) for EO9, EO5a and EO9-Cl, with the responses of the 
analytes at 2 times the response of the blank was established in three analytical runs in 
human urine.  
 
2.8.4 Specificity and selectivity 
To investigate whether endogenous matrix constituents interfered with the assay, six 
individual batches of control drug-free human and dog urine samples containing neither 
analyte nor internal standard (double blank), samples containing only internal standard 
(blank), and samples spiked at the LLOQ were prepared. Samples were prepared and 
analyzed according to the described procedures. Peak areas of compounds co-eluting 
with the analyte or internal standard should not exceed 20% of the analyte peak area at 
the LLOQ or 5% of the internal standard area. Deviations from the nominal 
concentrations should be within ± 20% for the LLOQ samples (17,18). 
 
2.8.5 Ion suppression  
Ion suppression was determined by comparing the analytical response of processed 
quality control samples with the analytical response of blank samples reconstituted with 
solutions containing the analytes and internal standards in 0.1 M ammonium acetate 
pH 8.5 - methanol (7:3, v/v). The loss of signal represents the ion-suppression. These 
experiments were performed in triplicate at three concentration levels. Ion suppression 
experiments for the internal standards were performed in a similar way.  
 
2.7.6 Carry-over 
Carry-over was tested by injecting two blank matrix samples after injecting an ULOQ 
sample. Carry-over is considered acceptable when response in the first blank matrix at 
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the retention times of the analytes are less than 20% of the response in an LLOQ 
samples. 
 
2.7.7 Stability 
To test the stability of EO9, EO5a and EO9-Cl during processing at the clinical sites, 
the stability of analytes was evaluated in the non-stabilized control human urine 
maintained on an ice/water bath. The stability of analytes in stabilized human and dog 
urine after 3 freeze/thaw cycles was investigated by comparing quality control samples 
that had been frozen and thawed three times with freshly prepared quality control 
samples. The stability of EO9, EO5a and EO9-Cl in human and dog urine under 
processing (ambient temperatures) and storage (-70oC) conditions was evaluated. 
Furthermore, the stability in the final solution and the re-injection reproducibility in the 
auto sampler was determined after 24h. Finally, the long-term stability of EO9, EO5a 
and EO9-Cl was evaluated in the stock solutions, in the working solutions after storage 
at -70oC and in human and dog urine after storage at -70oC. 
Stability experiments in the biomatrix were executed at 2 concentration levels for EO9 
(0.3 and 40 µg/mL), for EO5a (0.6 and 40 µg/mL) and for EO9-Cl (0.3 and 3.0 µg/mL) in 
triplicate. The analytes were spiked separately to the biological matrix. EO9, EO5a and 
EO9-Cl are considered stable in the stock and working solutions when 90-110% of the 
fresh sample’s ratio is found and they are considered stable in biological matrices or 
final solutions when 85-115% of the initial concentration is recovered (17,18).  
 
3. Results and Discussion 
3.1  Sample pretreatment 
Liquid-liquid extraction (LLE) was investigated for the extraction of EO9, EO5a and 
EO9-Cl from urine, but the recoveries of EO9 were low and not reproducible (data not 
shown). To examine whether the recovery of EO9 could be increased more 
reproducibly with a direct injection, the urine samples were diluted with ammonium 
acetate (pH 8.5; 0.1M) – methanol (7:3, v/v). This approach was indeed successful and 
interestingly, we also detected a new compound in the urine, which was identified as 
EO9-Cl  (9). 
Therefore, dilution of the urine samples was chosen as the sample pretreatment. The 
samples were diluted 10 times prior to analysis to ascertain that the final concentration 
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would fit into the linear calibration range and to prevent contamination of the mass 
spectrometer with salts present in urine.  
 
3.2 Chromatography 
To our knowledge, no other assay has been described so far for the simultaneous 
determination of EO9, EO5a and EO9-Cl in human urine using HPLC coupled to the 
tandem MS. The chromatography was described earlier by us for determination of EO9 
and EO5a in human plasma (16). Representative chromatograms of EO9, EO5a and 
the internal standards at their LLOQ levels in stabilized human urine are depicted in 
Figure 2. Peak shapes were excellent with the asymmetry factors of 1.0 for EO9, EO9-
Cl and EO9-d3 and 1.2 for EO5a and EO5a-d4 and the capacity factors (k') for all 
analytes of approximately 3. LC run time was only 6 min. 
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Figure 2. Representative HPLC-MS/MS chromatograms of validation sample at the 
LLOQ (0.1 µg/mL) for EO9, EO5a, EO9-Cl and the internal standards EO9-d3 and 
EO5a-d4 in stabilized human urine. 
 
3.3  Mass Spectrometry 
In Figures 3, Q1 mass spectrum EO9-Cl is presented. Apart from the protonated 
species at m/z 325 for EO9-Cl, sodium adducts are also observed at m/z 347, and the 
characteristic Cl isotope abundances are visible.  
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Figure 3. Q1 (m/z 200-400) mass spectrum of EO9-Cl.  
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Figures 4-6, show MS/MS product ion scans (Q3 scan) of EO9, EO5a and EO9-Cl, 
respectively, across the range of m/z 100-400. An ion corresponding to the elimination 
of water (m/z 271) from the molecular ion of EO9 was chosen for the parent mass 
transition of EO9, because it was the most prominent, with its elimination occurring 
immediately in the ion source. The most abundant fragments observed in the 
fragmentation of the m/z of 271 (EO9; Figure 4), 307 (EO5a; Figure 5) and 325 (EO9-
Cl; Figure 6) were product ions at m/z of 241, 231 and 241, respectively, corresponding 
to the loss of the CH2O from the allylic alcohol (m/z 241), the cleavage of the amine 
moiety and the elimination of water (m/z 231) and the loss of the CH2O from the allylic 
alcohol and the elimination of the Cl atom (m/z 241), respectively. 
As expected, no typical Cl pattern is seen at the m/z of 241. Consequently, multiple 
reaction monitoring (MRM) parameters were optimized on the m/z of 271/241, 307/231 
and 325/241 transitions for EO9, EO5a and EO9-Cl. 
For EO9-d3 and EO5a-d4 similar transitions as for EO9 and EO5a, respectively, were 
selected and optimized. 
 
Figure 4. MS/MS product ion scan of EO9 (precursor ion m/z 271). 
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Figure 5. MS/MS product ion scan of EO5a (precursor ion m/z 307). 
 
Figure 6. MS/MS product ion scan of EO9-Cl (precursor ion m/z 325). 
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3.4 Validation 
3.4.1 Linearity 
The assay was linear over a concentration range of 0.1 µg/mL to 50 µg/mL for EO9, 0.2 
µg/mL to 50 µg/mL for EO5a and 0.1 µg/mL to 4 µg/mL for EO9-Cl in stabilized human 
and dog urine. This range proved to be sufficient when measuring the samples from the 
(pre)-clinical studies with EO9. Interestingly, the linear range of EO9-Cl was much 
smaller than for EO5a and EO9. This may be due to the different ionization properties 
of EO9-Cl compared to EO9 and EO5a. 
Namely, it is believed that signal suppression occurs when matrix components compete 
with the analyte ions for access to the droplet surface for gas phase emission (19). This 
is described in a widely accepted model, proposed by Iribarne and Thomson, which 
explains the formation of gas phase ions by direct emission from the surface of highly 
charged spray droplets (19). Therefore, when contaminants, from samples processing 
or analyte extraction from physiological matrices, are ionized at the same time as the 
compound of interest (EO9-Cl), matrix signal ionization tend to occur, leading to the 
signal suppression of the analyte (20). 
Another model, which may explain the limited linear range of EO9-Cl, is based on the 
hypothesis that the ion evaporation rate from the droplet is proportional to the ion 
concentration in the droplet (21). The basis of this model was the assumption that the 
Iribarne and Thomson (as described above) ion evaporation model was the principal 
mechanism for the ion transfer to the gas phase (19) and involves the competition 
among ions for the limited number of excess charge sites on the generated droplet 
during ESI (22,23). This model was proposed and supported by the observations of 
Enke et al, that at low concentrations of analyte, the response curves were linear and 
indifferent of other present low concentration analytes. However, at higher analyte 
concentrations, the response became independent of analyte concentration, but highly 
affected by the presence of other analytes (22-24).  
Because EO9-Cl has different chemical properties (less hydrophilic) than EO9 and 
EO5a, the above described models might contribute to the explanation of the non-linear 
behavior of EO9-Cl. 
Using linear regression and 1/x2 weighing, the lowest total bias and the most constant 
bias across the range were obtained. Correlation coefficients of the calibration curves in 
human urine were better than 0.9945 for EO9, better than 0.9933 for EO5a and better 
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than 0.9914 for EO9-Cl. Correlation coefficients of the calibration curve in dog urine 
were 0.9984 for EO9, 0.9974 for EO5a and 0.9948 for EO9-Cl. At all concentration 
levels, deviation of measured concentrations from nominal concentration were between 
-8.9% and 6.8% with C.V. values less than 11.7% for human urine and between -8.4% 
and 12.4% with C.V. values less than 16.3% for dog urine. 
 
3.4.2 Accuracy and precision 
Assay performance (inter-assay accuracies and precisions) data for EO9, EO5a and 
EO9-Cl is summarized in Table I.  
 
Table I. Assay performance data for EO9, EO5a and EO9-Cl in stabilized human and 
dog urine. 
  Nominal Measured Overall Intra-assay Inter- assay Number  
Compound Matrix Concentration Concentration Accuracy Precision Precision of 
  (urine) (µg/mL) (µg/mL) (%) (%) (%) Replicates 
EO9 human  0.103 0.102 99.0 7.79 7.42 15 
 human  0.309 0.312 101 4.60 9.12 15 
 human  10.3 10.3 99.2 4.26 8.39 15 
 human  41.1 42.2 102 3.23 2.32 15 
 dog  0.103 0.101 97.8 7.62 - 5 
 dog  0.309 0.319 103 6.47 - 5 
 dog  10.3 10.7 104 2.84 - 5 
  dog  41.1 41.7 101 4.77 - 5 
EO5a human  0.211 0.207 97.9 12.8 12.0 15 
 human  0.632 0.600 94.9 10.1 8.97 15 
 human  10.5 9.89 94.2 5.27 5.60 15 
 human  42.1 41.3 98.1 5.43 5.57 15 
 dog  0.211 0.201 95.1 9.07 - 5 
 dog  0.632 0.625 98.8 10.6 - 5 
 dog  10.5 10.3 98.3 3.99 - 5 
  dog  42.1 38.3 91.0 3.93 - 5 
EO9-Cl human  0.101 0.105 104 4.91 7.83 15 
 human  0.304 0.306 101 5.32 8.11 15 
 human  2.02 2.07 102 5.42 4.69 15 
 human  3.04 3.36 110 3.22 3.40 15 
 dog  0.101 0.102 101 12.7 - 5 
 dog  0.304 0.298 97.9 8.43 - 5 
 dog  2.02 2.05 102 10.4 - 5 
  dog  3.04 3.31 109 2.96 - 5 
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The intra-assay accuracies (% bias) in human urine were within ± 12.4% for EO9, 
within ± 10.7% for EO5a and within ± 13.6% for EO9-Cl for all concentrations and 
found to be acceptable (data not shown) (17,18). The intra-assay precisions for EO9 in 
human urine were less than 7.79%, for EO5a less than 12.8% and for EO9-Cl less than 
5.42% for all concentrations and found to be acceptable (17,18).  
The intra-assay accuracies (% bias) in dog urine were within ± 4.3% for EO9, within ± 
9.0% for EO5a and within ± 9.0% for EO9-Cl for all concentrations and found to be 
acceptable (data not shown) (17,18). The intra-assay precisions in dog urine for EO9 
were less than 7.62%, for EO5a less than 10.6% and for EO9-Cl less than 12.7% for all 
concentrations and found to be acceptable (17,18). As defined by the lower and upper 
validation sample concentrations possessing acceptable accuracy and precision, the 
validated range for EO9, based on 20 µL of stabilized human/dog urine is from 0.1 
µg/mL to 50 µg/mL, for EO5a is from 0.2 µg/mL to 50 µg/mL and for EO9-Cl is from 0.1 
µg/mL to 4 µg/mL, respectively. 
 
3.4.3 Limit of detection 
The limit of detection is the concentration of EO9, EO5a and EO9-Cl in which the 
response of the analyte is 2 times higher than the response of the blank, and is 
established in three analytical runs in human urine. The mean LOD concentration is 
estimated at 6.7 ng/mL for EO9, 31.4 ng/mL for EO5a and 3.3 ng/mL for EO9-Cl. 
 
3.4.4 Specificity and selectivity 
MRM chromatograms of six batches of stabilized control drug-free human and dog 
urine contained no co-eluting peaks >20% of the EO9, EO5a and EO9-Cl area at the 
LLOQ level, and no co-eluting peaks >5% of the area of internal standards. Deviations 
from the nominal concentrations at the LLOQ level in human urine were between -14.0 
and 18.8% for EO9, between -18.5 and 3.8% for EO5a and between -19.6 and -5.7% 
for EO9-Cl and found to be acceptable (17,18) . Deviations from the nominal 
concentrations at the LLOQ level in dog urine were between -18.2 and 5.8% for EO9, 
between -4.3 and 10.9% for EO5a and between -18.2 and -7.0% for EO9-Cl and found 
to be acceptable (17,18).  
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3.4.5 Ion suppression  
The mean ion-suppressions for EO9 and its internal standard EO9-d3 in human urine 
were 22.4 ± 7.5% and 22.7 ± 11.4%, respectively. The mean ion-suppressions for 
EO5a and its internal standard EO5a-d4 were 29.3 ± 4.9% and 30.0 ± 9.5%, 
respectively. The mean ion-suppression for EO9-Cl was 24.9 ± 6.7%. The ion-
suppression was much higher in human urine in comparison to human plasma (± 5%) 
(16). The high ion-suppression in urine is probably due to the salts present, which 
compete with the analytes for access to the droplet surface for gas phase emission. 
 
3.4.6 Carry-over 
No responses in the first blank matrix at the retention times of EO9, EO5a and EO9-Cl 
were measured, indicating that no carry-over takes place. 
 
3.4.7 Stability 
The stability data for EO9, EO5a and EO9-Cl are summarized in Tables IIa, IIb and IIc, 
respectively. EO9, EO5a and EO9-Cl are stable in blank formulation in human urine for 
up to 1 hour at an ice/water bath. EO9, EO5a and EO9-Cl are stable in human and dog 
urine for at least three freeze (-70 oC) / thaw cycles, and are also stable in human and 
dog urine stored at nominally ambient temperatures for up to 6 hours. Furthermore, 
EO9, EO5a and EO9-Cl are stable up to 10 days in the final extract (from human urine) 
at ambient temperatures. Re-injection reproducibility was established and the analytical 
run can be re-injected after at least 24 hours of storage in the autosampler. 
Finally, EO9, EO5a and EO9-Cl are stable in the stock solutions for up to 6 months of 
storage at –20°C16. EO9, EO5a and EO9-Cl are stable in the working solutions in 
ethanol and in the stabilized human urine for up to 6 months and in the stabilized dog 
urine for up to 3 months at nominally -70°C.  
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Table II a. Stability data of EO9 (S.D.: Standards Deviation; C.V.: Coefficient of 
Variation; DEV.: Deviation from time zero). 
 
Compound Conditions Matrix Initial conc Found conc Dev C.V. Number  
      (µg/mL) (µg/mL) (%) (%) of replicates 
EO9 Ice/water batch, Blank formulation 0.236 0.227 -3.79 5.51 3 
 1h - urine (1:2, v/v) 40.8 41.1 0.731 1.33 3 
EO9 3 freeze (-70ºC)/  human urine 0.312 0.309 -0.744 4.51 3 
 thaw cycles  39.8 36.1 -9.16 3.74 3 
EO9 3 freeze (-70ºC)/ dog urine 0.349 0.366 4.88 3.73 3 
  thaw cycles  43.2 40.0 -7.54 0.250 3 
EO9 Ambient, 6h human urine 0.312 0.296 -4.99 2.35 3 
   39.8 40.1 0.666 5.09 3 
EO9 Ambient, 6h dog urine 0.349 0.311 -10.8 4.74 3 
   43.2 45.0 4.25 3.45 3 
EO9 4ºC, 15 days final extract 0.312 0.301 -3.61 11.1 3 
   39.8 38.4 -3.58 0.259 3 
EO9 Autosampler,  final extract 0.280 0.288 2.96 5.12 3 
 10ºC, 24h (human urine) 9.82 10.0 2.12 4.06 3 
   41.6 44.3 6.45 1.53 3 
EO9 Autosampler,  final extract  0.320 0.329 2.71 1.68 3 
 10ºC, 24h (dog urine) 10.7 10.4 -2.80 2.88 3 
   41.6 41.6 0.00 5.54 3 
EO9  -20ºC, 6 months working solutions 1.00 0.951 -5.01 7.09 3 
  in ethanol 2.02 1.86 -7.88 22.0 3 
   10.0 10.4 4.56 1.87 3 
   20.2 21.5 6.59 8.00 3 
   100 94.6 -5.34 5.67 3 
   202 196 -3.52 2.38 3 
   403 369 -8.37 2.00 3 
   503 551 9.71 3.72 3 
EO9  -70ºC, 6 months stabilized human 0.315 0.320 1.60 12.4 3 
  urine 39.8 41.9 5.30 6.07 3 
EO9  -70ºC, 3 months stabilized dog  0.349 0.319 -8.60 19.6 3 
     urine 43.2 44.4 2.93 5.61 3 
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Table II b. Stability data of EO5a (S.D.: Standards Deviation; C.V.: Coefficient of 
Variation; DEV.: Deviation from time zero). 
 
Compound Conditions Matrix Initial conc Found conc Dev C.V. Number  
      (µg/mL) (µg/mL) (%) (%) of replicates 
EO5a ice/water batch, 1h Blank formulation 0.603 0.581 -3.65 10.8 3 
  -urine (1:2, v/v) 40.4 39.1 -3.22 7.13 3 
EO5a 3 freeze (-70ºC)/  human urine 0.600 0.602 0.333 7.26 3 
 thaw cycles  38.9 37.0 -4.80 3.32 3 
EO5a 3 freeze (-70ºC)/ dog urine 0.611 0.589 -3.65 10.5 3 
 thaw cycles  39.1 39.5 1.02 2.16 3 
EO5a Ambient, 6h human urine 0.600 0.593 -1.11 9.02 3 
   38.9 37.7 -2.92 3.77 3 
EO5a Ambient, 6h dog urine 0.611 0.601 -1.64 4.52 3 
   39.1 41 4.86 6.88 3 
EO5a 4ºC, 15 days final extract 0.600 0.566 -5.67 3.93 3 
   38.9 36.8 -5.32 3.55 3 
EO5a Autosampler,  final extract  0.591 0.652 10.2 6.39 3 
 10ºC, 24h (human urine) 9.76 10.2 4.17 8.31 3 
   38.8 40.4 4.21 5.85 3 
EO5a Autosampler, final extract  0.619 0.653 5.44 1.53 3 
 10ºC, 24h (dog urine) 10.4 9.80 -5.50 6.62 3 
   39.0 38.9 -0.342 1.71 3 
EO5a  -20ºC, 6 months working solutions  2.04 2.05 0.404 7.35 3 
  in ethanol 5.10 4.77 -6.46 11.7 3 
   10.2 9.85 -3.52 5.73 3 
   20.4 20.5 0.290 11.9 3 
   102 101 -1.02 7.29 3 
   204 197 -3.33 8.02 3 
   408 388 -4.65 2.07 3 
   510 518 1.69 6.48 3 
EO5a  -70ºC, 6 months stabilized human  0.600 0.612 2.00 15.1 3 
  urine 38.9 39.3 1.03 7.36 3 
EO5a  -70ºC, 3 months stabilized dog 0.611 0.592 -3.22 3.13 3 
     urine 39.1 41.0 4.86 4.03 3 
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Table II c. Stability data of EO9-Cl (S.D.: Standards Deviation; C.V.:Coefficient of 
Variation; DEV.: Deviation from time zero). 
 
Compound Conditions Matrix Initial conc Found conc Dev C.V. Number  
      (µg/mL) (µg/mL) (%) (%) of replicates 
EO9-Cl ice/water batch, 1h Blank formulation -  0.293 0.304 3.76 4.76 3 
  urine (1:2, v/v) 2.59 2.69 3.73 3.36 3 
EO9-Cl 3 freeze (-70ºC)/  human urine 0.305 0.275 -9.85 6.52 3 
 Thaw cycles  2.84 2.61 -8.09 2.24 3 
EO9-Cl 3 freeze (-70ºC)/ dog urine 0.328 0.362 10.3 3.61 3 
 Thaw cycles  2.67 2.78 4.38 4.98 3 
EO9-Cl Ambient, 6h human urine 0.305 0.275 -9.74 2.62 3 
   2.84 2.63 -7.50 5.93 3 
EO9-Cl Ambient, 6h dog urine 0.328 0.287 -12.6 11.5 3 
   2.67 2.69 0.875 6.72 3 
EO9-Cl 4ºC, 10 days final extract 0.305 0.329 7.88 0.63 3 
   2.84 3.16 11.1 4.66 3 
EO9-Cl Autosampler,  final extract  0.297 0.274 -7.64 0.73 3 
 10ºC, 24h (human urine) 2.06 1.99 -3.55 4.52 3 
   3.31 3.38 2.01 2.52 3 
EO9-Cl Autosampler,  final extract  0.302 0.309 2.32 3.79 3 
 10ºC, 24h (dog urine) 2.00 2.19 9.68 8.03 3 
   3.27 3.12 -4.69 9.05 3 
EO9-Cl  -20ºC, 6 months stock solution  1000 956 -4.44 11.1 3 
EO9-Cl  -20ºC, 6 months working solutions in  2.00 1.91 -4.64 6.73 3 
  ethanol 10.0 9.20 -8.00 1.56 3 
   20.0 21.1 5.57 3.89 3 
   30.0 27.4 -8.67 4.33 3 
EO9-Cl  -70ºC, 6 months stabilized human  0.305 0.260 -14.7 3.81 3 
  urine 2.84 2.83 -0.362 4.77 3 
EO9-Cl  -70ºC, 3 months stabilized dog urine 0.328 0.324 -1.32 14.9 3 
      2.67 2.58 -3.25 2.54 3 
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4. Conclusions 
An accurate, simple, reproducible, and selective LC-MS/MS assay has been developed 
for the quantification of EO9 and its conversion products EO5a and EO9-Cl in human 
and dog urine. Using 20 μL stabilized human and dog urine aliquots, the assay 
quantifies a range of 0.1 µg/mL to 50 µg/mL for EO9, 0.2 µg/mL to 50 µg/mL for EO5a, 
and of 0.1 µg/mL to 4 µg/mL for EO9-Cl. Validation results demonstrate that the EO9, 
EO5a and EO9-Cl concentrations can be accurately and precisely quantified in human 
and dog urine. This assay is used to support (pre)-clinical pharmacologic studies with 
EO9.  
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Abstract 
A sensitive and specific LC-MS/MS assay for the determination of paclitaxel and its 3´p- 
and 6-α-hydroxy metabolites is presented. A 200 μL plasma aliquot was spiked with a 
13C6-labeled paclitaxel internal standard and extracted with 1.0 mL tert-
butylmethylether. Dried extracts were reconstituted in 0.1 M ammonium acetate – 
acetonitrile (1:1, v/v) and 25 μL-volumes were injected onto the HPLC system. 
Separation was performed on a 150 x 2.1 mm C18 column using an alkaline eluent (10 
mM ammonium hydroxide – methanol (30:70, v/v)). Detection was performed by 
positive ion electrospray followed by tandem mass spectrometry. The assay quantifies 
a range for paclitaxel from 0.25 ng/mL to 1,000 ng/mL and metabolites from 0.25 ng/mL 
to 100 ng/mL using 200 μL human plasma samples. Validation results demonstrate that 
paclitaxel and metabolites concentrations can be accurately and precisely quantified in 
human plasma. This assay is now used to support clinical pharmacologic studies with 
paclitaxel. 
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1. Introduction 
Plants of the genus Taxus (yews) produce a class of natural products, taxoids, 
characterized by the taxane (pentamethyl triclopentadecane) skeleton. Over 380 
taxoids and modified taxoids have been isolated and characterized (1). One of the most 
economically, pharmaceutically promising and important member of the taxoids is the 
anticancer drug paclitaxel (Figure 1), known commercially as Taxol® (1;2). Its activity is 
derived from its ability to increase the assembly and stability of microtubules in dividing 
cells, thereby blocking the cell cycle.  Paclitaxel has significant clinical activity against a 
broad range of tumor types including breast, lung, head and neck, bladder, and 
platinum-refractory ovarian carcinoma (3). 
Accurate information on the disposition and the metabolism of paclitaxel is of crucial 
importance to be able to optimize its administration (4;5). Paclitaxel is metabolized in 
the human liver by cytochromes P450 (CYP) 2C8 and 3A4 (6). Previous studies have 
shown that the major hepatic metabolite is 6α-hydroxy paclitaxel (6OHP; Figure 1) with 
an OH-group at C6 at the taxane ring (7;8). A minor metabolite is 3’-p-hydroxy 
paclitaxel (3’OHP; Figure 1) with an OH-group at the C3’ of the phenyl in the side chain 
at C13 (4;9). Both metabolites exhibit the excessive microtubule stabilizing properties of 
the parent compound (6). 
With the introduction of routine liquid chromatography-mass spectrometry (LC-MS) 
hyphenation, MS detection has become the method of choice for the determination of 
paclitaxel in biological samples, due to its extremely high sensitivity and selectivity (10). 
There have been several LC-MS methods reported for the quantitative bioanalysis of 
paclitaxel (11-16). Most assays employ solid phase extraction (SPE) as a means of 
sample pretreatment, but SPE is generally a labor-intensive and time-consuming 
procedure (12-15). A few liquid-liquid extraction (LLE) procedures have also been 
reported for paclitaxel (2;11;16). Alexander et al. described a simple LLE procedure 
with tert-butylmethylether for the extraction of paclitaxel and two metabolites (3’OHP 
and 6OHP) from 400 μL of human and dog plasma. In his assay the analytes are 
chromatographically separated from matrix components using an acidic mobile phase. 
Stokvis et al. reported that mobile phases containing ammonium hydroxide in 
combination with positive ionization can be very well suited for the bioanalysis of weak 
basic drugs, such as paclitaxel (16). 
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Our goal was to design a sensitive, specific and fully validated method using coupled 
liquid chromatography and tandem mass spectrometry for the determination of 
paclitaxel, 3’OHP and 6OHP in human plasma. 
We achieved our goals successfully by developing a simple, sensitive and reproducible 
assay. During development however, we were confronted with degradation of the 
metabolites which required more investigation into stability of these analytes. The 
assay we developed has been successfully applied to support clinical pharmacologic 
studies with paclitaxel. 
 
2. Experimental 
2.1 Materials 
Paclitaxel (C47H51NO14; Figure 1) originated from Hauser Inc (El Segundo, CA, USA) 
and the 13C6-paclitaxel internal standard (C47H51NO14) was kindly supplied by 
Pharmacia Corporation (Nerviano, Italy).  
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Figure 1. Chemical structure of paclitaxel, 3´-p-hydroxy paclitaxel and 6-α-hydroxy 
paclitaxel. 
 
The metabolites 3΄-p-hydroxy paclitaxel (C47H51NO15; Figure 1) and 6α-hydroxy 
paclitaxel (C47H51NO15, Figure 1) were purchased from the Gentest Corporation 
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(Woburn, MA, USA). Methanol (LC gradient grade) was obtained from Bissolve Ltd. 
(Amsterdam, The Netherlands). Ammonia solution 25% and tert-butyl-methylether (both 
analytical grade) were from Klinipath (Duiven, The Netherlands). All other solvents or 
chemicals were analytical grade or better. Distilled water was used throughout the 
analyses. Drug free human plasma was obtained from the Central Laboratory for Blood 
Transfusion (Sanquin Amsterdam, The Netherlands). 
 
2.2 Preparation of stock and working solutions 
Two sets of stock solutions of paclitaxel were prepared from independent weightings in 
methanol at a concentration of 1 mg/mL. These solutions were further diluted with 
methanol to obtain working solutions. One set of working solutions was used to prepare 
calibration standards, the other to prepare quality control samples.  
A stock solution of 13C6-paclitaxel internal standard was prepared in methanol at a 
concentration of 100 μg/mL and was further diluted with methanol to a final 
concentration of 1 μg/mL. Plasma stock solution of 3’OHP was prepared by adding 25 
μL of methanol to the vial containing 25 nmol of 3’OHP, vortex mixing and subsequently 
adding a volume of control human plasma to give an analyte concentration of 20.0 
μg/mL. 
A plasma stock solution of 6OHP was prepared by adding 25 μL of methanol to the vial 
containing 12.7 nmol of 6OHP, vortex mixing and subsequently adding a volume of 
control human plasma to yield a concentration of 10.0 μg/mL. 
A plasma working solution containing all three compounds: paclitaxel, 3’OHP and 
6OHP, was prepared by mixing a fixed amount of each of the stock solutions and 
diluting them with human plasma to give a concentration of 1000 ng/mL for paclitaxel 
and 100 ng/mL for 3’OHP and 6OHP. All solutions were stored at -20 oC. 
 
2.3 Preparation of calibration standards and quality control samples in human plasma 
Control human plasma (heparinized) was centrifuged for approximately 5 minutes at 
0,600 g and placed in an ice/water bath prior to use. 
Calibration standards of the mixture of the paclitaxel, 3’OHP and 6OHP were prepared 
freshly in a range from 0.25 to 100 ng/mL for 3’OHP and 6OHP and from 0.25 to 1,000 
ng/mL for paclitaxel, and vortex mixed for approximately 30 seconds before processing. 
Standards were processed in singli and analyzed in duplicate. 
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Validation samples for 3’OHP and 6OHP were prepared in human plasma at 
concentrations of 0.75, 50, and 75 ng/mL in volumetric flasks and vortex mixed for 
approximately 30 seconds. Validation samples for paclitaxel were prepared in human 
plasma at concentrations of 0.75, 500 and 800 ng/mL. Also, an additional validation 
sample at the lower limit of quantitation (LLOQ) level (0.25 ng/mL) was prepared for 
paclitaxel and metabolites. 
Replicate 200 µL aliquots were transferred to 2.0 mL tubes for storage at nominally –20 
°C. 
 
2.4 Sample preparation 
Sample pretreatment was performed on an ice/water bath. Paclitaxel, metabolites and 
internal standard were extracted from plasma using LLE. To 200 μL sample volumes 25 
μL of internal standard working solution in methanol (1,000 ng/mL) and subsequently 
1.0 mL of tert-butylmethylether were added. The samples were vortexed for 10 
seconds, followed by automatic shaking for 10 min at 1,250 rpm (Labinco, Breda, The 
Netherlands). Samples were then centrifuged for 5 min at 23,100 g, the aqueous layer 
was frozen in an ethanol-dry ice mixture and the organic layer was decanted into a 
clean 1.5 mL-eppendorf tube. The organic solvent was evaporated under a gentle 
stream of nitrogen gas at 40 oC. The residue was reconstituted with 100 µL of 
reconstitution solvent (0.1 M ammonium acetate – acetonitrile (1:1, v/v)) by vortex 
mixing for 30 seconds. After centrifuging for 10 min at 23,100 g the clean supernatant 
was transferred to a glass autosampler vial with insert and 25 µL was injected onto the 
HPLC column. 
 
2.5 HPLC 
The HPLC system comprised an HP1100 (Agilent Technologies, Palo Alto, CA) binary 
pump, degasser and HP1100 (Agilent Technologies) autosampler. Isocratic 
chromatography was performed using a Zorbax Extend C18 column (150 x 2.1mm ID, 
particle size 5 μm). The mobile phase was 10 mM ammonium hydroxide in water – 
methanol (30:70, v/v) and was pumped at a flow-rate of 0.2 mL/min. Sample injections 
of 25 μL were carried out and the auto sampler temperature was kept at 10 oC.   
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2.6 Mass spectrometry 
The LC eluate was let directly into an API 3000 triple quadrupole MS equipped with an 
electrospray (ESI) ion source (Sciex, Thornhill, ON, Canada). Positive ionization 
electrospray mass spectrometry was performed for selective and sensitive detection. 
The resulting multiple reaction monitoring (MRM) chromatograms were used for 
quantification using Analyst™ software version 1.2 (Sciex). Mass transitions of m/z 854 
→ 509 and 860 → 515 were optimized for paclitaxel and 13C6-paclitaxel, respectively, 
with dwell times of 150 ms. Mass transitions of m/z 870 → 509 and 870 → 525 were 
optimized for 3’OHP and 6OHP, respectively, with dwell times of 150 ms. Nebulizer and 
turbo gas (both compressed air) were operated at 1.6 and 7 L/min, respectively. The 
curtain gas was 1.2 L/min and the collision gas (N2) was 1.8* 1015 molecules /cm2. 
Finally, the ionspray voltage was kept at 5500 V, with a source temperature of 300 oC. 
 
2.7 Validation procedures 
For the paclitaxel, 3’OHP and 6OHP quantification in human plasma, a full validation 
was performed (17;18).  
 
2.7.1 Linearity 
For the validation, calibration standards (7 non-zero standards of the analytes) were 
prepared in control human heparinized plasma and analyzed in duplicate in three 
analytical runs.  
The linear regression of the ratio of the areas of the analyte and internal standard 
peaks versus the concentration were weighted by 1/x2 (the reciprocal of the squared 
concentration). Concentrations were back calculated from the constructed calibration 
curve and deviations from the nominal concentrations should be within ± 20% for the 
LLOQ and within ± 15% for other concentrations with coefficient of variation (C.V.) 
values less than 20% and 15% respectively (17;18). 
 
2.7.2 Accuracy and precision 
Five replicates of each human plasma sample were analyzed in three analytical runs 
together with a calibration curve independently prepared from the quality control 
samples containing 0.25, 0.75, 500 and 750 ng/mL of paclitaxel and 0.25, 0.75, 50 and 
75 ng/mL of 3’OHP and 6OHP as described in Section 2.3.  
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Accuracies were determined as the percentage difference of the measured 
concentration from the nominal concentration and the coefficient of variation was used 
to report the precision:   
The intra and inter-assay accuracies (% bias) should be within ±20% at the LLOQ level 
and within ±15% at the other concentrations (17;18). The intra and inter-assay 
precisions should be less than 20% at the LLOQ level and less than 15% at the other 
concentrations (17;18). Stable isotopic labeled (SIL) internal standard yield better assay 
performance results for quantitative bioanalytical LC-MS assays than other internal 
standards. For the quantification of the metabolites 3’OHP and 6OHP, no SIL internal 
standards were available and the labeled structural analogue 13C6-paclitaxel was used. 
Therefore the accuracy and precision criteria for the metabolites were set to 25% at the 
LLOQ level and to 15% at the other concentrations. 
  
2.7.3 Specificity and selectivity 
To investigate whether endogenous matrix constituents interfered with the assay, six 
individual batches of control drug-free plasma samples containing neither analyte nor 
internal standard (double blank), samples containing only internal standard (blank), and 
LLOQ samples were prepared. Samples were prepared according to the described 
procedures and analyzed. Peak areas of compounds co-eluting with the analyte or 
internal standard should not exceed 20% of the analyte peak area at the LLOQ or 5% 
of the internal standard area. Deviations from the nominal concentrations should be 
within ± 20% for the LLOQ samples (17;18). 
 
2.7.4 Ion suppression and recovery 
For the determination of ion suppression, control drug-free plasma was processed and 
dry extracts were dissolved with working solutions that represented 100% recovery 
containing the analytes and internal standard in 0.1 M ammonium acetate – acetonitrile 
(1:1, v/v). Ion-suppression was determined by comparing the analytical response of 
these samples to that of the working solutions. The loss of signal represents the ion-
suppression. LLE recovery was determined by comparing the analytical response of 
processed quality control samples with the analytical response of blank samples 
reconstituted with working solutions as described above. These experiments were 
performed in triplicate at three concentration levels. Overall recovery corresponded to 
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the net response after subtraction of the ion-suppression and signal loss due to the 
extraction. Ion suppression and recovery experiments for the internal standard were 
performed in a similar way.  
 
2.7.5 Stability 
The stability of paclitaxel and metabolites in spiked human plasma samples after 3 
freeze-thaw cycles from nominally –20 °C to 0 °C (ice/water bath) was assessed in 
triplicate at 0.750 and 750 ng/mL for paclitaxel and 0.750 and 75 ng/mL for 3’OHP and 
6OHP. This was determined by comparing the mean paclitaxel and metabolites 
concentrations after 3 freeze-thaw cycles against freshly prepared extracts.  
The stability of paclitaxel and metabolites in spiked whole blood maintained in an 
ice/water bath for 1 hour was evaluated at 0.750 and 750 ng/mL for paclitaxel (in 
replicates of 3) and 0.750 and 75 ng/mL for the metabolites ( in replicates of 3) by 
comparing the paclitaxel and metabolites concentrations against freshly prepared 
extracts. 
Also, the stability of paclitaxel and metabolites in spiked human plasma samples 
maintained in an ice/water bath for 6 hours was evaluated at 0.750 and 750 ng/mL for 
paclitaxel (in replicates of 3) and 0.750 and 75 ng/mL for 3’OHP and 6OHP (in 
replicates of 3) by comparing the mean paclitaxel and metabolites concentrations 
against freshly prepared extracts.  
Furthermore, the stability of dried extracted analyte samples in human plasma was 
determined at 0.750 and 80 ng/mL (in replicates of 3) at ambient temperatures by 
comparing the mean calculated concentrations against the nominal concentrations after 
41 days of storage.  
Additionally, processed extracted sample stability in human plasma was assessed at 
0.75 and 750 ng/mL for paclitaxel (in replicates of 3) at ambient temperatures by 
comparing the mean paclitaxel concentration against freshly prepared extracts after 5 
days of storage. For the metabolites, processed extracted sample stability in human 
plasma was assessed at 0.75 and 80 ng/mL (in replicates of 3) at ambient 
temperatures by comparing the mean metabolites concentrations against freshly 
prepared extracts after 5 days of storage.  
Finally, re-injection reproducibility of paclitaxel and metabolites in human plasma was 
determined in duplicate at three concentration levels (0.75, 500 and 750 for paclitaxel; 
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0.75, 50 and 75 ng/mL for metabolites) after 24 hours at nominally 10 °C by comparing 
the mean concentrations against freshly prepared and analyzed extracts. The paclitaxel 
is considered stable in biological matrix or extracts when 85-115% of the initial 
concentration is found. Metabolites are considered stable in biological matrix or extracts 
when 80-120% of the initial concentration is found.   
 
2.7.6 Clinical Study 
The analytical method described in this article has been used to support a study in 
humans. In this study paclitaxel is administrated orally. Patients received 10 mg/kg CsA 
30 min prior to the oral dose of paclitaxel. The dose of paclitaxel was 90 mg in liquid 
filled capsules. Blood samples were collected at several time points and after 
centrifugation, plasma was removed and stored at – 20 oC until analysis.  
 
3. Results and Discussion 
3.1 Mass Spectrometry 
MS detection was chosen because of its high sensitivity and selectivity, which is 
especially important in the analysis of the structurally analogous compounds. Moreover 
for a sensitive and selective detection of the paclitaxel and the metabolites an alkaline 
mobile phase appeared to be most appropriate, as described in 3.2. In Figure 2 a Q1 
mass spectrum of paclitaxel is presented. Apart from the protonated  
species at m/z 854, also ammonium, sodium and potassium adducts are detected.  In 
addition, a peak corresponding to the elimination of water from the molecular ion is 
observed at m/z 836. The protonated molecule of paclitaxel was induced to fragment in 
the collision cell and the resulting product ion spectrum is presented in Figure 3. For 
paclitaxel (m/z 854), the main fragment ion corresponds to the cleavage of the side 
chain at the C-13 position (m/z 569).  After the elimination of acetic acid, the fragment 
ion at m/z 509 was most abundant and used for quantitative MRM of paclitaxel. The 
proposed fragmentation pattern for paclitaxel is presented in Figure 3. 
The protonated molecules of 3’OHP and 6OHP at m/z 870 were used as precursor ions 
to generate the product ion spectra presented in Figures 4 and 5, respectively. The 
proposed fragmentation pattern for 3’OHP and 6OHP is presented in Figure 4 and 5, 
respectively. For MRM, the fragment at m/z 509 was used for 3’OHP and m/z 525 was 
for 6OHP.  
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Figure 2. Q1 (m/z 500-900) mass spectrum of paclitaxel. Peaks labeled with an asterisk 
correspond to fragment ions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. MS/MS product ion scan of paclitaxel (precursor ion m/z 854). 
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Figure 4. MS/MS product ion scan of 3´-p-hydroxy paclitaxel (precursor ion m/z 870). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. MS/MS product ion scan of 6-α-hydroxy paclitaxel (precursor ion m/z 870). 
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3.2 Chromatography 
The most appropriate eluent appeared to be an alkaline eluent : methanol – aqueous 
10 mM ammonium hydroxide (70:30, v/v). Various assays have been described for the 
determination of paclitaxel in human plasma using LC-MS techniques (2;11-15). In all 
of them the analytes are chromatographically separated from matrix components using 
acidic mobile phases containing mostly an acetic or formic acid mixture of water and 
either acetonitrile or methanol. Stokvis et al. have described that alkaline mobile 
phases containing ammonium hydroxide in combination with positive ionization is very 
well suited for the bioanalysis of weak basic drugs such as paclitaxel (16). 
Predominantly protonated molecules are formed under these conditions. The addition 
of ammonium acetate, ammonium formate, or ammonium hydroxide to the aqueous 
phase of eluent resulted in higher signal-to-noise ratio for the basic analytes than the 
addition of acetic acid, formic acid, or no addition to the eluent. Furthermore, the best 
results for paclitaxel concerning signal to noise ratio and peak width were obtained 
using an alkaline mobile phase containing 10 mM ammonium hydroxide (16). We 
proved that the same is true for the paclitaxel metabolites. We observed the highest 
signal to noise ratio using 10 mM ammonium hydroxide in the eluent. Positive ionization 
in the electrospray ion source in the presence of ammonium hydroxide most likely 
results from ion-molecule reactions (IMR) between the analyte molecule (M) and 
ammonium ions or collision–induced dissociation (CID) of ammonium adducts of the 
analyte under influence of the electrospray voltage (19). 
IMR: NH+4 (g) + M   →  NH3 (g) + MH+ (g) 
or  
CID: (NH3-H+-M) (g) → NH3(g) + MH+ (g) 
For either reaction to be thermodynamically favoured requires that paclitaxel (and its 
metabolites) is a stronger gas-phase base than NH3. As far as we know, the gas-phase 
basicity (GB) for pacitaxel is not available in the literature. Because using the alkaline 
mobile phase resulted in a higher signal to noise ratio than when using an acidic mobile 
phase, we might assume that the GB of paclitaxel > GB of NH3, so proton transfer from 
NH+4 to neutral paclitaxel is thermodynamically favoured.  
Consequently, the alkaline mobile phase containing aqueous 10 mM ammonium 
hydroxide could successfully be used for the separation and MS detection of the 
paclitaxel and its metabolites.  
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Figure 6. Representative HPLC-MS/MS chromatograms of an LLOQ sample (0.25 
ng/mL) for 3´-p-hydroxy paclitaxel, 6-α-hydroxy paclitaxel, paclitaxel, and the internal 
standard from control human plasma. 
 
Representative chromatograms of paclitaxel, the internal standard, 3’OHP and 6OHP at 
the LLOQ level of 0.25 ng/mL from human plasma are depicted in Figure 6. Peak 
shapes were excellent and the LC run time was 9 min. 
 
3.3 Sample pretreatment 
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unstable in plasma at room temperature. We observed that in 24 hours 20% of the 
nominal amount of 3’OHP in human plasma had disappeared. Consequently, we 
investigated the sample processing on an ice-water bath which was successful and no 
significant degradation was seen. The results on stability of paclitaxel and metabolites 
on an ice-water bath are described in section 3.4.2.3. In addition to this we examined 
various reconstitution solvents: acetonitrile - water (1:1, v/v), methanol - water (70:30, 
v/v), methanol - water (1:1,v/v), 0.1 M ammonium acetate – acetonitrile (1:1, v/v) and 
water – acetonitrile – trifluoroacetic acid (70:30:0.1, v/v). The reconstitution solvent 
containing 0.1 M ammonium acetate – acetonitrile (1:1, v/v) proved to give the best 
results as seen in Table I. The percentage differences between paclitaxel, 3’OHP, and 
6OHP nominal concentrations and concentrations after 18 hours of storage in the 
autosampler are minimal when using 0.1 M ammonium acetate – acetonitrile (1:1, v/v) 
as a reconstitution solvent. This indicates that the paclitaxel and metabolites are the 
most stable in this solvent. LLE was used, due to its simplicity and good recoveries, as 
described in section 3.4.3. Moreover, we replaced the time-consuming procedure of 
freezing the aqueous layer in a –60 oC freezer, as stated in Alexander et al [14], by 
instant freezing in an ethanol-dry ice bath. 
Table I. The stability experiments with paclitaxel, 3’OHP and 6OHP in various 
reconstitution solvents. 
Reconstitution solvent Analyte The % difference* 
Acetonitrile-Water (1:1, v/v) Paclitaxel 2.0 
Acetonitrile-Water (1:1, v/v) 3’OHP 30 
Acetonitrile-Water (1:1, v/v) 6OHP 6.5 
Methanol-Water (1:1, v/v) Paclitaxel 2.0 
Methanol-Water (1:1, v/v) 3’OHP 35 
Methanol-Water (1:1, v/v) 6OHP 6.5 
0.1 M Ammonium acetate–Acetonitrile (1:1, v/v) Paclitaxel 2.4 
0.1 M Ammonium acetate–Acetonitrile (1:1, v/v) 3’OHP 3.2 
0.1 M Ammonium acetate–Acetonitrile (1:1, v/v) 6OHP 1.4 
Water-Acetonitrile-Trifluoroacetic acid (70:30:0.1, v/v) Paclitaxel 0.4 
Water-Acetonitrile-Trifluoroacetic acid (70:30:0.1, v/v) 3’OHP 13 
Water-Acetonitrile-Trifluoroacetic acid (70:30:0.1, v/v) 6OHP 1.0 
Methanol-Water (7:3, v/v) Paclitaxel 8.5 
Methanol-Water (7:3, v/v) 3’OHP 30 
Methanol-Water (7:3, v/v) 6OHP 11 
 
* The % difference between the nominal concentration of the analyte and the concentration after 18 hours of storage in 
the reconstitution solvent. 
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3.4 Validation 
3.4.1 Linearity 
The assay was linear over a concentration range of 0.25-1,000 ng/mL for paclitaxel and 
0.25-100 ng/mL for the metabolites in human plasma. With linear regression and 1/x2 
weighting the lowest total bias and the most constant bias across the range were 
obtained. Correlation coefficients of the calibration curves for paclitaxel and metabolites 
respectively were better than 0.9916. At all concentration levels deviation of measured 
concentrations from nominal concentration were between -9.1 and 10.2 % with C.V. 
values less than 10.8 %. 
 
3.4.2 Accuracy and precision 
Assay performance (inter-assay accuracies and precisions) data for paclitaxel and 
metabolites is summarized in Table II. The intra-assay accuracies (% bias) for 
paclitaxel were within ± 9.3% for all concentrations and found to be acceptable (data 
not shown) (17;18). The intra-assay accuracies (% bias) for metabolites were within ± 
15.1 % for all concentrations and are acceptable (data not shown).  
 
Table II: Assay performance data for paclitaxel and metabolites. 
Compound Nominal concentration 
(ng/mL) 
Calculated 
concentration (ng/mL) 
Accuracy 
(%) 
Precision 
(%) 
Number of 
replicates 
Paclitaxel 0.250 0.261 4.9 7.5 15 
 0.750 0.691 -7.6 4.4 15 
 500.0 490 -1.8 2.4 15 
 750.0 792 5.9 1.7 15 
3’OHP 0.250 0.244 -2.4 13 15 
 0.750 0.717 -4.4 9.3 15 
 50.0 50.5 1.1 6.8 15 
 75.0 78.8 5.1 7.0 15 
6OHP 0.250 0.252 0.80 7.0 15 
 0.750 0.692 -7.7 6.4 15 
 50.0 49.6 -0.88 7.2 15 
 75.0 76.5 2.0 6.2 15 
 
The intra-assay precisions for paclitaxel were less than 9.48 % for all concentrations 
and found to be acceptable (17;18). The intra-assay precisions for the metabolites were 
less than 22% for the LLOQ levels and less than 7.1 % for all other concentrations and 
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found to be acceptable. As defined by the lower and upper validation sample 
concentrations possessing acceptable accuracy and precision, the validated range for 
paclitaxel based on 200 µL of human plasma is from 0.25 to 1,000 ng/mL. The 
validated range for metabolites is 0.25 to 100 ng/mL. 
 
3.4.3 Specificity and selectivity 
MRM chromatograms of six batches of control drug-free plasma contained no co-
eluting peaks >20% of the paclitaxel and metabolites area at the LLOQ level, and no 
co-eluting peaks >5% of the area of internal standard. Deviations from the nominal 
concentrations at the LLOQ level were between -16.9 and 10.4 % for paclitaxel and 
found be acceptable (17;18). Deviations from the nominal concentrations at the LLOQ 
level for the metabolites were between -11.6 and 15.2 % and thus acceptable (17;18). 
 
3.4.4 Ion suppression and recovery 
The mean ion-suppression for paclitaxel and its internal standard were 6.2 and 8.2 %, 
respectively. The mean ion-suppressions for the metabolites were 18.4 for 3’OHP and 
12.4 % for 6OHP.  
LLE recovery for paclitaxel, 3’OHP, 6OHP and the internal standard were 93.1, 98.5, 
82.0 and 92.5%, respectively. Total recovery of paclitaxel, 3’OHP, 6OHP and internal 
standard were 88.6, 80.4, 72.0 and 85.0 %, respectively.  
 
3.4.5 Stability 
Paclitaxel and metabolites are stable in human plasma for at least three freeze (-20 oC) 
/ thaw cycles. Paclitaxel and metabolites are stable in whole blood and human plasma 
when kept in an ice/water bath for at least 1 hour and 6 hours, respectively. 
Furthermore, paclitaxel and metabolites are stable for at least 41 days in the dry extract 
at ambient temperatures. Additionally, paclitaxel and metabolites are stable in the final 
extract for at least 5 days when stored at ambient temperatures. Finally, re-injection 
reproducibility was established. The analytical run can be re-injected after at least 24 
hours of storage in the autosampler. 
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3.5 Clinical study 
In Figure 7 the concentration vs. time plots are presented for paclitaxel and metabolites 
from a patient treated orally with 90 mg paclitaxel. Five hours after administration of the 
drug a maximum paclitaxel concentration of 254 ng/mL was reached. The highest 
plasma level for 3’OHP was 33.7 ng/mL, and the highest plasma level for 6OHP was 
299 ng/mL.  
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Figure 7. Concentration vs. time profiles of paclitaxel and metabolites in a patient 
treated orally with 90 mg paclitaxel. 
 
4. Conclusions 
For the quantification of paclitaxel and metabolites in human plasma, an accurate, 
reproducible and selective LC-MS/MS assay has been developed. The assay quantifies 
a range for paclitaxel from 0.25 ng/mL to 1,000 ng/mL and for the metabolites from 0.25 
ng/mL to 100 ng/mL using 200 μL human plasma aliquots. Validation results 
demonstrate that the paclitaxel and metabolites concentrations can be accurately and 
precisely quantified in human plasma. This assay is now used to support clinical 
pharmacologic studies with paclitaxel. 
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Abstract 
A sensitive and rapid LC-MS/MS assay for the quantitative determination of 5-methyl 
indirubine (5-MI) in murine plasma is described. A 50-μL-murine plasma aliquot was 
spiked with an internal standard, indirubine-3-monoxime (IMO) and extracted with 1.25 
mL diethyether. Dried extracts were reconstituted in methanol - water (8:2, v/v) and 10 
μL-volumes were injected onto the HPLC system. Separation was achieved on a 
Gemini C18 column (150 x 2.1 mm ID, particle size 5 μm) using an alkaline eluent (10 
mM ammonium hydroxide – methanol (5:95, v/v)). Detection was performed by negative 
ion electrospray followed by tandem mass spectrometry. The assay quantifies 5-MI in a 
range from 1 to 500 ng/mL using 50 μL of murine EDTA plasma samples. Validation 
results demonstrate that 5-MI concentrations can be accurately and precisely quantified 
in murine plasma. This assay is used to support pre-clinical pharmacologic studies with 
5-MI. 
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1. Introduction 
Organic colorants and their derivatives, such as indigo and indirubin, are among the 
most important components of historical paintings and textiles (1,2). However, indirubin 
is also known as the active ingredient of Danggui Longhui Wan, a traditional Chinese 
antileukaemia medicine, which constitutes a mixture of 11 plants (3-6). Using oxidation 
and dimerization, indirubin is derived from indoxyl and isatin, which are extracted from 
colorless precursor conjugates indican (from Indigofera and Polygonum species among 
others) and isatan B (from Isatis tinctoria) (3,7). 
Studies exploring the mechanism of action of indirubin indicated that it inhibits DNA and 
protein synthesis in several cell lines, in cell-free systems, and in vivo in rats with 
Walker -256 sarcoma (8-13). A weak binding of indirubin to DNA in vitro has also been 
described (13). 
Recently, indirubin and a few indirubin derivatives such as 5-methylindirubine (5-MI) 
have been reported to inhibit cyclin-dependant kinases (CDKs) by competing in the 
ATP-binding sites with high selectivity among several kinase families, which has an 
anti-proliferative effect on human cancer cells (3,14-16). 
Indirubin and its derivatives are quite difficult to identify due to the low stability, poor 
solubility in water and organic solvents, and similarity in the chemical structure (17). 
Moreover, indirubin is no longer used in China to treat chronic myelogenous leukemia, 
because of its poor water solubility and gastrointestinal tract problems (18). Studies 
performed by Fiebig et al., which investigated the influence of indirubin and potent 
analogues on the growth of human tumor xenografts in vitro and in vivo, suggested that 
the indirubin analogue 5-methyl-indirubin (5-MI) is very active and effective (19). 
Moreover, 5-MI showed antitumor efficacy in a variety of solid tumor xenografts, e.g. 
colon cancer, non small cell lung cancer, mammary cancer, melanoma, prostate 
cancer, and renal cancer, following oral administration (20).  
For the detection of indirubin and indigo, TLC, HPLC-UV (21) and fast atom 
bombardment mass spectrometry methods (22) have been described. Puchalska et al 
and Szostek et al (1,23) recently used LC-MS to determine and to investigate the 
natural dyes (including indirubin) in textiles and paintings. Liau et al developed an LC-
APCI-MS method for detection and analysis of tryptanthrin, indigo, and indirubin in the 
leaves and roots of Isatis Indigotica and Strobilathes cusia (24). 
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However, no methods have been described so far to quantify indirubins and their 
derivatives in biological matrices. We successfully achieved our goal to develop an 
accurate and selective assay for the determination of 5-MI in murine plasma, in order to 
apply this assay in a pre-clinical study with 5-MI carried out in mice.  
 
2. Experimental 
2.1 Materials 
5-Methyl-indirubin (5-MI, C17H12N2O2; Figure 1A) was kindly supplied by Oncotest 
GmbH (Freiburg, Germany). Indirubin-3-monoxime (IMO; C16H11N3O2; Figure 1B) (25) 
was obtained from Sigma Aldrich Chemie (Steinheim, Germany). Methanol (LC 
gradient grade) was obtained from Bissolve Ltd. (Amsterdam, The Netherlands). All 
other solvents or chemicals were analytical grade or better. Distilled water was used 
throughout the analyses. Drug-free murine EDTA plasma was obtained from Oncotest 
GmbH (Freiburg, Germany). 
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Figure 1. Chemical structures of 5-MI (A), IMO (B) and Indigo (C). 
 
2.2 Standard, quality control and internal standard solutions 
Two sets of stock solutions of 5-MI in ethanol were prepared from two independent 
weightings at a target concentration of 0.5 mg/mL. The solutions were placed in the 
ultrasonic bath for 1 hour to dissolve all the 5-MI in ethanol. These solutions were 
further diluted with control murine EDTA plasma to obtain working solutions. One set of 
working solutions was used to prepare calibration standards, the other to prepare 
quality control samples. The plasma working solutions of 5-MI used for calibration 
curves were further diluted in control murine EDTA plasma to yield the concentrations 
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of 50,000, 5,000, 2,500, 1,000, 500, 100, 50, 20 and 10 ng/mL. Calibration standards 
were prepared freshly at concentrations of 1, 2, 5, 10, 50, 100, 250 and 500 ng/mL by 
diluting 15 μL of the plasma working solutions with 135 μL of control murine EDTA 
plasma. Standards were processed in singlicate and analyzed in duplicate.  
The plasma working solutions of 5-MI used for the preparation of the quality control 
samples were further diluted in control murine EDTA plasma to yield the concentrations 
of 50,000, 10,000, 1,000, 100 and 10 ng/mL. Quality control samples for 5-MI were 
prepared in murine EDTA plasma at concentrations of 1, 3, 50, and 375 ng/mL, by 
diluting the working solutions in control murine EDTA plasma in volumetric flasks. 
Replicate 50 µL aliquots were transferred to 2.0 mL tubes for storage at nominally –
20°C. The calibration standards and quality control samples were vortex-mixed for 
approximately 30 seconds before processing. 
A stock solution of IMO was prepared in ethanol at a concentration of 0.1 mg/mL. An 
internal standard working solution of IMO was prepared by transferring 50 μL of IMO 
stock solution to a 50.0 mL volumetric flask and adding methanol – water (8:2, v/v) to 
give a final concentration of 100 ng/mL. All solutions were stored at -20oC. 
 
2.3 Sample preparation 
Sample pretreatment was performed at ambient temperatures. 5-MI and internal 
standard were extracted from murine EDTA plasma using liquid-liquid extraction (LLE). 
To 50 μL sample aliquots, 20 μL of internal standard working solution in methanol – 
water (8:2, v/v) and subsequently 1.25 mL of diethyl ether were added. The samples 
were vortexed for 10 sec, followed by automatic shaking for 10 min at 1,250 rpm 
(Labinco, Breda, The Netherlands). Samples were then centrifuged for 10 min at 
23,100 g, the aqueous layer was frozen in an ethanol-dry ice mixture and the organic 
layer was decanted into a clean 2.0 mL-eppendorf tube. The organic solvent was 
evaporated under a gentle stream of nitrogen gas at 30oC. The residue was 
reconstituted with 50 µL of reconstitution solvent (methanol – water (8:2, v/v)) by vortex-
mixing for 30 seconds. After shaking for 15 min and centrifuging for 5 min at 23,100 g, 
the clean supernatant was transferred to a glass autosampler vial with insert. 
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2.4 Liquid chromatography / mass spectrometry 
A HP1100 binary pump, degasser and HP1100 autosampler (Agilent Technologies, 
Palo Alto, CA) and an API 365 triple quadrupole MS equipped with an electrospray 
(ESI) ion source (Sciex, Thornhill, ON, Canada) were used. Isocratic chromatography 
was performed using a Gemini C18 column (150 x 2.1 mm ID, particle size 5 µm; 
Phenomenex, Torrance, CA, USA). The mobile phase of 10 mM ammonium hydroxide 
in water - methanol (5:95, v/v) was pumped at a flow-rate of 0.2 mL/min. Sample 
injections of 10 μL were carried out and the autosampler temperature was gauged at 
10oC.  
Negatively charged ions were created at atmospheric pressure and the mass analyzer 
was operated in the multiple reaction monitoring (MRM) mode using unit resolution for 
the quadrupoles. The resulting MRM chromatograms were used for quantification 
utilizing Analyst™ software version 1.2 (Sciex). The ESI-MS/MS operating parameters 
used in this study are listed in Table 1.  
 
Table 1. Settings of the API365. 
Parameter   Setting 
Run time duration  4.5 min 
Ionspray voltage (negative ion mode)  -4500 V 
Q1 Resolution  Unit 
Q3 Resolution  Unit 
Nebulizer gas (compressed air)  10 psi 
Curtain gas (Nitrogen)  6 psi 
Temperature  400 ºC 
Collision Actived Dissociation Gas  9 psi 
5-MI Q1 mass 275 amu 
 Q2 mass 171 amu 
 Dwell time 150 ms 
IMO Q1 mass 276 amu 
 Q2 mass 246 amu 
  Dwell time 150 ms 
 
2.5 Method Validation 
Partial validation of this method was performed due to the limited availability of murine 
plasma. To determine the linear range, calibration standards (8 non-zero standards as 
described in section 2.2) were prepared in control murine EDTA plasma, processed 
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and analyzed in duplicate in one analytical run. The linear regression of the ratio of the 
areas of the analyte and internal standard peaks versus the concentration were 
weighed by 1/x2 (the reciprocal of the squared concentration). Concentrations were 
back-calculated from the constructed calibration curve and deviations from the nominal 
concentrations should be within ± 20% for the lower limit of quantitation (LLOQ) and 
within ± 15% for other concentrations with coefficient of variation (C.V.) values less 
than 20% and 15% respectively (26,27). 
The accuracy and precision of the analytical method were assessed by analyzing five 
replicates of each murine quality control EDTA plasma sample in one analytical run 
together with a calibration curve independently prepared from the quality control 
samples containing 1, 3, 50, and 375 ng/mL of 5-MI, as described in Section 2.2.  
Accuracies were determined as the percentage difference of the measured 
concentration from the nominal concentration and the C.V. was used to report the 
precision. 
The intra-assay accuracies (% bias) should be within ±20% at the LLOQ level and 
within ±15% at the other concentrations (26,27). The intra-assay precisions should be 
less than 20% at the LLOQ level and less than 15% at the other concentrations (26,27).  
Carry-over was tested by injecting two blank matrix samples after injecting an upper 
limit of quantitation (ULOQ) sample. 
To test the stability of 5-MI in murine plasma after 3 freeze/thaw cycles, the quality 
control samples that had been frozen and thawed three times were compared with 
freshly prepared quality control samples. The stability of 5-MI in murine EDTA plasma 
under processing (ambient temperatures) was also evaluated. The long-term stability of 
5-MI in murine plasma and the stability of stock and working solutions at -20 oC are 
ongoing. 
The above described stability experiments were executed in triplicate at 2 concentration 
levels (3.25 ng/mL and 406 ng/mL) for 5-MI. 5-MI is considered stable in the stock and 
working solutions when 90-110% of the fresh sample’s ratio is found and it is 
considered stable in biological matrixes or extracts when 85-115% of the initial 
concentration is recovered (26,27).  
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2.6 Pre-clinical Study 
The analytical method described in this article has been used to support a pre-clinical 
study in mice, carrying the large cell lung cancer LXFL 529 as solid tumor xenograft. 
During the study carried out at Oncotest GmbH, mice received a single oral dose of 150 
mg/kg 5-MI, formulated as fine homogeneous suspension at 10.0 mg/mL in PEG-200. 
Blood samples were collected in EDTA-coated polystyrene tubes (EDTA-1000A Kabe 
Labortechnik, Nümbrecht-Elsenroth, Germany) from three mice per time point at 2, 8, 
24 and 48 hours following administration of 5-MI. After centrifugation, plasma was 
removed and stored at – 20 oC until analysis.  
 
3. Results and Discussion 
3.1  Sample pretreatment 
Several methods of sample pretreatment were investigated. Recoveries were 
determined by comparing responses from murine plasma samples processed 
according to the procedures mentioned below to the response of 5-MI standard 
solutions in reconstitution solvent (methanol – water (8:2, v/v)), which represented a 
100% recovery. Protein precipitation of murine EDTA plasma samples containing 5-MI 
using methanol and acetonitrile was tested.  This resulted in very low recoveries 
(around 30%), broad peaks, and ion suppression, therefore protein precipitation was 
discarded for these reasons. Liquid-liquid extraction (LLE) using diethyl ether, ethyl 
acetate, dichloromethane, ethyl acetate-diethyl ether (1:1, v/v) and hexane - diethyl 
ether (1:1, v/v) was investigated. Diethyl ether yielded highest and most reproducible 
recoveries for 5-MI, along with low ion suppression. The overall recovery of 5-MI from 
murine plasma, which corresponds to the LLE recovery plus the contribution of the ion-
suppression, was 98%. This means that the effect of the ion-suppression can be 
neglected. Therefore the sample pretreatment using LLE with diethyl ether was chosen. 
To concentrate the analytes, the organic layer was evaporated under a stream of 
nitrogen gas at 30 oC. We observed that 5-MI was not stable in either a very acidic or 
basic environment. When 5-MI was dissolved in a solution containing more than 30 % 
water, 5-MI was crystallized due to the very poor solubility of 5-MI in water. Due to the 
facts mentioned above, we chose a neutral organic solution to reconstitute 5-MI, such 
as methanol-water (8:2, v/v). The use of methanol resulted in better peaks than using 
acetonitrile.  
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3.1.1 Internal standards 
Due to the absence of the labeled and/or deuterated internal standards, structurally 
related compounds to 5-MI have been tested. Indigo (C15H10 N2O2; Figure 1C) is a 
structural analog of 5-MI and differs from 5-MI in the absence of the methyl group and, 
furthermore, the molecular skeleton is arranged differently. However, the solubility of 
indigo and the ionization were very different from that of 5-MI. Moreover, the 
chromatographic properties of Indigo were poor when the analytical system developed 
for 5-MI was applied. For these reasons, Indigo was discarded and another internal 
standard was tested, namely Indirubin-3’-monoxime (IMO). This compound appeared to 
be a suitable internal standard: it was ionized in the negative mode, the solubility was 
comparable to 5-MI, and it eluted just before the analyte with acceptable 
chromatographic properties.  
 
3.2 Liquid Chromatography 
Thus far, no other assay has been described for the determination of 5-MI in murine 
EDTA plasma using HPLC coupled to the tandem MS. We tested several solvents as 
possible eluents, such as 1 mM ammonium acetate, 10 mM ammonium acetate and 
ammonium formate buffer pH 4. An alkaline mixture of an aqueous 10 mM ammonium 
hydroxide solution pH 10.5 and methanol appeared to be most appropriate to elute 5-
MI from the column with small peak widths at base and acceptable peak symmetries. 
Moreover, the highest signal to noise ratio at the LLOQ was observed using 10 mM 
ammonium hydroxide in the eluent. 
Representative chromatograms of IMO and 5-MI in the blanks and at the LLOQ levels 
in murine plasma are depicted in Figure 2. Peak shapes were excellent with the 
asymmetry factors of 1.2 for 5-MI and IMO and the capacity factors (k') of 2.7 for 5-MI 
and of 2.1 for IMO. LC run time was only 4.5 min. 
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Figure 2.Representative HPLC-MS/MS chromatogram of a blank sample for 5-MI (A) 
and for the internal standard IMO (B), a validation sample at the LLOQ (1 ng/mL) for 5-
MI (C) and IMO (100 ng/mL; D) in murine plasma 
 
3.3  Mass Spectrometry 
No ions other than the [M-H]- ions were observed in the Q1 mass spectra of 5-MI (m/z 
275) and IMO (m/z 276). In deprotonation, which is seen in our case, a proton is 
transferred from the analyte 5-MI and IMO to the deprotonated eluent additive (NH3) if 
the proton affinity (PA) of the deprotonated eluent molecule is higher than that of the 
deprotonated analyte. Ammonia used as an eluent modifier is a stronger base than 5 
MI and/or IMO and therefore will have higher PA, leading to the deprotonation of the 
analytes.  
The deprotonated molecular ions of 5-MI and IMO were induced to fragment in the 
collision cell and the resulting product ion spectra and proposed fragmentation patterns 
are presented in Figures 3 and 4, respectively. Namely, when the N atom of an amide 
is attached directly to an aromatic ring, which is the case in the 5-MI molecule, the 
fragmentation may occur which involves a four-atom cyclic intermediate. The first step 
in each of these eliminations is best explained by radical-site-induced migration of a H 
atom via a four atom intermediate.  
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Figure 3. MS/MS product ion scan of 5-MI (precursor ion m/z 275). 
 
Figure 4. MS/MS product ion scan of IMO (precursor ion m/z 276). 
 
The fragment ions formed in this manner are essentially as stable as their precursor 
ions. They form, by a H migration that has minimal energy requirements, followed by 
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elimination of a molecule containing a newly formed π-bond (28).  The main proposed 
fragment ion of 5-MI corresponds to the loss of the 1-amine-4-methylbenzene group 
(m/z 171). After optimization of the MS parameters the fragment ion was still most 
abundant and used for quantitative multiple reaction monitoring (MRM) of 5-MI. The 
main fragment ion of IMO corresponds to the loss of the oxime group (m/z 246).  
 
3.4 Method Validation 
The assay was linear over a concentration range of 1-500 ng/mL for 5-MI in murine 
plasma. Using linear regression and 1/x2 weighing, the lowest total bias and the most 
constant bias across the range were obtained. Correlation coefficient of the calibration 
curve was 0.9943. At all concentration levels, deviation of measured concentrations 
from nominal concentration were between -9.0% and 4.7% with C.V. values less than 
18.2%. 
Assay performance (intra-assay accuracies and precisions) data for 5-MI is 
summarized in Table 2. The intra-assay accuracies (% bias) were within ± 8.0% for all 
concentrations and found to be acceptable (26,27). The intra-assay precisions for 5-MI 
were less than 10.8% for all concentrations and found to be acceptable (26,27). 
Moreover, no carry-over takes place. 
 
Table 2. Assay performance data 
Nominal Conc. Measured Conc. Intra-assay Intra-assay Number of  
(ng/mL) (ng/mL) Accuracy (%) Precision (%) Replicates 
1.08 1.17 7.75 10.8 5 
3.25 3.33 2.52 8.6 5 
54.2 49.9 -7.96 9.72 5 
406 418 2.84 7.32 5 
 
The stability data are summarized in Table 3. 5-MI is stable in murine plasma for at 
least three freeze (-20 oC) / thaw cycles, and is also stable in murine plasma stored at 
nominally ambient temperatures for up to 6 hours. Furthermore, the analytical run can 
be re-injected after at least 24 hours of storage in the autosampler. The long-term 
stability testing of 5-MI in murine plasma is ongoing. 
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Table 3. Stability data of 5-MI. 
  Intitial  Found Deviation C.V. Number of  
Conditions Matrix Conc. (ng/mL) Conc. (ng/mL) (%) (%) Replicates 
3 freeze /thaw murine plasma 3.31 3.46 4.54 9.45 3 
cycles  372 406 9.24 18.1 3 
Ambient, 6h murine plasma 3.31 3.35 1.31 10.5 3 
  417 474 13.6 0.645 3 
Autosampler,  final extract  3.46 3.74 8.29 0.408 3 
10ºC, 24h (murine plasma) 49.0 55.9 14.1 0.473 3 
    450 421 -6.30 7.96 3 
 
3.5 Pre-clinical Study 
The plasma concentration-time profile following a single oral administration of 150 
mg/kg 5-MI is given in Figure 5. 
 
Figure 5. 5-MI levels in the mice plasma after oral administration of 5-MI; logarithmic 
concentration (±SD) vs. time profile. 
 
The maximum 5-MI plasma concentration of 136 ng/mL was already reached within 2 
hours after administration. Levels decreased continuously over time with concentrations 
of 35.1 ng/mL after 8 hours, and 10.9 ng/mL after 24 hours, respectively. After 48 hours 
less than the lower limit of quantitation (<1 ng/mL) of 5-MI was present in the plasma 
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(data not shown in Figure 5). Whether the concentration at 2 hours post administration 
represents the peak level of 5-MI remains to be identified by analyzing further samples 
taken at smaller time intervals after administration. 
 
4. Conclusions 
A reproducible and selective LC-MS/MS assay has been developed for the 
quantification of 5-MI in murine plasma. Using 50 μL murine plasma aliquots, the assay 
quantifies the drug in a concentration range of 1 to 500 ng/mL. Validation results 
demonstrate that the 5-MI concentrations can be accurately quantified in murine EDTA 
plasma. This assay was successfully used to support a pre-clinical pharmacologic 
study with 5-MI.  
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Abstract 
A sensitive and specific LC-MS/MS assay for the quantitative determination of 
gemcitabine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine  (dFdU) is presented. 
A 200-μL aliquot human plasma was spiked with a mixture of internal standards 
didanosine, lamivudine and fludarabine and extracted using solid phase extraction. 
Dried extracts were reconstituted in 1 mM ammonium acetate – acetonitrile (97:3, v/v) 
and 10 μL-volumes were injected onto the HPLC system. Separation was achieved on 
a 150 x 2.1 mm C18 bonded phase endcapped with polar groups (Synergi Hydro-RP 
column) using the eluent composed of 1 mM ammonium acetate pH 6.8 - acetonitrile 
(94:6, v/v). Detection was performed by positive ion electrospray followed by tandem 
mass spectrometry. The assay quantifies a range from 0.5 to 1,000 ng/mL for 
gemcitabine and from 5 to 10,000 ng/mL for dFdU using 200 μL of human plasma 
samples. Validation results demonstrate that gemcitabine and dFdU concentrations can 
be accurately and precisely quantified in human plasma. This assay is used to support 
clinical pharmacologic studies with gemcitabine. 
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1. Introduction 
Gemcitabine (2', 2'-difluorodeoxycytidine, or dFdC) is one of the most commonly used 
anti-cancer agents and has demonstrated antitumor activity against a broad range of 
solid tumors, such as non-small cell lung cancer (NSCLC), breast, ovarian, urothelial, 
pancreatic and bladder cancer (1-4). 
Gemcitabine (2', 2'-difluorodeoxycytidine, or dFdC) is a deoxycytidine analog in which 
the deoxyribose moiety contains two fluorine atoms (Figure 1A). In blood, gemcitabine 
is rapidly metabolized by cytidine deaminase to its metabolite 2',2'-difluorodeoxyuridine  
(dFdU; Figure 1B) (5,6). 
Intracellularly, gemcitabine is metabolized by deoxycytidine kinase and other nucleotide 
kinases to form the active gemcitabine 5'-diphosphate and 5'-triphosphate metabolites 
(7-12).  
Several methods have been developed over the recent years for the quantification of 
gemcitabine and dFdU in human plasma and urine featuring enzyme linked 
immunosorbance assay (ELISA) (9), derivative-spectrophotometric (13), 19F-NMR 
(nuclear magnetic resonance) (14), both reversed- and normal phase high performance 
liquid chromatography (HPLC) methods with UV detection (5,15-17), HPLC with diode 
array detector (DAD) (18), ion-pair reversed-phase HPLC-UV (19) and HPLC coupled to 
MS or MS/MS detection (20,21). These methods have a lower limit of quantitation 
(LLOQ) in human plasma for gemcitabine ranging from 5 – 200 ng/mL and for dFdU 
from 5 – 500 ng/mL.  
Gemcitabine, like most anticancer drugs, has a narrow therapeutic window. Therefore, 
it is of pivotal importance to be able to accurately and reliably evaluate the 
pharmacokinetic and pharmacodynamic profiles of gemcitabine and dFdU in clinical 
trials. To accomplish this goal, we developed a simple and sensitive method for the 
accurate determination of gemcitabine and its metabolite dFdU in human heparinized 
and EDTA plasma. Using a sample volume of 200 µL, our method is 10-fold more 
sensitive for gemcitabine in human plasma, compared to the HPLC-MS/MS method 
that has been published thus far (20). However, in human urine a low limit of 
quantitation for the prodrug has been validated (21) using a samples volume of 2.0 mL. 
The method has been fully validated according to the current FDA guidelines on 
bioanalytical validation (22), and is now applied in clinical pharmacokinetic and 
pharmacodynamyc studies with gemcitabine. 
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2. Experimental 
2.1  Chemicals and materials 
Gemcitabine hydrochloride (2', 2'-difluorodeoxycytidine; C9H11F2N3O4) and 2',2'-
difluorodeoxyuridine  (dFdU, C9H10F2N2O5) were kindly provided by Eli Lilly 
(Indianapolis, IN, USA). The internal standards didanosine (C10H12N4O3; Figure 1C), 
lamivudine (C8H8N3SO3; Figure 1D), and fludarabine (C10H12F1N4O4; Figure 1E),  were 
purchased from Sigma–Aldrich Chemie (Steinheim, Germany). Tetrahydrouridine (THU) 
was obtained from Calbiochem (San Diego, CA, USA). Methanol (LC gradient grade) 
was obtained from Bissolve Ltd. (Amsterdam, The Netherlands). All other solvents or 
chemicals were analytical grade or better. Distilled water was used throughout the 
analyses. Drug-free human EDTA and heparinized plasma was obtained from the 
Central Laboratory for Blood Transfusion (Sanquin Amsterdam, The Netherlands; 
Bioreclamations, Hicksville, NY, USA). 
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Figure 1. Chemical structures of gemcitabine (A), dFdU (B), didanosine (C), lamivudine 
(D) and fludarabine (E). 
 
2.2 Preparation of EDTA/heparinized human plasma stabilized with THU 
Gemcitabine is metabolized by cytidine deaminase present in plasma, which can be 
efficiently inhibited by THU (23,24). THU, purchased as a 10 mg vial, was dissolved in 1 
mL of water. This solution was stored and is stable for at least 4 weeks at 2-8oC. To 
inhibit cytidine deaminase 100 μL of the above described solution was added to 10 mL 
of human EDTA or heparinized plasma. 
 
2.3 Preparation of stock and working solutions 
Two sets of stock solutions of both gemcitabine and dFdU were prepared from two 
independent weighings and dissolution in water at a target concentration of 1 mg/mL. 
These solutions were further diluted with control human EDTA plasma stabilized with 
THU to obtain working solutions. One set of working solutions was used to prepare 
calibration standards, the other to prepare quality control samples. The plasma working 
solutions of gemcitabine were further diluted in control human plasma to yield the 
concentrations of 100,000, 10,000, 5,000, 1,000, 500, 100, 50, 10 and 5 ng/mL. The 
plasma working solutions of dFdU were further diluted in control human plasma to yield 
the concentrations of 100,000, 50,000, 10,000, 5,000, 1,000, 500, 100 and 50 ng/mL.  
Separate stock solutions of didanosine, lamivudine and fludarabine were prepared in 
water at a concentration of 0.5 mg/mL. An internal standards working solution was 
prepared by transferring 200 μL of didanosine stock solution, 20 μL of lamivudine stock 
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solution and 20 μL of fludarabine stock solution to a 10.0 mL volumetric flask and 
addition of water to give a final concentration of 10,000 ng/mL for didanosine and 1,000 
ng/mL for lamivudine and fludarabine. All solutions were stored at -20oC. 
 
2.4 Preparation of calibration standards and quality control samples in human plasma 
Before use, control human plasma (EDTA or heparinized) stabilized with THU was 
centrifuged for approximately 5 min at 3,900 g. 
Calibration standards containing both gemcitabine and dFdU were prepared freshly at 
concentrations of 0.5, 1, 5, 10, 50, 100, 500 and 1,000 ng/mL for gemcitabine and at 
concentrations of 5, 10, 50, 100, 500, 1,000, 5,000 and 10,000 ng/mL for dFdU by 
adding 50 μL of gemcitabine and dFdU working solutions (described in section 2.3) to 
400 μL of control human plasma. The calibration standards were vortex-mixed for 
approximately 30 sec before processing. Standards were processed in singlicate and 
analyzed in duplicate. 
Quality control samples for gemcitabine and dFdU were prepared in human EDTA 
plasma stabilized with THU at concentrations of 0.5, 1.5, 300 and 750 ng/mL for 
gemcitabine and 5, 15, 3,000 and 7,500 ng/mL for dFdU, by diluting the working 
solutions for quality control samples in control human plasma in volumetric flasks. 
Replicate 200 µL aliquots were transferred to 2.0 mL tubes for storage at nominally –
20°C. The quality control samples were vortex-mixed for approximately 30 seconds 
before processing. 
 
2.5 Extraction procedure 
Gemcitabine, dFdU and internal standards didanosine, lamivudine and fludarabine 
were isolated from plasma using solid-phase extraction (SPE). To 200 μL sample 
aliquots, 20 μL of internal standards working solution was added. The OASIS® HLB 30 
gram solid phase extraction catridges (Waters, Etten-Leur, The Netherlands) were 
activated with 0.5 mL of methanol and 0.5 mL of water. A plasma sample (total volume 
220 μL) was loaded onto the cartridge, followed by 0.5 mL of water. After drying the 
cartridge for 2 min with air, the analytes were eluted with 400 μL of methanol. Methanol 
was evaporated under a gentle stream of nitrogen at 40oC and the residue was 
redissolved in 100 µL of reconstitution solvent (1 mM ammonium acetate pH 6.8 – 
acetonitrile (97:3, v/v)) by vortex-mixing for 30 seconds. After shaking for 15 min and 
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centrifuging for 10 min at 23,100 g, the clean supernatant was transferred to a glass 
autosampler vial with insert. 
 
2.6 Chromatographic conditions 
Chromatographic separations of gemcitabine, dFdU, didanosine, lamivudine and 
fludarabine were carried out using a Solvent delivery system (HPLC pomp Shimadzu) 
LC-20AD Prominence, degasser and Sil – HTc with SCL -10 Avp system controler 
(Shimadzu, Kyoto, Japan). Isocratic chromatography was executed using a Synergi 
Hydro RP column (150 x 2.1mm ID, particle size 4 μm Phenomenex, The Netherlands), 
that was kept at 30oC. The mobile phase consisted of 1 mM ammonium acetate pH 6.8 
- acetonitrile (94:6, v/v) and was pumped at a flow-rate of 0.2 mL/min. The run time was 
9.5 min. Sample injections of 10 μL were carried out and the autosampler temperature 
was gauged at 10oC.  
 
2.7 Mass spectrometry 
The Finnigan TSQ Quantum Ultra Triple Quadrupole Mass Spectrometer equipped with 
an electrospray (ESI) ion source (Thermo Fisher, Waltham, MA, USA) operating in 
positive mode was used to obtain both the mass spectra (MS1) and the product ion 
spectra (MS2). LCquan™ 2.5 software (Thermo Fisher) was used to process the 
quantitative data. Positive ions were created at atmospheric pressure and the mass 
analyzer was operated in the multiple reaction monitoring (MRM) mode using unit (0.7 
Da) resolution for the quadrupoles. Mass transitions of m/z 264 → 112 and 265 → 113 
were optimized for gemcitabine and dFdU, respectively. Mass transitions of m/z 230 → 
112, 237 → 137 and 286 → 154 were optimized for lamivudine, didanosine and 
fludarabine, respectively. The ESI-MS/MS operating parameters used in this study are 
listed in Table 1. 
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Table I. Settings of the Finningan TSQ Quantum ultra triple quadrupole mass 
spectrometer. 
Parameter   Setting 
Run duration  9.5 min 
Ionspray voltage (positive ion mode)  +3000 V 
Sheath gas  8 psi 
Capillary Temperature  275 ºC 
Collision pressure  1.5 torr 
Quad MS/MS bias  3.8 V 
Gemcitabine Q1 mass 264 amu 
 Q3 mass 112 amu 
 Dwell time 150 ms 
 Collision energy 19 V 
 Tube lens voltage 74 V 
 Source CID Collision energy 10 V 
dFdU Q1 mass 265 amu 
 Q3 mass 113 amu 
 Dwell time 150 ms 
 Collision energy 23 V 
 Tube lens voltage 74 V 
 Source CID Collision energy 12 V 
Didanosine Q1 mass 237 amu 
 Q3 mass 137 amu 
 Dwell time 150 ms 
 Collision energy 24 V 
 Tube lens voltage 28 V 
 Source CID Collision energy 10 V 
Lamivudine Q1 mass 230 amu 
 Q3 mass 112 amu 
 Dwell time 150 ms 
 Collision energy 26 V 
 Tube lens voltage 86 V 
 Source CID Collision energy 10 V 
Fludarabine Q1 mass 286 amu 
 Q3 mass 154 amu 
 Dwell time 150 ms 
 Collision energy 20 V 
 Tube lens voltage 74 V 
  Source CID Collision energy 6 V 
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2.8 Validation procedures 
A full validation according to the FDA guidelines was performed for the assay in human 
EDTA plasma. For the assay in human heparinized plasma, a partial validation was 
performed by means of accuracy and precision (22). 
 
2.8.1 Linearity 
For the validation, calibration standards (8 non-zero standards of the analytes, as 
described in section 2.4) were prepared in control human EDTA plasma stabilized with 
THU and analyzed in duplicate in three analytical runs.  
The linear regression of the ratio of the areas of the analyte and internal standard 
peaks versus the concentration were weighed by 1/x2 (the reciprocal of the squared 
concentration). Concentrations were back-calculated from the constructed calibration 
curve and deviations from the nominal concentrations should be within ± 20% for the 
lower limit of quantitation (LLOQ) and within ± 15% for other concentrations with 
coefficient of variation (C.V.) values less than 20% and 15% respectively (22,25). 
 
2.8.2 Accuracy and precision 
To investigate the accuracy and precision in human EDTA plasma, five replicates of 
each human EDTA plasma stabilized with THU samples were analyzed in three 
analytical runs together with a calibration curve independently prepared from the quality 
control samples containing 0.5, 1.5, 300, and 750 ng/mL of gemcitabine and 5, 15, 
3,000, and 7,500 ng/mL of dFdU, as described in Section 2.4.  
To investigate the accuracy and precision in human heparinized plasma, five replicates 
of each human heparinized plasma stabilized with THU samples were analyzed in one 
analytical run together with a calibration curve in a similar way as described above for 
the EDTA plasma samples. 
Accuracies were determined as the percentage difference of the measured 
concentration from the nominal concentration and the C.V. was used to report the 
precision. 
The intra and inter-assay accuracies (% bias) should be within ±20% at the LLOQ level 
and within ±15% at the other concentrations (22,25). The intra and inter-assay 
precisions should be less than 20% at the LLOQ level and less than 15% at the other 
concentrations (22,25).  
Chapter 5.1 
 
250 
Samples with gemcitabine and dFdU concentrations 10-fold higher than the upper limit 
of quantitation (ULOQ) of the calibration curve were analyzed after dilution. Five 
replicates of each sample were analyzed in one analytical run after dilution in control 
human EDTA plasma stabilized with THU. 
 
2.8.3 Limit of detection 
The limit of detection (LOD) for gemcitabine and dFdU, with the responses of the 
analytes at 2 times the response of the blank was established in three analytical runs.  
 
2.8.4 Specificity and selectivity 
To investigate whether endogenous matrix constituents interfered with the assay, six 
individual batches of control drug-free EDTA plasma stabilized with THU, and samples 
containing neither analyte nor internal standard (double blank), samples containing only 
internal standard (blank), and samples spiked at the LLOQ were prepared. Samples 
were prepared and analyzed according to the described procedures. Peak areas of 
compounds co-eluting with the analyte or internal standard should not exceed 20% of 
the analyte peak area at the LLOQ or 5% of the internal standard area. Deviations from 
the nominal concentrations should be within ± 20% for the LLOQ samples (22,25). 
 
2.8.5 Matrix effect study 
For the determination of ion suppression, control drug-free EDTA plasma stabilized with 
THU was processed and dry extracts were dissolved in solutions that represented 
100% recovery containing the analytes (at concentrations of 3, 600 and 1,500 ng/mL 
for gemcitabine and at concentrations of 30, 6,000 and 15,000 ng/mL for dFdU) and 
internal standards (at concentrations of 20,000 ng/mL for didanosine and 2,000 ng/mL 
for lamivudine and fludarabine) in 1 mM ammonium acetate pH 6.8 - acetonitrile (97:3, 
v/v). Ion-suppression (matrix effect) was determined by comparing the analytical 
response of these samples to that of the solutions containing only analytes and internal 
standards in 1 mM ammonium acetate pH 6.8 – acetonitrile (97:3, v/v) at the same 
concentrations as mentioned above (26). The loss of signal represents the ion-
suppression.  
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2.8.6 Recovery 
SPE recovery was determined by comparing the analytical response of processed 
quality control samples (at the concentrations of 1.5, 300 and 750 ng/mL for 
gemcitabine, at concentrations of 15, 3,000 and 7,500 ng/mL for dFdU, at 
concentrations of 10,000 ng/mL for didanosine and 1,000 ng/mL for lamivudine and 
fludarabine) with the analytical response of blank samples reconstituted with solutions 
as described in section 2.8.5. The concentrations of the matrix effect samples are 2 
times higher than that of the processed quality control samples, due to the 
concentration step in the extraction procedure. These experiments were performed in 
triplicate. Overall recovery was determined by comparing the analytical response of 
processed quality control samples with the analytical response of the samples 
containing only analytes and internal standards in 1 mM ammonium acetate pH 6.8 – 
acetonitrile (97:3, v/v).  
 
2.8.7 Stability 
The stability of analytes in human EDTA plasma after 3 freeze/thaw cycles was 
investigated by comparing quality control samples that had been frozen and thawed 
three times with freshly prepared quality control samples. The stability of gemcitabine 
and dFdU in human plasma stabilized with THU under processing (ambient 
temperatures) and storage (-20oC) conditions was evaluated. Additionally, the stability 
of the dry extract at 4oC and in the reconstituted extract was determined for both 
analytes. Also, the re-injection reproducibility in the auto sampler was determined after 
24h. The stability of gemcitabine and dFdU in the stock solutions, the long-term stability 
in human EDTA plasma stabilized with THU and the stability of working solutions at -20 
oC are ongoing. 
The above described stability experiments were executed at 2 concentration levels for 
gemcitabine (1.5 and 750 ng/mL) and dFdU (15 and 7,500 ng/mL) in triplicate. The 
analytes were spiked separately to the biological matrix. The analytes are considered 
stable in the stock and working solutions when 90-110% of the fresh sample’s ratio is 
found and they are considered stable in biological matrixes or extracts when 85-115% 
of the initial concentration is recovered.  
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3. Results and Discussion 
3.1 Internal standards 
Due to the absence of the stable isotopically labeled internal standards, several other 
structurally to gemcitabine and/or dFdU related compounds have been tested. 2'-
deoxycytidine and cytarabine eluted after 2 min (k' ≈ 0.5) in our chromatographic 
system. Moreover, they experienced a reasonably high and varying percentage of ion 
suppression, probably due to the elution along with the other endogenous plasma 
components. 2'-Deoxycytidine and cytarabine were discarded for these reasons. On the 
contrary, 3'-deoxy-3-fluorothymidine, cladribine and zidovudine eluted very late, and 
thus would require a modification of the isocratic system, resulting in an increase of the 
analysis time. Stavudine was not chosen because of the varying recovery from human 
EDTA plasma. Initially, adenosine, which is an endogenous compound, was considered 
as a possible internal standard. However, because of the presence of endogenous 
adenosine, the inter-batch variability in recovery of adenosine from human plasma was 
unacceptably high (200-300%), despite the high concentration of spiked adenosine. 
Finally, didanosine, lamividune and fludarabine proved to have acceptable retention 
times and their recoveries from plasma were comparable with those of gemcitabine and 
dFdU. Therefore, they were all selected and tested as possible internal standards for 
gemcitabine and dFdU. The luxury of having three suitable, commercially available, 
internal standards is a powerful advantage of this assay. Namely, if patients are 
diagnosed with HIV, fudarabine can be used as an internal standard. Consequently, in 
the case of the co-medication (when gemcitabine is given together with fludarabine) 
lamividine and/or didanosine are appropriate internal standards. 
 
3.2  Sample pretreatment 
Different methods of sample pretreatment were investigated. Recoveries were 
determined by comparing responses from human EDTA plasma stabilized with THU 
samples processed according to the procedures mentioned below to responses of 
gemcitabine and dFdU standard solutions in reconstitution solvent (1 mM ammonium 
acetate pH 6.7 – acetonitrile (97:3, v/v)), which represented 100% recovery. Protein 
precipitation of plasma samples containing gemcitabine and dFdU using either 
methanol, acetonitrile and methanol – acetonitrile (1:9, v/v), followed by evaporation 
and reconstitution in 1mM ammonium acetate pH 6.8 – acetonitrile (97:3, v/v) were 
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tested, because it is a straightforward, simple, and fast extraction method. However, 
most likely due to the small size and hydrophilic nature of nucleosides, such as 
gemcitabine and dFdU, this resulted in non-reproducible recoveries and high ion-
suppression. Protein precipitation was discarded for these reasons. Subsequently, 
liquid-liquid extraction (LLE) was investigated as an alternative means of sample 
pretreatment using diethylether, ethyl acetate, trichloroacetic acid, precipitation with 
acetonitrile followed by extraction using ethyl acetate (data not shown). Unfortunately, 
none of these solvents were able to efficiently extract the analytes and to obtain 
sufficient selectivity. Thus, liquid-liquid extraction was discarded as well. The 
hydrophilic nature of the compounds led us to explore OASIS® HLB cartridges suitable 
for SPE. This method yielded clean samples, reproducible recoveries and sufficient 
selectivity for both analytes. 
To concentrate the analytes, the organic extract was evaporated under a stream of 
nitrogen at 40 oC, and the residue was dissolved in 1 mM ammonium acetate pH 6.8 – 
acetonitrile (97:3, v/v). 
 
3.3 Chromatography 
Since gemcitabine and dFdU are highly hydrophilic, it is quite a challenge to develop a 
sensitive and selective chromatographic method. With commonly used reversed-phase 
columns, it appeared cumbersome to separate the analytes of interest from 
endogenous nucleosides. Several columns have been tested: Gemini C-18, Zorbax 
Extend C18 (150 x 2.1 ID, 5 µm particle size), Polaris 5 C18 chromsep (150 x 2.1 ID, 5 
µm particle size), Synergi Fusion-RP (150 and 50 x 2.1 ID, 5 µm particle size), Synergi 
Polar-RP (150 x 2.1 ID, 4 µm particle size), Synergi Luna (150 x 2.1 ID, 3 µm particle 
size) and finally Synergy Hydro-RP (150 x 2.1 ID, 5 µm particle size). As mentioned 
above, the highly polar nature of the analytes causes them to elute rapidly from 
reversed-phase columns even with very a low (3%) organic content in the mobile 
phase. Consequently, Gemini C18 and Zorbax Extend columns appeared to be 
unsuitable for this application. Very broad and asymmetric peak shapes were obtained 
when Polaris, which consists of polar groups bonded to a C-18 silica beads with 
hydrophobic ligands extended outwards, was used. Gemcitabine and dFdU were more 
strongly retained on reversed phase columns, such as Synergi Fusion-RP, Polar-RP 
and Luna, which consists of polar embedded and hydrophobic ligand, ether-linked 
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phenyl phase with hydrophilic endcapping and phenyl phase which employs a hexyl 
alkyl linker, respectively. However, varying levels of free silanols, and hydroxyl groups 
from column-to-column appeared to cause poor reproducibility and selectivity, shifting 
retention times, varying peak shapes and non-linearity.  
Finally, Synergi Hydro-RP, that consists of C18 bonded phase endcapped with polar 
groups providing retention via polar interactions, hydrogen bonds and electrostatic 
interactions, was used. The peak shapes and retention appeared to be excellent, 
calibration curves were linear and reproducible and column-to-column variability was 
nil. Therefore, Synergi Hydro-RP proved to be the most suitable column for this 
application. 
Several buffers have been investigated in the search for an appropriate eluent, as 
described in Figure 2, where the log of capacity factor (k’) is plotted against the pH.  
 
Figure 2. Capacity Factor k' versus pH for gemcitabine (○) and dFdU (●) 
chromatography. 
 
The pKa of gemcitabine (cytidine moiety) is 4.2, however the pKa of dFdU (uridine 
moiety) is 9.2. Gemcitabine is, at the tested pH of 6.7 to 9.5, almost constantly 
deprotonated (pKa = 4.2) and therefore interacts with the column similarly throughout 
the tested pH range. However, dFdU (pKa of 9.2) is neutral below pH 7 and becomes 
Ultrasensitive determination of gemcitabine and dFdU in human plasma 
 
                                                                                                                         255 
deprotonated at higher pH values. As a result, the interaction with the column weakens 
and dFdU will elute from the column quicker, as proved from our experiments 
presented in Figure 2. In conclusion, we found that the most appropriate eluent was a 
mixture of an aqueous 1 mM ammonium acetate pH 6.7 – acetonitrile (94:6, v/v). The 
highest signal to noise ratio was also observed and the best selectivity was achieved 
using 1 mM ammonium acetate pH 6.7 as the eluent. Synergi Hydro material is suited 
to handle 100% aqueous mobile phase, which is pivotal in this case.  
Representative chromatograms of gemcitabine, dFdU and the internal standards at 
their LLOQ levels in human EDTA plasma are depicted in Figure 3. Peak shapes were 
excellent with the asymmetry factors of 1.1 for gemcitabine, dFdU and didanosine and  
1.3 for lamivudine and fludarabine. The capacity factors (k') were approximately 2.5 for 
gemcitabine, 4.2 for dFdU, 5.4 for didanosine, 4.3 for lamivudine and 6.5 for 
fludarabine. LC run time was 9.5 min. 
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Figure 3. Representative HPLC-MS/MS chromatograms of a validation samples at the 
LLOQ (0.5 ng/mL) for gemcitabine (A) at the LLOQ (5 ng/mL) for dFdU (B), the internal 
standards didanosine (10,000 ng/mL; C), lamivudine (1,000 ng/mL; D) and fludarabine 
(1,000 ng/mL; E) in human plasma. 
 
3.4 Mass Spectrometry 
Several mass spectrometers and ion sources were investigated: API 365 and API 2000 
(Sciex, Toronto, Canada) equipped with turboionspray and Finnigan TSQ Ultra 
equipped with the atmospheric pressure ionization (APCI) and electrospray ionization 
(ESI) sources.  
Q1 spectra obtained using API 365 and API 2000 in combination with turboionspray, 
showed the prominent presence of the cytidine and uridine protonated moieties. This 
indicates that the elimination of the ribose moiety is a favorable reaction for the 
molecule, which occurs immediately in the ion source. This reaction was not 
reproducible, resulting in the varying signal of the protonated analytes when monitoring 
a Q1 spectrum. On contrary, when Finnigan TSQ Ultra equipped either with APCI or 
ESI sources was used, only the protonated molecules of gemcitabine and dFdU were 
observed in Q1 spectrum. This may be explained by the fact that the turboionspray 
source in the Sciex machines is heated, but the APCI and ESI in the Finnigan TSQ 
Ultra are not. Apparently, temperature is critical for the sensitivity and linearity of 
gemcitabine and dFdU. Consequently, the highest sensitivity and reproducibility was 
achieved when Finnigan TSQ Ultra was used and therefore this platform was chosen 
for the further method development. With APCI, a protonated solvent molecule donates 
a proton to the analyte in the gas phase. Therefore, in general, APCI is better suited for 
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ionization of non-polar, volatile low molecular weight molecules while ESI is better 
suited for more polar, non-volatile molecules. This agrees with our observation, that 
when using the ESI source, the highest signal to noise ratio at the LLOQ was obtained 
for the polar gemcitabine and dFdU. Consequently, Finnigan TSQ Ultra equipped with 
the electrospray ionization source was chosen.  
Figures 4-8, show a MS/MS product ion scan (Q3 scan) of gemcitabine, dFdU, 
didanosine, lamivudine, and fludarabine, respectively, across the range of m/z 100-300. 
A clear response is observed at m/z of 264, 265, 237, 230 and 286 corresponding to 
the protonated molecules [M+H]+ of gemcitabine, dFdU, didanosine, lamivudine and 
fludarabine, respectively.  Sodium adducts are visible in the spectrum of lamivudine 
(m/z 252). The primary, most abundant product ions observed in the collisional spectra 
of the m/z of 264 (gemcitabine), 265 (dFdU), 237 (didanosine), 230 (lamivudine), and 
286 (fludarabine) were product ions at m/z of 112, 113, 137, 112 and 154, respectively, 
corresponding to the loss of the ribose moiety. Also, significantly smaller product ions 
are observed at m/z of 142, 102 and 134 in the spectra of dFdU, didanosine and 
fludarabine, respectively, which corresponds to the detached ribose unity. 
Consequently, multiple reaction monitoring (MRM) parameters were optimized on the 
m/z of 264/112, 265/113, 237/137, 230/112 and 286/154 transitions for gemcitabine, 
dFdU, didanosine,  lamivudine and fludarabine, respectively.  
 
Figure 4. MS/MS product ion scan of Gemcitabine (precursor ion m/z 264). 
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Figure 5. MS/MS product ion scan of dFdU (precursor ion m/z 265). 
 
Figure 6. MS/MS product ion scan of Didanosine (precursor ion m/z 237). 
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Figure 7. MS/MS product ion scan of Lamivudine (precursor ion m/z 230). 
 
Figure 8. MS/MS product ion scan of Fludarabine (precursor ion m/z 286). 
 
Moreover, we found that the Source Collision Induced Dissociation (CID) energy 
(voltage across the octapole lenses) and the capillary temperature are critical for the 
linear range of the gemcitabine. When the source CID was too low (0V) or too high 
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(20V), the linear range decreased and the signal of gemcitabine became less 
reproducible. However, when the source CID was set at 10V, the signal became 
reproducible and the linear range between 0.5-1,000 ng/mL was achieved. The 
capillary temperature of 275 ºC proved to be the most optimal for the ionization and the 
linear range of gemcitabine. 
 
3.5 Validation 
3.5.1 Linearity 
The assay was linear over a concentration range of 0.5-1,000 ng/mL for gemcitabine 
and 5-10,000 ng/mL for dFdU in human EDTA stabilized with THU plasma. Using linear 
regression and 1/x2 weighing, the lowest total bias and the most constant bias across 
the range were obtained. Correlation coefficients (r2) of the calibration curves in human 
EDTA plasma were better than 0.99 for both gemcitabine and dFdU, using didanosine, 
lamivudine and fludarabine, respectively, as internal standards. At all concentration 
levels (using all three internal standards), deviations of measured concentrations from 
nominal concentration were between -8.36% and 3.72% with C.V. values less than 
9.73% for gemcitabine and between -6.97% and 9.10% with C.V. values less than 
9.65% for dFdU. Moreover, the samples with gemcitabine and dFdU can be diluted 100 
times. 
 
3.5.2 Accuracy and precision 
Assay performance (inter-assay accuracies and precisions) data for gemcitabine and 
dFdU in human EDTA plasma is summarized in Table II. Assay performance (intra-
assay accuracies and precisions) data for gemcitabine and dFdU in human heparinized 
plasma is summarized in Table III. The intra-assay accuracies (% bias) for gemcitabine 
in human EDTA plasma were within ± 14.3% for all concentrations (using all internal 
standards) and found to be acceptable (data not shown) (22,25). The intra-assay 
accuracies (% bias) for dFdU in human EDTA plasma were within ± 13.3% for all 
concentrations (using all internal standards) and were also acceptable (data not shown) 
(22,25).  
The intra-assay precisions for gemcitabine in human EDTA plasma were less than 
10.5% for all concentrations (using all internal standards) and found to be acceptable 
(22,25). The intra-assay precisions for dFdU in human EDTA plasma were less than 
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9.85% for all concentrations (using all internal standards). As defined by the lower and 
upper validation sample concentrations possessing acceptable accuracy and precision, 
the validated range for gemcitabine is from 0.5 to 1,000 ng/mL and for dFdU from 5 to 
10,000 ng/mL based on 200 μL of human EDTA plasma and human heparinized 
plasma. 
 
Table II. Assay performance data for gemcitabine and dFdU in human EDTA plasma. 
Compound Internal Nominal Measured  Inter-Assay Inter-Assay Mean overall Number of 
 standard Conc. Conc. Accuracy Precision Accuracy  replicates 
    (ng/mL) (ng/mL) (%) (%) (%)   
dFdC Didanosine 0.502 0.536 5.56 8.08 107 15 
  1.51 1.62 6.07 5.26 107 15 
  301 285 -1.13 6.82 94.7 15 
    753 717 -3.77 5.01 95.3 15 
dFdC Lamivudine 0.502 0.531 3.63 9.47 106 15 
  1.51 1.46 -1.52 7.45 97.0 15 
  301 295 0.487 9.03 98.1 15 
    753 745 -2.77 7.50 98.9 15 
dFdC Fludarabine 0.502 0.527 1.24 10.9 105 15 
  1.51 1.49 -3.05 7.83 98.9 15 
  301 316 3.72 7.59 105 15 
    753 806 3.22 6.77 107 15 
dFdU Didanosine 4.98 5.32 6.87 8.65 107 15 
  14.9 16.3 9.75 3.13 109 15 
  2987 2714 -1.77 11.4 90.9 15 
    7467 6644 -4.17 11.9 89.0 15 
dFdU Lamivudine 4.98 4.60 -1.63 11.1 92.4 15 
  14.9 15.1 3.89 4.39 102 15 
  2987 2990 4.06 7.71 100 15 
    7467 7092 -0.668 9.44 95.0 15 
dFdU Fludarabine 4.98 5.29 7.01 7.23 106 15 
  14.9 15.8 5.68 4.12 106 15 
  2987 3363 11.4 2.61 113 15 
    7467 8129 8.60 4.50 109 15 
 
3.5.3 Limit of detection 
The limit of detection is the concentration of gemcitabine and dFdU at which the 
response of the analyte is 2 times higher than the response of the blank, and is 
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established in three analytical runs. The mean LOD concentration is estimated at 0.145 
ng/mL for gemcitabine, and 1.18 ng/mL for dFdU.  
 
Table III. Assay performance data for gemcitabine and dFdU in human heparinized 
plasma. 
Compound Internal Nominal Measured  Intra-assay Intra-assay Mean overall Number of 
 standard Conc. Conc. Accuracy Precision Accuracy  Replicates 
    (ng/mL) (ng/mL) (%) (%) (%)   
dFdC Didanosine 0.502 0.498 -0.876 8.45 99.1 5 
  1.51 1.67 10.5 2.45 110 5 
  301 336 11.5 2.28 111 5 
    753 769 2.07 0.375 102 5 
dFdC Fludarabine 0.502 0.474 -5.58 3.87 94.4 5 
  1.51 1.62 7.28 2.18 107 5 
  301 299 -0.731 1.19 99.3 5 
    753 675 -10.4 1.14 89.6 5 
dFdU Didanosine 4.98 5.69 14.2 3.48 114 5 
  14.9 16.3 9.53 0.799 110 5 
  2987 3318 11.1 1.33 111 5 
    7467 7667 2.67 7.35 103 5 
dFdU Lamivudine 4.98 5.30 6.43 5.62 106 5 
  14.9 16.4 10.2 2.33 110 5 
  2987 2895 -3.07 3.03 96.9 5 
    7467 6606 -11.5 3.26 88.5 5 
dFdU Fludarabine 4.98 5.26 5.66 2.82 106 5 
  14.9 15.6 4.97 2.66 105 5 
  2987 3160 5.80 1.58 106 5 
    7467 7494 0.356 4.12 100 5 
 
3.5.4 Specificity and selectivity 
MRM chromatograms of six batches of control drug-free EDTA plasma stabilized with 
THU contained no co-eluting peaks >20% of the gemcitabine and dFdU area at the 
LLOQ level, and no co-eluting peaks >5% of the area of all internal standards. 
Deviations from the nominal concentrations at the LLOQ level were between -0.797% 
and 15.7% for gemcitabine (using all internal standards) and found to be acceptable 
(22,25). Deviations from the nominal concentrations at the LLOQ level for dFdU (using 
all internal standards) were between -18.3% and 2.21% and also acceptable (22,25). 
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Table IV. Stability data for Gemcitabine (dFdC). 
Compound Internal Conditions Matrix Initial Conc. Found Conc. Dev. C.V. Number  
  Standard     (ng/mL) (ng/mL) (%) (%) of replicates 
dFdC Didanosine 3 freeze  Plasma 1.59 1.43 -10.4 8.86 3 
  /thaw cycles  795 763 -4.03 6.79 3 
dFdC Didanosine Ambient, 6h Plasma 1.59 1.62 1.92 1.38 3 
    795 696 -12.4 1.96 3 
dFdC Didanosine 4ºC, 10 days Dry extract 1.59 1.70 6.92 1.68 3 
    795 685 -13.8 3.26 3 
dFdC Didanosine 4ºC, 24 days Reconstitution 1.59 1.57 -1.34 3.20 3 
   solvent 795 722 -9.19 6.14 3 
dFdC Didanosine Autosampler,  Reconstitution 1.61 1.62 0.821 6.29 3 
  10ºC, 24h solvent 316 313 -0.745 0.975 3 
        808 770 -4.89 1.62 3 
dFdC Lamivudine 3 freeze/ Plasma 1.61 1.53 -5.18 7.58 3 
  thaw cycles  816 809 -0.898 9.00 3 
dFdC Lamivudine Ambient, 6h Plasma 1.61 1.60 -0.435 2.69 3 
    816 767 -6.00 2.41 3 
dFdC Lamivudine 4ºC, 10 days Dry extract 1.61 1.69 4.83 2.04 3 
    816 797 -2.33 1.92 3 
dFdC Lamivudine 4ºC, 24 days Reconstitution 1.61 1.60 -0.663 3.46 3 
   solvent 816 794 -2.78 3.62 3 
dFdC Lamivudine Autosampler,  Reconstitution 1.57 1.62 3.09 1.56 3 
  10ºC, 24h solvent 318 301 -5.64 2.16 3 
        784 702 -11.8 1.15 3 
dFdC Fludarabine 3 freeze/ Plasma 1.55 1.47 -5.25 8.36 3 
  thaw cycles  769 765 -0.477 11.7 3 
dFdC Fludarabine Ambient, 6h Plasma 1.55 1.58 2.02 0.633 3 
    769 705 -8.28 1.99 3 
dFdC Fludarabine 4ºC, 10 days Dry extract 1.55 1.70 9.77 1.18 3 
    769 732 -4.77 3.10 3 
dFdC Fludarabine 4ºC, 24 days Reconstitution 1.55 1.60 3.42 5.16 3 
   solvent 769 789 2.56 4.39 3 
dFdC Fludarabine Autosampler,  Reconstitution 1.53 1.63 5.74 6.57 3 
  10ºC, 24h solvent 301 317 4.94 2.73 3 
        751 758 0.923 1.34 3 
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Table V. Stability data for dFdU. 
Compound Internal Conditions Matrix Initial Conc. Found Conc. Dev. C.V. Number of 
  Standard     (ng/mL) (ng/mL) (%) (%) replicates 
dFdU Didanosine 3 freeze / Plasma 15.6 14.7 -5.76 11.4 3 
  thaw cycles  7966 7337 -7.90 9.08 3 
dFdU Didanosine Ambient, 6h Plasma 15.6 15.4 -1.71 7.54 3 
    7966 7836 -1.64 3.47 3 
dFdU Didanosine 4ºC, 10 days Dry extract 15.6 13.7 -12.4 8.26 3 
    7966 7909 -0.716 0.698 3 
dFdU Didanosine 4ºC, 24 days Reconstitution 15.6 15.3 -2.35 2.65 3 
   solvent 7966 6849 -14.0 5.16 3 
dFdU Didanosine Autosampler,  Reconstitution 16.0 14.3 -11.9 2.52 3 
  10ºC, 24h solvent 3204 2955 -8.44 2.61 3 
        8040 7596 -5.85 1.80 3 
dFdU Lamivudine 3 freeze/ Plasma 15.8 14.9 -5.91 10.5 3 
  thaw cycles  7378 6971 -5.52 5.30 3 
dFdU Lamivudine Ambient, 6h Plasma 15.8 15.1 -4.43 7.64 3 
    7378 7403 0.343 5.83 3 
dFdU Lamivudine 4ºC, 10 days Dry extract 15.8 15.3 -3.16 5.70 3 
    7378 8265 12.0 2.64 3 
dFdU Lamivudine 4ºC, 24 days Reconstitution 15.8 16.6 5.06 5.22 3 
   solvent 7378 6575 -10.9 0.546 3 
dFdU Lamivudine Autosampler,  Reconstitution 15.6 14.6 -6.61 2.76 3 
  10ºC, 24h solvent 3161 2850 -10.9 2.01 3 
        7753 6977 -11.1 3.96 3 
dFdU Fludarabine 3 freeze / Plasma 15.7 14.4 -8.07 10.5 3 
  thaw cycles  7695 7036 -8.56 4.18 3 
dFdU Fludarabine Ambient, 6h Plasma 15.7 14.7 -6.58 6.55 3 
    7695 7880 2.41 2.32 3 
dFdU Fludarabine 4ºC, 10 days Dry extract 15.7 14.0 -10.8 8.11 3 
    7695 8557 11.2 0.243 3 
dFdU Fludarabine 4ºC, 24 days Reconstitution 15.7 16.7 6.37 2.16 3 
   solvent 7695 7384 -4.04 4.43 3 
dFdU Fludarabine Autosampler,  Reconstitution 15.2 14.3 -6.06 3.20 3 
  10ºC, 24h solvent 3042 2992 -1.66 3.61 3 
        7555 7477 -1.05 1.57 3 
 
3.5.5  Matrix effect study  
The mean ion suppression of -2.40% (enhancement) and 3.21% were detected for 
gemcitabine and dFdU, respectively. The mean ion suppressions for didanosine, 
lamivudine and fludarabine were 9.54%, 8.98% and -5.91% (enhancement). 
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3.5.6 Recovery 
SPE recoveries for gemcitabine, dFdU, didanosine, lamivudine and fludarabine were 
86.1 ± 5.67%, 83.6 ± 8.61%, 95.3 ± 16.1%, 81.6 ± 7.37% and 84.9 ± 9.52%, 
respectively. The total recoveries of gemcitabine, dFdU, didanosine, lamivudine and 
fludarabine were 88.2 ± 6.26%, 81.1 ± 1.10%, 86.2 ± 9.73%, 74.2 ± 5.50% and 89.9 ± 
11.1%, respectively. 
 
3.5.7 Stability 
The stability data of gemcitabine and dFdU are summarized in Tables IV and V, 
respectively. Gemcitabine and dFdU are stable in human EDTA plasma stabilized with 
THU for at least three freeze (-20 oC) / thaw cycles, and are also stable in human 
plasma stabilized with THU stored at nominally ambient temperatures for up to 6 hours. 
Furthermore, gemcitabine and dFdU are stable up to 10 days in the dry extract and up 
to 23 days in the final extract at ambient temperatures. Re-injection reproducibility was 
established and the analytical run can be re-injected after at least 24 hours of storage 
in the autosampler. 
Finally, the long-term stability of gemcitabine and dFdU in stock solutions and in 
working solutions in human EDTA plasma stabilized with THU is ongoing at nominally -
20°C.  
 
4. Conclusions 
A novel, sensitive, highly selective and quantitative reversed phase HPLC coupled to 
tandem mass spectrometry method for the determination of gemcitabine and dFdU in 
human EDTA and heparinized plasma stabilized with THU is developed. The validation 
results proved to demonstrate that the gemcitabine and dFdU concentrations can be 
accurately, precisely, reproducibly, and selectively quantified in human EDTA plasma. 
Using 200 μL human plasma aliquots, the assay quantifies a range of 0.5 ng/mL to 
1,000 ng/mL for gemcitabine and 5 ng/mL to 10,000 ng/mL for dFdU. The selectivity 
and the linearity over a wide range makes this method applicable to clinical 
pharmacologic studies with gemcitabine.  
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Abstract 
A rapid and selective liquid chromatography/tandem mass spectrometric (LC-MS/MS) 
method was developed for the simultaneous determination of capecitabine and its 
metabolites 5΄-deoxy-5-fluorocytidine (5΄-DFCR), 5΄-deoxy-5-fluorouracil (5΄-DFUR), 5-
fluorouracil (5-FU) and dihydro-5-fluorouracil (FUH2) in human plasma. A 200-μL-
human plasma aliquot was spiked with a mixture of internal standards fludarabine and 
5-chlorouracil. A single-step protein precipitation method was employed using 10% 
(v/v) trichloroacetic acid (TCA) in water to separate analytes from bio-matrices. 20 μL-
volumes of the supernatant were directly injected onto the HPLC system. Separation 
was achieved on a 30 x 2.1 mm Hypercarb (porous graphitic carbon) column using a 
gradient by mixing 10 mM ammonium acetate and acetonitrile – 2-propanol – 
tetrahydrofuran (1:3:2.25, v/v/v). The detection was performed using a Finnigan TSQ 
Quantum Ultra equipped with the electrospray ion source operated in positive and 
negative mode. The assay quantifies a range from 10 to 1,000 ng/mL for capecitabine, 
from 10-5,000 ng/mL for 5΄-DFCR and 5΄-DFUR, and from 50-5,000 ng/mL for 5-FU and 
FUH2 using a plasma sample of 200 μL. The described method was successfully 
applied for the evaluation of the pharmacokinetic profile of capecitabine and its 
metabolites in plasma of cancer patients treated with capecitabine. 
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1. Introduction 
Capecitabine (N4-pentoxycarbonyl-5΄-deoxy-5-fluorocytidine, Xeloda®), is an anticancer 
prodrug, that was designed to undergo conversion in liver and tumor tissue to 5-
fluorouracil (5-FU) (1-4).  
5-Fluorouracil is one of the most commonly used anti-cancer agents in the treatment of 
solid tumors, predominantly at the digestive tract, head and neck and breast (5). 
Unfortunately, 5-FU lacks sufficient selectivity towards tumor cells and, therefore, 
exhibits significant toxicity at clinically applied dosages (1,5-7). Capecitabine was 
designed to be readily absorbed from the human gastro-intestinal tract and to take 
advantage of enzymatic conversion in tumors to achieve better targeting of 5-FU (2,5). 
As shown in Figure 1, bio-activation of capecitabine to 5-FU is considered to take place 
in three steps by three different enzymes (2-4,8-10). First, capecitabine is hydrolyzed to 
its first metabolite 5΄-deoxy-5-fluorocytidine (5΄-DFCR) by carboxylesterase, which is 
mainly present in intestine and the liver. Next, 5΄-DFCR is converted into 5΄-deoxy-5-
fluorouracil (5΄-DFUR) by cytidine deaminase, which is expressed in many tissues 
including the liver and tumors. Finally, 5΄-DFUR is converted into 5-FU by thymidine 
phosphorylase, which activity is high in tumor tissue compared to most normal tissues 
(8,11). 
5-FU is enzymatically cleared from plasma to produce dihydro-5-fluorouracil (FUH2), 
which is the rate-limiting step catalyzed by dihydropyrimidine dehydrogenase (DPD). 
Two following steps result in the formation of fluoroureidopropionic acid and α-fluoro-β-
alanine (FBAL), respectively with release of CO2 and NH2 (12).  
The peak plasma concentrations for capecitabine and its metabolites 5΄-DFCR, 5΄-
DFUR and 5-FU occur very shortly (tmax ~ 2h) after oral administration and their 
elimination half-life is approximately 1h (13).  
The anti-tumor activity of 5-FU is attributed to inhibition of the enzyme thymidylate 
synthase (TS) that is essential for DNA synthesis. However, in humans, 70% of 5-FU is 
catabolized by DPD to FUH2 and ultimately to FBAL, concluding that DPD limits the 
amount of 5-FU available for conversion into the active metabolites (cellular) that 
mediate its cytotoxic activity. DPD activity varies widely between patients due to the 
genetic polymorfisms in the DYPD gene. Therefore, the optimal dosage to achieve 
antitumor response and low systemic toxicity is different in patients, dependant upon 
a.o. patients DYPD genotypes (14,15).  Several side effects, including hematological, 
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mucosal and gastrointestinal toxicity, have been observed during 5-FU treatment and 
have been attributed to a genetically determined deficiency of DPD activity (13,16,17) 
Therefore, evaluation of DPD activity by calculating the FUH2/5-FU plasma ratio may be 
of significant importance to improve both treatment efficacy and safety. Thus, it is of 
pivotal importance to determine capecitabine and its metabolites: 5΄-DFCR, 5΄-DFUR, 
5-FU and FUH2 simultaneously to be able to predict the efficacy and toxicity of 
capecitabine treatment as efficient as possible. 
Several high performance liquid chromatography (HPLC) methods have been 
developed over the last years for the analysis of the capecitabine and its metabolites. 
Xu et al set up a high performance liquid chromatography mass spectrometry (HPLC-
MS) method to determine capecitabine, 5΄-DFCR and 5΄-DFUR. This method required 
on-line sample extraction and it was not possible to quantify 5-FU (11). Zufia et al 
developed an HPLC-UV method that allowed the simultaneous determination of 
capecitabine, 5΄-DFUR, 5-FU and FUH2 using 500 μL human plasma, but required 
elaborate extraction and purification steps and reasonably long analysis times (8). 
Siethoff et al published a liquid chromatography tandem mass spectrometry (LC-
MS/MS) assay, but it only quantifies capecitabine and 5-FU using column switching 
techniques (18). Reigner et al. described an LC-MS/MS method for simultaneous 
determination of capecitabine, 5΄-DFCR, 5΄-DFUR, 5-FU and FBAL, but due to the lack 
of the details in their paper, it is not possible to replicate their method (13,19,20). 
Recently, Guichard et al developed an HPLC-MS/MS method to quantify capecitabine, 
5΄-DFCR, 5΄-DFUR and 5-FU, which was validated for mouse plasma, liver and human 
xenograft tumors, and cross-validated in human plasma and tumor tissue (1). 
Dhananjeyan et al published an elegant method to determine capecitabine, 5΄-DFCR, 
5΄-DFUR and 5-FU in mouse plasma, mouse serum and in rabbit bile using HPLC-UV; 
however the lower limit of quantitation for this method was 1 μg/mL, which is not 
sufficient for clinical studies with capecitabine (21). 
The aim of our work was to develop a selective and sensitive HPLC-MS/MS method for 
the simultaneous quantitation of capecitabine, 5΄-DFCR, 5΄-DFUR, 5-FU and FUH2 in 
human plasma, in which we succeeded. This assay has a run time of 15 minutes and a 
simple and effective sample pretreatment using 10% trichloroacetic acid (TCA) in water.  
The method has been fully validated according to the FDA guidelines on bioanalytical 
validation (22,23), and is applied in clinical pharmacokinetic studies with capecitabine. 
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Figure 1. Bioactivation pathway of Capecitabine (CES, carboxylesterase; CDA, cytidine 
deaminase; dThdPhase, thymidine phosphorylase; DPD, dihydropyrimidine 
dehydrogenase; DHP, dihydropyrimidinase; BUP, β-alanine synthase). 
 
2. Experimental 
2.1 Chemicals and reagents 
Capecitabine (C15H22N3O6F; Figure 1), 5΄-DFCR (C9H12N3O4F; Figure 1), 5΄-DFUR 
(C0H11N2O5F; Figure 1), 5΄-FU (C4H3N2O2F; Figure 1) originated from Sequoia 
Research Products Ltd (Pangbourne, United Kingdom). FUH2 (C4H5N2O2F; Figure 1) 
was supplied by Toronto Research Chemicals (North York, Canada). Fludarabine 
(C15H22N3O6F) and 5-chlorouracil (C15H22N3O6F) was from by Sigma Aldrich Chemie 
(Steinheim, Germany). Methanol (LC gradient grade), acetonitrile, 2-propanol, 
tetrahydrofuran (LC gradient grade) were obtained from Bissolve Ltd. (Amsterdam, The 
Netherlands). All other solvents or chemicals were analytical grade or better. Distilled 
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water was used throughout the analyses. Drug-free human sodium EDTA plasma was 
obtained from Bioreclamations (Hicksville, NY, USA).  
 
2.2 Preparation of stock and working solutions 
Two sets of stock solutions of each capecitabine and its metabolites were prepared 
from two independent weightings. The reference standards capecitabine and 5΄-DFCR 
were dissolved in methanol at a target concentration of 0.1 and 1 mg/mL, respectively; 
5΄-DFUR, 5-FU and FUH2 were dissolved in dimethylsulfoxide (DMSO) at a target 
concentration of 1 mg/mL. Stock solutions were further diluted with water to obtain 
working solutions. One set of working solutions was used to prepare calibration 
standards, the other to prepare quality control samples. Separate working solutions 
used to prepare calibration standards of capecitabine and metabolites were further 
diluted in water to yield concentrations of 100,000, 75,000, 50,000, 25,000, 10,000, 
5,000, 2,500 and 1,000 ng/mL for capecitabine, concentrations of 500,000, 200,000, 
100,000, 25,000, 10,000, 5,000, 2,500 and 1,000 ng/mL for 5΄-DFCR and 5΄-DFUR, 
and concentrations of 500,000, 200,000, 100,000, 75,000, 50,000, 25,000, 10,000 and 
5,000 ng/mL for 5-FU and FUH2. The quality control working solutions in water 
contained 10,000, and 1,000 ng/mL for capecitabine, 100,000 and 1,000 ng/mL for 5΄-
DFCR, 5΄-DFUR, 5-FU and FUH2. 
Separate stock solutions of the internal standards fludarabine and 5-chlorouracil were 
prepared in methanol at a concentration of 0.1 and 1 mg/mL, respectively. An internal 
standard working solution was prepared by adding 100 μL of  fludarabine stock solution 
and 1000 μL of 5-chlorouracil stock solution to 10.0 mL of water to give a final 
concentration of 1,000 ng/mL for fludarabine and 100,000 ng/mL for 5-chlorouracil. All 
solutions were stored at -70oC. 
 
2.3 Preparation of calibration standards and quality control samples 
Before use, control human heparinized plasma was centrifuged for approximately 5 min 
at 3,900 g. 
Calibration standards containing capecitabine and metabolites were prepared freshly at 
the concentrations of 10, 25, 50, 100, 250, 500, 750 and 1,000 ng/mL for capecitabine, 
10, 25, 50, 100, 250, 1,000, 2,000 and 5,000 ng/mL for 5΄-DFCR and 5΄-DFUR, 50, 
100, 250, 500, 750, 1,000, 2,000 and 5,000 ng/mL for 5-FU and FUH2 by adding 15 μL 
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of each capecitabine and metabolites working solutions (described in section 2.2) to 
1425 μL of control human plasma. The calibration standards were vortex-mixed for 
approximately 30 sec before processing. Standards were processed in singular and 
analyzed in duplicate. 
Quality control samples for the analytes were prepared by spiking control human 
plasma at concentrations of 10, 30, 500 and 800 ng/mL for Capecitabine; 10, 30, 500 
and 4,000 ng/mL for 5΄-DFCR and 5΄-DFUR; 50, 150, 1,000 and 4,000 ng/mL for 5-FU 
and FUH2, by diluting the working solutions for quality control samples in control human 
plasma in volumetric flasks. Replicate 200 µL aliquots were transferred to 2.0 mL tubes 
for storage at nominally –70°C. The quality control samples were vortex-mixed for 
approximately 30 seconds before processing. 
 
2.4 Sample processing 
Sample pretreatment was performed at ambient temperature. 20 μL of internal standard 
working solution was added to 200 μL sample aliquots and vortex mixed for 10 sec. 
Plasma proteins were then precipitated with 100 μL 10% (v/v) trichloacetic acid in water 
(TCA), followed by automatic shaking for 10 min at 1,250 rpm (Labinco, Breda, The 
Netherlands). Samples were then centrifuged for 10 min at 23,100 g, and the clear 
supernatant was transferred to a glass autosampler vial with insert. 
 
2.5 Chromatography 
Chromatography was carried out using a Solvent delivery system LC-20AD 
Prominence, degasser and Sil – HTc with SCL -10 Avp system controler (Shimadzu, 
Kyoto, Japan). Gradient chromatography was performed using a Hypercarb column (30 
x 2.1 mm ID, particle size 5 μm; Interscience, Breda, The Netherlands). Gradient 
elution was applied with 10 mM ammonium acetate in water (A) and acetonitrile – 2-
propanol – tetrahydrofuran (1:3: 2.25, v/v/v) mixture (B) at a flow-rate of 0.2 mL/min. In 
the first 3 min, an eluent consisted of 99% A and 1% B, the proportion of eluent B 
increased linearly to 90% B in 4 min, followed by 90% B for 5 min. To stabilize the 
column, 100% A was used for 3 min. Sample injections of 20 μL were carried out and 
the autosampler temperature was gauged at 10oC. The total run time including the 
stabilization phase was 15 min. 
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2.6 Mass spectrometry and analytical data processing 
The mass spectrometric analyses were performed using a Finnigan TSQ Quantum 
Ultra Triple Quadrupole Mass Spectrometer equipped with an electrospray (ESI) ion 
source (Thermo Fisher, Waltham, MA, USA). The mass spectrometers were operating 
in positive mode to obtain both the mass spectra (MS1) and the product ion spectra 
(MS2). Positive ions were created at atmospheric pressure. The Finnigan TSQ 
Quantum Ultra was operating in positive ESI selective reaction monitoring (MRM) mode 
at unit resolution, with the Q1/Q3 resolution set at 0.7 Th (Da/z) full width at half 
maximum (FWHM). The ESI-MS/MS operating parameters of Finnigan TSQ Ultra used 
in this study are listed in Table 1. LCquan™ 2.5 software (Thermo Fisher) was used to 
process the data obtained from the Finnigan TSQ Ultra instrument.  
 
Table I. Settings of the Finnigan TSQ Quantum ultra triple quadrupole mass 
spectrometer. 
Parameter   Setting 
Run duration  15 min 
Ionspray voltage (positive ion mode)  +3800 V 
Sheath gas  23 psi 
Ion sweep gas  2 psi 
Auxillary gas  5 psi 
Capillary Temperature  300 ºC 
Collision pressure  1.5 torr 
Quad MS/MS bias  2.8 V 
Capecitabine Q1 mass 360 amu 
 Q3 mass 174 amu 
 Collision energy 25 V 
 Tube lens voltage 66 V 
 Source CID Collision energy 10 V 
 Ionization mode Positive 
5’-DFCR Q1 mass 246 amu 
 Q3 mass 130 amu 
 Collision energy 20 V 
 Tube lens voltage 36 V 
 Source CID Collision energy 5 V 
 Ionization mode Positive 
5’-DFUR Q1 mass 245 amu 
 Q3 mass 108 amu 
 Collision energy 17 V 
 Tube lens voltage 52 V 
 Source CID Collision energy 20 V 
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 Ionization mode Negative 
5-FU Q1 mass 129 amu 
 Q3 mass 42 amu 
 Collision energy 16 V 
 Tube lens voltage 50 V 
 Source CID Collision energy 0 V 
 Ionization mode Negative 
FUH2 Q1 mass 131 amu 
 Q3 mass 83 amu 
 Collision energy 12 V 
 Tube lens voltage 36 V 
 Source CID Collision energy 6 V 
  Ionization mode Negative 
Fludarabine Q1 mass 286 amu 
 Q3 mass 154 amu 
 Collision energy 20 V 
 Tube lens voltage 74 V 
 Source CID Collision energy 6 V 
 Ionization mode Positive 
5-chlorouracil Q1 mass 145 amu 
 Q3 mass 102 amu 
 Collision energy 19 V 
 Tube lens voltage 65 V 
 Source CID Collision energy 10 V 
 Ionization mode Negative 
 
2.7 Validation procedures 
A full validation of the assay according to the FDA guidelines was executed (22,23). 
 
2.7.1 Linearity 
For the validation, calibration standards (8 non-zero standards of the analytes as 
described in section 2.3) were prepared in control human plasma and analyzed in 
duplicate in three analytical runs.  
The linear regression of the ratio of the areas of the analyte and internal standard 
peaks versus the concentration were weighed by 1/x2 (the reciprocal of the squared 
concentration) and 1/x (the reciprocal of the concentration) for 5-FU. Concentrations 
were back-calculated from the constructed calibration curve and deviations from the 
nominal concentrations should be within ± 20% for the lower limit of quantitation 
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(LLOQ) and within ± 15% for other concentrations with coefficient of variation (C.V.) 
values less than 20% and 15% respectively (22,23). 
 
2.7.2 Accuracy and precision 
Five replicates of each human plasma sample were analyzed in three analytical runs 
together with calibration standards independently prepared from the quality control 
samples containing the concentrations of capecitabine and its metabolites, as 
described in Section 2.3.  
Accuracies were determined as the percentage difference of the measured 
concentration from the nominal concentration and the C.V. was used to report the 
precision. 
The intra and inter-assay accuracies (% bias) should be within ±20% at the LLOQ level 
and within ±15% at the other concentrations (22,23). The intra and inter-assay 
precisions should be less than 20% at the LLOQ level and less than 15% at the other 
concentrations (22,23). 
The ability to dilute samples originally above the upper limit of quantitation (ULOQ) of 
the calibration curve was demonstrated by analyzing validation samples containing 10 
times the ULOQ for the analytes. Five replicates of each sample were analyzed in one 
analytical run after dilution in control human plasma. 
 
2.7.3 Specificity and selectivity 
To investigate whether endogenous matrix constituents interfered with the assay, six 
individual batches of control drug-free plasma samples containing neither analyte nor 
internal standard (double blank), samples containing only internal standard (blank), and 
samples spiked at the LLOQ were prepared. Samples were prepared and analyzed 
according to the described procedures. Peak areas of compounds co-eluting with the 
analyte or internal standard should not exceed 20% of the analyte peak area at the 
LLOQ or 5% of the internal standard area. Deviations from the nominal concentrations 
should be within ± 20% for the LLOQ samples (22,23). 
 
2.7.4 Matrix effect 
For the determination of the matrix effect (ion suppression), control drug-free plasma 
was processed according to the procedure described in 2.4 and the supernatant was 
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spiked with solutions of the capecitabine and its metabolites (“ion suppression 
samples”) to yield the same concentrations as in the processed quality control samples. 
The unprocessed samples were prepared in 10% TCA at the same concentrations as 
the processed quality control samples. Ion-suppression was determined by comparing 
the analytical response of the “ion suppression samples” to that of the unprocessed 
samples (24) 
 
2.7.5 Recovery 
Protein precipitation (PP) recovery was determined by comparing the analytical 
response of processed quality control samples with the analytical response of the “ion 
suppression samples”. These experiments were performed in triplicate at three 
concentration levels.  
Overall recovery corresponded to the net response after subtraction of the ion-
suppression and signal loss due to the extraction.  
 
2.7.6 Stability 
The stability of capecitabine and its metabolites in human plasma after 3 freeze/thaw 
cycles at -700C was investigated by comparing quality control samples that had been 
frozen and thawed three times with freshly prepared quality control samples. The 
stability of capecitabine and its metabolites in human plasma under processing 
(ambient temperature) and storage (-70oC) conditions was evaluated. Additionally, the 
stability of the final extract was determined for all compounds. Also, the re-injection 
reproducibility in the auto sampler was determined after 48 h. The long-term stability of 
capecitabine and its metabolites in human plasma and the stability of working solutions 
at -70 oC are ongoing. 
The above described stability experiments were executed at 2 concentration levels for 
all compounds (low and high) in triplicate. The analytes were spiked separately to the 
biological matrix. The analytes are considered stable in the stock and working solutions 
when 90-110% of the fresh sample’s ratio is found and they are considered stable in 
biological matrixes or extracts when 85-115% of the initial concentration is recovered.  
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2.7.7 Clinical studies 
The analytical method described in this article has been used to support a clinical 
study, in which capecitabine is administrated orally at a dose of 1,000 mg. Blood 
samples were collected at several time points after intake and after centrifugation, 
plasma was collected and stored at – 70 oC until analysis.  
 
3. Results and Discussion 
3.1 Internal standards 
Due to the absence of the stable isotopically labeled internal standards, several others 
structurally to the analytes of interest related compounds have been tested. 5-
bromouracil and bromodeoxyuridine experienced a reasonably high and varying 
percentage of ion suppression, probably due to the elution along with the other 
endogenous plasma components. These compounds were discarded for these 
reasons. Fludarabine and 5-chlorouracil proved to have acceptable retention times and 
their recoveries from plasma were comparable with those of capecitabine and its 
metabolites. Therefore, they both were selected and tested as possible internal 
standards for the analytes.  
Finally, 5-chlorouracil proved to be suitable internal standard for FUH2, 5-FU, 5΄-DFCR 
and 5΄-DFUR and fludarabine for capecitabine. 
 
3.2  Sample pretreatment 
Different methods of sample pretreatment were investigated. Recoveries were 
determined by comparing responses from human plasma samples processed 
according to the procedures mentioned below to responses of capecitabine and its 
metabolites standard solutions in water, which represented 100% recovery. Protein 
precipitation of plasma samples containing all analytes was tested using methanol and 
acetonitrile, because it is a simple and fast extraction method. This resulted in sufficient 
recoveries of capecitabine, 5΄-DFCR, 5΄-DFUR (around 70-90%), but in non-
reproducible recoveries and high ion-suppression for 5-FU and FUH2, most likely due to 
the hydrophilic nature of these two compounds. Protein precipitation using methanol 
and acetonitrile was discarded for these reasons. Subsequently, liquid-liquid extraction 
(LLE) was investigated as an alternative means of sample pretreatment using 
diethylether, ethyl acetate, ethyl acetate-2-propanol (9:1, v/v), precipitation with either 
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acetonitrile or methanol, followed by extraction using ethyl acetate (data not shown). 
Unfortunately, none of these solvents were able to efficiently extract all analytes and to 
obtain sufficient selectivity. Thus, LLE ethylacetate extraction was discarded as well. 
Moreover, it was observed that when FUH2 was extracted from plasma either by means 
of protein precipitation or LLE, followed by the evaporation of the supernatant either by 
10-400C or by vacuum evaporation, the degradation of FUH2 as high as 70% was 
found. Moreover, it was observed that FUH2 exhibited an extensively high binding to the 
plasma proteins, which posed difficulties with its extraction from plasma. 
To surpass the evaporation step and more efficiently precipitate the plasma proteins, 
10% TCA was tested as a strong solvent to precipitate the proteins (25). This method 
yielded clean samples, reproducible and high recoveries and sufficient selectivity for all 
analytes. 
 
3.3 Development of a PGC-HPLC-MS/MS method 
3.3.1 The choice of the stationary phase 
Since capecitabine and 5-FU and FUH2 strongly differ in polarity, it posed quite a 
challenge to develop a sensitive and selective chromatographic method, which enables 
to measure these compounds simultaneously.  
Several columns have been tested: Gemini C-18, Zorbax Extend C18 (150 x 2.1 ID, 5 
µm particle size), Polaris 5 C18 chromsep (150 x 2.1 ID, 5 µm particle size), Synergi 
Fusion-RP (150 and 50 x 2.1 ID, 5 µm particle size), Synergi Polar-RP (150 x 2.1 ID, 4 
µm particle size), Synergi Luna (150 x 2.1 ID, 3 µm particle size) and Synergy Hydro-
RP (150 x 2.1 ID, 5 µm particle size). However, due to the highly polar nature, 5-FU 
and FUH2 showed no affinity to the reversed-phase columns even with extremely low 
(3%) organic content in the mobile phase. A competition in the ionization efficacy 
between 5-FU and FUH2 and other polar endogenous compounds from plasma may 
induce a varying percentage of ion suppression and a reduction of the intensity of the 
signal of both analytes. Moreover, capecitabine was strongly retained on the above 
mentioned columns, which resulted in prolonged run time and poor chromatography for 
this compound. Consequently, all columns, mentioned above, proved to be unsuitable 
for this application.  
Nevertheless, remarkable physical properties and retention mechanism of the 
Hypercarb column has allowed us to develop an analytical method where capecitabine 
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and its metabolites could be measured simultaneously with high specificity, selectivity 
and reproducible overall recovery. 
Since its first description as a stationary phase for liquid chromatography, porous 
graphitic carbon column (PGC; Hypercarb) has been shown to exhibit unique chemical 
and physical properties. The ability of this graphitic material to retain small polar 
molecules is superior to that of silica-based sorbents (14,15,26-47). Moreover, porous 
graphitic carbon proved to be chemically and pH stable, inert stationary phase. The 
following factors seem to influence the chromatographic behavior of PGC 
(31,33,34,37,44,45,47): 
(i) Dispersion forces and solvophobic effects due to the delocalization of the 
π-electrons in the graphite. This interaction causes PGC to behave as a 
reversed phase and predominantly important to retain non-polar 
compounds 
(ii) Charge induced interactions, such as electron-pair donor-acceptor and 
dipole-dipole induced interactions of the polarizable stationary phase with 
the polarizable functional groups of the polar analytes. This polar retention 
effect on graphite is believed to result in increased retention when polarity 
of the analytes increases. 
(iii) Steric effects from the interaction with the flat graphitic surface. Namely, 
PGC consists of flat sheets of hexagonally arranged carbon atoms with sp2 
hybridization, resulting in strong π-π interactions with the aromatic 
analytes. These interactions enable the separation of closely related 
compounds.  
(iv) “Ion exchange” interactions, meaning that the presence of ionic species in 
the mobile phases have shown to have effects on the chromatographic 
behavior of ionic species, such as mono-, di-, and tri-phosphate 
nucleotides.  
The above mentioned retention mechanisms have been seen, described and discussed 
by various groups (14,15,26-47). 
 
3.3.2 The choice of the mobile phase 
PGC chromatography usually employs water, acetonitrile or methanol for the elution of 
small polar compounds. Indeed, 5-FU, FUH2, 5΄-DFCR and 5΄-DFUR eluted rather 
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rapidly from the column with the percentage of acetonitrile in the mobile phase varying 
from 3 to 30%. The influence of the composition of the mobile phase on the capacity 
factor (k΄) of the analytes (expect for capecitabine, because the eluotropic strength of 
acetonitrile was not strong enough to elute this compound from the Hypercarb column) 
is depicted in Figure 2. It is remarkable that the dependency of the k΄ on the percentage 
of the organic solvent in the mobile phase differs significantly from the traditional 
reversed phase system. As seen in this Figure 2, the “U-shaped” curve is obtained. 
This might be due to the “mixed-mode” effect of the interactions mentioned in section 
3.3.1 under (i) and (ii). 
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Figure 2. Chromatographic behavior of 5’-DFCR, 5’-DFUR, 5-FU and FUH2 on the 
Hypercarb column as a function of the percentage of the organic phase (acetonitrile; 
Eluent B). 10 mM Ammonium acetate is used as eluent A. 
 
Nonetheless, while methanol or acetonitrile might have enough power to elute polar 
molecules, less polar capecitabine required significantly stronger organic solvent to 
achieve its elution from the column. Several organic solvents were tested, such as 
mixture of acetonitrile-2-propanol (1:1, v/v and 1:3, vv), 2-propanol, dichloromethane 
and tertrahydrofuran (THF). Best results were obtained when 90% THF was used; 
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capecitabine rapidly was eluted from the column with the sufficient peak shape and 
width.  
However, we found that when 90% THF was used in the mobile phase, the noise in the 
window of the FUH2 increased 100-fold, and signal to noise, consequently, decreased 
100-fold compare to a THF-free mobile phase. To keep the noise under the 20 cps 
(comparable to the elution with only water), the maximum of 36% of THF in the mobile 
phase could be used. For this reason, we chose a mixture of acetonitrile - 2-propanol -
THF (1:3:2.25, v/v/v) as eluent B. Since the pH of the plasma extracts is low sample 
(final extracts are in 10% TCA pH 1), an acetate buffer (10 mM ammonium acetate pH 
6.7) was chosen as an aqueous phase to stabilize the pH and to secure the elution 
order of capecitabine and its metabolites. As a result, the mixture of 10 mM ammonium 
acetate and acetonitrile - 2-propanol - THF (1:3:2.25, v/v/v) was chosen as a suitable 
and optimal eluent, yielding excellent baseline separation and peak shapes for all 
compounds of interest. 
In Figure 3, the experiment is presented, where the log k΄ of capecitabine against the 
percentage of the eluent B is plotted, to determine when and how rapidly capecitabine 
will elute from the 3 cm Hypercarb column using 10 mM ammonium acetate as an 
eluent A and the mixture of acetonitrile-2-propanol-THF (1:3:2.25, v/v/v) as an eluent B.  
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Figure 3. Dependency of the elution of capecitabine on the percentage eluent B (ACN-
2-propanol-THF=1:3:2.25, v/v/v) on the Hypercarb column. 
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As shown in this figure, capecitabine eluted within 4 minutes from the column using 
90% eluent B with acceptable peak shape (data not shown). 
Finally, the elution gradient as described below was chosen. During the first 1.5 min of 
the gradient the valve was switched to waste, to flush away both the 10% TCA, present 
in the samples, and all possible interfering polar endogenous molecules. This was 
aimed to reduce the ion suppression effect and contamination of the MS. To ensure 
sufficient retention and therefore ion efficacy of FUH2, 1% B was used in the first 3 min 
of the gradient. The linear increase to 90% B in 4 min was chosen to elute 5-FU and 
consequently separate this compound from 5΄-DFUR, which showed interference in the 
5-FU chromatogram (due to the degradation of 5΄-DFUR into 5-FU in the ion source). 
When 90% of the phase B was pumped through the column for 5 min, 5΄-DFCR, 5΄-
DFUR and capecitabine were eluted. 
 
We found that Hypercarb columns require long stabilization time for up to 2 h, 
depending on the length of the column, percentage and volume of the organic phase 
used, before the next injection could take place. 
This observation is supported by the literature; namely, Remaud at al. described the 
Hypercarb stabilization time of 25 minutes before the next injection and Holmgren et al. 
suggested an extensive clean up of the Hypercarb after only 50-100 “dirty samples” 
injections (5,47).  
We also observed that the extent of the time period when 90% of eluent B is used and 
the dimensions such as length of the column have a significant influence on the 
stabilization time needed before the next injection. Based on this knowledge, we chose 
3 cm Hypercarb column, which proved to yield enough selectivity for all compounds 
and required the least stabilization time.  
 
3.3.3 Developing of a dynamically stable system 
Unconventionally, we chose to stabilize the column with 100% of eluent A instead of its 
initial condition, which is 1% eluent B. As shown in Figure 4, stabilizing the column with 
100% eluent A yielded stable, reproducible capacity factors for all analytes already after 
3 minutes of stabilization. Conditioning the column with only aqueous phase, residues 
of organic solvents were flushed from the column, possibly preventing mixed retention 
mechanisms. 
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Representative chromatograms of capecitabine and its metabolites and the internal 
standards at their LLOQ levels in human plasma are depicted in Figure 5. Peak shapes 
were sufficient with the asymmetry factors of 1.1 for capecitabine, 5-FU and FUH2; 1.2 
for 5’-DFUR and 1.4 for 5’-DFCR. The capacity factors (k') were approximately 23, 15, 
12, 11, 10, 9 and 4 for capecitabine, fludarabine, 5΄-DFUR, 5-chlorouracil, 5΄-DFCR, 5-
FU and FUH2, respectively. LC run time was 15 min. 
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Figure 4. Dependency of k’of capecitabine and its metabolites on the stabilization time 
of the column with 100% eluent A (10 mM ammonium acetate). 
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Figure 5 . Chromatograms at the LLOQ for capecitabine (10 ng/mL; A), 5’-DFCR (10 
ng/mL; B), 5’-DFUR (10 ng/mL; C), 5-FU (50 ng/mL: D), FUH2 (50 ng/mL; E), 
fludarabine (1,000 ng/mL: F) and 5-chlorouracil (100,000 ng/mL; G). 
 
3.4 Mass Spectrometry 
Finnigan TSQ Ultra equipped with the electrospray ionization (ESI) source was used. 
Figures 6-10, show MS/MS product ion scans (Q3 scan) of capecitabine, 5΄-DFUR, 
DFCR, 5-FU and FUH2, respectively, across the range of m/z 100-400. A clear 
response is observed at m/z of 360, 246, 245, 129 and 131 corresponding to the 
protonated molecular ions [M+H]+ of capecitabine and 5΄-DFCR and deprotonated 
molecular ions [M-H]- of 5΄-DFUR, 5-FU and FUH2, respectively. The most abundant 
fragments observed in the fragmentation of the m/z of 360 (capecitabine; Figure 6) and 
246 (5’-DFCR; Figure 7), were product ions at m/z of 174 and 130, respectively, 
corresponding to the loss of the sugar moiety and pentane chain in the capecitabine 
molecule and sugar moiety from the 5’-DFCR molecule. For 5’-DFUR (m/z 245; Figure 
8) the primary fragment was detected at m/z of 108, corresponding to the loss of the 
sugar moiety and a fluorine atom. For 5-FU (m/z 129; Figure 9) and FUH2 (m/z 131; 
Figure 10), the most abundant fragments were detected at m/z 42 and m/z 83, 
corresponding to the detached formamide moiety and the loss of fluoroethane moiety, 
respectively. The proposed fragmentation is presented in Figures 6-10. Consequently, 
multiple reaction monitoring (MRM) parameters were optimized on the most abundant 
product ions. For the internal standards, fludarabine and 5-chlorouracil, the MRM 
parameters on the m/z of 286/154 (the fragment corresponds to the loss of the ribose 
unity) and m/z 145/102 (the fragment corresponds to the loss of the formamide moiety) 
transitions, respectively, were optimized. 
 
3.5 Validation 
3.5.1 Linearity 
The assay was linear over a concentration range of 10-1,000 ng/mL for capecitabine, 
10-5,000 ng/mL for 5΄-DFCR, 5΄-DFUR and 50-5,000 ng/mL for 5-FU and FUH2 in 
human plasma. Using linear regression and 1/x weighing for 5-FU and 1/x2 weighing for 
the other compounds, the lowest total bias and the most constant bias across the range 
were obtained. 
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Figure 6. MS/MS spectrum of capecitabine (product ions of m/z 360 Da). 
 
Figure 7. MS/MS spectrum of 5’-DFCR (product ions of m/z 246 Da). 
 
Simultaneous determination of capecitabine and its metabolites in human plasma 
 
                                                                                                                         291 
 
Figure 8. MS/MS spectrum of 5’-DFUR (product ions of m/z 245 Da) 
 
 
Figure 9. MS/MS spectrum of 5-FU (product ions of m/z 129 Da). 
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Figure 10. MS/MS spectrum FUH2 (product ions of m/z 131 Da). 
 
Correlation coefficients (r2) of the calibration curves in human plasma were better than 
0.99 for all compounds. At all concentration levels, deviations of measured 
concentrations from nominal concentration were between -4.41% and 3.65% with C.V. 
values less than 12.0% for capecitabine, between -7.00% and 6.59% with C.V. values 
less than 13.0 for 5’-DFUR, between -3.25% and 4.11% with C.V. values less than 
9.34% for 5’-DFCR, between -5.54% and 5.91% with C.V. values less than 9.69% for 5-
FU and -4.26% and 6.86% with C.V. values less than 14.9% for FUH2. Moreover, the 
samples with all analytes can be diluted 10 times. 
 
3.5.2 Accuracy and precision 
Assay performance (inter-assay accuracies and precisions) data for capecitabine and 
its metabolites in human plasma is summarized in Table II. The intra-assay accuracies 
(% bias) for capecitabine in human plasma were within ± 16.0% (at the LLOQ), for 5’-
DFUR within ± 11.7%, for 5’-DFCR within ± 10.6%, for 5-FU within ± 16.5 (at the 
LLOQ), for FUH2 within ± 15.8% (at the LLOQ) and found to be acceptable (data not 
shown) (22,23). 
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Table II. Assay performance data for Capecitabine and its metabolites in human 
heparinized plasma. 
Compound Internal Nominal Measured  Inter-Assay Inter-Assay Number of 
 standard Conc. (ng/mL) Conc. (ng/ml) Accuracy (%) Precision (%) replicates 
Capecitabine Fludarabine 10.9 11.8 8.70 8.82 15 
  32.8 32.4 -1.20 6.53 15 
  547 550 0.618 8.46 15 
    876 847 -3.30 5.38 15 
5’-DFCR 5-Chlorouracil 9.79 9.66 -1.31 11.3 15 
  29.4 28.3 -3.62 10.3 15 
  489 489 -0.0277 5.75 15 
    3914 3767 -3.76 2.30 15 
5’-DFUR 5-Chlorouracil 10.1 10.8 6.80 7.39 15 
  30.3 28.8 -5.03 12.2 15 
  505 511 1.24 5.35 15 
    4040 3824 -5.34 3.06 15 
5-FU 5-Chlorouracil 51.3 57.2 11.4 8.45 15 
  154 148 -3.65 9.58 15 
  1027 980 -4.57 8.23 15 
    4108 3841 -6.50 2.38 15 
FUH2 5-Chlorouracil 54.3 59.1 8.82 12.0 15 
  163 162 -0.606 9.36 15 
  1085 1062 -2.16 11.5 15 
    4342 4192 -3.46 6.71 15 
 
The intra-assay precisions for capecitabine in human plasma were less than 13.9%, for 
5’-DFUR less than 14.7%, for 5’-DFCR less than 12.2%, for 5-FU less than 12.9% and 
for FUH2 less than 16.5 (at the LLOQ) and found to be acceptable (22,23). 
 
3.5.3 Specificity and selectivity 
MRM chromatograms of six batches of control drug-free plasma contained no co-
eluting peaks >20% of all analytes area at the LLOQ level, and no co-eluting peaks 
>5% of the area of all internal standards. Deviations from the nominal concentrations at 
the LLOQ level were between -18.6% and 19.1% for all compounds and found to be 
acceptable (22,23). 
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3.5.4 Ion suppression and recovery 
The mean ion suppression of -46.8%, -24.7%, -4.28% and -47.9% (enhancement) were 
detected for capecitabine, 5’-DFUR, 5’-DFCR and 5-FU, respectively. Ion suppression 
experiment could not be performed for FUH2, due to its instability in 10% (v/v) TCA. The 
mean ion suppression values for fludarabine and 5-chlorouracil were 12.0% and -
8.88% (enhancement). Protein precipitation recoveries for capecitabine, 5’-DFUR, 5’-
DFCR, 5-FU, FUH2, fludarabine and 5-chlorouracil were 69.9 ± 1.84%, 86.0 ± 7.12%, 
85.5 ± 9.44%, 87.6 ± 14.9%, 70.1 ± 7.69%, 97.5% and 89.2%, respectively. The total 
recoveries of capecitabine, 5’-DFUR, 5’-DFCR, 5-FU, fludarabine and 5-chlorouracil 
were 103 ± 7.34%, 107 ± 13.2%, 88.5 ± 1.61%, 125 ± 16.7% , 85.8% and 97.2%, 
respectively. 
 
3.5.5 Stability 
The stability data of capecitabine and its metabolites are summarized in Table III. All 
compounds are stable in human plasma for at least three freeze (-70 oC) / thaw cycles, 
and are also stable in human plasma stored at ambient temperatures for up to 6 hours. 
Furthermore, all compounds are stable up to 3 days in the final extract at 4-8oC. Re-
injection reproducibility was established and the analytical run can be re-injected after 
at least 48 hours of storage in the autosampler. 
Finally, the long-term stability of capecitabine and its metabolites in stock solutions and 
in working solutions is ongoing at nominally -70°C.  
 
Table III. Stability data for Capecitabine and its metabolites. 
Compound Internal Conditions Matrix Initial Conc. Found Conc. Dev. C.V. # of 
  Standard     (ng/mL) (ng/mL) (%) (%) Repl. 
Capecitabine Fludarabine 3 freeze / Plasma 28.5 28.8 0.810 6.47 3 
  thaw cycles  710 702 -1.09 6.35 3 
Capecitabine Fludarabine Ambient, 6h Plasma 28.5 28.5 -0.113 5.52 3 
    710 702 -1.06 4.42 3 
Capecitabine Fludarabine 4ºC, 3 days Extraction 28.5 25.0 -12.3 4.73 3 
   solvent 710 636 -10.4 6.44 3 
Capecitabine Fludarabine Autosampler, Extraction 31.4 33.6 6.50 8.35 3 
  10ºC, 48h solvent 555 514 -7.87 7.46 3 
        819 829 1.23 5.42 3 
5’-DFCR 5-chlorouracil 3 freeze / Plasma 27.2 27.3 0.475 1.38 3 
  thaw cycles  3588 3608 0.556 6.46 3 
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5’-DFCR 5-chlorouracil Ambient, 6h Plasma 27.2 27.2 -0.0678 2.26 3 
    3588 3503 -2.36 2.71 3 
5’-DFCR 5-chlorouracil 4ºC, 5 days Extraction 27.2 26.7 -1.82 3.38 3 
   solvent 3588 3482 -2.96 2.38 3 
5’-DFCR 5-chlorouracil Autosampler, Extraction 29.9 26.7 -12.1 5.44 3 
  10ºC, 48h solvent 482 477 -1.00 1.94 3 
        3789 3483 -8.80 3.14 3 
5’-DFUR 5-chlorouracil 3 freeze / Plasma 27.6 27.0 -2.12 9.74 3 
  thaw cycles  3652 3975 8.82 7.50 3 
5’-DFUR 5-chlorouracil Ambient, 6h Plasma 27.6 29.0 5.14 17.6 3 
    3652 3514 -3.79 1.42 3 
5’-DFUR 5-chlorouracil 4ºC, 5 days Extraction 27.6 30.3 9.75 14.0 3 
   solvent 3652 3712 1.63 5.00 3 
5’-DFUR 5-chlorouracil Autosampler, Extraction 29.0 30.4 4.35 12.3 3 
  10ºC, 48h solvent 497 565 12.0 1.64 3 
        3954 3916 -0.948 7.92 3 
5-Fluorouracil 5-chlorouracil 3 freeze / Plasma 156 155 -0.419 4.13 3 
  thaw cycles  3900 3757 -3.65 5.99 3 
5-Fluorouracil 5-chlorouracil Ambient, 6h Plasma 156 156 0.428 5.64 3 
    3900 3820 -2.03 1.39 3 
5-Fluorouracil 5-chlorouracil 4ºC, 5 days Extraction 156 148 -5.19 16.3 3 
   solvent 3900 3725 -4.48 2.39 3 
5-Fluorouracil 5-chlorouracil Autosampler, Extraction 165 150 -9.69 13.6 3 
  10ºC, 48h solvent 965 936 -3.05 5.20 3 
        3835 3604 -6.43 1.91 3 
FUH2 5-chlorouracil 3 freeze / Plasma 156 173 10.5 7.85 3 
  thaw cycles  3945 4330 9.75 9.75 3 
FUH2 5-chlorouracil Ambient, 6h Plasma 156 151 -3.03 20.1 3 
    3945 3943 -0.0657 3.73 3 
FUH2 5-chlorouracil 4ºC, 5 days Extraction 156 168 7.65 11.6 3 
   solvent 3945 4239 7.44 2.79 3 
FUH2 5-chlorouracil Autosampler, Extraction 157 158 0.966 7.06 3 
  10ºC, 48h solvent 937 1008 7.05 3.85 3 
        3935 3982 1.20 4.26 3 
 
3.5.6  Clinical studies 
In Figure 11 the concentration vs. time plot is presented for capecitabine and 
metabolites from a patient treated orally with 1000 mg capecitabine. The maximal 
plasma concentration of capecitabine was reached 0.8 h after administration of the 
drug and was 5,929 ng/mL. The highest plasma level of 5’DFCR, 5’-DFUR and 5-FU 
was measured after 1 h after the administration of capecitabine and was 2,499 ng/mL, 
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3,375 ng/mL and 110 ng/mL, respectively. The highest plasma level of FUH2 was 
reached at 1.5 hours after intake (585 ng/mL).  
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Figure 11. Concentration vs. time profiles of capecitabine and metabolites in a patient 
treated orally with 1000 mg capecitabine. 
 
4. Conclusions 
A simultaneous, accurate and selective LC-MS/MS assay has been developed for the 
quantification of capecitabine, 5΄-DFCR, 5΄-DFUR, 5-FU and FUH2 in human plasma. 
Using 200 μL human plasma aliquots, the assay quantifies a range of 10-1,000 ng/mL 
for capecitabine, 10-5,000 ng/mL for 5΄-DFCR and 5΄-DFUR and 50-5,000 ng/mL for 5-
FU and FUH2. The results clearly demonstrate that porous graphitic carbon material 
has unique separation properties and is capable to retain a wide range of small polar 
and non-polar compounds. This assay is now used to support clinical pharmacologic 
studies with capecitabine. 
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Conclusions  
The major aim was to develop and to validate sensitive analytical High Performance 
Liquid Chromatography coupled to tandem triple quadrupole Mass Spectrometry 
(HPLC-MS/MS) methods for the bioanalysis of selected anti-cancer agents, their 
metabolites and degradation products, in which we succeeded. These methods were 
successfully applied to study the pharmacokinetics of licensed (Chapter 3.1 (paclitaxel), 
Chapter 5.1 (gemcitabine), and Chapter 6.1 (capecitabine)) and investigational anti-
cancer agents (Chapter 2.1, 2.2, 2.5 (EO9), Chapter 4.1 (5-methyindirubine)) and to 
investigate their stability in biological matrices (Chapter 2.3 and 2.4). The developed 
assays have also supported pre-clinical and clinical studies of these agents when 
administered locally (Chapter 2.2). 
 
Mass Spectrometry and Drug Development 
HPLC-MS/MS is applied in nearly every stage of drug development. For synthetic 
chemists MS is pivotal to obtain information about the progress of the synthesis of a 
new drug and for quality control purposes. To obtain an ideal molecule, usually, 
hundreds of novel “lead compounds” need to be screened for biological activity. For 
this, as well as for structural identification of metabolites and degradation products, 
HPLC-MS or MS/MS are very powerful tools. Orthogonal-acceleration reflection time-of-
flight instruments (oa-TOF) combine the ability to perform accurate mass determination 
with excellent full-scan ability. The ion-trap storage-reflection TOF instruments can be 
useful to identify metabolites and degradation products accurately also in low 
concentrations. We used triple quadrupole MS systems also for identification purposes. 
In the search for degradation products of the anti-cancer agent EO9, as described in 
Chapter 2.3, we found a novel degradation product which was identified as EO9-Cl. 
Screening strategies based on the precursor-ions, product ions and neutral-loss scans 
in MS-MS were employed. These studies were needed to develop and to choose a 
suitable pharmaceutical formulation of EO9 for intravesical administration in the bladder 
(Chapter 2.4). The chosen formulation, described in Chapters 2.3 and 2.5, is currently 
used in the ongoing Phase III studies with EO9. 
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Mass Spectrometry in Quantitative Bioanalysis 
Quantitative bioanalysis is a necessity to support preclinical and clinical studies and to 
provide pharmacokinetic and pharmacodynamic (PK-PD) data. A big step in the 
bioanalytical analysis was achieved when HPLC was successfully coupled to MS. This 
hyphenation allowed the selective and ultrasensitive detection of a broad range of anti-
cancer compounds and their metabolites. With the introduction of atmospheric pressure 
ionization, atmospheric pressure chemical ionization and electrospray ionization in the 
1980’s, these techniques were applied more and more for quantitative drug analysis. 
Nowadays, improved HPLC-MS interfaces such as ionspray, turbo-ionspray or heated 
electrospray and heated nebulizer facilitate the evaporation of the HPLC solvents, 
leading to better ionization and detection of the analytes of interest. 
As a result, HPLC-MS/MS has become the method of choice in quantitative bioanalysis 
within hospitals, universities and pharmaceutical industries. 
Before its routine use, every analytical method must be validated to demonstrate that it 
is suitable for its intended purpose. Most of the bioanalytical assays described in this 
thesis have been fully validated according to the FDA guidelines on bioanalytical 
validation (Chapters 2.1, 2.2, 2.5, 5.1 and 6.1). Triple quadrupole mass spectometers 
(API 2000, API 3000 and Finnigan TSQ Quantum Ultra) equipped with an electrospray 
(ESI) ion source were employed. Positive and/or negative ions were created at 
atmospheric pressure and the mass spectrometer was operated in the multiple reaction 
monitoring (MRM) mode using unit resolution for the quadrupoles for most of the 
assays. For the ultra sensitive quantitation of EO9 and EO5a in human plasma, 
detection was performed by a Finnigan TSQ Quantum Ultra equipped with the 
electrospray ion source operated in positive mode, with enhanced mass-resolution 
capability (Chapter 2.2). It demonstrated improved sensitivity with the factors of 10 and 
20 for EO9 and EO5a, respectively, over 3-decades dynamic range, with acceptable 
accuracy and precision, when compared with the assay for EO9 and EO5a using an 
API 2000 (Chapter 2.1).   
 
Mass Spectrometry and Preclinical Studies 
The main goals of preclinical studies are to determine a drug's pharmacokinetics 
((absorption, distribution, metabolism, elimination (ADME)), pharmacodynamics and 
toxicity through animal testing. These data allow the estimation of a safe starting dose 
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of the drug for clinical trials in humans. Typically, both in vitro and in vivo tests are 
performed in animal models, such as rat or mice, yielding low amounts of sample 
available and, consequently, requiring very sensitive bioanalytical methods to 
determine the concentrations of anti-cancer agent in body fluids and tissues of these 
animals. 
To support the intravesical dose ranging study of EO9 in beagle dogs, the plasma 
concentrations of EO9 were measured using a highly sensitive enhanced resolution 
HPLC-MS/MS method to determine whether EO9 has leaked into the systemic 
circulation, leading potentially to systemic toxicity (Chapter 2.2). The lower limit of 
quantitation (LLOQ) of the assay is 0.5 ng/mL for EO9 and EO5a. Although, after an 
intravesical dose 30 times higher than administered to humans, low concentrations of 
EO9 were found in dog plasma, the hypothesis was supported that EO9 may be 
absorbed through the cellular levels in the bladder facilitating its uptake by the tumour 
cells (Chapter 2.2), but with no systemic exposure. To support a pre-clinical study with 
the experimental anti-cancer agent 5-methylindirubine in mice carrying the large cell 
lung cancer LXFL 529 as solid tumor xenograft, a sensitive HPLC-MS/MS assay with a 
short run time utilizing only 50 µL murine plasma was developed. (Chapter 4.1). The 
research question was to study whether 5-MI is taken up after ingestion. Due to the 
very low concentrations of 5-MI measured in plasma, it is expected that 5-MI has a low 
bioavailability, large distribution volume and/or rapid metabolism. Further preclinical 
studies are planned for which our developed HPLC-MS/MS assay is instrumental. 
 
Mass Spectrometry and Clinical Studies 
To support PK-PD studies, LC-MS/MS has become the gold standard for sensitive 
detection and accurate quantitation of anti-cancer agents tested in all Phases of drug 
development. For high-throughput analysis it is important to increase the specificity, 
selectivity and sensitivity of the analytical method. Most bioanalytical assays are 
developed on triple-quadrupole instruments with or without enhanced resolution 
capability. Chromatography is not limited anymore to reversed-phase mode, but more 
and more other approaches such as supercritical fluid chromatography and Hydrophilic 
Interaction Chromatography (HILIC) (“normal-phase” chromatography) are employed. 
Moreover, porous graphitic carbon material enables chromatographic separation and 
analysis of analytes with varying structural differences and polarities in a single 
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analytical run, as described for capecitabine and four of its metabolites (Chapter 6.1). In 
the case of paclitaxel, a simple and sensitive method for the parent drug and its 
hydroxylated metabolites was developed (Chapter 3.1). Gemcitabine and its metabolite 
dFdU were quantified in human plasma by use of HPLC-MS/MS (Chapter 5.1) and this 
is the most sensitive assay for these analytes published thus far. 
 
Perspectives in Mass Spectrometry 
HPLC-MS/MS can be used for multiple research questions.  
Automation of sample preparation, such as online sample pre-treatment, would allow a 
more rapid determination of anti-cancer agents in different matrices. 
The use of a hybrid RF/DC quadrupole-linear ion-trap mass spectrometer, capable of 
all conventional tandem MS scan modes as well as several high sensitivity ion-trap MS 
scans using the final quadrupole as linear ion-trap, also opens new perspectives to 
speed up method development with multi-components analysis (parent drug, 
metabolites and degradation products). 
Phase 0 trials are the next step in the drug development trajectory. These are designed 
to expedite the development of promising agents by establishing in the early stage of 
the development whether it behaves in human subjects as was anticipated from 
preclinical studies. Because the distinctive features of Phase 0 trials include the 
administration of single subtherapeutic doses of the study drug, it is obvious that 
ultrasensitive methods are required. Accelerated mass spectrometry is a very useful 
tool for this application. The relatively less expensive HPLC-MS/MS such as API5000 
and TSQ Quantum Ultra’s with enhanced mass resolution capability, Q-TOF 
instruments and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-
ICR-MS) might also be adequate platforms for the determination of very low levels of 
the compound of interest. Moreover, in view of increasing potency of anti-cancer agents 
(e.g. ET-743) ultra sensitive methods are essential to explore the drug’s 
pharmacokinetics. 
With the successful online hyphenation of LC-NMR and LC-MS, using triple 
quadrupoles or ion-trap systems, an even more accurate and rapid characterization of 
new identities such as degradation products and metabolites might be achieved. Ultra 
high performance liquid chromatography (UPLC) has been coupled with tandem mass 
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spectrometry yielding a shorter run time and simultaneous multi-component analysis 
which may be cost-effective.  
Finally, the development of more sensitive assays is also required to support e.g. 
metronomic therapies and monitoring of hospital personnel potentially exposed to 
cytotoxic agents. 
 
Future of Applied Mass Spectrometry 
Reading the impressive review by Prof. Nibbering (1), entitled “ Four decades of joy in 
mass spectrometry”, one can only be amazed and inspired by the exponential progress 
that was made in the last 40 years of development in the field of mass spectrometry. In 
the book on LC-MS, by Willoughby and co-workers, the development of LC-MS and its 
acceptance as an analytical technique is presented, which is discussed in the review by 
Niessen et al (1999) (2) (Figure 1). Now, 10 years later, this technique is widely 
applied. 
 
Figure 1. Model for the distribution of people applying LC-MS (from ref. 2) 
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However, HPLC-MS/MS appliance should grow even wider than that and be employed 
as a scientific tool for further optimization, but moreover, in an ideal situation, as an 
instrument taking its place at the bed of the hospitalized patient receiving highly toxic 
anti-cancer agents with a small therapeutic window. Most anti-cancer agents have a 
small therapeutic window and due to the large inter-individual pharmacokinetic 
variability a therapeutic benefit is to be expected from therapeutic drug monitoring 
(TDM). Immediate individual dose adaptation may reduce the over-and under dosing, 
toxicity, lack of efficacy and other unwanted effects. Obviously, the realization of this 
proposal is difficult and encounters many hurdles to be taken. This application would 
require extensive training of the personnel to operate the mass spectrometer, higher 
health-care costs and practical difficulties with the use of a not easily transportable 
mass spectrometer. However, the last may be overcome by the miniaturization of the 
instrument, such as using chip-based capillary electrophoresis/mass spectrometry. 
Moreover, the wide use of MS in various laboratories and industries will result in the 
decrease of the instrument’s cost and consequently become financially available to a 
broader customer base. 
Overall and in conclusion, MS has a great future! 
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Summary 
 
To understand the pharmacologic mechanisms of action, efficacy and toxicity of any 
anti-cancer drug it is important to know how the compound is transformed in the body: 
either into active metabolites or inactive and toxic (degradation) products. This 
information may lead to the success or failure of a drug in arresting cancer cell growth, 
and facilitates the design of more effective drugs. To quantify the drug and to follow its 
absorption, distribution, metabolism, and elimination (ADME) in body fluids, ultra 
sensitive and specific analytical methods are of pivotal importance. In recent years, 
High Performance Liquid Chromatography coupled to tandem triple quadrupole Mass 
Spectrometry (HPLC-MS/MS) technique has shown a steep, fascinating development 
into the most powerful and important tool in the quantitative determination of 
investigational anti-cancer agents and identification of metabolites.  
For this thesis, the major aim was to develop and to validate sensitive analytical HPLC-
MS/MS methods for the analysis of anticancer agents, metabolites and degradation 
products in biological matrices. These methods were applied to support 
pharmacokinetic studies of licensed and experimental anticancer agents. For our 
studies we selected the investigational cytotoxic agents: apaziquone (EO9), 5-
methylindirubine and licensed drugs: paclitaxel, gemcitabine and capecitabine. 
 
Chapter 1 presents an overview of the most common locally administered cytotoxic 
drugs with particular focus on available, sensitive bioanalytical assays developed to 
determine the low levels of the drugs that could have passed into the bloodstream and 
which may lead to the systemic toxicity.  
 
Chapters 2.1 describes a study on the development of the sensitive HPLC-MS/MS 
assay for the bioanalysis of the anti-cancer agent EO9 (apaziquone) in the treatment of 
the superficial bladder cancer. Bioreductive alkylating agents such as EO9 are 
designed to require reduction for their activation to form cytotoxic species. EO9 is a 
pro-drug and exerts activity through redox cycling and formation of alkylating 
intermediates under bioreductive conditions. The mechanism of action of EO9 has 
been assumed to involve enzyme (NQO1) catalyzed one- or two-electron reduction, 
followed by the generation of either drug-derived DNA alkylating moieties or DNA-
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damaging reactive oxygen species. EO9 is extensively metabolized. One of the 
principal metabolites is EO5a, which has an open aziridine ring and much lower 
cytotoxicity that EO9. A sensitive and specific LC-MS/MS assay for the quantitative 
determination of EO9 and its metabolite EO5a was developed. A 200-μL-human 
plasma aliquot was spiked with a mixture of deuterated internal standards EO9-d3 and 
EO5a-d4 and extracted with 1.25 mL ethyl acetate. After reconstitution in 0.1 M 
ammonium acetate – methanol (7:3, v/v), 25 μL-volumes were injected onto the HPLC 
system. Separation was achieved on a 150 x 2.1 mm C18 column using an alkaline 
eluent (1 mM ammonium hydroxide – methanol (gradient system)). Detection was 
performed by positive ion electrospray followed by tandem mass spectrometry (API 
2000). The assay quantifies a range from 5 ng/mL to 2,500 ng/mL for EO9 and from 10 
ng/mL to 2,500 ng/mL EO5a using 200 μL of human plasma samples. Validation results 
demonstrated that EO9 and EO5a concentrations can be accurately and precisely 
quantified in human plasma. This assay is used to support pre-clinical and clinical 
pharmacologic studies with EO9. 
Despite three partial responses in phase I evaluation, no anti-tumor activity was 
reported in subsequent phase II studies in breast, gastric, non-small cell lung cancer 
(NSCLC), pancreatic and colorectal cancers. EO9 has a very short half-life in plasma (t 
½ values ranging from 0.8 to 19 min in humans) and a relatively poor ability to penetrate 
through multicell layers in vitro . These properties are assumed to be the main reason 
for EO9’s lack of clinical activity. Therefore, this drug was tested for the treatment of 
cancers that arise in a delimited compartment, such as superficial bladder cancer. 
However, when the drug is administered intravesically at a high dose, it is of the utmost 
importance to be able to determine if any EO9 and/or EO5a passes into the central 
blood circulation from the bladder in order to predict the toxicity of the drug. For the 
ultra sensitive quantitation of EO9 and EO5a in human plasma, detection was 
performed by a Finnigan TSQ Quantum Ultra equipped with the electrospray ion source 
operated in positive mode, with enhanced mass-resolution capability (Chapter 2.2). It 
demonstrated improved sensitivity with the factors of 10 and 20 for EO9 and EO5a, 
respectively, over 3-decades dynamic range, with acceptable accuracy and precision, 
when compared with the assay for EO9 and EO5a using an API 2000 (Chapter 2.1). 
Consequently, the lower limit of quantitation (LLOQ) of this assay was 0.5 ng/mL for 
EO9 and EO5a.  
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To support the intravesical dose ranging study of EO9 in beagle dogs, the plasma 
concentrations of EO9 were measured using this highly sensitive method to determine 
whether EO9 has leaked into the systemic circulation, leading potentially to systemic 
toxicity (Chapter 2.2). Although, after an intravesical dose 30 times higher than 
administered to humans, low concentrations of EO9 were found in dog plasma, the 
hypothesis was supported that EO9 was absorbed through the cellular levels in the 
bladder facilitating its uptake by the tumour cells (Chapter 2.2), but with no systemic 
exposure. Namely, no detectable levels of either EO9 or EO5a were found in the 
samples from the two phase II clinical studies, where EO9 was administered 
intravesically at a dose of 4 mg/40 mL of instillation. We also investigated stability 
implications of this compound in the various pharmaceutical formulations, human 
plasma, and urine (Chapter 2.3 and 2.4). In the search for degradation products of the 
anti-cancer agent EO9, as described in Chapter 2.3, we found a novel degradation 
product which was identified as EO9-Cl. Screening strategies based on the precursor-
ions, product ions and neutral-loss scans in MS-MS were employed. These studies 
were needed to develop and to choose a suitable pharmaceutical formulation of EO9 
for intravesical administration in the bladder (Chapter 2.4). An HPLC-MS/MS assay for 
the determination of EO9 and both degradation products, EO5a and EO9-Cl, in urine 
was validated (Chapter 2.5). A 20-μL-urine aliquot was spiked with a mixture of 
deuterated internal standards EO9-d3 and EO5a-d4 and diluted with 180 µL 0.1 M 
ammonium acetate – methanol (7:3, v/v). 25 μL-volumes were injected onto the HPLC 
system. The assay quantifies a range from 0.1 µg/mL to 50 µg/mL for EO9, from 0.2 
µg/mL to 50 µg/mL for EO5a and 0.1 µg/mL to 4 µg/mL for EO9-Cl using 20 μL of 
stabilized urine samples (stabilized at pH 8.5, where EO9 appeared to be the most 
stable at). Validation results demonstrate that EO9, EO5a and EO9-Cl concentrations 
can be accurately and precisely quantified in human and dog urine. This assay is used 
now to support pre-clinical and clinical pharmacologic studies with intravesically 
administered EO9. 
The developed formulation (Chapters 2.3) is currently used in the ongoing Phase III 
studies with EO9. The bioanalytical assays have been used to support several 
(pre)clinical studies with EOquin® (pharmaceutical formulation of EO9 for 
administration into the bladder).  
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Chapter 3 deals with the development of the HPLC-MS/MS assay and the supported 
clinical studies with the taxane anti-cancer agent paclitaxel and its metabolites in 
human plasma. Paclitaxel’s activity is derived from its ability to increase the assembly 
and stability of microtubules in dividing cells, thereby blocking the cell cycle. Paclitaxel 
has significant clinical activity against a broad range of tumor types including breast, 
lung, head and neck, bladder, and platinum-refractory ovarian carcinoma. Accurate 
information on the disposition and the metabolism of paclitaxel is of crucial importance 
to be able to optimize its administration, because both metabolites exhibit the excessive 
microtubule stabilizing properties of the parent compound. A sensitive and specific 
HPLC-MS/MS assay for the determination of paclitaxel and its 3´p- and 6-α-hydroxy 
metabolites is presented. A 200 μL plasma aliquot was spiked with a 13C6-labeled 
paclitaxel internal standard and extracted with 1.0 mL tert-butylmethylether. Dried 
extracts were reconstituted in 0.1 M ammonium acetate – acetonitrile (1:1, v/v) and 25 
μL-volumes were injected onto the HPLC system. Separation was performed on a 150 
x 2.1 mm C18 column using an alkaline eluent (10 mM ammonium hydroxide – 
methanol (30:70, v/v)). Detection was performed by positive ion electrospray followed 
by tandem mass spectrometry. The assay quantifies a range for paclitaxel from 0.25 
ng/mL to 1,000 ng/mL and metabolites from 0.25 ng/mL to 100 ng/mL using 200 μL 
human plasma samples. Validation results demonstrate that paclitaxel and metabolites 
concentrations can be accurately and precisely quantified in human plasma. This assay 
is now used to support clinical pharmacologic studies with paclitaxel. 
 
Chapter 4 depicts the analytical HPLC-MS/MS assay and the pre-clinical study in mice 
with the experimental anticancer agent 5-methylindirubine (5-MI), administered orally, 
to investigate the distribution and pharmacokinetics of this compound. 5-MI has been 
reported to inhibit cyclin-dependant kinases (CDKs) by competing in the ATP-binding 
sites with high selectivity among several kinase families, which has an anti-proliferative 
effect on human cancer cells. To support a pre-clinical study with 5-MI in mice carrying 
the large cell lung cancer LXFL 529 as solid tumor xenograft, a sensitive HPLC-MS/MS 
assay with a short run time utilizing only 50 µL murine plasma was developed (Chapter 
4.1). A 50-μL-murine plasma aliquot was spiked with an internal standard, indirubine-3-
monoxime (IMO) and extracted with 1.25 mL diethylether. Dried extracts were 
reconstituted in methanol - water (8:2, v/v) and 10 μL-volumes were injected onto the 
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HPLC system. Separation was achieved on a Gemini C18 column using an alkaline 
eluent (10 mM ammonium hydroxide – methanol (5:95, v/v)). Detection was performed 
by negative ion electrospray followed by tandem mass spectrometry. The assay 
quantifies 5-MI in a range from 1 to 500 ng/mL using 50 μL of murine EDTA plasma 
samples. Validation results demonstrate that 5-MI concentrations can be accurately 
and precisely quantified in murine plasma.  
The research question was to study whether 5-MI is taken up after ingestion. Due to the 
very low concentrations of 5-MI measured in plasma, it is expected that 5-MI has a low 
bioavailability, large distribution volume and/or rapid metabolism. Further preclinical 
studies are planned for which our developed HPLC-MS/MS assay is instrumental. 
 
Chapter 5 illustrates the ultra-sensitive assay with the registered, widely used, 
anticancer drug gemcitabine and its metabolite 2', 2'- difluorodeoxyuridine (dFdU) in 
human plasma with the lower limit of quantitation of 0.5 ng/mL. Gemcitabine is one of 
the most commonly used anti-cancer agents and has demonstrated antitumor activity 
against a broad range of solid tumors, such as non-small cell lung cancer (NSCLC), 
breast, ovarian, urothelial, pancreatic and bladder cancer. However, gemcitabine, like 
most anticancer drugs, has a narrow therapeutic window. Therefore, it is of pivotal 
importance to be able to accurately and reliably evaluate the pharmacokinetic and 
pharmacodynamic profiles of gemcitabine and dFdU in clinical trials. To accomplish this 
goal, we developed a simple and sensitive method for the accurate determination of 
gemcitabine and its metabolite dFdU in human heparinized and EDTA plasma. A 200-
μL aliquot human plasma was spiked with a mixture of internal standards didanosine, 
lamivudine and fludarabine and extracted using solid phase extraction. After 
reconstitution of dried extracts in 1 mM ammonium acetate – acetonitrile (97:3, v/v), 10 
μL-volumes were injected onto the HPLC system. Separation was achieved on a 150 x 
2.1 mm C18 bonded phase endcapped with polar groups (Synergi Hydro-RP column) 
using the eluent composed of 1 mM ammonium acetate pH 6.8 - acetonitrile (94:6, v/v). 
Detection was performed by positive ion electrospray followed by tandem mass 
spectrometry (TSQ Ultra). The assay quantifies a range from 0.5 to 1,000 ng/mL for 
gemcitabine and from 5 to 10,000 ng/mL for dFdU using 200 μL of human plasma 
samples. Validation results demonstrate that gemcitabine and dFdU concentrations can 
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be accurately and precisely quantified in human plasma. This assay is used to support 
clinical pharmacologic studies with gemcitabine. 
 
Chapter 6 describes a novel, simultaneous method for the quantitation of capecitabine 
and its metabolites 5΄-deoxy-5-fluorocytidine (5΄-DFCR), 5΄-deoxy-5-fluorouridine (5΄-
DFUR), 5-fluorouracil (5-FU) and 5-fluorodihydrouracil (FUH2) in human plasma. We 
were the first to develop the sensitive analytical HPLC-MS/MS method that allowed 
determination of all these compounds simultaneously in one analytical run. 
Capecitabine is an anticancer prodrug that was designed to undergo conversion in liver 
and tumors to active agent 5-fluorouracil, which is one of the most commonly used anti-
cancer agents in the treatment of solid tumors, predominantly in digestive tract, head, 
neck, and breast tumors. The anti-tumor activity of 5-FU is attributed to inhibition of the 
enzyme thymidylate synthase (TS) that is essential for DNA synthesis. However, in 
humans 70% of 5-FU is catabolized by dihydropyrimidine dehydrogenase (DPD) to 
FUH2 and ultimately to α-fluoro-β-alanine (FBAL), concluding that DPD limits the 
amount of 5-FU available for conversion into the active metabolites (cellular) that 
mediate its cytotoxic activity. DPD activity varies widely between patients due to the 
genetic polymorfisms. Consequently, evaluation of DPD activity by calculating the 
FUH2/5-FU plasma ratio is of significant importance to optimize the treatment efficacy 
without increasing toxicity.  
Therefore, it was extremely important to determine capecitabine and its metabolites (5΄-
DFCR, 5΄-DFUR, 5-FU and FUH2) simultaneously to be able to predict the efficacy and 
toxicity of 5-FU as efficiently as possible. A 200-μL-human plasma aliquot was spiked 
with a mixture of internal standards fludarabine and 5-chlorouracil. A single-step protein 
precipitation method was employed using 10% (v/v) trichloroacetic acid (TCA) in water 
to separate analytes from bio-matrices. 20 μL-volumes of the supernatant were directly 
injected onto the HPLC system. Separation was achieved on a 30 x 2.1 mm Hypercarb 
(porous graphitic carbon) column using a gradient by mixing 10 mM ammonium acetate 
and acetonitrile – 2-propanol – tetrahydrofuran (1:3:2.25, v/v/v). The detection was 
performed using a Finnigan TSQ Quantum Ultra equipped with the electrospray ion 
source operated in positive and negative mode. The assay quantifies a range from 10 
to 1,000 ng/mL for capecitabine, from 10-5,000 ng/mL for 5΄-DFCR and 5΄-DFUR, and 
from 50-5,000 ng/mL for 5-FU and FUH2 using a plasma sample of 200 μL.  
Summary 
 
316 
The results clearly demonstrate that porous graphitic carbon material has unique 
separation properties and is capable to retain a wide range of small polar and non-polar 
compounds. This assay is now used to support clinical pharmacologic studies with 
capecitabine. 
 
In conclusion (Chapter 7), HPLC-MS/MS has become the method of choice in 
quantitative bioanalysis within pharmaceutical industries, universities, and hospitals. 
The development of more sensitive assays is required to support e.g. pharmacokinetic 
– pharmacodynamic (PK-PD) studies, Phase 0 studies, metronomic therapies and 
monitoring of hospital personnel potentially exposed to cytotoxic agents.  
Overall and in conclusion, HPLC-MS/MS has become the gold standard for sensitive 
detection and accurate quantitation of anti-cancer agents tested in all Phases of drug 
development. 
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Samenvatting 
 
Om de farmacologische mechanismen, effectiviteit en toxiciteit van iedere anti-kanker 
geneesmiddel te doorgronden, is het belangrijk om te onderzoeken hoe het 
geneesmiddel in het lichaam metaboliseert naar actieve, niet-actieve en/of toxische 
metabolieten. Deze informatie kan al dan niet tot een succes van het geneesmiddel 
leiden en het vergemakkelijkt de ontwikkeling van effectievere geneesmiddelen. Ultra 
gevoelige en specifieke analytische methoden zijn uitermate belangrijk om het 
geneesmiddel te kwantificeren zodat de absorptie, distributie, metabolisme en klaring in 
biologische vloeistoffen kan worden gemeten. In de laatste jaren heeft hoge druk 
vloeistofchromatografie gekoppeld met tandem massaspectrometrie (HPLC-MS/MS)  
een razend snelle en indrukwekkende ontwikkeling doorgemaakt; het is momenteel de 
belangrijkste techniek geworden in het veld van de kwantitatieve bioanalyse van 
experimentele anti-kanker middelen en de identificatie van metabolieten. 
Het doel van het onderzoek was de ontwikkeling en validatie van nieuwe gevoelige 
analytische HPLC-MS/MS methoden om anti-kanker middelen, metabolieten en 
afbraakproducten in biologische matrices te meten. Deze methoden zijn gebruikt ter 
ondersteuning van farmacokinetische studies met experimentele en geregistreerde 
anti-kanker geneesmiddelen. Voor ons onderzoek hebben we de volgende 
experimentele middelen geselecteerd: apaziquone (EO9), 5-methylindirubine en de 
geregistreerde geneesmiddelen: paclitaxel, gemcitabine en capecitabine. 
 
In Hoofdstuk 1 wordt een overzicht gegeven van de meest gebruikte lokaal 
toegediende anti-kanker geneesmiddelen en de gepubliceerde bio-analytische 
methoden waarmee zeer lage concentraties van deze geneesmiddelen in plasma 
kunnen worden bepaald om de opname in het bloed te kunnen meten hetgeen tot 
systemische toxiciteit kan leiden.  
 
In Hoofdstuk 2.1 wordt een ontwikkeling van een gevoelige HPLC-MS/MS methode 
beschreven voor de bioanalyse van het anti-kanker middel EO9 (apaziquone), dat 
tegen een vorm van blaaskanker wordt gebruikt waarbij de tumoren zich aan de 
oppervlakte van de blaaswand bevinden. Het alkylerende middel EO9 wordt 
gereduceerd naar een actief cytotoxisch intermediair. EO9 is een “pro-drug” en werkt 
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via “redox cycling” en de vorming van alkylerende tussenvormen onder bioreductieve 
omstandigheden. Er wordt aangenomen dat het werkingsmechanisme van EO9 
gebaseerd is op één- of twee-elektronen reducties, gekatalyseerd door een enzym 
(NQO1), gevolgd door de vorming van intermediaire DNA alkylerende stoffen of 
zuurstof radicalen die het DNA kunnen beschadigen. EO9 wordt uitvoerig 
gemetaboliseerd. EO5a, één van de belangrijkste metabolieten, heeft een geopende 
aziridine ring en is veel minder cytotoxisch dan EO9. Er is een gevoelige en specifieke 
HPLC-MS/MS methode voor de kwantitatieve bepaling van EO9 en zijn metaboliet 
EO5a in plasma ontwikkeld. Aan 200 μL humaan plasma werd een mengsel van de 
gedeutereerde interne standaarden EO9-d3 en EO5a-d4 toegevoegd en het monster 
werd vervolgens geëxtraheerd met 1.25 mL ethylacetataat. Het droge extract werd 
opgenomen in 0.1 M ammonium acetaat – methanol (7:3, v/v) en 25 μL werd 
geïnjecteerd in het HPLC systeem. De chromatografische scheiding tussen de stoffen 
werd verkregen op een 150 x 2.1 mm C18 kolom gebruik makend van gradientelutie 
met een alkalische eluens (1 mM ammonium hydroxide – methanol). De stoffen werden 
met positieve electrospray en tandem massaspectrometrie gedetecteerd (API 2000). 
Het lineaire bereik van deze methode is van 5 tot 2,500 ng/mL voor EO9 en van 10 tot 
2,500 ng/mL voor EO5a uitgaande van 200 μL humaan plasma. De validatie resultaten 
laten zien dat de concentraties van EO9 en EO5a accuraat en met de hoge precisie 
kunnen worden gemeten. De methode wordt gebruikt om de concentraties van EO9 en 
EO5a in de preklinische en klinische farmacologische studies met EO9 te bepalen. 
In fase I studies met EO9 werd drie maal een partiële respons waargenomen, echter in  
fase II werd geen activiteit gezien in studies met patiënten met borst-, maag-, niet klein-
cellige long-, alvleesklier- en dikke darm kanker. EO9 heeft een hele korte 
halfwaardetijd in plasma (t ½ waarden variëren van 0.8 tot 19 min in de mens) en een 
relatief slechte penetratie door meervoudige cellulaire lagen in vitro. Waarschijnlijk is 
EO9 door deze eigenschappen niet actief in vivo. Het geneesmiddel is vervolgens 
getest tegen blaaskanker waarbij EO9 rechtstreeks in de blaas werd gebracht om 
lokaal actief te kunnen zijn. Wanneer het geneesmiddel in de blaas in een hoge dosis 
wordt toegediend, is het van belang om vast te stellen of EO9 en/of EO5a vanuit de 
blaas naar het bloed wordt getransporteerd om de toxiciteit van het geneesmiddel te 
voorspellen. Om EO9 en EO5a zeer gevoelig te kunnen meten in humaan plasma, 
werd een Finnigan TSQ Quantum Ultra massaspectrometer gebruikt, uitgerust met een 
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electrospray bron en op verhoogde massa resolutie ingesteld (Hoofdstuk 2.2). Over 3-
decades lineair bereik, werden EO9 en EO5a 10 tot 20 keer zo gevoelig gemeten, met 
acceptabele nauwkeurigheid en precisie in vergelijking met de methode waarbij gebruik 
werd gemaakt van een API 2000 (Hoofdstuk 2.1). De laagste bepalingsgrens voor deze 
methode was 0.5 ng/mL voor EO9 en EO5a. De ultra gevoelige methode om EO9 
concentraties te meten (Hoofdstuk 2.2) werd gebruikt om een preklinische studie in 
honden (beagles) te ondersteunen waarbij verschillende EO9 doseringen in de blaas 
werden toegediend. Door het plasma van de honden te analyseren werd onderzocht of 
EO9 vanuit de blaas in de bloedstoom werd opgenomen hetgeen tot mogelijke 
systemische toxiciteit kan leiden. Na de toediening van een 30 keer zo hoge dosis als 
die in de mens, werden zeer lage concentraties van EO9 in het plasma van honden 
gemeten. Daarmee werd de hypothese bevestigd, dat EO9 door de blaascellen heen 
kan penetreren en op deze wijze in de tumor opgenomen kan worden, echter zonder 
hoge systemische blootstelling. Er werden namelijk geen meetbare spiegels van EO9 
of EO5a gemeten in het plasma van patiënten in twee fase II klinische studies 
(Hoofdstuk 2.2), waarbij EO9 in de concentratie van 4 mg/40 mL blaasinstallatie 
vloeistof in de blaas werd toegediend.  
De stabiliteit van EO9 werd in verschillende farmaceutische formuleringen, humaan 
plasma en urine onderzocht (Hoofdstukken 2.3 en 2.4). Tijdens de zoektocht naar  
afbraakproducten van EO9, (Hoofdstuk 2.3) werd een nieuwe stof gedetecteerd en als 
EO9-Cl geïdentificeerd. Identificatie bleek mogelijk door het uitvoeren van “precursor-
ion-“, “product ion-“ en “neutral-loss scans” met de massaspectrometer. 
Stabiliteitsstudies werden uitgevoerd om een geschikte farmaceutische formulering 
voor EO9 te ontwikkelen voor de toediening in de blaas (Hoofdstuk 2.4). Een HPLC-
MS/MS methode voor de bepaling van EO9 en beide degradatie producten, EO5a en 
EO9-Cl, in urine werd ontwikkeld en gevalideerd (Hoofdstuk 2.5). Aan 20 μL urine werd 
een mengsel van de gedeutereerde interne standaarden EO9-d3 and EO5a-d4 
toegevoegd en de urine werd verdund met 180 µL 0.1 M ammonium acetaat – 
methanol (7:3, v/v). Een volume van 25 μL werd geïnjecteerd in het HPLC systeem. De 
methode was lineair van 0.1 tot 50 µg/mL voor EO9, van 0.2 tot 50 µg/mL voor EO5a 
en van 0.1 tot 4 µg/mL for EO9-Cl waarbij 20 μL gestabiliseerde urine (pH 8.5 om EO9 
te stabiliseren) in opwerking werd genomen. Validatie resultaten laten zien dat EO9, 
EO5a en EO9-Cl concentraties accuraat en precies kunnen worden bepaald in 
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humane- en honden urine. Deze methode wordt momenteel gebruikt om preklinische 
en klinische farmacologische studies met EO9, toegediend als de blaasspoeling, te 
ondersteunen. 
De ontwikkelde formulering (Hoofdstuk 2.3), wordt momenteel gebruikt in een fase III 
studie met EO9. De bioanalytische methoden worden gebruikt om de (pre)klinische 
studies met EOquin® (farmaceutische formulering met EO9 voor de toediening in de 
blaas) te ondersteunen. 
 
In Hoofdstuk 3 is de ontwikkeling van een HPLC-MS/MS methode voor het taxaan anti-
kanker middel paclitaxel en zijn metabolieten in humaan plasma beschreven. De 
toepassing van de methode wordt gedemonstreerd aan de hand van een klinische 
studie. Paclitaxel stimuleert het samenvoegen en de stabilisatie van de microtubuli in 
delende cellen waardoor de cyclus van de cel wordt geblokkeerd. Paclitaxel is klinisch 
actief tegen verscheidene soorten tumoren, zoals borst-, long-, hoofd en nek-, blaas- 
en ovarium tumoren. Accurate informatie betreffende de verdeling en metabolisme van 
paclitaxel is van cruciaal belang als men een effectieve toediening wil bewerkstelligen, 
omdat beide metabolieten overmatige microtubili stabiliserende eigenschappen 
hebben, net zoals paclitaxel. Een gevoelige en specifieke HPLC-MS/MS methode voor 
de bepaling van paclitaxel en zijn 3´p- en 6-α-hydroxy metabolieten is ontwikkeld en 
gevalideerd. Aan 200 µL humaan plasma werd een gelabelde 13C6-paclitaxel interne 
standaard toegevoegd en de te bepalen stoffen werden geëxtraheerd met 1.0 mL tert-
butylmethylether. Droge extracten werden opgenomen in 0.1 M ammonium acetaat – 
acetonitril (1:1, v/v) en 25 μL werd geïnjecteerd op de HPLC kolom. Chromatografische 
scheiding werd uitgevoerd op een 150 x 2.1 mm C18 kolom gebruik makend van een 
alkalische eluens (10 mM ammonium hydroxide – methanol (30:70, v/v)). Detectie werd 
uitgevoerd door middel van positieve ion electrospray gevolgd door tandem 
massaspectrometrie. De methode is gevalideerd over het lineaire bereik van 0.25 tot 
1,000 ng/mL voor paclitaxel en van 0.25 tot 100 ng/mL voor de metabolieten. 
Resultaten van de validatie laten zien dat de concentraties van paclitaxel en 
metabolieten accuraat en precies kunnen worden gekwantificeerd in humaan plasma. 
De methode wordt momenteel gebruikt om klinische farmacologische studies met 
paclitaxel te ondersteunen. 
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In Hoofdstuk 4 wordt een analytische HPLC-MS/MS methode voor de bepaling van het 
experimentele anti-kanker middel 5-methyl indirubine (5-MI) beschreven. Deze 
methode is gebruikt in een orale preklinische studie in muizen om de verdeling en 
farmacokinetiek van 5-MI te onderzoeken. 5-MI blokkeert “cyclin-dependant kinases” 
(CDKs) door een competitie aan te gaan met betrekking tot de ATP-bindingsplaatsen 
waarbij de stof een hoge selectiviteit heeft in vergelijking met andere kinasen, die een 
antiproliferatie werking hebben op humane kanker cellen. Om een preklinische studie in 
muizen met geïmplanteerde solide groot-cellige long carcinomen (LXFL 529) te 
ondersteunen, werd een gevoelige HPLC-MS/MS methode ontwikkeld voor de bepaling 
van 5-MI in plasma waarbij slechts 50 µL plasma van de muis in bewerking werd 
genomen (Hoofdstuk 4.1). Aan dit plasma volume werd de interne standaard, 
indirubine-3-monoxime (IMO), toegevoegd en het monster werd geëxtraheerd met 1.25 
mL diethylether. Droge extracten werden opgenomen in methanol - water (8:2, v/v) en 
10 μL werd geïnjecteerd op een HPLC kolom. Chromatografische scheiding werd 
uitgevoerd met een Gemini C18 kolom, gebruik makend van een alkalische eluens (10 
mM ammonium hydroxide – methanol (5:95, v/v)). 5-MI en IMO werden negatief 
geïoniseerd in een electrospray bron en vervolgens gedetecteerd met behulp van 
tandem massaspectrometrie. De methode omvat het lineaire bereik van 1 tot 500 
ng/mL gebruikmakend van 50 μL muizen plasma (EDTA). Validatie resultaten laten 
zien dat de concentraties van 5-MI accuraat en precies kunnen worden 
gekwantificeerd.  
De ontwikkelde methode werd gebruikt om te onderzoeken of 5-MI in de bloedstroom 
wordt opgenomen na een orale toediening. Zeer lage concentraties van 5-MI werden in 
het plasma van de muizen gemeten en hieruit kan worden opgemaakt dat 5-MI een 
lage biologische beschikbaarheid heeft, of een groot verdelingsvolume heeft en/of snel 
metaboliseert. Het vervolg onderzoek is gaande en monsters zullen met behulp van de 
ontwikkelde HPLC-MS/MS methode worden gemeten. 
 
In Hoofdstuk 5 wordt een zeer gevoelige methode voor het geregistreerde, veel 
toegepaste anti-kanker middel gemcitabine en zijn metaboliet 2', 2'- 
difluorodeoxyuridine (dFdU) in humaan plasma beschreven met een laagste 
bepalingsgrens van 0.5 ng/mL. Gemcitabine is een van de meest gebruikte middelen 
met antitumor activiteit tegen een breed scala aan tumoren, o.a. niet klein-cellig long-, 
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borst-, uterus-, ovarium-, pancreas en blaas kanker. Gemcitabine heeft, zoals de 
meeste anti-kanker stoffen, een zeer nauw therapeutische bereik. Daarom is het 
uitermate belangrijk om accuraat en betrouwbaar het farmacokinetische en 
farmacodynamische profiel van gemcitabine en dFdU te onderzoeken in klinische trials. 
Om dit doel te bereiken werd een eenvoudige, gevoelige methode ontwikkeld om 
gemcitabine en zijn metaboliet dFdU in humaan heparine- en EDTA plasma te bepalen. 
Aan 200 μL plasma werd een mengsel van interne standaarden toegevoegd: 
didanosine, lamivudine en fludarabine. Vervolgens werd het monster geëxtraheerd met 
behulp van vaste fase extractie. Nadat de droge extracten in 1 mM ammonium acetaat 
– acetonitril (97:3, v/v) werden opgelost, werd een volume van 10 μL van het extract 
geïnjecteerd in een HPLC system. Chromatografische scheiding werd bewerkstelligd 
op een 150 x 2.1 mm C18 kolom met polaire groepen (Synergi Hydro-RP kolom) en 
een eluens bestaande uit een mengsel van 1 mM ammonium acetaat pH 6.8 - 
acetonitril (94:6, v/v). Het eluens werd verdampt en positieve ionen werden gecreëerd 
in de electrospray bron. Met tandem massaspectrometrie (TSQ Ultra) werden de ionen 
geselecteerd en gedetecteerd. De methode is gevalideerd voor het lineaire bereik van 
0.5 tot 1,000 ng/mL voor gemcitabine en van 5 tot 10,000 ng/mL voor dFdU waarbij 200 
μL humaan plasma in bewerking werd genomen. Validatie resultaten laten zien dat 
gemcitabine en dFdU concentraties accuraat en precies kunnen worden bepaald in 
humaan plasma. De ontwikkelde methode is geschikt om klinische farmacologische 
studies met gemcitabine te ondersteunen. 
 
In Hoofdstuk 6 wordt een nieuwe methode voor de simultane detectie van capecitabine 
en zijn metabolieten 5΄-deoxy-5-fluorocytidine (5΄-DFCR), 5΄-deoxy-5-fluorouridine (5΄-
DFUR), 5-fluorouracil (5-FU) en 5-fluorodihydrouracil (FUH2) in humaan plasma 
beschreven. Dit is de eerste gevoelige analytische HPLC-MS/MS methode die in staat 
is om al deze stoffen simultaan te meten. Capecitabine is een anti-kanker “prodrug”, 
ontwikkeld om in de lever omgezet te worden naar het actieve geneesmiddel 5-
fluorouracil (5-FU). 5-FU is één van de meest gebruikte anti-kanker middelen dat 
werkzaam is tegen vaste tumoren die aanwezig zijn in het spijsverteringskanaal, het 
hoofd, de nek en de borst. De antitumor activiteit van 5-FU wordt toegeschreven aan 
de remming van het enzym thymidylate synthase (TS) dat een essentiële rol speelt in 
de DNA synthese. Echter 70% van 5-FU wordt in de mens door dihydropyrimidine 
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dehydrogenase (DPD) omgezet in FUH2 en uiteindelijk tot α-fluoro-β-alanine (FBAL). 
DPD beperkt dus de hoeveelheid 5-FU dat beschikbaar is voor de omzetting naar 
actieve metabolieten (intracellulair) die verantwoordelijk zijn voor de cytotoxische 
activiteit. De DPD activiteit varieert aanzienlijk van patiënt tot patiënt door genetische 
polymorfismen. Vandaar dat de evaluatie van de DPD activiteit door de berekening van 
de FUH2/5-FU ratio in plasma zeer belangrijk is om de effectiviteit van de behandeling 
te optimaliseren zonder toename van toxiciteit.  
Het is uiterst belangrijk om de capecitabine en zijn metabolieten (5΄-DFCR, 5΄-DFUR, 5-
FU and FUH2) gelijktijdig te kunnen bepalen om de effectiviteit en toxiciteit van 5-FU zo 
goed mogelijk te kunnen voorspellen. Aan humane plasma monsters (200 µL) werd een 
mengsel van de interne standaarden fludarabine en 5-chlorouracil toegevoegd. De 
eiwitten werden vervolgens neergeslagen met 10% (v/v) trichloorazijnzuur (TCA) in 
water. Een volume van 20 μL van de bovenstaande, heldere vloeistof werd direct 
geïnjecteerd in het HPLC systeem. Chromatografische scheiding geschiedde op een 
30 x 2.1 mm Hypercarb (poreus grafiet koolstof) kolom met een gradiënt van de 
volgende vloeistoffen: 10 mM ammonium acetaat en acetonitril – 2-propanol – 
tetrahydrofuran (1:3:2.25, v/v/v). Een Finnigan TSQ Quantum Ultra massaspectrometer 
met een electrospray bron werd gebruikt om de positieve en negatieve ionen te 
detecteren. De methode heeft een lineair bereik van 10 tot 1,000 ng/mL voor 
capecitabine, van 10 tot 5,000 ng/mL voor 5΄-DFCR en 5΄-DFUR en van 50 tot 5,000 
ng/mL voor 5-FU en FUH2, uitgaande van 200 μL plasma.  
De resultaten van dit onderzoek laten zien dat een kolom met poreus grafiet koolstof 
materiaal unieke scheidingseigenschappen bezit en in staat is om kleine polaire en 
niet-polaire moleculen te scheiden. De beschreven methode wordt gebruikt ter 
ondersteuning van klinische farmacologische studies met capecitabine. 
 
In Hoofdstuk 7 wordt geconcludeerd dat HPLC-MS/MS de eerste keus is geworden 
voor de kwantitatieve bioanalyse in de farmaceutische industrie, universiteiten en 
ziekenhuizen. De ontwikkeling van gevoeligere methoden is noodzakelijk om 
farmacologische-farmacodynamische studies, fase 0 studies, metronomische 
therapieën en het monitoren van het ziekenhuis personeel dat mogelijk blootgesteld is 
aan cytostatica, te kunnen ondersteunen.  
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Kortom, HPLC-MS/MS is een gouden standaard geworden voor de gevoelige detectie 
en accurate bepaling van anti-kanker middelen tijdens alle ontwikkelingsfasen die deze 
middelen doorlopen.  
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Sir Walter Raleigh zei: “I can’t write a book commensurate with Sheakespeare, but I 
can write a book by me”. Ik sluit me erbij aan: het is gelukt, het is klaar en ik ben er 
trots op! 
Allereerst wil ik mijn promotores, Prof. Dr Jos Beijnen en Prof. Dr Jan Schellens en mijn 
co-promotor, Dr Hilde Rosing bedanken. Beste Jos, jij bruist van innovatieve en 
uitdagende ideeën. Ik vind het ongeloofelijk hoe jij de science, het management, de 
farmacie en tal van andere dingen zo voortreffelijk kan combineren. Bedankt voor je 
vertrouwen in mij. Jouw aanmoedigingen hebben me geïnspireerd om alles 
zelfstandiger, beter en sneller te doen en om beslissingen te durven nemen, in de 
wetenschap en in mijn werk als studieleider. Ik ben je zeer erkentelijk dat je deur 
letterlijk en figuurlijk altijd voor me open stond. Bedankt voor je goede 
wetenschappelijke begeleiding, maar ook voor de juiste woorden die je wist te vinden 
als ik even ‘in de put zat’. Dit hoofdstuk is nu klaar, maar het volgende hoofdstuk staat 
op het punt van beginnen. Ik heb er zin in en ga er voor 100% voor! 
Beste Jan, ik ben je zeer erkentelijk voor de snelle beoordeling van mijn manuscripten 
en je adviezen over klinische studies. Bedankt voor de discussies over EO9. Mede 
daardoor, heb ik meer inzicht gekregen over de klinische werking van dit belangrijke 
geneesmiddel. Ik hoop dat we nog vele jaren zullen samenwerken! 
Lieve Hilde, waar moet ik beginnen? Zoals ik al eerder zei, dacht ik bij mijn 
sollicitatiegesprek: die prof (Jos) is OK, maar die vrouw (Hilde)....ik hoop dat ik niet  
veel met haar zal samenwerken. Niets bleek minder waar: ik moest veel met je 
samenwerken. En nu, bijna 4 jaar later, kies ik heel bewust voor een positie binnen de 
Apotheek van het Slotervaart Ziekenhuis om onze samenwerking te continueren en wat 
mij betreft nog lange tijd! Hilde, ik had me geen betere leidinggevende en co-promotor 
kunnen wensen. Ik heb ontzettend veel van jou geleerd: jouw wetenschappelijke 
manier van denken, jouw pragmatische aanpak om snel tot een resultaat te komen, de 
wijze waarop je weloverwogen beslissingen neemt en jouw organisatorisch vermogen 
zijn bewonderenswaardig! Jij bent echt mijn voorbeeld van een ‘sterke’ vrouw. Lieve 
Hilde, jij bent een vriendin geworden die ik kan vertrouwen en daarmee is alles gezegd. 
Ik wens jou, Albert en jullie schitterende meisjes, Menke en Zhuzan, alle ‘joy and 
happiness’ van de wereld toe!  
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De leden van de beoordelingscommissie Prof. Dr H.J. Guchelaar, Prof. Dr G.J. de 
Jong, Prof. Dr C. Neef, Prof. Dr D.R.A. Uges en Dr D. Mirejovsky ben ik zeer erkentelijk 
voor het beoordelen van mijn proefschrift.  
I would like to kindly thank Dorla Mirejovsky, Luigi Lenaz, Guru Reddy, Van Huynh and 
Shanta Chawla from Spectrum Pharmaceuticals for our great, fruitful and extremely 
pleasant scientific collaboration and friendship. I truly hope to continue working with you 
on the development of EO9 and on other projects. Although, I performed my research 
on other compounds as well, EO9 feels like my baby…Dear Dorla, I am truly looking 
forward and it is a great pleasure to see you and your husband on the 21st of February. 
I also would like to thank Luis López-Lázaro and Arturo Soto Matos-Pita from Pharma 
Mar, for our pleasant co-operation. Dear Arturo, I hope I will see you next year and 
continue our friendship. From Eli Lilly, I would like to thank Enaksha Wickremsinhe for 
supplying me with the needed reference standards. Prof. Dr Heinz-Herbert Fiebig and 
Dr Armin Maier, thank you for our discussions and interesting work on the experimental 
anti-cancer agent 5-methylindirubine. I hope you will continue its development. 
Mijn lieve ‘”oude en nieuwe” collega’s. Ik ben ontzettend blij dat ik bij jullie blijf en we 
samen in een team gaan werken! Lieve Bas, mijn kamergenoot, bedankt voor je 
bijdrage aan de paclitaxel en gemcitabine bepalingen; al je hulp bij technische vragen 
en problemen en je zorgzaamheid toen ik zo druk was in de laatste maanden met het 
schrijven van mijn review. Mijn andere kamergenoot, Michel, jij ook hartelijk bedankt 
voor je hulp met alle MS problemen en het altijd willen meedenken over alle perikelen 
van mijn onderzoek. Tevens wil ik je bedanken voor de onuitputtelijk aanvoer van 
DVD’s met spannende (wat zeer ontspannend werkt) films! Ik hoop dat we in de 
toekomst nog vaker DVDtjes kunnen wisselen. Mariët, jammer dat je weg bent, maar 
gelukkig houden we contact en gaan we binnenkort weer eens afspreken! Ik wil je 
hartelijk bedanken voor al je werk met betrekking tot EO9, ES-286, KF en D-24851. 
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